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PREFACE 
In this thesis, the term written medicine information (WMI) is used to refer to any form 
of printed information leaflet about medications intended for consumers and unless 
otherwise specified, excludes package labels and internet-based information. Although 
synonymous with WMI, the term written drug information (WD/) has not been used in 
this thesis to prevent confusion; however, it has been used in previous publications. In 
addition to WMI, the term Consumer Medicine Information (CMI) has also been used in 
this thesis. CMI refers to brand-specific, manufacturer-produced written information 
about medicines intended for consumers in Australia (Dowling, 1996). 
In the literature, different terms have been used to refer to individuals who utilise 
healthcare, ranging from patient to consumer to client. Preferences seemed to vary 
between groups of individuals [e.g. preference for patient by attendees of a back-pain 
clinic (Wing, 1997) and client by attendees of a mental health service (Lloyd, King, 
Bassett eta/., 2001 )]. In this thesis, the term patient will be used specifically to refer to 
individuals who are unwell and receiving medical treatment (Zanni and Wick, 2001 ). On 
the other hand, the term consumer will be used more broadly to refer to all who use 
goods or services (Zanni and Wick, 2001 ), in this case provided by health 
professionals. Thus, patients who are unwell and receiving medical treatment are also 
considered as consumers. 
The CMI Study formed part of a larger study funded by the Commonwealth Department 
of Health and Aged Care and a report has previously been submitted to the funding 
body (Aslani, Koo and Krass, 2001 ). This study was approved by the Human Research 
Ethics Committee of the University of Sydney. 
The WMI Study Phase 1 and WMI Study Phase 2 were approved by the Human 
Research Ethics Committees of the University of Sydney, StGeorge Hospital, Concord 
Hospital and St Vincent's Hospital. 
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ABSTRACT 
Background and aims 
Written medicine information (WMI) has been available in various forms since the 
1960s. Over the past few decades, spurred on by consumer needs and demands, WMI 
has evolved to form an important tool in consumer education. A plethora of studies 
have been dedicated to examining the readership, use and impact of WMI on 
consumers. In Australia, Consumer Medicine Information (CMI), a brand-specific, 
standardised form of WMI for consumers produced by the manufacturer, was 
introduced in the early 1990s. Despite the extensive research on the readership, use 
and impact of WMI internationally, there is a noticeable lack of contribution from 
Australia hence research was needed to determine the use and impact of CMI on 
Australian consumers. Such research will also advance the current understanding of 
consumers' needs and thus may inform the development of measures that will ensure 
optimal use of medicines to improve health outcomes for consumers. 
In contrast to the wealth of literature on the use and impact of WMI on consumers, little 
is known about the steps that precede a consumer using WMI, that is, the factors which 
influence a consumer's use of WMI, including the way they evaluate, read and seek 
WMI. Research in this area is worthwhile as research focussing on consumers' 
perceptions has the potential to inform and shape the future direction of health practice. 
Moreover, there is evidence that health information which is tailored to the patient is 
more effective than non-tailored information; however, for WMI to be tailored optimally, 
health professionals and researchers first need to understand the factors which 
influence the way a consumer uses information. 
To address these gaps in the literature, this research aimed to investigate the: 
• use of CMI and WMI by consumers 
• influence of consumer factors on consumers' reading and seeking of WMI 
• influence of consumer characteristics on consumers' evaluation and future use of 
CMI. 
Methods 
The research consisted of three studies. In the first study (CMI Study), a structured 
questionnaire was administered to 226 eligible consenting consumers from 17 
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randomly selected community pharmacies in metropolitan Sydney. The questionnaire 
consisting of five sections examined consumer's knowledge of CMI, current and past 
receipt of CMI, experiences when receiving CMI, readership and action taken after 
reading CMI, attitudes towards CMI and demographic characteristics. Most questions 
in the questionnaire consisted of multiple-choice closed-ended questions. Frequency 
distributions were examined for responses to all these questions. The items that were 
used to measure consumer attitudes towards CMI were developed to represent five 
constructs which appeared to be related to the use of CMI by consumers, based on 
data from an earlier focus group study. These were: readability and presentation (six 
items), perception of disease/condition (five items), role of carer (five items), health 
locus of control (six items) and experience of problems with medications in the past 
(five items). The construct validity and reliability of the "attitude toward CMI" scales 
were tested using exploratory factor analysis and Cronbach's alpha, respectively. 
The findings from the CMI Study informed the development of the questionnaire for the 
second study, the WMI Study Phase 1. The questionnaire consisted of six sections 
used to gather the following patient-related information: interest and likelihood in 
reading and seeking WMI and general use of CMI/WMI, perceptions of CMI 
(comprehension, perceived usefulness and design rating) and likelihood of using CMI 
in the future, health locus of control, coping style, health literacy, demographics and 
disease state. The questionnaire was administered to 479 patients from three 
rheumatology/pain clinics in teaching hospitals (n=217) and 40 community pharmacies 
(n=262). Logistic regression was used to examine the relationships between patient 
factors and interest in reading and seeking WMI. Multiple regression and path analysis 
were used to examine associations between patient characteristics and their evaluation 
and intended future use of CMI. 
The final study, the WMI Study Phase 2, comprised a series of follow-up semi-
structured telephone interviews with 39 respondents from the WMI Study Phase 1 to 
triangulate the data from the WMI Study Phase 1. Content thematic analysis was 
conducted on these data. 
Results 
In the CMI Study, consumers (n=226) had variable understanding of CMI and most 
commonly associated CMI with written information leaflets inside the medication box 
(n=142, 62.8%), a reflection of the main form of CMI available at the time of the study. 
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The majority reported receiving a CMI on the day of the interview (n=132, 58.4%) or in 
the past (n=184, 81.4%), mainly as a package insert, and without the involvement of a 
health professional. Consumers (n=214) also expressed preferences to receive CMI 
mainly from the doctor (n= 82, 41.4%), pharmacist (n=66, 33.3%) or both (n=48, 
24.2%) and mainly at the doctor's surgery before the prescription was finalised (n=65, 
32.8%) or at the pharmacy after the prescription is dispensed (n=60, 30.3%). Of those 
who responded to the question on past readership of CMI (n=153), 64% (n=98) 
reported reading the CMI to different extents. These resulted mainly in positive 
outcomes, nonetheless, some consumers reported that they had concerns or queries 
and the majority of these reported contacting a health professional. Factor analysis of 
the "attitude to CMI" section yielded 4 factors explaining 52.8% of the total variance. 
These were interpreted as: perception of disease condition [5 items, factor loadings 
0.63-0.82, Cronbach's alpha (a)=0.86], role of carer (4 items, factor loadings 0.50-0.85, 
a=0.85), health locus of control (3 items, factor loadings 0.58-0.78, a=0.67) and 
readability and presentation (3 items, factor loadings 0.51-0.68, a=0.59). 
In the WMI Study Phase 1 (n=479), the majority of patients expressed interest in 
reading WMI (n=336, 70.1%) but were not interested in seeking WMI (n=328, 68.5%). 
Most (n=398, 83.1%) were unaware of the definition of 'Consumer Medicine 
Information'. However, after a description of CMI was given, most participants (n=377, 
78.7%) reported having read a CMI for their own medication(s) and approximately a 
third (n=143, 29.9%) also read CMI for someone in their care. In terms of interest in 
reading WMI, patients who coped by taking in information [odds ratio (OR)= 2.23, 95% 
confidence interval (CI) 1.18-4.20] and patients who had adequate health literacy levels 
(OR=4.09, Cl 1.53-10.91) were more likely to be interested in reading WMI than their 
counterparts while blue-collar workers were less likely to be interested in reading WMI 
when compared to homemakers (OR 0.26, Cl 0.08-0.82). When it came to seeking 
WMI, those with a symptomatic condition (pain/rheumatology conditions) were more 
likely to be interested in seeking WMI compared to those with an asymptomatic 
condition (hypertension) (OR 1.83, Cl1.10-3.04), those with adequate health literacy 
levels were more likely to be interested in seeking WMI than those with inadequate 
health literacy levels (OR 4.22, Cl 1.49-11.98) and an increase in powerful other health 
locus of control scores predicted a decreased likelihood in seeking WMI (OR 0.94, Cl 
0.90-0.99). 
In terms of evaluation of CMI, compared to their counterparts, patients who spoke 
mainly English at home [beta coefficient (8)=0.30, Cl 0.08-0.52], those with at least 
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secondary education (8=0.24, Cl 0.02-0.46) and those with adequate health literacy 
levels (8=0.59, Cl 0.35-0.84) had a better comprehension of CMI. Patients who were 
older (8=0.25, Cl 0.02-0.48) and those on greater number of medications (8=0.04, Cl 
0.00-0.07) found CMI more useful. Compared to younger patients, older patients also 
scored the design aspects of CMI more favourably (8=0.09, Cl 0.04-0.14). Finally, 
patients with adequate health literacy levels expressed greater intention to use CMI in 
the future compared to those with inadequate health literacy levels (8=0.46, Cl 0.07-
0.85). In addition to health literacy levels, increasing comprehension (8=0.41, Cl 0.25-
0.58) and increasing perceived usefulness of CMI (8=0.32, Cl 0.17 -0.46) also 
positively influenced intended use of CMI. 
The majority of consumers in the WMI Study Phase 2 expressed interest in obtaining 
information about their prescription medications but varied in their proactiveness in 
seeking information, sources of information used and preference for verbal or written 
information. Most participants felt that health professionals played a crucial role in the 
provision of information to consumers and should be more proactive in offering 
information to consumers. In addition to providing more in-depth information on issues 
surrounding consumer use of WMI, the results from this study also served to 
triangulate the results obtained in the WMI Study Phase 1. The general level of interest 
in reading and seeking WMI exhibited by patients in both phases of the studies were 
found to be similar. The interview data also directly supported some of the factors 
influencing use of WMI identified in Phase 1 but not others. For the latter, the findings 
provided some insight into the complexities of some of these associations. 
Conclusions 
This research contributes to the current understanding in the area of WMI from the 
perspective of the consumer. Findings revealed that many consumers are interested in 
WMI, do read CMI and benefit from it. However, there are issues that still need to be 
addressed in order to optimise the use of CMI by consumers. The research has also 
identified several consumer factors which may influence the way consumers read, seek 
or evaluate WMI. These findings have highlighted the need to consider individual 
consumer factors to ensure that information about medicines is tailored to meet 
individual needs and preferences. The overall findings from this research have 
provided useful insights which may be utilised to inform the development of strategies 
to enhance consumers' medicines use and thus improve consumer health outcomes. 
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OUTLINE OF CHAPTERS 
Chapter 1 
This chapter provides an overview of the implementation of WMI in the United States, 
Europe and Australia, the rationale for WMI, the readership and use of WMI and its 
impact on consumers. Next, the chapter reviews the international literature that 
highlights potential factors which may influence the use of WMI by consumers. The 
chapter concludes with a summary of the research needs identified from the literature. 
Chapter 2 
Based on the findings in Chapter 1, this chapter provides the rationale, aims and 
objectives of the research project. It then provides an overview of the quantitative and 
qualitative research methods used in the studies. 
Chapter 3 
This chapter focuses on the CMI Study, a pilot questionnaire administered to a sample 
of consumers of prescription medicines recruited from community pharmacies. The 
objectives of this study were to determine consumers' awareness, knowledge, receipt 
and experience of CMI, to examine readership and impact of reading CMI and to 
explore consumer attitudes towards CMI. Following a description of the methods, the 
descriptive statistics for all sections are presented. The construct validity and reliability 
of the attitudinal items are assessed using factor analysis and Cronbach's alpha, 
respectively. The study results are then discussed. 
Chapter 4 
Informed by the findings from the CMI Study, this chapter focuses on the development 
and implementation of the WMI Study Phase 1, involving the administration of a 
questionnaire to patients with rheumatology/pain conditions from hospital clinics and 
patients with hypertension from community pharmacies. The objectives of this study 
were to determine patient's interest and likelihood in reading and seeking WMI, to 
determine patients" awareness, readership and use of CMI, and to investigate the 
influence of consumer factors on the way consumers read, seek and evaluate WMI. 
Logistic regression is used to examine the relationships between consumer factors and 
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interest in reading and seeking WMI. Multiple regression and path analysis are used to 
examine associations between consumer characteristics and their evaluation and 
intended future use of CMI. These findings are discussed at the end of the chapter. 
Chapter 5 
This chapter focuses on the WMI Study Phase 2, a follow-up telephone interview study 
with a sub-sample of respondents from the WMI Study Phase 1. The themes identified 
from the interviews are described, discussed and compared to the findings from the 
WMI Study Phase 1. This study also provides a further opportunity to gain in-depth 
information on the factors influencing patients' reading and seeking of WMI as well as 
to explore further issues surrounding the use of CMI and WMI in general. 
Chapter 6 
This chapter concludes the thesis by bringing together the three studies in the research 
project. The findings from these studies provide insights which may be used to inform 
the development of strategies to enhance consumers' medicines use. These insights 
and recommendations are discussed in terms of their potential implications on the 
development, dissemination and use of WMI. Following that, suggestions for future 
directions are raised, including research which targets both health professionals and 
consumers. 
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Ch 1- Background & Literature Review 
1 BACKGROUND AND LITERATURE REVIEW 
Written medicine information (WMI) intended for consumers of prescription medications 
has been a topic of international interest and debate since the 1960s. WMI refers to 
any form of printed information leaflet about medications intended for consumers. 
These range from simple one-page leaflets to more extensive brochures or texts (Buck, 
1998). 
In recent times, another source of 'virtual' written information about medicines has 
arisen through the birth of the internet. Internet-based medicine information is rapidly 
gaining popularity as it is considered an interactive and time-efficient source of up-to-
date information which can be accessed when required, in an anonymous and non-
threatening manner (Bessell, Silagy, Anderson eta/., 2002; Peterson-Clark, Aslani and 
Williams, 2004 ). Nonetheless, there are concerns that the information available on the 
internet is of variable quality and may be potentially harmful to an undiscerning 
consumer (Eysenbach, Powell, Kuss eta/., 2002). Moreover, despite its popularity, 
there are still many consumers who do not have ready access to internet-based 
information, for example, consumers who are older (Cameron, Marquis and Webster, 
2001; Tay, 2001 ), less educated (Taylor, 2002) or from poorer socio-economic 
backgrounds (Lawn, Bukachi and Xavier, 1998; Edejer, 2000; Taylor, 2002). 
For these reasons, traditional WMI which is much more tightly regulated and readily 
accessible will always have a pivotal role to play in educating consumers about their 
medicines. Notwithstanding, internet-based medicine information, which services a 
growing proportion of society, is increasing in importance and has attracted much 
research in recent years. The focus of this thesis and thus this literature review, 
however, is on traditional forms of WMI. To date, consumer-oriented research in the 
area of WMI has focussed mainly on the use and impact of WMI on consumers [e.g. 
Gotsch and Liguori (1982); George, Waters and Nicholas (1983); Johnson, Mitch, 
Sherwood eta/. (1986); Gibbs, Waters and George (1987, 1989a, b); Bandesha, 
Raynor and Teale (1996); Raynor and Knapp (2000)). Little is known, however, about 
the steps that precede a consumer using WMI, that is, the factors that influence the 
way consumers read, seek or evaluate WMI. 
In the first part of this chapter, an overview of the introduction of WMI in the United 
States (US), Europe and Australia will be provided, followed by the rationale for WMI, 
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an overview of studies examining the readership and use of WMI and its impact on 
consumers. The second part of this chapter will focus on studies that highlight potential 
factors which may influence the use of WMI by consumers. 
1.1 THE INTERNATIONAL SCENE 
1.1.1 The United States 
In the late 1960s, in response to consumer demands for more information about 
prescription medicines, the US Food and Drug Administration (FDA) proposed the 
introduction of patient package inserts (PPis) for certain classes of medications (such 
as oral contraceptives), specific medications (such as isoproterenol, isotretinoin and 
triazolam) and therapeutic devices (such as intrauterine contraceptive devices) 
(Johnson, Mitch, Sherwood eta/., 1986; Cariski, 1 g95; Steering Committee, 19g6a; 
Lyons and Rumore, 1 gg7). In 1 g79, the FDA proposed to extend PPis to include all 
prescription medications but this was opposed by health professionals and the 
pharmaceutical industry who contended that the proposal would: 
" ... encourage self-diagnosis and the transfer of prescription drug products 
among patients; produce adverse reactions in patients through suggestion; 
affect adversely the liability of drug manufacturers, physicians, and 
pharmacists; interfere with the patient-physician relationship; impose 
unnecessary burdens on manufacturers and pharmacists; and increase the cost 
of prescription drug products and health care in general" (p.400-401) 
(Nightingale, 1995). 
After considering these comments, in 1980, the FDA proposed a rule that would have 
required manufacturers to produce and distribute PPis for 10 medications or 
medication classes 1 (Nightingale, 1995; Steering Committee, 1996a). 
In 1982, the FDA decided to revoke the PPI program (Nightingale, 1995; Steering 
Committee, 1996a). This was in part based on assurances by pharmaceutical 
manufacturers, health professional associations and private-sector providers of WMI 
1 These medications or medication classes were ampicillin, benzodiazepines, cimetidine, 
clofibrate, digoxin, methoxsalen, propoxyphene, phenytoin, thiazide and warfarin (Nightingale, 
1995). 
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that the goals of providing consumers with information about prescription medications 
would be met more effectively and efficiently without regulation (Nightingale, 1995; 
FDA, 2005). 
The FDA proceeded to monitor the progress of these voluntary efforts and found that 
whilst distribution of WMI increased, the usefulness of the information was highly 
variable (FDA, 2005). Hence, in 1995, the FDA once again put forward another 
proposal, commonly known as the MedGuide proposal. This proposal set goals for the 
distribution of useful prescription medicine information to consumers and would have 
made it mandatory for manufacturers to provide medicine information for consumers 
(Norden berg, 1997). Whilst the concept of providing better information about 
prescription medicines to consumers was supported, there were disagreements with 
some of the plan's assumptions and opposition to some of the proposed organisational 
details included in the proposal (Steering Committee, 1996a; Thompson, 1996). 
In 1996, in conjunction with the passing of Public Law 104-180, the FDA's MedGuide 
proposal was put on hold to provide an opportunity for private sectors to develop a plan 
that would achieve similar goals as set out in the MedGuide proposal but be 
implemented on a voluntary rather than mandatory basis (Steering Committee, 1996a; 
Nordenberg, 1997). Public Law 104-180 mandated the formation of a committee of 
diverse interests to develop a long-range, comprehensive action plan to improve oral 
and written communication to consumers about their prescription medicines with the 
goal of distributing useful oral and written prescription information to 75% of individuals 
receiving new prescriptions by the year 2000 and 95% by the year 2006 (Anonymous, 
1996). 
Hence, the Steering Committee for the Collaborative Development of a Long-Range 
Action Plan for the Provision of Useful Prescription Medicine Information was formed. 
The Action Plan was required to address six specific issues: identify plan goals; assess 
effectiveness of current approaches used to provide oral and written prescription 
information to consumers; develop guidelines for providing effective oral and written 
prescription information; contain elements necessary to ensure transmittal of useful 
information to consumers; develop a mechanism to periodically assess the quality of 
information and how frequently it is provided to consumers; and provide for compliance 
with relevant State board regulations on medications (Steering Committee, 1996a). The 
action plan was accepted in 1997. 
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'Useful' prescription medicine information has since been referred to as Consumer 
Medication Information. Ongoing efforts spearheaded by various organisations are 
currently underway to meet the goals set for 2006. A FDA-commissioned study to 
assess the receipt and usefulness of Consumer Medication Information revealed that 
89% of consumers received written information about their prescription medications, 
usually in the form of computer-generated printouts. Whilst this figure surpassed the 
75% goal set for 2000, the overall usefulness of the information provided (based on the 
criteria suggested in the Action Plan) was approximately 50% (Svarstad and Mount, 
2001 ). Given this progress, the FDA is continuing to work with the private sector to 
improve the usefulness of Consumer Medication Information and meet the goal for 
2006 (FDA Office of Public Affairs, 2002). In May 2005, the FDA also released a draft 
document providing guidance for writing 'useful' Consumer Medication Information 
(FDA, 2005). 
Public Law 104-180 prohibited the FDA from taking further regulatory steps if private 
sector initiatives met the goals of the Action Plan within the specified time frames. 
Whilst the production of 'useful' Consumer Medication Information remained a 
voluntary initiative, Public Law 104- 180 did not preclude the FDA from using its 
existing authority to implement a mandatory program for a small number of medications 
which posed a "serious and significant public health concern requiring immediate 
distribution of FDA-approved patient medication information" (p.66378) (FDA, 1998). 
This FDA-approved patient medication information is known as Medication Guides. It 
exists for medications such as isotretinoin, serotonin selective reuptake inhibitors and 
non-steroidal anti-inflammatory drugs (NSAIDs). 
1.1.2 Europe 
In Europe, WMI has been available for consumers since 1977 (Whittet, 1977; White, 
1988). However, due to the considerable variation in content and format (Wilkes, 
1992), the European Economic Community published Council Directive 92/27/EEC 
(Council Directive, 1992) which required all medicines to be accompanied by a 
comprehensive information leaflet produced by the manufacturer of the medication 
(Biattmann, 1992; Vander Stichele and Bogaert, 1995; Dickinson, Raynor and Duman, 
2001 ). The main purpose of this Directive was to provide consumers of medications 
with full and comprehensible information so that medicines could be used safely and 
effectively (Patient Information Working Group, 2005). The content of the leaflets are 
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closely defined by regulations (Raynor, Savage, Knapp eta/., 2004 ). More specifically, 
these information leaflets must contain all the information in the Summary of Product 
Characteristics, but be written in language suitable for consumers (Dickinson, Raynor 
and Duman, 2001 ). In January 1999, the Directive came into full effect across the 
European Union including the UK following a five-year phasing-in period (Dickinson, 
Raynor and Duman, 2001 ). 
In conjunction with Council Directive 92/27/EEC, the European Commission published 
a set of guidelines on the readability of the leaflets (European Commission, 1998). For 
the first time, these guidelines also made recommendations on consumer testing of the 
leaflets based on the concept of diagnostic testing from Australia (see Section 1.1.3). In 
2004, changes to the European legislation introduced a new legal obligation to ensure 
that all Plls reflected the results of consultations with consumers who are the intended 
users of the information (Patient Information Working Group, 2005). This legislation 
was to be implemented across Europe by October 2005; the UK decided to implement 
it from 1 July 2005. 
In the UK, in 2004, the Committee on Safety of Medicines of the Medicines and 
Healthcare products Regulatory Agency (MHRA) established a Patient Information 
Working Group to provide advice on a strategy to improve the quality of PIL, propose 
criteria for assessing the quality of patient information and the process by the which the 
criteria will be monitored (Patient Information Working Group, 2005). In addition to this 
committee which focussed on the mandatory PIL, another collaboration was also set 
up. The Medicines Information Project (MIP), a collaborative partnership between 
various organisations including private and government bodies, aimed to provide 
information that will encourage and enable consumers to "make informed decisions 
about their own health, be more involved in treatment choices and make best use of 
their medicines" (Anonymous, 2003). This was to be achieved through the production 
of Medicine Guides which are intended to complement PIL and are designed to be 
available to the consumer before a medicine is prescribed (currently available online) 
(Anonymous, 2004 ). The MIP is an ongoing project and to date, Medicine Guides are 
available for three different conditions: epilepsy, influenza and cholesterol. 
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1.1.3 Australia 
In 1g91, a standardised format of WMI (known as Consumer Medicine Information or 
CMI 2) resulted from two recommendations of a report on drug evaluation in Australia 
(Baume, 1991 ). The incorporation of these recommendations into the Australian 
legislation (Therapeutic Goods Regulations 9A) led to a mandatory requirement for all 
new prescription medicines and existing prescription medicines with changes to their 
Product Information (PI) approved after 1 January 1993 to be accompanied by CMI 
(Therapeutic Goods Regulations, 1993a; Therapeutic Goods Regulations Amendment 
No. 364, 1994 ). It was intended that as of January 2002, all existing prescription 
medications would have a CMI (Baker, 1994 ). This date was subsequently revised to 
January 2003 (Wilmington, 2002). The requirements were further extended to require 
'pharmacist only' medications which were approved on or after 1 July 2005 to be 
accompanied by written information (Therapeutic Goods Regulations Amendment No. 
208, 1995). However, the focus of this thesis will be on CMI for prescription 
medications. 
The required content of CMI for prescription medicines is specified by Schedule 12 of 
the Therapeutic Goods Regulations (Therapeutic Goods Regulations, 1993b ). The CMI 
is required to be consistent with the medication's PI but be written in English and in 
language that is easily understood by consumers. It can be produced in three formats: 
computer printout, package insert or loose leaflet (Therapeutic Goods Regulations 
Amendment No. 364, 1994; Dowling, 1996). Computer printout CMI is usually available 
in prescribing/dispensing software or electronic drug references. It is printed by health 
professionals at the time of prescribing or dispensing and is currently the main form of 
CMI used. With the advent of the internet as a popular source of medicine information, 
computer printout CMI for many medicines is now also available via several different 
websites. The second format of CMI, package insert CMI, is located inside or around 
the medication box/bottle. This is currently being phased out and replaced by computer 
printout CMI as the latter is considered easier to update (D. Monk, personal 
communication, 2 November 2004). Lastly, loose leaflet CMI consists of a booklet, 
tear-off pad or loose leaflet supplied directly to health professionals for distribution by 
the manufacturers; this form of CMI is rarely used. 
2 Consumer Medicine Information (CMI) was originally known as Consumer Product Information 
(CPI). In 1997, the term CPI was changed to CMI to "promote better consumer awareness of 
CPI, as well as harmonising with New Zealand nomenclature" (p.445) (Anonymous, 1997). In 
this thesis, only the term CMI will be used. 
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Although the content of CMI is specified in the legislation, its design and presentation is 
not. In 1994, the Commonwealth Department of Health and Family Services funded the 
development of usability guidelines by the Communication Research Institute of 
Australia to assist producers of CMI to communicate information about medicines 
effectively in the CMI and also provided a method of testing CMI with consumers 
known as diagnostic testing (Dowden, Clear, Fogg eta/., 1996; Siess and Wiseman, 
1997). Diagnostic testing involves finding out what is wrong with a CMI through 
observing a consumer as he/she uses the CMI and asking questions to ascertain if the 
consumer can appropriately interpret and apply the information they have read (Siess 
and Wiseman, 1997). 
The Australian Pharmaceutical Manufacturers Association (now Medicines Australia) 
also established CMI consistency working groups to encourage consistency between 
CMI (Dowden, Clear, Fogg eta/., 1996). These working groups consisted of CMI 
writers from different pharmaceutical companies who collaborated to prepare a core 
CMI for a given therapeutic area (Shenfield and Tasker, 1997). 
In addition, in 1995, a Quality Assurance Reference Group (QARG) was established by 
the Pharmaceutical Health and Rational Use of Medicines (PHARM) 3 committee. The 
main role of QARG is to promote high quality and useful CMI, to oversee the work of 
the CMI consistency working groups and to consider matters related to the content and 
quality of CMI (Dowden, Clear, Fogg eta/., 1996). 
In 2001, the Medicines Information to Consumer (MIC) Program was implemented by 
the Pharmacy Guild of Australia as part of the Third Community Pharmacy Agreement 
(Benton, Snow and Parr, 2004 ). The MIC Program is a voluntary program that provides 
participating pharmacies with financial incentives to encourage them to use CMI in their 
daily practice (Koo and Aslani, 2004 ). In 2001, the first incentive consisted of a once-off 
payment to pharmacies wishing to be part of the program to assist pharmacies in 
upgrading their resources (e.g. purchasing printers) to enable them to provide CMI 
(Benton, Snow and Parr, 2004 ). From 2002 onwards, pharmacies were required to 
register in order to participate in the second phase of the program. This phase of the 
program provided an ongoing participation allowance for providing CMI. The ongoing 
3 PHARM is a multidisciplinary committee that provides expert advice to the Minister for Health 
and Ageing and the Department of Health and Ageing on strategies for quality use of medicines. 
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allowance is dependent on prescription volume4 and is paid bi-monthly in arrears 
(Benton. Snow and Parr. 2004 ). 
1.1.4 Comparison of WMI between regions 
Overall, while there are some similarities in the history of WMI implementation between 
US. Europe and Australia. there are also distinct differences. A summary comparing 
WMI in these three regions is presented in Table 1.1 Comparison of current written 
medicine information for prescription medicines in US. Europe and Australia. Although 
there are differences in the way WMI has been implemented. a comparison of the 
contents of the resulting WMI revealed a high degree of similarity between the regions 
(Table 1.2). 
4 The ongoing allowance is calculated based on the number of claimable prescriptions 
dispensed by the pharmacy (10 cents per claimable prescription) in a two-month cycle (Benton, 
Snow and Parr. 2004). 
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Table 1.1 Comparison of current written medicine information for prescription medicines 
in US, Europe and Australia 
us Europe Australia 
Name 'Useful' prescription Patient Consumer Medicine 
medicine information information Information (CMI) 
(recently Consumer leaflet (PIL) 
Medication Information)* 
Associated Public Law 104-180 Council Therapeutic Goods 
legislation (year) (1996) Directive Regulations 9A (1993) 
92/27/EEC 
(1992) 
Implementation Voluntary but subject to Compulsory Compulsory by 
evaluation in 2006 by January January 2003 
1999 
Form Not specified but usually Package Computer printout, 
computer printout insert package insert or 
loose leaflet 
Producer Private organisations Manufacturer Manufacturer/sponsor 
Legislation/ Action Plan for the Council Schedule 12 and 13 
guidelines Provision of Useful Directive of Therapeutic Goods 
specifying content Prescription Medicine 92/27/EEC Regulations 
Information 
• This refers to the main form of WMI available in the US. As mentioned in Section 1.1.1. 
mandatory FDA-approved Medication Guides exist for a small number of medications (not 
covered in the table). 
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Table 1.2 Comparison of specified contents for WMI in US, Europe and Australia 
Content• us Europe Australia 
Identification (trade name, Yes Yes Yes 
generic name, ingredients 
and excipients) 
lndication(s) and how it works Indications only Yes Yes 
Precautions before using Yes (includes the Yes (includes Yes (includes 
medicine (contraindications, FDA black box risk of habit forming 
precautions, interactions, warning and risk of withdrawal) potential) 
special warnings) tolerance/ 
dependence) 
How to use medication Yes Yes Yes 
properly 
Unwanted effects Yes Yes Yes 
Overdose and missed doses Yes Yes Yes 
Storage Yes Special Yes 
storage only 
Reference to expiry date Yes Yes Yes 
Sponsor/producer Yes Yes Yes 
Date of last revision Yes Yes Yes 
Statement encouraging Yes Only in Yes 
discussion with health relation to 
professional/ where to go for unwanted 
further information effects 
*Content based on Steering Committee (1996a); Council Directive (1992); Therapeutic Goods 
Regulations (1993b). 
NB: Categories of information may not be listed in the same order in actual WMI. 
1.2 RATIONALE FOR WMI 
The existing literature suggests several reasons for the provision of WMI. Firstly, there 
is a burgeoning desire and demand for information by consumers (Ley and Morris, 
1984), ranging from information about their conditions [e.g. Kay and Punchak (1988); 
Beisecker and Beisecker (1990); Trewin and Veitch (2003)] to their medicines [e.g. 
Baksaas and Helgeland (1980); Kay and Punchak (1988); Gibbs, Waters and George 
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(1989a); Livingstone, Pugh, Winn eta/. (1996)] and general health matters (Lam and 
Krass, 1995). Furthermore, some consumers have expressed a specific preference for 
written information as it could be read at their own pace and referred to when 
necessary (Kay and Punchak, 1988). 
Secondly, in line with the increasing demand for information by consumers, in the past 
few decades, there has been a gradual shift from a paternalistic approach by health 
professionals to a growing recognition of consumer autonomy with respect to their 
health care (Graham and Kwok, 1995; Mills and Sullivan, 1999). Hence, there has 
been an emphasis on consumer rights to evidence-based, consumer-centred, accurate 
and balanced information to empower consumers to actively participate in their own 
health care (Coulter, 1998; Dixon-Woods, 2001; Benton, Snow and Parr, 2004) and to 
ensure that consumers are equipped to use their medications correctly and optimally 
(Anonymous, 1993; Benton, Snow and Parr, 2004). 
Thirdly, written information serves to reinforce verbal information (Schommer and 
Wiederholt, 1994) as consumers may simply forget the verbal information they have 
been given (Ley and Morris, 1984; Weinman, 1990; Wilson, Robinson, Blenkinsopp et 
a/., 1992) or struggle to understand what they are being told (Ley and Morris, 1984; 
Weinman, 1990). These situations could be further aggravated by possible anxiety at 
the time of the consultation or the use of medical jargon by health professionals (Katz, 
1991; Benton, Snow and Parr, 2004 ). In other cases, written information serves to 
supplement inadequate verbal information provided by health professionals (Coulter, 
1998) due to insufficient time, lack of knowledge or an underestimation of consumers' 
desire and ability to cope with information (Coulter, Entwistle and Gilbert, 1999; 
Benton, Snow and Parr, 2004 ). 
Last but by no means least, the rationale for the provision of WMI lies in its positive 
impact on consumers' medication-taking behaviours (Section 1.4 ). 
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1.3 READERSHIP AND USE OF WMI 
1.3.1 Readership and use of WMI in Europe and the United States 
The majority of studies reporting the readership and use of WMI have originated from 
Europe and the US and involved specific classes of medications [e.g. Morris, Mazis 
and Gordon (1977); Van haecht, Vander Stichele, De Backer et at. (1991); Sleath and 
Wurst (2002)) or prescription medicines in general [e.g. Bandesha, Raynor and Teale 
(1996); Raynor and Knapp (2000)]. 
Despite the apparent demand for drug information by consumers, the readership5 of 
WMI varies considerably. Studies examining the readership of package insert WMI 
without any prompting or encouragement from health professionals reported readership 
ranging from 40% (Raynor and Knapp, 2000) to 89% (Vander Stichele, Van haecht, 
Braem et at., 1991 ). When a health professional was involved in handing out WMI, 
readership as high as 81% (consumer's attention not drawn to WMI) (Gibbs, Waters 
and George, 1989a) and 94% (consumer's attention drawn to PPI and encouraged to 
read it) (Gotsch and Liguori, 1982) have been reported. 
Within this range, some consumers read the information thoroughly or partially and 
others have delegated the task to a relative (Vander Stichele, Van haecht, Braem et at., 
1991; Bandesha, Raynor and Teale, 1996; Knapp and Raynor, 1999). Sections of 
particular interest or deemed the most useful included information on the indication, 
potential side effects, dosage and administration of the drug (Dodds and King, 1989; 
Amery and Van Winkel, 1995; Graham and Kwok, 1995; Berry, Michas, Gillie et at., 
1997; Dickinson, Raynor and Duman, 2001; Raynor, Savage, Knapp et at., 2004 ). The 
impact of reading WMI on consumers is reported in Section 1.4. 
5 Some studies in the literature have reported readership as the proportion of consumers who 
reported reading WMI out of the total number of consumers who were aware of the presence of 
WMI. As this artificially inflates readership in most cases, in this review, readership is defined as 
the proportion of consumers who reported reading WMI out of the total study population. 
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1.3.2 Readership and use of CMI in Australia 
The introduction of WMI occurred much later in Australia compared to Europe and the 
US. Nonetheless, more than a decade after its introduction in 1993, very few published 
studies have examined the readership and use of CMI by Australian consumers. 
A qualitative study in late 1993 found that consumers favoured the concept of CMI and 
reported that they were likely to read the information in detail (Emjay Research 
Consultants Ply Ltd, 1994 ). Several impacts were also observed as a result of 
consumers reading CMI (Section 1.4 ). Although informative, the study involved only a 
small sample, only three different prescription medications and was not conducted in a 
natural setting. 
Another qualitative study focusing on older people conducted in 1998 found that the 
majority of consumers had previously received some form of WMI together with the 
medication (Lawrence and Fogg, 1998). Most consumers believed CMI would be useful 
to them but expressed a preference to receive WMI in their own language. Once again, 
due to the qualitative nature of the study and the inclusion of only older consumers, the 
results cannot be generalised. 
In addition to these qualitative studies, a report on quality use of medicines noted that 
approximately 36% in 1996 and 57% in 1999 of consumers reported reading WMI. 
However, not all of these consumers received CMI specifically (Quality Use of 
Medicines and Pharmacy Research Centre- University of South Australia, 2001 ). 
More recently, in 2003 and 2004, two surveys6 examining the readership and use of 
CMI by consumers were conducted as part of a larger study to evaluate the MIC 
Program (Benton, Snow and Parr, 2004) (see Section 1.1.3). The first survey was a 
self-completion questionnaire distributed by pharmacists in July to October 2003 to 30 
consecutive consumers to whom they provided a CMI (total n=200) (Benton, Snow and 
Parr, 2004). From this survey, 94% of consumers (total n=200) reported receiving a 
computer printout CMI from the pharmacist. This high rate is most likely attributed to 
the fact that the provision of CMI was part of the inclusion criteria. In light of this, it is 
6 It is important to note that these surveys were conducted after the completion of CMI Study 
described in this research project (see Chapter 3). 
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interesting to note that not all consumers who were given a CM I by the pharmacist 
were actually aware of it. 
The second survey consisted of two telephone surveys to a representative sample of 
1000 Australian consumers (in July 2003 and April 2004) (Benton, Snow and Parr, 
2004). This survey may provide a more realistic receipt rate with 24% (July 2003) and 
29% (April 2004) of consumers remembering receiving a computer printout CMI from 
their pharmacist some time in the past. However, as some consumers may have 
forgotten that they had been given a computer printout in the past, this rate may be an 
underestimation of the actual number of consumers who received a computer printout. 
Moreover, as the study only took into account computer printout CMI printed by the 
pharmacist, these receipt rates are also likely to be an underestimation of the actual 
number of consumers who have access to CMI in its different forms. 
In the self-completion questionnaire, 78% of consumers read CMI in detail and 13% 
read it briefly (Benton, Snow and Parr, 2004 ). This level of readership falls within the 
range observed in the international literature. However, several factors may have 
influenced this result. Firstly, it is important to bear in mind that this study only 
examined the readership of computer printout CMI and not package insert CMI (which 
was excluded from the study}. Secondly, it is not sure whether pharmacists 
encouraged consumers to read CMI when handing it to them. Lastly, the response rate 
for the self-completion questionnaire was only 16% which may have biased the results. 
Nonetheless, several impacts were observed from this study. These are discussed in 
Section 1.4 along with the international literature. 
1.4 IMPACT OF WMI 
A plethora of studies conducted mainly in the US and Europe have examined the 
impact of various types of WMI on consumers' knowledge, understanding, satisfaction 
and compliance with their medications as well as their experience of side effects 
following exposure to WMI. This area has also been covered in several reviews [e.g. 
Morris and Halperin (1979); Ley and Morris (1984); Arthur (1995); Raynor (1998a)]. 
Hence, the aim of the following sections is to provide a summary of some of the 
observed impacts of WMI from the literature. 
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1.4.1 Knowledge and understanding of medications 
In many studies, provision of WMI has been associated with an increase in consumers' 
knowledge and understanding in some aspects of their medications (Gotsch and 
Liguori, 1982; George, Waters and Nicholas, 1983; Wiederholt and Kotzan, 1983; 
Johnson, Mitch, Sherwood eta/., 1986; Punchak and Kay, 1988; Gibbs, Waters and 
George, 1989a, b, 1990; Jones, Clarbour and Erskine, 1990; Baker, Roberts, 
Newcombe eta/., 1991; Connolly and McGlynn, 1992; Peura, Klaukka, Hannula eta/., 
1993; Emjay Research Consultants Pty Ltd, 1994; Smith and Whitfield, 1995; 
Bandesha, Raynor and Teale, 1996; Little, Griffin, Kelly eta/., 1998; Benton, Snow and 
Parr, 2004; AI-Saffar, Deshmukh, Carteret a/., 2005). Although most of these studies 
measured short-term changes in knowledge post-exposure to WMI {in the order of 
days [e.g. Johnson, Mitch, Sherwood eta/. (1986); Peura, Klaukka, Hannula eta/. 
(1993)], or weeks [e.g. Punchak and Kay (1988); Baker, Roberts, Newcombe eta/. 
(1991)]}, in other studies, the increased knowledge of consumers who received WMI 
compared to those who did not was still evident several months to a year later [e.g. 
Gibbs, Waters and George (1989a); Little, Griffin, Kelly eta/. (1998)]. 
It is noteworthy, however, that improvement in knowledge was not obtained on all 
measures but only on specific aspects [e.g. name of medication (George, Waters and 
Nicholas, 1983), how to take the medication (Gibbs, Waters and George, 1989a, b) and 
side effects (George, Waters and Nicholas, 1983; Gibbs, Waters and George, 1989a, 
b)]. Furthermore, Morris (1989) expressed scepticism about the generalisability of 
some of these studies as they frequently occurred in settings where consumers were 
aware that they would be questioned about the WMI that they had received. 
1.4.2 Consumer satisfaction 
In terms of consumer satisfaction, the results to date are mixed. In some studies, 
consumers who received WMI expressed greater satisfaction with the amount of 
information that they had received (Gotsch and Liguori, 1982; Baker, Roberts, 
Newcombe eta/., 1991) and with the efforts of the pharmacist (Benton, Snow and Parr, 
2004) compared to those who did not receive WMI. According to Ley and Llewelyn 
(1995), this finding is not surprising as most consumers want to know as much as 
possible hence informed consumers are more satisfied consumers. 
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In other studies, satisfaction seemed to be influenced by different factors, such as the 
class of medication being studied or the way satisfaction was defined. As an example, 
in a series of related studies (George, Waters and Nicholas, 1983; Gibbs, Waters and 
George, 1989a, b, 1990), consumers who received WMI were found to be consistently 
more satisfied with the amount of information received (compared to those who did not 
receive WMI) for most classes of medications (NSAIDs, diuretics, benzodiazepines, 13-
blockers, bronchodilators) except penicillin. For the latter, increased satisfaction was 
observed in two studies (George, Waters and Nicholas, 1983; Gibbs, Waters and 
George, 1990) but not in another (Gibbs, Waters and George, 1989b}. Furthermore, as 
illustrated by one of these studies (George, Waters and Nicholas, 1983), greater 
satisfaction with the amount of information received did not equate to a significant 
increase in satisfaction with the treatment as a whole. 
A study investigating consumer satisfaction with pharmacist consultation found that 
consumers who received longer consultations and were provided with more types of 
information about their medication were more likely to report that their expectations 
were exceeded and were more satisfied with the service (Schommer, 1995). Hence, 
the author suggested that a key to consumer satisfaction may be exceeding consumer 
expectations (Schommer, 1995). To this end, WMI may serve as a tool to be used 
during counselling to improve consumer satisfaction. 
1.4.3 Adherence to therapy 
A study undertaken to compare the views of pharmacists, general practitioners and 
consumers on the value of WMI indicated that most participants believed that the 
medication was more likely to be taken as directed as a result of reading the WMI 
(Mottram and Reed, 1997). However, that particular scenario was hypothetical and to 
date, results from studies examining the impact of WMI on actual adherence to 
therapies are somewhat mixed. 
For example, one study reported a significant increase in compliance among 
consumers receiving WMI for an antidepressant compared to those who did not (Myers 
and Calvert, 1984 ). However, the authors postulated that it was the attention given to 
the consumer whilst providing WMI rather than the nature of the information (negative 
information about side effects or positive information about benefits of therapy) which 
positively influenced compliance. Recently, another study involving antidepressant 
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WMI concluded that consumers receiving a PIL were more likely to be adherent to their 
medication regimen, especially when the PIL was accompanied by verbal counselling 
by the pharmacist (AI-Saffar, Deshmukh, Carteret at., 2005). On the other hand, 
another study demonstrated that antidepressant WMI had no effect on adherence, 
either on its own or in combination with counselling (Peveler, George, Kinmonth et at., 
1999). 
The contrasting findings of the above studies mirror general findings in the literature 
whereby provision of WMI improved compliance in some studies but not in others 
(Morris and Halperin, 1979; Ley and Morris, 1984; Haynes, McKibbon and Kanani, 
1996). Morris and Halperin (1979) observed that WMI can be effective in improving 
adherence to short-term therapies but has not been shown to be sufficient on its own to 
improve adherence to long-term therapies. 
As WMI is only one of many factors which could influence consumer adherence 
(Stockwell Morris and Schulz, 1993), the results of these studies suggest that WMI may 
be best used in conjunction with other strategies to promote adherence. Moreover, 
health professionals need to be mindful that non-adherence is not necessarily the fault 
of the consumer and in some cases can serve the interest of the consumer (Raynor, 
1992a). 
1.4.4 Perception and experience of side effects 
Traditionally, some health professionals have been opposed to the provision of WMI to 
consumers, claiming that they cause anxiety or side effects by suggestion, and thus 
decrease adherence to therapy (Vander Stichele, De Potter, Vyncke et at., 1996; 
Morris, 1989; Vander Stichele, Van haecht, Braem et at., 1991 ). In more recent studies, 
some health professionals, including pharmacists, doctors and nurses still subscribed 
to this view (Bowles, 1996; Aslani, 1999; Krag, Nielsen, Norup et at., 2004). 
Some studies have shown that WMI caused anxiety in some consumers [e.g. Dodds 
and King (1989); Gibbs, Waters and George (1989a); Bandesha, Raynor and Teale 
(1996); Livingstone, Pugh, Winn et al. (1996); Benton, Snow and Parr (2004)] and in 
some cases led to increased reporting of side effects (Gibbs, Waters and George, 
1989a, b; Van haecht, Vander Stichele, De Backer et at., 1991) and cessation of 
therapy (some in consultation with health professionals) (Gibbs, Waters and George, 
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1989a; Bandesha, Raynor and Teale, 1996; Benton, Snow and Parr, 2004). However, 
other studies have observed that the provision of WMI increased knowledge and 
awareness of potential side effects [e.g. Morris and Kanouse (1982); Gibbs, Waters 
and George (1989b); Baker, Roberts, Newcombe eta/. (1991); Peura, Klaukka, 
Hannula eta/. (1993); Emjay Research Consultants Pty Ltd (1994)], did not cause 
increased anxiety (Quaid, Faden, Vining eta/., 1990; Oldman, Moore and Collins, 
2004) or did not cause spurious reporting of side effects (George, Waters and 
Nicholas, 1983; Myers and Calvert, 1984 ). In fact, one study reported that those who 
read WMI were less worried about side effects (Baker, Roberts, Newcombe eta/., 
1991 ). 
A study by Morris and Kanouse (1982) demonstrated that informing consumers about 
side effects did not significantly increase reporting of these side effects but informed 
consumers were more likely to attribute any experienced effect to the medication. 
Thus, WMI seemed to increase the saliency of the medication as a possible cause of 
bothersome experiences (Morris, 1989). 
Even if the provision of WMI did increase spontaneous reporting of side effects, several 
authors argue that this is not necessarily a bad outcome (Van haecht, Vander Stichele, 
De Backer eta/., 1991; Harada, Yamazaki and Fujimura, 1999). Some consumers may 
have been spuriously alarmed but for others, the concern may well be justified hence 
educating consumers about side effects through WMI can lead to early detection of 
medication-related adverse events. 
1.5 FACTORS INFLUENCING USE OF WMI 
Potential factors influencing the use of WMI by consumers were identified from studies 
published in English since the late 1970s. Due to the lack of design consistency and 
the heterogeneity of the studies, subjective assessment rather than criteria-based 
objective review was used. Moreover, due to the paucity of literature directly 
investigating the factors influencing the use of WMI, related literature on written 
information for various disease states was also considered. The quality, relevance and 
limitations of each study were taken into consideration prior to its inclusion in the 
following sections. 
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Although it is reasonable to assume that some factors overlap, that is, are inter-related, 
for ease of discussion, these factors have been arbitrarily divided into three broad 
areas: written information document factors, environmental factors and consumer 
factors. Written information document factors refer to the properties of the actual 
physical printed document. Environmental factors are associated with the context in 
which WMI is given or used and consumer factors relate to factors associated with the 
user of the WMI. These factors are discussed in turn below. 
1.5.1 Written information document factors 
Of the three areas, written information factors, which refer to factors associated with 
the actual written information document, has attracted the most attention in the past 
decades. These include the readability and presentation of the documents. 
1.5.1.1 Readability 
The readability of written information for general health information or disease states 
(Meade and Byrd, 1989; Davis, Crouch, Wills eta/., 1990; Sarma, Alpers, Prideaux et 
a/., 1995; Beaver and Luker, 1997; Smith, Gooding, Brown eta/., 1998; Fitzmaurice 
and Adams, 2000; Payne, Large, Jarrett eta/., 2000; Foster and Rhoney, 2002; 
Wallace and Lennon, 2004) as well as medications (Basara and Juergens, 1994; 
Bradley, Singleton and Po, 1994; Baker, 1997; Buck, 1998; Kenny, Wilson, Purves et 
a/., 1998; Wong, 1999; Estrada, Martin Hryniewicz, Barnes Higgs eta/., 2000; Rolland, 
2000; Buchbinder, Hall, Grant eta/., 2001; Foster and Rhoney, 2002; Rees, Ford and 
Sheard, 2003; Kirksey, Harper, Thompson eta/., 2004) has been extensively studied. 
Readability assessment usually involves the use of readability formulae. The use of 
these formulae in the health care setting has previously been reviewed (Ley and Florio, 
1996) and commonly used readability formulae include Flesch Reading Ease Formula, 
Simplified Measure of Gobbledygook (SMOG) Grading, Fry Readability Graph, 
Gunning's Fog Index and Flesch-Kincaid Formula (Arthur, 1995; Ley and Florio, 1996; 
Buck, 1998). 
Although most formulae have acceptable validity and reliability (Ley, 1998), they are 
still criticised for their limitations. They take into account sentence length, syllable count 
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or vocabulary index (Kenny, Wilson, Purves eta/., 1998) but are insensitive to word 
order or grammatical complexity (Kitching, 1990; Dickinson, Raynor and Duman, 
2001 ). Moreover, they fail to consider a consumer's personal interest, motivation, 
background or circumstance and can overestimate the difficulty of a passage (Kitching, 
1990; Bradley, Singleton and Po, 1994; Mayberry and Mayberry, 1996; Kenny, Wilson, 
Purves eta/., 1998). Variation in readability estimates for the same text using different 
formulae has also been reported (Krass, Svarstad and Bultman, 2002). 
Despite these limitations, readability formulae have their place in the evaluation of 
written information for consumers. Focussing on WMI in particular, WMI in general has 
been criticised for being written at a level beyond the comprehension of most of the 
population (Basara and Juergens, 1994; Bradley, Singleton and Po, 1994; Baker, 1997; 
Estrada, Martin Hryniewicz, Barnes Higgs eta/., 2000; Buchbinder, Hall, Grant eta/., 
2001; Foster and Rhoney, 2002) although exceptions do exist (Wong, 1999). Ideally, 
written information should aim for a reading level of Grade 5 or 6 (Griffin, McKenna and 
Tooth, 2003). 
Whilst many studies have explored the readability of WMI and found it to be too high, 
far fewer studies have actually explored the relationship between high reading levels 
and consumer's use of WMI. However, a study involving warfarin WMI found that 
consumers receiving fifth-grade WMI exhibited significantly better comprehension and 
had more favourable perceptions of the material than those receiving tenth-grade WMI 
(Eaton and Holloway, 1980). Hence, the readability of WMI may potentially influence a 
consumer's use of it. 
Although the concerns with readability of WMI is warranted, WMI which is too simple 
can also be problematic in that it could be perceived as dull, patronising, or lacking in 
authority (Kenny, Wilson, Purves eta/., 1998; Coulter, 1998). Hence, in the production 
of WMI, the needs of the audience as well as the aims of the educators should be 
considered and balanced (Mayberry and Mayberry, 1996). 
1.5.1.2 Presentation 
In addition to their poor readability, consumers have also reported that WMI are 
unattractive (Koo, Krass and Aslani, 2002), difficult to read due to small print (Vander 
Stichele, Van haecht, Braem eta/., 1991; Bandesha, Raynor and Teale, 1996; 
Bernardini, Ambrogi, Fardella et al., 2001; Koo, Krass and Aslani, 2002) and are 
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printed on paper with poor quality (Bandesha, Raynor and Teale, 1996). In line with 
these consumer complaints, Raynor and Knapp (2000) observed that "multi-folded 
leaflets on thin paper which contain large amounts of information, in small type and 
inserted in the pack may not invest the importance in the leaflet that professionals 
assume" (p.269). 
In an attempt to improve the presentation of WMI, guidelines to facilitate the production 
of well-presented WMI have been produced. These include government-initiated 
guidelines (Steering Committee, 1996b; Siess and Wiseman, 1997; Patient Information 
Working Group, 2005) as well as guidelines developed by individual groups of 
researchers (Kitching, 1990; Raynor, 1992b; Bandesha, Raynor and Teale, 1996; 
Doak, Doak and Root, 1996; Baker, 1997). Favourable design characteristics from 
these guidelines are summarised in Table 1.3. 
Table 1.3 Features of well-presented written medicine information 
Characteristic 
Font Typeface 
Style 
Size 
Desirable features• 
Serif 
No italics 
Bold for emphasis 
Mix of upper and lower cases 
10-point (equivalent to "x" height of 1.5mm) 
12-point (equivalent to "x" height of 2mm) if for older persons 
(some authors recommend this as the norm) 
Numerals Arabic (e.g. 1, 2, 3) rather than Roman (e.g. I, II, Ill) 
Colour Increase appeal and enhance text but NOT distract from it 
lllustrationslpictograms (See text) 
Paper Contrast 
Quality 
Format Bullets 
Good contrast between text and paper 
75-90 g/m2 
Use encouraged 
Heading Clear and outstanding with a mix of upper and lower cases 
Justification Justified on left but not right 
Line length 30-50 characters and spaces 
Paragraph Indent first line 
White space Ample (so leaflet does not appear over-crowded with text) 
*based on Ley and Morris (1984); Kitching (1990); Raynor (1992b); Bandesha eta/. (1996); 
Doak eta/. (1996); Mayeaux eta/. (1996); Steering Committee (1996b); Baker (1997); Ley 
(1997); Giorgianni (1998); Raynor (1998a); Hartley (2000); Andrus and Roth (2002); Krass et al. 
(2002); Griffin eta/. (2003); Patient Information Working Group (2005). 
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Although in most respects there is strong agreement on what constitutes favourable 
design characteristics, there is still some uncertainty surrounding the use of illustrations 
or pictograms in WMI. They have been used to increase understanding, to increase the 
appeal of written materials (Ley, 1997) and to help consumers in finding the information 
needed (Bernardini, Ambrogi, Perioli eta/., 2000). However, there are concerns that 
illustrations may distract from the text (Ley and Morris, 1984 ), interfere with processing 
of the text (Dolinsky, Gross, Deutsch eta/., 1 983) or that pictograms may be 
misinterpreted (Amery and Van Winkel, 1995; Hanson and Hartzema, 1995). In relation 
to the latter, age (Knapp, Raynor, Jebar eta/., 2005), educational level (Dowse and 
Ehlers, 2003; Knapp, Raynor, Jebar eta/., 2005), cultural background (Kassam, 
Vaillancourt and Collins, 2004 ), repeated exposure to pictograms (Dowse and Ehlers, 
2001; Knapp, Raynor, Jebar eta/., 2005) and size of pictograms (Knapp, Raynor, 
Jebar eta/., 2005) have been shown to be factors that influenced interpretation of 
pictograms. Hence, illustrations or pictograms should be used only if the meaning of 
the symbol is unambiguous as perceived by the intended users (Patient Information 
Working Group, 2005), when it is relevant to the text (Dolinsky, Gross, Deutsch eta/., 
1983; Ley and Morris, 1984) and when it can save on the amount of text (Ley and 
Morris, 1984 ). 
Several authors have incorporated the guidelines presented in Table 1.3 in the 
development of instruments (partly or wholly) to evaluate the design characteristics of 
written information in general or WMI specifically. These include the 'User-Friendliness 
Index' (Basara and Juergens, 1994 ), 'Suitability Assessment of Material' (SAM) (Doak, 
Doak and Root, 1996), 'Baker Able Leaflet Design' (Baker, 1997), 'Readability 
Assessment Instrument' (described by Kirkpatrick and Mohler (1999) and Singh 
(2000)], 'Medication Information Design Assessment Scale' (MIDAS) (Krass, Svarstad 
and Bultman, 2002) and a 'checklist' developed by Paul eta/. (1997). Although all were 
based on recommended guidelines and have been through some form of testing, with 
the exception of SAM, MIDAS and the 'checklist' (Doak, Doak and Root, 1996; Paul, 
Redman and Sanson-Fisher, 1997; Krass, Svarstad and Bultman, 2002), the rest of 
these instruments do not appear to be validated. Moreover, some of the tools only 
examine one aspect of WMI (e.g. Readability Assessment Instrument (Kirkpatrick and 
Mohler, 1999)] or lack consumer involvement (e.g. Baker Able Leaflet Design (Baker, 
1997)]. 
It is striking, however, that research on improving the usability of WMI, using various 
methods listed above, has involved limited input from consumers. The Communication 
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Research Institute of Australia pioneered the concept of diagnostic testing in the 
preparation of CMI in 1994 (Siess and Wiseman, 1997). This concept involved testing 
the usability of CMI as perceived by its intended audience, the consumer. According to 
Siess and Wiseman (1997), this is crucial: 
"CM/s are complex documents and each one is different. Consumers are also 
complex and highly varied. Put CMI and consumers together and the resulting 
dialogue can at times be surprising and unpredictable. No known principles of 
good writing or design, nor any readability scores or measures of reading age 
have been found which can predict how successfully a document will be used" 
(p.73). 
The involvement of consumers in the development and evaluation of written 
information has also been advocated by other researchers (Bernier, 1993; 
Blenkinsopp, Bashford, Dickinson eta/., 1998; Coulter, Entwistle and Gilbert, 1999; 
Griffin, McKenna and Tooth, 2003) with the hope of improving the usefulness of WMI 
from the consumer's perspective. In March 2004, the European Union was one of the 
first to officially mandate consumer involvement in the development of WMI. Changes 
to the legislation introduced a new legal obligation to ensure that all PILs reflected the 
results of consultations with consumers who are the intended users of the information 
(Patient Information Working Group, 2005). 
In conjunction with this push for consumer involvement, the Consumer Information 
Rating Scale (CIRF) (Krass, Svarstad and Bultman, 2002) was developed and 
validated as a direct method for evaluating consumer's perceptions of WMI, including 
its comprehensibility, utility and design quality. Compared to existing leaflets, leaflets 
that were specifically designed to meet favourable design criteria were rated more 
positively by consumers not only in terms of design quality but also in terms of 
perceived usefulness and comprehensibility, thus highlighting the potential influence 
and importance of design quality in affecting consumer's perception of the information 
(Krass, Svarstad and Bultman, 2002). 
The value of consumer testing as a convenient and powerful tool to identify potential 
problems with WM I and improve consumers' ability to use the information has similarly 
been demonstrated in other studies (Dickinson, Raynor and Duman, 2001 ). 
Interestingly though, in a study by Gustafsson eta/. (2003), expert and consumer 
evaluations of WMI were found to concur hence the authors conceded that the expert 
evaluations alone would suffice. 
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Overall, it is acknowledged that the presentation of WMI is an important aspect of WMI 
and much effort has been put into improving this aspect of WMI. Whilst some studies 
have shown that improved presentation improved the perceived usability (Krass, 
Svarstad and Bultman, 2002) or perceived effectiveness of the material (Paul, Redman 
and Sanson-Fisher, 1997), other studies have shown that improving design 
characteristics of written information did not increase its effectiveness (Davis, 
Fredrickson, Arnold eta/., 1998; Paul, Redman and Sanson-Fisher, 2003). Thus, more 
research is required to explore the associations between improved presentation of WMI 
and consumers' use. 
1.5.2 Environmental factors 
Environmental factors are associated with the context in which WMI is given or used, 
and includes timing and delivery of information as well as the consumer's experience of 
the whole encounter. Lenz (1984) proposed that the physical and interpersonal 
environment may facilitate or impede a consumer's search for information. For 
example, privacy and comfortable familiar surroundings can facilitate information 
exchange between consumer and health professional whilst a cooperative and 
supportive atmosphere can facilitate a consumer's search for information from health 
professionals (Lenz, 1984 ). 
1.5.2.1 Timing of information 
No study has considered timing of information, be it verbal or written, as an 
independent variable affecting the use of disease state or medicine information. 
However, several studies suggest that timing can play a crucial role in the use of this 
information. For example, patients with arthritis were noted to go through a phase of 
'desperation' where any information given about the disease seemed to further revolt 
and depress patients (Donovan, Blake and Fleming, 1989). Similarly, in another study, 
it was mentioned that consumers could often be physically or emotionally incapacitated 
or exhausted at the time they are prescribed or when they are collecting a prescription 
medication hence are unable to fully take in the verbal information provided by health 
professionals at that stage (Benton, Snow and Parr, 2004 ). 
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Several other studies have looked at consumer preference in terms of timing of 
information. In one study, cancer patients preferred to receive general information 
about chemotherapy around the time of the treatment decision and specific information 
just prior to treatment (Bulow, Brindle, McConnell eta/., 1998). In another study, some 
patients preferred to receive colposcopy information leaflets at the time they were 
informed of their abnormal smear results rather than with the colposcopy clinic letter 
that was received later (Byrom, Dunn, Hughes eta/., 2003). The authors postulated 
that the greatest fear for women awaiting colposcopy was the fear of cancer; hence to 
reduce anxiety, this fear had to be alleviated at the earliest possible stage, that is, 
when the patient was first informed of the abnormal smear results (Byrom, Dunn, 
Hughes eta/., 2003). 
More recently, D'haese eta/. (2000) examined the importance of the time sequence of 
information provision on the anxiety and satisfaction of patients undergoing 
radiotherapy. Two types of information were given. The first was a booklet describing 
radiotherapy procedures and the sensations that the patients would experience; the 
second was selected teaching sheets with specific information related to side effects of 
the treatment site. The group who received the information stepwise (booklet at first 
appointment; teaching sheets three to four days into treatment) were found to be 
significantly less anxious and more satisfied with their treatment compared to the group 
who received both kinds of information at the first appointment. Two possible 
explanations were given for the greater anxiety observed in the latter group: firstly, they 
received information about side effects four to fourteen days before treatment but had 
no opportunity to verify the information with a health professional prior to treatment; 
secondly, knowledge of side effects prior to treatment may actually increase anxiety 
(D'haese, Vinh-Hung, Bijdekerke eta/., 2000). 
In a preliminary qualitative study to investigate the factors affecting the use of CMI in 
Australia, some consumers commented that CMI could be redundant if given when 
they were feeling physically unwell or emotionally upset (Koo, Krass and Aslani, 2002). 
In addition to this psychological consideration, some consumers wanted to receive CMI 
from their doctor during their consultation time so that they could make informed 
decisions about whether or not to take certain medications. Others wanted to receive it 
in the pharmacy before they paid for their medications to prevent wasting money on 
ineffective or unsuitable medications. 
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The above studies highlight the importance of correct timing in imparting information to 
consumers. Providing information when the consumer is preoccupied with other issues 
may be counterproductive (Donovan, Blake and Fleming, 1989) and may reflect 
insensitivity on the health professional's part. Moreover, consumers may want 
information at specific times to facilitate their own decision-making process or prevent 
unnecessary expenditure (Koo, Krass and Aslani, 2002). 
1.5.2.2 Experience 
Consumer's experience can potentially influence their future actions. According to 
different models of health behaviour (e.g. Leventhal's self-regulatory model), after 
implementing a certain behaviour, consumers carry out an appraisal in which they 
evaluate how effective their behaviour has been, leading to a possible change in future 
action (James and Horne, 2000). 
Health professionals are reminded that the healthcare consumer is not a "blank sheet" 
(p.58) (Donovan, Blake and Fleming, 1989). Rather, they have complex sets of beliefs, 
drawn from their own and their families' experiences, which can influence their use of 
WMI. Consequently, a consumer who has a positive experience of using WMI is more 
likely to respond positively in the future when provided with WMI. This positive 
experience can be directly related to the usefulness of previous WMI (Stewart, Erikson, 
McHardy et at., 2000) or the worthwhile interaction with a health professional whilst 
receiving WMI. 
1.5.3 Consumer factors 
Notwithstanding the influence of written information factors and environmental factors, 
consumer factors arguably exert the most influence on the use of WMI by the individual 
consumer. Consumer factors can be divided into non-psychological factors which are 
relatively independent of the individual's personality (health literacy, disease state, role 
of caregiver and demographics) and psychological factors which are intrinsically related 
to the individual's psyche and disposition (health locus of control, coping style and 
Health Belief Model). 
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1.5.3.1 Health literacy 
According to the World Health Organisation (WHO), health literacy: 
"represents the cognitive and social skills which determine the motivation and 
ability of individuals to gain access to, understand and use information in ways 
which promote and maintain good health" (p.1 0) (Nutbeam, 1998). 
In contrast to this broad and all encompassing definition, in the literature on health 
information, a narrower and simpler definition has usually been adopted whereby 
health literacy has largely been examined as 'functional health literacy'. Functional 
health literacy has been defined as 'the ability to read, understand, and act on health 
information" (p.282) (Andrus and Roth, 2002). This is considered one of the most 
fundamental types of health literacy (Nutbeam, 2000). 
Thus, health literacy focuses on the reader of the information. This is in contrast to 
readability tests which focus on the reading material. The assumption underpinning the 
use of the latter is that the reader will have adequate functional health literacy to read 
and understand the information presented to them; however, it is known that this is not 
necessarily the case (Williams, Parker, Baker et at., 1995). Hence, in recent years, 
there has been a shift in interest from the reading material to the reader (Rudd, 
Moeykens and Colton, 2000). 
In conjunction with the rising interest in health literacy, various tools have been 
developed to assess the health literacy of consumers. These can be divided into word 
recognition tests and comprehension tests (Doak, Doak and Root, 1996; Davis, 
Michielutte, Askov eta/., 1998). The more commonly used word recognition tests in 
health care include the 'Rapid Estimate of Adult Literacy in Medicine' (REALM), the 
'Wide Range Achievement Test-Revised' (WRAT-R) and the 'Siosson Oral Reading 
Test-Revised' (SORT-R) (Davis, Michielutte, Askov eta/., 1998; Andrus and Roth, 
2002). The main limitation of these tests is that they do not test comprehension of 
written information (Andrus and Roth, 2002) and it is known that the ability to read does 
not imply the ability to understand what is being read (Doak, Doak and Root, 1996). 
Comprehension tests used in the health care setting include the 'Test of Functional 
Health Literacy in Adults' (TOFHLA) (Parker, Baker, Williams eta/., 1995; Baker, 
Williams, Parker eta/., 1999) and the Gloze technique (Taylor, 1953). The main 
features of these commonly used literacy tests are summarised in Table 1.4. 
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Table 1.4 Common literacy and health literacy tests 
Variable WRAT-R* SORT-R* 
Description Word recognition Word recognition test 
test 
Administration 3-5 (includes 5-1 0 
time (min) scoring time) 
Scoring Raw score of 1-57. Results converted to age 
converted to grade and grade equivalents 
equivalent 
Advantages Quick Quick 
Limitations Difficult test; does Does not test 
REALM* TOFHLA* Cloze Test 
Medical word recognition Functional health Passage with every fifth 
test literacy test deleted word to be replaced 
exactly 
2-7 (<2 for short version) 22 (7 for short 10-20 suggested 
(includes scoring time) version) 
Approximated grade Results interpreted Results interpreted as 
level: 3rd and below, 4th- as inadequate, material understood, material 
can be used but requires 
supplemental teaching or 
material unsuitable 
6th, 7th-8th, or 9th and marginal or 
above 
Quick; uses medical 
terminology; available in 
shortened form 
Does not test 
functional health 
literacy 
Measures Measures reading ability and 
functional health comprehension; can be 
literacy; available in adapted for any passage 
a shortened form 
and in Spanish 
Long version is 
not test 
comprehension 
comprehension; small print comprehension; assigns time consuming; 
Test needs to be constructed 
each time; time consuming; 
not recommended for 
consumers with 
and many items only grade-range timed test can be 
intimidating, not 
recommended for poor 
readers 
equivalents frustrating 
WRAT/REALM score below 
sixth grade 
NB: Table adapted from Andrus and Roth (2002) based on Taylor (1953); Davis eta/. (1993); Murphy eta/. (1993); Parker et at. (1995); Davis eta/. 
(1998); Baker eta/. (1999); Basset a/. (2003). 
•REALM =Rapid Estimate of Adult Literacy in Medicine; SORT-R = Slosson Oral Reading Test-Revised; TOFHLA =Test of Functional Health Literacy 
in Adults; WRAT =Wide Range Achievement Test; WRAT-R =Wide Range Achievement Test-Revised 
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Utilising these tools, a myriad of studies in the area of health literacy have been 
conducted and there is consensus that there is a link between poor literacy and poorer 
health in general. However, this link is unlikely to be directly causal in nature and the 
underlying mechanisms are yet to be fully elucidated (Weiss, Coyne, Michielutte eta/., 
1998). Nonetheless, poor health literacy levels have been shown to result in decreased 
use of preventive health services (Scott, Gazmararian, Williams eta/., 2002), 
decreased knowledge of chronic conditions (Williams, Baker, Honig eta/., 1998; 
Williams, Baker, Parker eta/., 1998; Gazmararian, Williams, Peel eta/., 2003), 
increased hospital visits (Gordon, Hampson and Capell, 2002) or hospitalization 
(Baker, Parker, Williams eta/., 1997), poorer patient-provider communication (Williams, 
Davis, Parker eta/., 2002; Schillinger, Bindman, Wang eta/., 2004), poorer physical 
health (Weiss, Hart, McGee eta/., 1992; Baker, Parker, Williams eta/., 1997) and 
poorer health outcomes (Schillinger, Grumbach, Piette eta/., 2002). In addition to these 
studies, there is a growing number of reviews on health literacy [e.g. Weiss, Hart and 
Pust (1991 ); Weiss, Coyne, Michielutte eta/. (1998); Parker, Williams, Weiss eta/. 
(1999); Rudd, Moeykens and Colton (2000); Tooth, Clark and McKenna (2000); Andrus 
and Roth (2002); Bernhardt and Cameron (2003)]. 
Based on what is known in the literature thus far, it is clear that the ability to identify 
consumers with potential health literacy problems is crucial if health professionals are 
to attempt to overcome the impact of poor health literacy. However, given that illiteracy 
is often associated with social stigma (Doak, Doak and Root, 1996; Brez and Taylor, 
1997) and shame (Baker, Parker, Williams eta/., 1996; Parikh, Parker, Nurss eta/., 
1996), poor health literacy is not always easily identifiable and many consumers with 
literacy problems may attempt to conceal this with excuses such as 'I forgot my 
glasses' (Doak, Doak and Root, 1996). Some health professionals also seem to have 
limited awareness of potential health literacy problems in some consumers (Praska, 
Kripalani, Seright eta/., 2005). 
Moreover, the administration of a literacy test in practice is not often practical or 
feasible. It is also known that the highest level of education is not a reliable indication of 
a consumer's actual reading abilities (Meade and Byrd, 1989; French and Larrabee, 
1999; Wilson, Racine, Tekieli eta/., 2003). Recently, several practical methods for 
identifying poor literacy have been advocated. Chew eta/. (2004) developed some 
screening questions and Praska eta/. (2005) suggested several consumer behaviours 
which may serve as clinical red flags for identifying consumers with poor literacy. Whilst 
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these methods offer an important advancement towards identifying poor literacy in 
practice, their use in a large population remains to be tested. 
Despite the plethora of research in the area of health literacy, there are limited studies 
examining the relationship between health literacy and use of written information, thus 
the implications of poor literacy on the use of written information by consumers are 
largely unknown. A positive relationship between reading ability and perceived 
usefulness of an educational pamphlet has previously been demonstrated (French and 
Larrabee, 1999). However, in another study, the majority of consumers, regardless of 
their reading ability, expressed a desire for information on their condition (Foltz and 
Sullivan, 1996) but the mode of desired information (verbal or written) was not 
explored. 
In addition, it is important to bear in mind that most of the current research on health 
information focuses only on functional health literacy, the most fundamental type of 
health literacy. Beyond this, there are two more sophisticated types of health literacy, 
namely interactive7 and critical 8 health literacy (Nutbeam, 2000). Notwithstanding, 
studies on functional health literacy form an essential foundation for understanding the 
implications of health literacy in consumer health care. Indeed, in the relatively 
unexplored area of WMI, further research using this fundamental concept of health 
literacy is required to elucidate the relationship between health literacy and use of WMI. 
Hence, this thesis will focus on functional health literacy. Once this is established, 
future research can then focus on more sophisticated types of health literacy. 
1.5.3.2 Disease state 
Many different aspects of symptoms including factors influencing perception of 
symptoms, response to symptoms and role of symptoms in health, disease and illness 
have been explored [e.g. Smith, Sharpe and Banahan Ill (1981); Harding and Taylor 
7 Interactive literacy is defined as "more advanced cognitive and literacy skills which, together 
with social skills, can be used to actively participate in everyday activities, to extract information 
and derive meaning from different forms of communication, and to apply new information to 
changing circumstances"(p.263-264) (Nutbeam, 2000). 
8 Critical literacy is defined as "more advanced cognitive skills which, together with social skills, 
can be applied to critically analyse information, and to use this information to exert greater 
control over life events and situation" (p.264) (Nutbeam. 2000). 
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(2002); Martin, Rothrock, Leventhal eta/. (2003); Cameron and Moss-Morris (2004 )]. 
Notwithstanding, there is a paucity of studies comparing the differences in health 
behaviour between consumers who do and do not experience symptoms as part of 
their disease or illness. However, studies examining the impact of symptoms (or lack 
there of) in certain diseases suggest that there may be differences in health behaviours 
between these two groups of consumers. These differences are further explored using 
the examples of rheumatology conditions which are symptomatic and hypertension 
which is asymptomatic. 
Rheumatology conditions such as rheumatoid arthritis, osteoarthritis, ankylosing 
spondylitis and fibromyalgia are characterised by pain and stiffness which can lead to 
various degrees of functional disability and incapacitation (Taal, Seydel, Rasker eta/., 
1993). These physical symptoms have been shown to greatly impact on patients' ability 
to perform daily tasks (Woolf, Zeidler, Haglund eta/., 2004), even in the early stages of 
disease (Griffith and Carr, 2001 ). In addition, the persistence of symptoms as well as 
pain and functional impairment were cited as an important impetus for seeking medical 
help (Sakalys, 1997). 
In contrast to rheumatology conditions, hypertension is primarily an asymptomatic 
disease (Galton, 1973; Grueninger, 1995)9. According to the WHO, '1wo of the most 
important factors contributing to poor adherence are undoubtedly the asymptomatic 
and lifelong nature of [hypertension]" (p.1 09) (World Health Organisation, 2003). The 
absence of symptoms (Viswanathan and Lambert, 2005) in conjunction with a lack of 
readily apparent perceived benefit of treatment (Feldman, Bacher, Campbell eta/., 
1998), potential side effects associated with treatment (Krousei-Wood, Thomas, 
Muntner eta/., 2004) and/or lack of symptoms on discontinuation of therapy (Hussar, 
1995) have resulted in the absence of a compelling reason for patients to persistently 
take their prescribed medications. 
Indeed, in one study, the main reason given by respondents for discontinuing their 
antihypertensive medications was that they felt fine without the medications 
(Cummings, Kirsch!, Binder eta/., 1982). The same reason was cited by some as their 
9 Although some patients assert that symptoms were associated with changes in blood pressure 
(Meyer, Leventhal and Guttman, 1985), results from other studies revealed that blood pressure 
was not reliably related to symptom reports or patient's predictions of blood pressure (Baumann 
and Leventhal, 1985). 
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reason for missing some doses of their antihypertensive medication(s). In another 
study, under a quarter of participants took their antihypertensive medications only when 
they were having symptoms, a worrying finding given that hypertension is primarily 
asymptomatic (Ogedegbe, Mancuso and Allegrante, 2004). In yet another study, the 
majority of patients on antihypertensive therapy were found to have a careless attitude 
towards hypertension, difficulties in accepting the diagnosis of hypertension and lack 
motivation for follow-up of hypertension (Jokisalo, Kumpusalo, Enlund eta/., 2001 ). 
The former was attributed to the common and asymptomatic nature of the disease, but 
the latter two observations could potentially be attributed to the same factors. 
Although no studies have investigated the impact of the presence or absence of 
symptoms on a consumer's interest and use of WMI, given the contrasting nature and 
thus contrasting patient reactions to the two different disease states, it is plausible that 
patients experiencing a symptomatic condition would be more interested in seeking 
and reading WMI compared to those with an asymptomatic condition. Such studies are 
important as they assist in understanding the information needs and attitudes towards 
information of consumers with different diseases. 
1.5.3.3 Role of caregiver 
Studies examining the information needs of caregivers as well as the medication-
related activities of caregivers provide some insight into the role of caregiver as a 
potential factor which may influence the use of WMI. 
In a study investigating the perceptions and knowledge of stroke among surviving 
patients and their caregivers, compared to patients, caregivers were more likely to want 
to know all the details about the patient's condition and treatment, to discuss the risk of 
recurrence, to receive written information and to join information groups (Wellwood, 
Dennis and Warlow, 1994 ). Also, where there was no receipt of information, 
significantly higher proportion of caregivers than patients would have liked to receive 
some information. 
Similarly, studies investigating the information needs of caregivers have consistently 
reported that caregivers have a desire for information, although the type of information 
desired varied depending on the type and stage of the care-recipient's illness 
(Fortinsky and Hathaway, 1990; lconomou, Vagenakis and Kalofonos, 2001; Fukui, 
2002; Kendall, Thompson and Could ridge, 2004 ). In one of these studies, caregivers 
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felt that their need for information was not recognised, and most had inadequate 
information at the time of diagnosis and had to seek ways of finding information 
themselves (Kendall, Thompson and Couldridge, 2004). 
When it came to medication-related activities, studies have noted that caregivers 
undertake a wide range of activities and responsibilities including providing advice on 
medicines (Gupta, Smith and Francis, 2002), gathering information from health 
professionals and relaying information, selectively in some cases, to care recipients 
(Francis, Smith, Gray eta/., 2002). Some of these studies highlight that caregivers do 
not receive adequate information regarding their care recipient's medications (Mallet 
and King, 1993; Ranelli and Aversa, 1994; Goldstein and Rivers, 1996), with the 
majority of caregivers in one study stating that they personally purchased reference 
books to obtain information regarding medications (Mallet and King, 1993). 
Interestingly, in contrast to this general observed need for information, Gray eta/. 
(2000) found that the majority of caregivers who did not receive any medicine 
information from the pharmacist perceived no need for any information despite 
experiencing problems with the medication-related activities. However, the reasons for 
this were not reported. 
With regards to WMI in particular, Koo eta/. (2002) observed that being a caregiver 
motivated some consumers to read CMI. Caregivers not only read CMI for their care 
recipient's medications to assist them in caring for their care recipient, but also for their 
own medications in order to be well and able to resume their duties as caregivers. 
From these studies, it is fair to postulate that caregivers are interested in obtaining 
information because they perceive a need for information in order to properly discharge 
their roles as caregivers. However, the relationship between a caregiver role and the 
use of WMI has yet to be clearly defined. 
1.5.3.4 Demographics 
Consumer demographic characteristics potentially influence many aspects of health 
care, ranging from preferences for participation in clinical decision making to attitude 
towards medications and information-seeking behaviour. Examples of the influence of 
some demographic variables on different aspects of health care are provided in Table 
1.5. 
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Table 1.5 Influence of demographic variables on aspects of health care 
Aspect of health care Demographic predictors 
Preference for passive Lower level of education, minority ethnic group, male and 
role in clinical decision older age (Benbassat, Pilpel and Tidhar, 1998) 
making 
Involvement in health- Younger age, higher socio-economic status and higher level 
enhancing behaviours of education (Conner and Norman, 1998) 
Information needs Age, gender and education influential in some studies but not 
in others (Mills and Sullivan, 1999) 
Negative attitude Younger age and female gender (lsacson and Bingefors, 
towards medications 2002) 
Propensity for seeking Younger age (Cassileth, Zupkis, Sutton-Smith eta/., 1980; 
health-related Lenz, 1984; Hibbard and Weeks, 1987; Czaja, Manfredi and 
information Price, 2003), higher socio-economic status (Lenz, 1984 ), 
higher level of education (Cassileth, Zupkis, Sutton-Smith et 
a/., 1980; Hibbard and Weeks, 1987), female gender (Lenz, 
1984; Hibbard and Weeks, 1987; Rakowski, Assaf, Lefebvre 
eta/., 1990) 
Awareness of health 
leaflets 
Use of health leaflets 
Younger age (Jesson, Pocock, Jepson el a/., 1994) 
Older age, female gender and higher level of education 
(Jesson, Pocock, Jepson eta/., 1994) 
In the area of WMI, observations regarding consumer demographics are inconclusive. 
Whilst no studies have directly investigated the relationship between consumer 
demographics and use of WMI, several observations have been made. Van haecht et 
a/. (1991) observed a positive relationship between education level and readership of 
both technical inserts and PPis but found no association between gender and 
readership. However, in a related study, the reverse was true; women were shown to 
read the inserts more often than men but no associations were found between 
education level and readership (Vander Stichele, Van haecht, Braem eta/., 1991 ). 
Several observations have also been made linking consumer demographics to 
preference for written or verbal medicine information. In one study, it was found that 
females and younger consumers were significantly more interested in receiving WMI 
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compared to males and older consumers (Dodds and King, 1989). In contrast, Harvey 
and Plumridge (1991) found no significant age or gender differences in terms of 
preference for written or verbal medicine information. In two other studies, consumers 
with lower levels of education expressed a preference for verbal instead of written 
medicine information (Culbertson, Arthur, Rhodes et at., 1988; Sleath and Wurst, 
2002). 
Hence it seems that consumer demographics may be associated with use of WM I but 
the exact nature of the associations is yet to be clarified. 
1.5.3.5 Health locus of control 
One of the most widely explored concepts spanning many areas of psychology is the 
locus of control concept introduced by Rotter in 1966 (Furnham and Steele, 1993). 
Since its introduction, a myriad of locus of control scales have been developed by 
different researchers, however, the most well-researched and widely used health-
specific locus of control scale is the Multidimensional Health Locus of Control (MHLC) 
(Furnham and Steele, 1993). The MHLC scales relate the degree to which individuals 
attribute their personal health outcomes to themselves [internal health locus of control 
(HLC)], to others (powerful other HLC) or to chance, luck or fate (chance HLC) 
(Wallston and Wallston, 1978b ). 
In the literature, HLC theory has mainly been used to predict preventive health 
behaviours where it is postulated that individuals with internal HLC are more likely to 
engage in health promoting activities (Shaw, 1999). In general, to date, the overall 
results from these studies have been inconclusive (McClelland and Rees, 2000; Shaw, 
1999) and the predictive relationship is still weak. Internal HLC has been found to 
positively influence health behaviours including cancer screening and adherence to 
medical treatment in some studies (Bundek, Marks and Richardson, 1993; Molassiotis, 
Nahas-Lopez, Chung et at., 2002; Norman, Bennett, Smith eta/., 1998; Stanton, 1987) 
but not in others (Abbott, Dodd and Webb, 1996; Holm, Frank and Curtin, 1999). 
Similarly, when it comes to the use of information, the results are mixed. There is some 
evidence to suggest that consumers with internal HLC had better knowledge of their 
conditions, were more inquisitive and less easily satisfied with the information given 
and were more active in their pursuit for information (Wallston and Wallston, 1978a; 
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Wallston and Wallston, 1982; Lenz, 1984 ), however, other studies failed to replicate 
these positive results (Wallston and Wallston, 1982). 
Given this, the role of HLC in the use of WMI is still undefined. One study found that 
some consumers felt that they should be personally in control of their own well being, 
suggesting that they may have had internal HLC. Conversely, others were happy to 
trust their doctors or pharmacists and expressed no desire to read WMI (Koo, Krass 
and Aslani, 2002). These findings may suggest a relationship between HLC and the 
use ofWMI. 
1.5.3.6 Coping style 
Coping is described as one of the stages in Leventhal's self-regulatory model of illness 
behaviour whereby a patient decides on a coping procedure based on his/her 
perception of the problem (James and Horne, 2000). The use of information has been 
shown to have positive effects on the psychological coping outcomes of the 
consumers, as exemplified in a study examining the effect of preparatory information 
prior to hip replacement surgery (Gammon and Mulholland, 1996). 
However, whilst some consumers cope by becoming actively involved in their treatment 
and avidly seek information, others cope by actively avoiding information (Humphrey, 
Littlewood and Kamps, 1992; van der Molen, 1999). Hence, the former would welcome 
information but the latter may find it distressing (Weinman, 1990). This is supported by 
the findings from a series of in-depth interviews with cancer patients where it was found 
that maintaining hope was an indispensable part of coping with cancer (Leyden. 
Boulton, Moynihan eta/., 2000). To maintain hope, some patients avidly searched for 
information, but others consciously limited their search for information, avoided new 
information, or enlisted the help of others to screen new information for them. 
When threatened with an aversive event such as illness, Miller eta/. (1988) proposed 
that individuals coped with the information available by either 'monitoring' or 'blunting'. 
Monitors actively seek out information and are more vigilant about cues in their 
surrounding where as blunters prefer to avoid information and signals from their 
surroundings (Elf and Wikblad, 2001 ). A study involving patient consultation with a 
physician found that high monitors desired more information about the cause of their 
medical problem, how healthy they were generally, how they could prevent future 
health problems and possible side effects of medication (Miller, Brody and Summerton, 
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1 988). However, when it came to making a decision about their own care, high 
monitors desired a less active role than low monitors. Hence, information-seeking was 
initiated not for decision-making purposes but for coping purposes. Similarly, in a 
review, cancer patients characterised by a monitoring coping style desired more 
voluminous information which is thought to help them attach appropriate meaning to 
their experience and enable them to 'work through' their conditions (Miller, 1995). 
If coping by means of information can be extended to the use of WMI, it is likely that 
consumers who cope by seeking information would welcome it but the converse may 
also be true. It is therefore important to cater for both types of consumers, providing 
information at a level and depth appropriate for each consumer and ensuring that their 
information needs are addressed. 
1.5.3.7 Health Belief Model 
According to the Health Belief Model (HBM), health behaviour is adopted if individuals 
regard themselves as susceptible to a condition which they perceive to be serious, if 
they believe their actions will reduce either the susceptibility to or severity of the 
condition, and if the perceived benefits of their actions outweigh the perceived barriers 
to performing the action (Rosenstock, 1991 ). 
The HBM has been utilised in studies looking at various health behaviours, from 
immunisation and practice of breast self examinations to compliance with medication 
regimens (Rosenstock, 1991 ). To date, the literature yields mixed results in terms of 
the usefulness of the HBM in predicting health behaviours. For example, in one study 
on osteoporosis, HBM appeared to provide a plausible model for the decision to use 
newer antiresorptive medications but not hormone therapies for the treatment of 
osteoporosis (Cline, Farley, Hansen eta/., 2005). In other studies, HBM was successful 
in predicting non-compliance to prescription medications (Fincham and Wertheimer, 
1985), complication prevention behaviours in Type 2 diabetes (Tan, 2004) and partially 
successful in predicting mammography behaviour (Holm, Frank and Curtin, 1999), but 
failed in predicting skin cancer prevention practices (Marlenga, 1995) or folic acid 
consumption to prevent neural tube defects (Quillin, Silberg, Board eta/., 2000) 
Although not a health behaviour per se, the use of information may be potentially 
influenced by the different variables described in the HBM. No studies have been 
conducted in this particular area, however, in a qualitative study examining the use of 
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CMI by consumers (Koo, Krass and Aslani, 2002), many participants agreed that they 
were more likely to read CMI if the medication was for a condition that was perceived 
(by the consumer) to be severe such as glaucoma as opposed to a less serious 
condition such as a common infection. 
However, in another study examining information-seeking behaviour in breast cancer 
chemotherapy patients, information-seeking was found to be negatively related to the 
severity of the cancer (Hopkins, 1986). A review by Benbassat eta/. (1998) reported a 
similar trend, whereby patients with more severe disease (hypothetical, cancer and 
non-cancer) preferred a more passive role in their doctor-patient relationship. The 
contradiction between these results and the observations by Koo eta/. (2002) warrants 
further investigation. Nonetheless, it is valid to postulate that severity of disease can 
affect an individual's information use. 
Besides perceived severity, perceived benefits and perceived barriers as described in 
the HBM can also potentially influence the use of WMI. Benefits of reading WMI can 
range from better understanding of therapy to better awareness of potential side 
effects; barriers can range from comprehension difficulties to lack of access or 
relevance of WMI and is covered in other sections of this review. Other potential 
barriers such as poor provider-consumer relationship, education level and consumer 
attitudes have also been identified from the literature (Melnyk, 1988). 
1.6 SUMMARY AND CONCLUSION 
Over the past few decades, spurred on by consumer needs and demands, WMI has 
evolved to form an important tool in consumer education. A plethora of studies have 
been dedicated to examining the readership, use and impact of WMI on consumers. 
From these efforts, it is known that consumers do read WMI. Moreover, WMI has been 
shown to have both positive and negative impacts. 
Despite this wealth of literature, most of these studies have originated from Europe and 
the US and there is a noticeable lack of contribution to the literature from Australia. As 
mentioned in Section 1.3.2, to date, the few studies examining the use of CMI in 
Australia have been small-scale (Emjay Research Consultants Ply Ltd, 1994; 
Lawrence and Fogg, 1998), not conducted in a natural setting (Emjay Research 
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Consultants Pty Ltd, 1994 ), focussed only on certain medications (Emjay Research 
Consultants Pty Ltd, 1994) or certain groups in the population (Lawrence and Fogg, 
1998); in some cases, there was also ambiguity as to whether the document being 
studied was actually CMI or some other form of WMI (Lawrence and Fogg, 1998; 
Quality Use of Medicines and Pharmacy Research Centre- University of South 
Australia, 2001 ). 
From this, it is clear that there is a need for further research to examine the use and 
impact of CMI on consumers. In order to provide a realistic view on what is going on in 
practice, this research also needs to be conducted in a natural setting, include different 
groups in the population and have a broad coverage of all prescription medications that 
are available. 
The recent study by Benton eta/. (2004) offered an improvement from the previous 
studies in terms of sample size and sampling frame. Nonetheless, several limitations 
were evident in the study, some of which may be associated with the fact that this 
study was designed with the aim of evaluating the MIC Program and not to examine 
the use of CMI by consumers per se. The main limitations with the self-completion 
questionnaire study conducted as part of the main study were its poor response rate, 
its exclusion of all forms of CMI except computer printout CMI and lastly, its inflated 
CMI receipt and readership rate that is not reflective of a real-life scenario as the 
provision of a computer printout CMI was a prerequisite to handing out a questionnaire. 
Notwithstanding the insights provided by this recent study, there remains a need for 
research which focuses on the use of CMI by consumers. 
In addition to filling a research gap, more importantly, research which focuses on the 
use of CMI by consumers has wider implications. As part of the National Strategy for 
quality use of medicines, CMI has been emphasised as a means to facilitate 
dissemination and uptake of objective information about medications (Commonwealth 
of Australia, 2002b). As users of medications, consumers are considered one of the 
key partners in developing and implementing initiatives to achieve quality use of 
medicines (Commonwealth of Australia, 2002a). Hence, research focussing on 
consumer perspectives of CMI will serve to advance current understanding of 
consumers' needs. This can then inform the development of measures that will ensure 
optima·l use of medicines to improve health outcomes for consumers. 
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Along with the need to know how consumers use WMI, there is the need to understand 
the factors which may influence the way consumers use WMI. This is worthwhile for 
several reasons. Firstly, as mentioned above, consumers' perceptions are crucial and 
valuable as they have the potential to inform and shape future direction of health 
practice. 
Secondly, there is evidence in the general health information literature to show that 
health information which is tailored to the consumer is more effective than non-tailored 
information (Skinner, Siegfried, Kegler eta/., 1993; Bental, Cawsey and Jones, 1999; 
Dijkstra and De Vries, 1999). This health information was tailored according to different 
consumer characteristics including health beliefs, stages of change and current health 
practices (e.g. dietary intake, smoking status) (Campbell, DeVellis, Strecher et at., 
1994; Skinner, Strecher and Hospers, 1994; Strecher, Kreuter, Den Boer eta/., 1994; 
Kreuter and Strecher, 1996). Based on these observations, understanding consumers' 
perceptions and tailoring WMI to suit consumer needs may serve to enhance 
consumers' experience of information use and allow them to gain maximum benefit 
from their WMI. By doing so, consumers will be well-informed and empowered to make 
decisions regarding their medicines. However, to date, the level of sophistication 
alluded to above has yet to be attained in the arena of WMI. There is some evidence of 
attempts at personal ising computer-generated WMI based on basic consumer 
information such as demographics and medication history (Raynor, 1998b; Davidse 
and Nieuwhof, 2003). Nonetheless, by and large, the standardised forms of WMI are 
not amenable to such individualisation partly due to the stringent legal requirements 
dictating the contents of these documents. Moreover, for WMI to be tailored optimally, 
health professionals and researchers first need an appreciation for the factors which 
influence the way a consumer uses information. 
Internationally, there is a paucity of research that has been conducted to examine the 
factors which potentially influence consumer's use of WMI. This is in stark contrast to 
the area examining consumer's use of WMI which is relatively well-established 
internationally, perhaps with the exception of Australia. 
By comparison, the written information factors, namely readability and presentation, are 
probably the rnost well-researched factors. Nonetheless, as mentioned in the literature 
review (Section 1.5.1.1 ), rnany studies have critiqued the readability of WMI but few 
have actually explored the relationship between high reading levels and a consumer's 
use of WMI. Similarly, in terms of presentation (Section 1.5.1.2), not many studies have 
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examined the relationship between this factor and consumer's use of WMI, and those 
that have done so have yielded conflicting results. Moreover, consumer involvement in 
the design and evaluation is now recognised as an important part of the development 
process of WMI, but once again, no studies have been conducted to determine any 
factors which may affect a consumer's evaluation of the material. 
No studies have been conducted in the area of WMI to examine the environmental or 
consumer factors potentially influencing the use of WMI. Several relationships have 
been suggested or observed in some studies; however, these have been exploratory in 
nature and are yet to be properly tested [e.g. timing, role of caregiver, HLC, HBM by 
Koo et at. (2002)] or have not taken into account possible confounding variables [e.g. 
demographics in Culbertson, Arthur, Rhodes et at. (1988); Dodds and King (1989); 
Harvey and Plumridge (1991); Van haecht, Vander Stichele, De Backer et at. (1991); 
Vander Stichele, Van haecht, Braem et at. (1991); Sleath and Wurst (2002)]. 
As described in the literature review, the wider literature offers some insight into these 
potential factors and provides a good background for future research. However, the 
applicability of these findings to the area of WMI is unknown. For example, many of the 
studies were from the cancer setting, and it is likely that there will be differences in the 
approach towards cancer-related information versus WMI in general. In light of this, 
research which specifically examines the influence of different factors on the use of 
WMI will make an important contribution to the development of strategies to improve 
the use of medicines and thus health outcomes. 
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2 AIMS AND GENERAL METHODS 
2.1 INTRODUCTION 
A review of the research in the area of WMI has revealed several important issues for 
further research. Firstly, there was a need for Australian research which examines 
consumer's readership and use of CMI as well as its impact on consumers. Secondly, 
the review highlights the lack of research examining the influence of different factors on 
consumers' use of WMI. 
In light of these needs, a research project consisting of three studies was designed to 
address some of the gaps observed in the literature. The aims of the overall research 
project are presented in Section 2.2.1 and the objectives for each of the studies are 
presented in Section 2.2.2. 
Although many potential factors were identified from the literature, patient factors 
arguably exert the most influence on a consumer's use of WMI, hence the project 
focussed on some of the patient factors covered in the review (Section 1.5.3). 
Furthermore, a decision was also made to explore specific aspects of consumers' 'use' 
of WMI, namely their readership of WMI, their search for WMI and their evaluation of 
WMI. 
2.2 RESEARCH PROJECT AIMS AND STUDY OBJECTIVES 
2.2.1 Research project aims 
In light of the issues identified in the literature, the aims of the research project were: 
• To investigate the use of CMI and WMI by consumers 
• To investigate the influence of consumer characteristics on consumers' evaluation 
and future use of CMI 
• To investigate the influence of consumer factors on consumers' reading and 
seeking of WMI 
In order to achieve these aims, the research project consisted of three studies: 
• Use of Consumer Medicine Information- pilot study (CMI Study) 
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• Factors influencing use of written medicine information- Phase 1 survey (WMI 
Study Phase 1) 
• Factors influencing use of written medicine information- Phase 2 follow-up 
interviews (WMI Study Phase 2) 
The objectives corresponding to each of these studies are listed below. 
2.2.2 Study objectives 
2.2.2.1 CMI Study 
The objectives of the CMI Study were: 
• To determine consumers' awareness and knowledge of CMI 
• To determine consumers' receipt and experience when receiving CMI 
• To examine consumers' readership and impact of reading CMI 
• To explore consumers' attitudes and opinions towards CMI 
2.2.2.2 WMI Study Phase 1 
The objectives of the WMI Study Phase 1 were: 
• To determine patients' interest and likelihood in reading and seeking WMI 
• To determine awareness, readership and use of CMI 
• To investigate the relationship between patient factors and patients' reading and 
seeking of WMI 
• To investigate the influence of patient characteristics on patients' evaluation and 
intended use of CMI 
• To determine the impact of patient CMI evaluation on their intended use of CMI 
2.2.2.3 WMI Study Phase 2 
The objectives of the WMI Study Phase 2 were: 
• To triangulate the results of the WMI Study Phase 1 by comparing patient 
responses from the WMI Study Phase 1 and Phase 2 
• To gain more in-depth information on factors influencing patients' reading and 
seeking of WMI 
• To explore further issues surrounding the use of CMI and WMI in general 
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2.3 OVERVIEW OF THE RESEARCH METHODS 
2.3.1 Quantitative and qualitative approaches 
In this research, both quantitative and qualitative methods have been used. 
Quantitative approaches are typically associated with enumeration and the 
establishment of relationship between variables whilst qualitative approaches focus on 
concepts and categories, but not their incidence or frequency (Brannen, 1995). Despite 
the ongoing debate over the relative merits of quantitative and qualitative methods, 
researchers have endeavoured to combine both approaches in an attempt to gain the 
advantages of both methods without compromising their differences (Grbich, 1999). 
Combining these approaches is an example of methodological triangulation, which 
refers to the use of a variety of methods to collect and interpret the same data (Arksey 
and Knight, 1999; Neuman, 2003). In this context, triangulation serves to provide 
confirmation and/or completeness of data (Arksey and Knight, 1999). 
More specifically, quantitative research conducted before qualitative research allows 
for suitable participants to be selected for the latter phase (Bryman, 2004 ). Conducted 
before a quantitative study, qualitative research facilitates quantitative research by 
generating hypotheses that could be tested in a systematic way (Bryman, 2004). It also 
assists in the planning of the content of the questionnaire and the design of the 
questions (Morton-Williams, 1985). On the other hand, conducted after a quantitative 
study, qualitative research provides an opportunity for verification and broader 
exploration of the issues covered in the quantitative phase; it may also facilitate 
interpretation of observed relationships between variables (Morton-Williams, 1985; 
Aldridge and Levine, 2001; Bryman, 2004 ). 
An earlier qualitative study on CMI involving patients in focus groups (Koo, Krass and 
Aslani, 2002) 10 was the first in a series of studies involving patients and CMI. The 
results from the qualitative focus groups provided insight into issues which were then 
incorporated as part of a qualitative pilot survey (CMI Study) to investigate the use of 
CMI by patients (Chapter 3). The results from both the focus groups and the CMI Study 
informed the development of a larger quantitative survey (WMI Study Phase 1) 
examining not only the use of CMI and WMI by patients, but also factors that influence 
10 This study was conducted as an honours project in 2000 during the researcher's 
undergraduate degree and does not form part of this thesis. 
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this (Chapter 4). Finally, qualitative follow-up interviews (WMI Study Phase 2) followed 
the WMI Study Phase 1 to confirm and explore the obtained results (Chapter 5). These 
series of qualitative and quantitative studies are summarised in Figure 2.1. 
Figure 2.1 Combination of quantitative and qualitative methods 
Focus groups I I WMI Study Phase 2 I 
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> :;:::; 
(Koo, Krass and Aslani, 2002) (Telephone interviews) ~ ;!:::: 
~ 
:J 
---l---------t----~ 
> 
:;:::; 
ro 
CMI Study I I WMI Study Phase 1 I -~ 
• 
c 
1- ... ~ (Survey) ---~" ro ~- (Survey) ~, :J 
a 
2.3.2 Quantitative method 
A survey was chosen as the most appropriate method for addressing the study 
objectives in the CMI Study and WMI Study Phase 1. In health care research, surveys 
are commonly used to investigate attitudes, opinions or beliefs of participants 
concerning health-related issues, to study characteristics of samples or populations on 
health-related variables, to establish the proportion of participants who hold particular 
views, to describe association between variables and to collect information about the 
demographic characteristics of samples or populations (Polgar and Thomas, 2000; 
Smith, 2002). Moreover, interesting patterns may arise from data collected from a 
survey; these can form the basis for hypotheses testing (Polgar and Thomas, 2000). 
A structured questionnaire is commonly used to conduct large-scale surveys as it 
allows the researcher to achieve uniformity by asking set questions and recording the 
answers hence maximising reliability of the survey (Quine, 1998). The three main 
methods of collecting data using a structured questionnaire are self-completion 
questionnaire, face-to-face interview and telephone interview (Aldridge and Levine, 
2001 ). Face-to-face interviews were chosen for the studies in this research project 
primarily because they are not restricted by the participant's literacy level as the 
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questionnaire is administered by the researcher (Hawe, Degeling and Hall, 1990). This 
allowed a wider sample of patients to be interviewed. 
Moreover, in the WMI Study Phase 1, patient health literacy was assessed as a 
potential factor which influenced use of WMI (Section 4.2.1.2.5). Self-completion 
questionnaires would exclude participants with inadequate literacy levels whereas 
telephone interviews would not allow the administration of a literacy test. Hence in 
order to allow this potential factor to be tested, face-to-face interviews were deemed 
the most suitable for the WMI Study Phase 1. 
Face-to-face interviews also have the advantage of allowing the researcher to answer 
participant's questions, clarify misunderstandings, probe answers to open-ended 
questions and observe participant's non-verbal behaviour (Hawe, Degeling and Hall, 
1990; de Vaus, 2002). Due to this, face-to-face interviews pose the fewest constraints 
in terms of questionnaire construction and question design (de Vaus, 2002). There is 
also the potential for higher response rates especially for surveys of general 
populations (Czaja and Blair, 1996; de Vaus, 2002) as the researcher will have the 
opportunity to explain the importance of the survey and assure the participant of the 
confidentiality of his/her responses (Salant and Dillman, 1994 ). A researcher who is 
successful at establishing rapport with the participant will also encourage better quality 
answers from the respondents (Aldridge and Levine, 2001 ). 
Despite these advantages, face-to-face interviews are associated with several 
limitations. Firstly, compared to self-completion questionnaires and telephone 
interviews, face-to-face interviews incur the greatest cost per questionnaire in terms of 
money, time and personnel (Hawe, Degeling and Hall, 1990; Aldridge and Levine, 
2001 ). Secondly, although rapport with the participant can possibly elicit better quality 
responses from participants, the mere presence of a researcher can also cause 
participants to give socially desirable answers rather than true answers (Aldridge and 
Levine, 2001; de Vaus, 2002; Hoyle, Harris and Judd, 2002) or to feel inhibited to give 
truthful answers to sensitive questions (Hawe, Degeling and Hall, 1990). Thirdly, there 
is the possibility that the researcher may introduce bias by offering comments that may 
lead the participant in a particular direction (Aldridge and Levine, 2001 ). The training 
and experience of the researcher is crucial to minimise this disadvantage. 
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2.3.2.1 Survey design 
As mentioned earlier, two questionnaires were used as part of this research. The CMI 
Study consisted of questions constructed by the researchers (Chapter 3) based on the 
responses provided by participants from the focus group study (Koo, Krass and Aslani, 
2002). The WMI Study Phase 1 consisted of a compilation of previously validated 
measures as well as questions constructed by the researchers (Chapter 4 ). 
In the WMI Study Phase 1, where possible, existing validated measures were 
incorporated (with permission) into the study. As these questions have already been 
through extensive testing, they can save a great amount of time and effort (Czaja and 
Blair, 1996). Reliability and validity testing has been conducted, hence the researcher 
will be aware of the quality of the questions (Bryman, 2004 ). Moreover, using 
previously validated questions allows comparisons to be drawn with other research 
(Bryman, 2004 ). Where previously validated questions did not exist or were not 
considered suitable, the survey questions were constructed by the researchers. 
For both the CMI Study and WMI Study Phase 1, the following survey design principles 
were taken into consideration when constructing the survey questions. One of the main 
considerations was the use of open-ended or closed-ended questions. Open questions 
allow respondents to express themselves freely and can provide valuable insight into a 
respondent's perception as well as indicate what is salient in a respondent's mind 
(Faddy, 1993; Jackson and Furnham, 2000; Aldridge and Levine, 2001; Bryman, 
2004 ). However, closed-questions are typically preferable for a survey (Czaja and Blair, 
1996; Jackson and Furnham, 2000; Bryman, 2004) as they are easier to complete for 
the respondents, and easier to code, analyse and compare for the researcher (Frazer 
and Lawley, 2000; de Vaus, 2002; Bryman, 2004). 
Nevertheless, in constructing the survey questions in the CMI Study and WMI Study 
Phase 1, some open-ended questions were used especially where it was not possible 
to provide an exhaustive list of responses, where the researcher wanted to elicit the 
salient issues for the respondents and for any other comments pertaining to the subject 
that the respondents may have volunteered, that were not directly examined in the 
survey. 
The rest of the survey consisted of closed-ended questions. These included simple yes 
or no questions and multiple-choice questions (with one answer or multiple answers 
allowed) (Hawe, Degeling and Hall, 1990) which were used to ask about respondent 
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behaviour and attributes (Salant and Dillman, 1994 ). For some of the multiple-choice 
questions, an "other" option was also included to allow respondents the opportunity of 
providing their own response if none of the choices given were considered applicable 
to them (Salant and Dillman, 1994 ). 
Another variant of the close-ended question used were rating scales (Salant and 
Dillman, 1994; McQueen and Knussen, 2002; de Vaus, 2002). In this research project, 
both Likert scales 11 and horizontal rating scales 12 were used. The Likert scale is one of 
the most frequently encountered formats for measuring attitudes (Foddy, 1993; 
Bryman, 2004) and was used in the CMI Study to measure participants' attitudes 
toward CMI. As it is difficult and inaccurate to measure attitudes using a single 
question, researchers employ a scaling technique, that is, a series of questions usually 
measured along a rating scale to improve measurement. Compared to other types of 
closed-ended questions, rating scales are considered a better method of measuring 
attitudes and beliefs (Salant and Dillman, 1994 ). 
However, in designing these scales, there is controversy surrounding the use of a 
middle ground (that is, where respondent neither agrees nor disagrees with the 
statement or question) and/or a 'don't know' or 'no opinion' option. The inclusion of 
these options means that respondents are not forced to express a view that they do not 
necessarily hold. However it is also argued that they may be too attractive an option for 
respondents who are not interested in thinking about the issue (Aldridge and Levine, 
2001; de Vaus, 2002; Bryman, 2004). In this research, both Likert scales (Section 4 in 
the CMI Study- Section 3.2.1.1.4) and horizontal rating scales (Section A in the WMI 
Study Phase 1- Section 4.2.1.2.1) constructed by the researchers included a middle 
ground to prevent respondents from being forced into creating an artificial opinion. 
11 Likert scale refers to a scale with several points (usually 5) ranging from "strongly disagree" to 
"strongly agree" where the respondent is asked to indicate their level of agreement or 
disagreement with the statement (de Vaus, 2002). 
12 Horizontal rating scale refers to a scale with opposite attitude positions where the respondent 
is asked to indicate with a number where his/her view falls (de Vaus, 2002). 
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An additional consideration in the construction of survey questions was the use of filter 
questions 13 . Filter questions were incorporated in the questionnaires where necessary 
to prevent asking questions that were irrelevant or not applicable to some participants 
(Neuman, 2003). In such cases, clear directions were written next to each response 
category of the filter question (e.g. go to Question 9) (Jackson and Furnham, 2000). 
One of the advantages of face-to-face surveys is that the interviewer has to do the 
skipping, not the participant; hence it is not a source of confusion for the participant 
(Aldridge and Levine, 2001 ). 
Effort was also made to ensure that the questions were concise, clear, uncomplicated 
and written in easy to understand language (Czaja and Blair, 1996; Jackson and 
Furnham, 2000; de Vaus, 2002; Bryman, 2004 ). Negatively worded questions (with the 
exception of attitude statements), leading questions and double-barrelled questions 
were avoided (Polgar and Thomas, 2000; Aldridge and Levine, 2001; de Vaus, 2002; 
Bryman, 2004 ). 
In addition to question construction, attention was also paid to other aspects of the 
survey. Questions were strategically and logically ordered to encourage completion by 
respondents. Relatively straightforward, non-sensitive and simple questions applicable 
and answerable by most if not all respondents were presented at the beginning of the 
surveys to capture interest and encourage cooperation (Czaja and Blair, 1996; Frazer 
and Lawley, 2000; Aldridge and Levine, 2001). Sensitive and more complicated 
questions were placed in the middle and towards the end of the survey (Hawe, 
Degeling and Hall, 1990; Jackson and Furnham, 2000). Some authors recommend that 
demographic questions be placed at the beginning of the survey as they are simple to 
answer (Jackson and Furnham, 2000; Polgar and Thomas, 2000). However, other 
authors argue that although simple to answer, demographic questions should be 
placed at the end of the questionnaire due to their personal and potentially sensitive 
nature (Czaja and Blair, 1996; Frazer and Lawley, 2000; Aldridge and Levine, 2001 ). In 
this research, the latter approach was adopted. 
13 Filter questions are questions whereby depending on the response to the previous question, 
the participant is required to proceed to the next question, or skip to a later one (Aldridge and 
Levine, 2001). 
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Transition statements were used between sections in the survey so that the respondent 
was aware of where the interview was heading (Hawe, Degeling and Hall, 1990; Salant 
and Dillman, 1994). 
Last but not least, the design and layout aspects of the survey were considered. These 
aspects are considered less critical for face-to-face interviews (used for both surveys in 
this research project) (Frazer and Lawley, 2000). Nonetheless, special attention was 
paid to the CMI Study as it was administered by multiple interviewers and to the WMI 
Study Phase 1 due to the presence of a self-completion section. These are discussed 
in Chapters 3 and 4, respectively. 
2.3.2.2 Survey reliability and validity 
Reliability and validity are two important qualities that help establish the credibility of 
findings measured by an instrument (Neuman, 2003). Reliability refers to the 
dependability or consistency of an instrument, that is, it is a measure of the extent to 
which the results of a particular test, question or instrument are consistent over time 
(Aldridge and Levine, 2001; Neuman, 2003). There are several different ways of 
establishing the reliability of a particular instrument: 
• Stability (or test-retest reliability): refers to reliability over time, and is usually 
examined using the test-retest method, where the instrument is retested on the 
same group of people to see if the same results are obtained (Polgar and Thomas, 
2000; Neuman, 2003; Bryman, 2004). 
• Internal reliability: applies to consistency across different iterns that are used to 
rneasure the same constructs or concepts (Bryman, 2004 ). A commonly used test 
for measuring the internal consistency of an instrument is Cronbach's alpha 14 
(Punch, 1999). 
• Inter-observer reliability: applies only when more than one observer is involved in a 
study which requires a high degree of subjective judgement (Bryman, 2004 ). 
14 Cronbach's alpha is a statistic that reflects the homogeneity of the scale, that is, "how well the 
different items complement each other in their measurement of different aspects of the same 
variable or quality" (p.22) (Litwin, 2003). The rule of thumb for an acceptable Cronbach's alpha 
is 0.70 or greater (Hair, Anderson, Tatham eta/., 1998; Jackson and Furnham, 2000). However, 
in exploratory research, 0.60 is considered acceptable (Hair, Anderson, Tatham eta/., 1998). 
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Validity on the other hand refers to the 'truthfulness' of an instrument, that is, it is a 
measure of the extent to which an instrument measures what it is claimed to measure 
(Punch, 1999; Neuman, 2003). There are four types of validity: 
• Face validity: concerned with whether the questionnaire appears to be measuring 
what it says it does (Jackson and Furnham, 2000). In other words, "do the 
questions appear to be relevant, reasonable, unambiguous and clear?" (p.133) 
(Bowling, 2000) 
• Content validity: concerned with the extent to which the content of the instrument 
appears to "examine and comprehensively include, in a balanced way, the full 
scope of the characteristic or domain it is intended to measure" (p.133) (Bowling, 
2000). It is usually achieved following an evaluation and critique of the instrument 
by individuals with expertise in the field (Jackson and Furnham, 2000). 
• Criterion validity: involves comparing the instrument with another instrument which 
is accepted as the gold standard, and is only possible if the latter exists in the 
literature (Bowling, 2000). 
• Construct validity: refers to the extent to which the instrument tests the hypothesis 
or theory it is measuring (Bowling, 2000). It is achieved when the proposed 
hypotheses are supported by the results of the survey (Jackson and Furnham, 
2000). There are two parts to construct validity: convergent validity (item to 
correlate with related variables) and discriminant validity (item not to correlate with 
unrelated variables) (Bowling, 2000). 
The reliability and validity of the CMI Study and WMI Study Phase 1 questionnaires as 
research instruments are discussed in more detail in Chapter 3 (Section 3.2.1.2) and 
Chapter 4 (Section 4.2.1.3), respectively. 
2.3.2.3 Survey pre-testing and piloting 
The credibility of a questionnaire as discussed above can be improved by pre-testing 
and piloting 15 the questionnaire. Pre-testing is an essential stage in survey studies as it 
15 Some authors use the term pre-testing and piloting interchangeably to refer to the evaluation 
of the questionnaire before its final administration (de Vaus, 2002). Other authors further 
distinguish between the two in terms of size: pre-testing involves a smaller number of 
individuals and is a preliminary stage to piloting; piloting involves a larger number of individuals 
(Czaja and Blair, 1996). In this research study, the term pre-testing will mainly be used unless a 
large sample is involved in which case the term piloting will be used. 
51 
Ch 2- Aims and General Methods 
provides an opportunity to test if the questionnaire works in the manner intended by the 
researcher (Czaja and Blair, 1996), and to identify and eliminate any potential problems 
in the questionnaire before its final administration (Frazer and Lawley, 2000). 
At the individual question level, pre-testing serves to establish how the participants 
interpret the question's meaning, to establish participants' ability to respond to the 
questions, to check if the range of response choices is sufficient, and to detect potential 
problems like non-response, acquiescence 16 or response set17 (Czaja and Blair, 1996; 
Bowling, 2000). 
At the questionnaire level, pre-testing serves to establish whether the whole 
questionnaire can be administered smoothly, that is, if it flows well, the amount of time 
required to complete the questionnaire, if the participants' attention and interest can be 
maintained for that duration of time, and if more complicated questioning patterns (e.g. 
question skips) work. 
In this research, all studies were subjected to pre-testing and this will be further 
discussed in the individual chapters. The CMI Study was actually designed to be a pilot 
study. 
2.3.3 Qualitative methods 
In this research, a qualitative method, namely interview, was chosen to complement 
the data obtained from the WMI Study Phase 1. Used following a quantitative method, 
interviews have the potential to yield rich data that complement the generalisable but 
relatively thin data from a questionnaire. It also provides the opportunity to clarify any 
puzzling responses or unexpected findings (Aldridge and Levine, 2001 ). 
16 Acquiescence is the tendency for some respondents to agree with a statement on a 
questionnaire, irrespective of its content (McBurney and White, 2004). It is an example of 
response set. 
17 Response set is the tendency for respondents to consistently respond in the same way to a 
set of statements or questions (Bryman, 2004 ). For example, for attitude statements, this can 
mean consistently agreeing, consistently disagreeing or consistently making moderate 
responses. 
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An interview is defined as a "verbal exchange in which the interviewer attempts to elicit 
information and/or opinion on a topic from another person or persons" (p.522) (Quine, 
1998) and is the most common technique used to gather research information (Grbich, 
1999). 
Although there are many ways of interviewing, semi-structured 18, open-ended one-to-
one telephone interviews were deemed the most appropriate to meet the objectives for 
this part of the research. 
The semi-structured nature of the interview ensured that all areas of interest to the 
researcher were able to be covered and thus allowed some degree of comparability 
(Arksey and Knight, 1999); this was particularly important as one of the objectives of 
this part of the research project was to verify responses provided in the WMI Study 
Phase 1. Moreover, in order to meet the other objectives set out for this study, the 
semi-structured nature of the interview also allowed the interviewer to probe 
responses, follow up ideas and ask for clarification (Arksey and Knight, 1999). 
Telephone interviews were chosen for this part of the research project mainly because 
it was a series of follow-up interviews from the WMI Study Phase 1. Hence, the 
researcher already had the opportunity to have a face-to-face encounter with the 
participant and was able to establish rapport at that time (Grbich, 1999). Hence, the 
lack of face-to-face contact and therefore the difficulty of establishing rapport, a 
common disadvantage associated with telephone interviews, was not an issue (Quine, 
1998). As a relationship with the participant had already been established, compared to 
face-to-face interviews, telephone interviews also presented a more convenient, cost-
effective and time-efficient option (Aldridge and Levine, 2001 ). 
18 Different authors advocate different definitions for the term 'semi-structured' [e.g. Grbich 
(1999); Arksey and Knight (1999)]. For the purposes of this research project, 'semi-structured' 
interviews refer to interviews whereby the main questions are fixed, but the interviewer is able to 
improvise follow-up questions to further explore responses and/or interesting issues that arise 
(Arksey and Knight, 1999). 
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3 USE OF CONSUMER MEDICINE INFORMATION- PILOT STUDY 
The CMI Study was a pilot study conducted in 2001 involving a structured 
questionnaire administered by trained interviewers to a sample of consumers of 
prescription medicines recruited from a random sample of community pharmacies in 
metropolitan Sydney 19 . 
3.1 OBJECTIVES 
The overall objectives of this study were: 
• 1. To determine consumers' awareness and knowledge of CMI 
• 2. To determine consumers' receipt and experience when receiving CMI 
• 3. To examine consumers' readership and impact of reading CMI 
• 4. To explore consumers' attitudes and opinions towards CMI 
3.2 METHODS 
3.2.1 Study questionnaire 
3.2.1.1 Content 
The questionnaire (Appendix A) consisted of five sections, Section 1 to Section 5. The 
development of the questionnaire was informed by the results of a qualitative study 
involving focus groups (Koo, Krass and Aslani, 2002) (Section 2.3.1 ). Table 3.1 
summarises the purpose of each section and the related objective(s). 
19 CMI Study formed the second phase of a larger study which was funded by the 
Commonwealth Department of Health and Aged Care. A report has previously been submitted 
to the funding body (Aslani, Koo and Krass, 2001 ). 
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Table 3.1 Summary of sections of the CMI Study questionnaire 
Section Purpose 
1 Examine awareness of CMI and its content 
Assess consumer's receipt of CMI 
To address 
objective 
1 
2 
2 Determine consumer's experience when receiving CMI 2 
3 Determine readership of CMI and impact of reading CMI 3 
4 Explore consumer's attitude towards CMI 4 
5 Collect demographic details and provide opportunity for All 
further comments 
Each section is described below in order of appearance in the questionnaire. The 
general survey design principles discussed in Section 2.3.2.1 were applied to all 
questions in the questionnaire. Some are elaborated with examples from the 
questionnaire. 
3.2.1.1.1 Section 1 
Section 1 consisted of questions assessing the consumer's knowledge of CMI and the 
current and past2° receipt of CMI. The information requested included the name 
and status'' of the prescription medication(s) for which a CMI was received. 
Consumers who had not received a CMI before were asked if they were interested in 
receiving a CMI for his/her prescription medication(s) in the future (Question 9 to 11 ). 
Most questions in Section 1 were multiple-choice close-ended questions (some with an 
"other" option) as described in Section 2.3.2.1. An open-ended question was used to 
gauge participant's knowledge and understanding of the content of a CMI (Question 2). 
It also allowed the researcher to validate whether the consumer was referring to CMI or 
2
° CMI received in the 'past' included any CMI received prior to the day of the interview. 
21 
'Status' of the prescriptions refer to whether they were new, repeat or received in the past. 
New prescriptions are those that the consumer had never taken before and may be acute or 
chronic medications. Repeat prescriptions refer to medications that the consumer takes 
continuously on a regular basis (e.g. oral contraceptive pill, anti-cholesterol medication). These 
are usually collected on a monthly basis. Prescriptions received in the past refer to medications 
that the consumer had taken previously but not on a regular basis (e.g. antibiotics, analgesics). 
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not. Open-ended questions were also used when requesting for names of medications 
for which CMI was received as it was not possible to include a comprehensive list of all 
prescription medicines. 
3.2.1.1.2 Section 2 
Section 2 examined the consumer's experience when receiving a CM I in the 
community pharmacy either on the day of the interview or in the past. Questions 
addressed the provider of the CMI (Question 12), whether the CMI was given or 
requested (Question 13), the type of CMI given/received (Question 14) and the 
interaction that occurred when the CMI was given/received (Questions 15 and 16). 
Section 2 concluded with several questions ascertaining the consumer's preference 
regarding when to receive a CMI (Question 17), the preferred provider of CMI 
(Questions 18 and 19) and the preferred interval for receiving CMI for repeat 
prescriptions (Question 20). 
All questions in Section 2 were multiple-choice questions with an "other" option. For 
some questions, the responses were not mutually exclusive and consumers were 
allowed to select more than one option. 
3.2.1.1.3 Section 3 
Section 3 examined the readership and action taken after reading a CMI, hence was 
only applicable to consumers who had received a CMI in the past. Consumers were 
requested to recall the most recent time they last received a CMI, and to base their 
responses on this incident. 
Questions asked of the consumer included the last time a CMI was received (Question 
21 ), whether they read the CMI and if so, the extent of readership (Questions 22 and 
23), and reasons for reading or not reading CMI (Questions 24 and 25, respectively). 
Consumers who read the CMI were asked to mention specific items they focused on 
when reading the CMI (Question 26). The questions which followed focused on the 
impact of reading a CMI (Questions 27 to 29) and the action taken after reading a CMI 
(Question 30 to 32). 
Section 3 concluded with two questions on reading CMI for a third party (e.g. child, 
parent or partner) (Questions 33 and 34 ). 
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Similar to Section 2, the questions in Section 3 were mainly multiple-choice questions 
with an "other" response and the responses were not mutually exclusive. However, 
open-ended questions were used when asking consumers what information from the 
CMI they focused on (Question 26) and what they learnt from reading CMI (Question 
27). 
3.2.1.1.4 Section 4 
This section focussed on consumer's attitude towards CMI. From the focus group data 
(Koo, Krass and Aslani, 2002), five constructs which appeared to be related to the use 
of CMI by consumers were identified. These five constructs formed the basis of the 
items in Section 4. These were: readability and presentation (six items), perception of 
disease/condition (five items), role of carer (five items), health locus of control (six 
items) and experience of problems with medications in the past (five items). Multiple 
items were used to measure each construct to improve its accuracy and reliability 
(Hoyle, Harris and Judd, 2002). 
General principles for question design previously discussed (Section 2.3.2.1) were 
taken into consideration when developing the attitudinal items. In addition, the items 
were worded both positively (in this case conveying a positive attitude towards CMI) 
and negatively (in this case conveying a negative attitude towards CMI). This was done 
to avoid acquiescence or response set (Hoyle, Harris and Judd, 2002; DeVellis, 2003). 
Consumer's responses were measured along a Likert scale ranging from "strongly 
disagree" (1) to "strongly agree" (5). A middle (third) point ("neither agree nor 
disagree") was present and a sixth point ("not applicable") was also included following 
feedback from pre-testing (Section 3.2.1.4 ). The advantages and disadvantages of 
including a middle point and a "not applicable" point had been discussed earlier 
(Section 2.3.2.1 ). 
3.2.1.1.5 Section 5 
The final section in the questionnaire collected demographic details from the 
participants. This was done in order to define the characteristics of the recruited 
sample and to identify possible trends associating a demographic variable to the use of 
CMI. Hence, standard demographic details were requested including gender, age, 
country of birth, main language spoken at home, marital status, number of children, 
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highest level of education, occupation, employment status and residential postcode. In 
addition, details about medical conditions and current prescription medications were 
collected to verify some of the responses provided in the preceding sections of the 
questionnaire. 
Finally, participants were given an opportunity to make any further comments regarding 
CMI or any related matter. 
3.2.1.2 Reliability and validity 
As this was a pilot study, the credibility of the whole questionnaire was established 
through the actual process of conducting the study. Nonetheless, specific reliability and 
validity assessments were still conducted. 
In general, of the three approaches to establishing the reliability of an instrument 
(Section 2.3.2.2), internal reliability was the main method used in this study. The 
internal reliability of the participant's responses was assessed by cross-checking 
responses provided in different sections of the questionnaire. For example, 
participants who did not report receiving a CMI in the past should not have responded 
to questions about the action taken after reading a CMI. Although filter questions 
(Section 2.3.2.1) should have prevented this from occurring in the first instance, extra 
checks such as these helped to ensure that the recorded responses were reliable. 
Cronbach's alpha was used to assess the internal reliability of the attitudinal items 
(Section 2.3.2.2). 
Criterion validity was not able to be established as no gold standard was available for 
comparison. In order to establish face validity, pre-testing of the questionnaire (Section 
3.2.1.4) was conducted on a convenience sample of individuals. All individuals 
considered the questions in the pre-test to be relevant to the research topic, however 
some changes had to be made to clarify certain ambiguities. Content validity was also 
established based on the comments and feedback from two other researchers 
associated with the study. Lastly, construct validity of the attitudinal items in Section 4 
was tested using exploratory factor analysis (Section 3.2.6). 
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3.2.1.3 Layout and appearance 
The questionnaire consisted of 12 printed pages (double-sided) of white A4 paper. 
Although the layout is generally considered less critical for personally administered 
questionnaires (Frazer and Lawley, 2000), in this case, as the questionnaire was to be 
administered by multiple interviewers, special attention was paid to the clarity of the 
questions and instructions on the questionnaire. The questionnaire was mainly typed in 
Arial font size 11. Questions were typed in bold, and where necessary, instructions to 
the interviewers were also highlighted in bold. Line spacing was set at one and a half to 
ensure that the questionnaire was clear and easy to read, and did not appear 
congested. 
3.2.1.4 Questionnaire pre-test 
The questionnaire was pre-tested with a convenience sample of 20 individuals to 
establish face validity and ensure the smooth administration of the questionnaire. 
There were two differences between the pre-test and the actual study. Firstly, pre-test 
individuals were not collecting a medication for themselves on the day of the interview, 
but had previously taken or were currently taking prescription medications. Secondly, 
pre-test individuals were informed of the nature and aim of the pre-test and were 
requested to provide feedback to the researcher; this helped to establish the validity of 
the survey. 
Based on the feedback received during pre-testing, several changes were made to the 
questionnaire (see Appendix A for questionnaire). The changes are summarised below: 
• Some of the offered choices for multiple-choice questions were not mutually 
exclusive, hence the phrase "you may tick more than one box" was added to clarify 
that participants were allowed to choose more than one response (e.g. Questions 1 
and 19). 
• For a more comprehensive list of choices, an additional option ("only when I ask for 
it") was added to Question 20. 
• Minor word changes were made to simplify and/or clarify questions and attitudinal 
items. For example, in Section 4, the item, "The print in CMI is too small" was 
changed to "I find the print in CMI too small to read" to clarify that the statement 
referred to the participant's own experience and not anyone else's. 
• Some instructions for the interviewer had to be clarified. This included the addition 
of instructions for question skips that were accidentally omitted (e.g. "Go to Section 
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4" following the "Don't know" option), and highlighting certain instructions for 
interviewers by using bold print (e.g. instructions for Section 2). 
• Tick boxes were added for the response choices in Question 19 to prevent any 
ambiguity when responses were ticked. 
• A "not applicable" option was added to the attitudinal items in Section 4 to prevent 
forcing participants to give a response to items that did not apply to them (e.g. if 
they do not have someone in their care) (see also Section 3.2.1.1.4 ). 
• Several typographical errors were corrected. 
3.2.2 Sampling frame and sample size 
3.2.2.1 Sampling frame 
As this pilot study was conducted to investigate the use of CMI by ambulatory 
consumers in the community setting, the sampling frame for this study consisted of all 
consumers collecting prescription medications in the randomly selected community 
pharmacies. 
3.2.2.2 Sample size 
The sample size was calculated using the standard error of proportions equation 
(Kalton, 1983), which determines the sample size required to detect a certain 
population proportion (Figure 3.1 ). 
Figure 3.1 Standard error of proportions equation 
where: 
also: 
SE(p) = ..,J (PQ/ n') 
p 
SE(p) 
p 
Q 
n' 
1.96 SE(p) 
= sample percentage 
= standard error of p 
= population percentage 
= 100- p 
= initial estimate of sample size 
= degree of precision 
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To calculate the sample size, the population proportion was taken as the proportion of 
consumers receiving computer printout and loose leaflet CMI from community 
pharmacists in a previous study, which was 7.3% (Aslani, 1999). At a 3% degree of 
precision, a total of approximately 300 consumers were required. 
3.2.3 Interviewer recruitment and training 
In face-to-face surveys, the interviewer is critical to data quality as he/she is the person 
who actually administers the questionnaire (Salant and Dillman, 1994). In this study, 
the questionnaires were administered by 12 interviewers with experience in market 
research. These interviewers were recruited by snowballing". 
Based on their availability, the interviewers recruited consumers from one or more 
pharmacies. The interviewers were instructed to visit each pharmacy consecutively for 
three days. Interviewers reported directly to the researcher who conducted the training 
session. They were remunerated AUD$20 per questionnaire completed. 
All interviewers were trained prior to the data collection period to ensure that 
interviewer behaviours did not compromise the quality of the collected data especially 
since multiple interviewers were involved (Czaja and Blair, 1996). The training which 
lasted for two hours covered various aspects of the study (Appendix B) and was 
conducted at the Faculty of Pharmacy. 
3.2.4 Consumer recruitment 
The rationale for consumer recruitment was to capture a broad sample of consumers of 
prescription medications. Hence, community pharmacy was considered the strategic 
recruitment site for these consumers. A list of community pharmacies from the Health 
Insurance Commission was obtained and stratified to include only community 
pharmacies in the Sydney metropolitan area. Assuming a maximum response rate of 
approximately 30% as previously observed (Aslani, 1999), a random sample of 75 
community pharmacies were selected to enable a broad cross-section of the population 
22 Snowballing is a form of convenience sampling where the researcher makes initial contact 
with known individuals and then uses these to establish contacts with others (Bryman, 2004). 
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to be reached. A sample of consumers was consecutively recruited from each of these 
pharmacies. 
One of the interviewers was responsible for contacting and inviting the pharmacist-in-
charge of each community pharmacy to participate in the study. Consenting 
pharmacies were informed that an interviewer would be contacting them to arrange a 
convenient time to recruit the consumers. After the list of consenting pharmacies was 
established, the names of consenting pharmacies were distributed amongst the 
interviewers. The interviewer was responsible for contacting the pharmacy to arrange a 
suitable time for him/her to visit the pharmacy and conduct the interviews. At the 
pharmacy, a Participant Information Sheet (Appendix C) was given to the pharmacist-
in-charge, and a consent form (Appendix C) was signed if he/she was willing to 
participate. 
With the assistance of the pharmacist-in-charge, the interviewer located a quiet area in 
the pharmacy where the interviews could be conducted. The interviewer also came to 
an agreement with the pharmacist whether the consumers would be approached 
directly by the interviewer as they were leaving the dispensary area or whether they 
would be referred to the interviewer by the pharmacist. 
Using either approach, the interviewer introduced himself/herself to the consumer and 
invited him/her to participate in the study. A brief explanation of the study was provided 
and the eligibility criteria were checked. Consumers were eligible to participate in the 
study if they were: 
• at least 18 years of age 
• able to take part in the study without the help of a translator 
• collecting a prescription medication for themselves on the day of the study. 
Eligible and consenting consumers were given a Participant Information Sheet 
(Appendix C) and requested to sign a consent form (Appendix C). The interview was 
then conducted. 
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3.2.5 Administration of questionnaire 
After written consent had been obtained from the participant, the interviewer 
commenced the interview using the structured questionnaire in a quiet area of the 
pharmacy. The questionnaire took approximately 15 minutes to administer. 
3.2.6 Data analysis 
All data were coded and entered into a database in SPSS (1999). The data were 
checked for incorrect entries and missing values using frequency distributions. 
Frequency distributions were compiled for categorical variables. Summary statistics 
were generated for continuous variables. The means and standard deviations were 
reported for normally distributed continuous variables. For non-normally distributed 
continuous variables, the medians and interquartile ranges (IQRs) were reported. 
As mentioned earlier, the construct validity of the attitudinal items in Section 4 were 
tested using exploratory factor analysis. Factor analysis is a class of multivariate 
statistical methods which are applied to a single set of variables to "discover which 
variables in the set form coherent subsets that are relatively independent of one 
another" (p.582) (Tabachnick and Fidell, 2001 ). In other words, factor analysis reduces 
a set of variables to a smaller number of factors (Graetz, 2003) and these factors are 
thought to reflect the underlying processes that have created the correlations among 
variables (Tabachnick and Fidell, 2001 ). 
Principal axis factoring, a commonly used technique, was chosen as the extraction 
technique (Tabachnick and Fidell, 2001; Pelt, Lackey and Sullivan, 2003). The number 
of factors was determined by selecting only factors with eigenvalue > 1.0 (Pelt, Lackey 
and Sullivan, 2003). Oblique rotation was considered most suitable as preliminary 
analysis showed the correlations among factors exceeded 0.3 (Tabachnick and Fidell, 
2001 ). The Promax solution gave the most interpretable solution23 . Individual items 
were retained if they had loadings greater than 0.30, had minimal or no cross-loading 
and aided interpretation of the factor (Comrey and Lee, 1992; Pelt, Lackey and 
Sullivan, 2003). 
23 Two oblique rotations were available in SPSS: Oblimin and Promax. Both were trialled but the 
Promax rotation gave the most interpretable solution hence is presented here. 
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Weighted factor-based scales were computed for the final factor solution to allow the 
identified factors to be used in subsequent analysis (de Vaus, 2002). These scales 
were chosen as they took into account the factor loadings of each item, so that items 
with a high factor loading contributed more to the weighted factor-based scales than an 
item with low factor loading (Comrey and Lee, 1992; de Vaus, 2002). By reversing the 
scoring of negatively-worded items and calculating the weighted factor-based scales, 
the original Likert scales ranging "strongly disagree" (1) to "strongly agree" (5) were 
converted to different scales unique to each factor. Descriptive statistics for the new 
scales were also computed, including a mid-point for each scale. Scores above the 
mid-point indicated agreement with the factor, and vice-versa. 
Following factor analysis, reliability tests using Cronbach's alpha were conducted to 
determine the internal consistency of the factors. Before conducting the tests, scoring 
of the negatively-worded items was reversed (Pelt, Lackey and Sullivan, 2003). 
3.2. 7 Response rates 
Of the 75 randomly selected community pharmacies, 18 (24%) agreed to participate in 
the study. 
A total of 241 consumers were recruited and completed the questionnaires. Of these, 
four questionnaires were discarded as the consumer was not actually eligible for the 
study. A further 11 questionnaires were discarded due to contradictory responses in 
different sections of the questionnaire. Hence, the final number of useable 
questionnaires was 226. The number of questionnaires administered and the number 
of useable questionnaires from each pharmacy is presented in Appendix D Table A1.1. 
3.3 RESULTS 
This section presents the results for the CMI Study. As mentioned in Section 3.2.7, a 
total of 226 useable questionnaires were collected. However, not all questions were 
answered by all participants, hence in the following sections, the number of 
respondents may vary for different questions. 
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3.3.1 Sample demographics 
3.3.1.1 Gender 
Of the 226 participants who completed the CMI Study, 87 (38.5%) were male, 138 
(61.1%) were female, and one participant was transgender (0.4%). 
3.3.1.2 Age 
Ages ranged from 18 to 92 years, with a median value of 56.5 years (IQR 36-73 years). 
Table 3.2 shows the distribution of the participants' age broken down into decades. 
Table 3.2 Frequency distribution of participant age by groups 
Age groups n % 
20 and below 8 3.5 
21-30 33 14.6 
31-40 23 10.2 
41-50 29 12.8 
51-60 35 15.5 
61-70 34 15.0 
71-80 48 21.2 
81-90 15 6.6 
91 and above 1 0.4 
Total 226 100.0 
3.3.1.3 Country of birth and language spoken 
The majority of participants were born in Australia (n=165, 73.0%) and the remainder 
were born overseas. At home most of the participants spoke only English (n=191, 
84.5%) whilst the remainder spoke a language other than English. The main non-
English languages spoken were Greek, Spanish, Italian and German. 
3.3.1.4 Marital status and number of children 
The majority of participants were married (Table 3.3). Of these, 66 (n=29.2%) stated 
that they did not have any children. The remaining had one child or more [range 1-5, 
median 2 (IQR 2-3)). 
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Table 3.3 Frequency distribution of participants' marital status 
Marital status n % Valid% 
Never married 45 19.9 20.2 
Married 109 48.2 48.9 
De facto 10 4.4 4.5 
Separated 6 2.7 2.7 
Divorced 29 12.8 13.0 
Widowed 24 10.6 10.8 
Missing 3 1.3 
Total 226 100.0 100.0 
3.3.1.5 Highest level of education 
Highest level of education varied across the sample (Table 3.4). Although most 
respondents had attained at least some level of secondary education, approximately a 
third of the participants did not complete secondary education. 
Table 3.4 Frequency distribution of participants' highest level of education 
Highest level of education n % Valid% 
None 9 4.0 4.0 
Primary School 1 0.4 0.4 
School Certificate 71 31.4 31.8 
Higher School Certificate 52 23.0 23.3 
Associate Diploma 21 9.3 9.4 
Undergraduate Diploma 24 10.6 10.8 
Bachelor Degree 29 12.8 13.0 
Postgraduate Diploma 7 3.1 3.1 
Higher Degree 9 4.0 4.0 
Missing 3 1.3 
Total 226 100.0 100.0 
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3.3.1.6 Occupation and work status 
Participants' occupations are shown below24 (Table 3.5). Some participants only 
mentioned that they were "retired" "or "unemployed" without stipulating their main 
occupation/training prior to retirement/unemployment hence the presence of two 
additional categories in Table 3.5. 
Table 3.5 Frequency distribution of participants' occupation 
Occupation n % Valid% 
Managers and administrators 9 4.0 4.2 
Professionals and associate professionals 66 29.2 31.0 
Tradesperson and related workers 21 9.3 9.9 
Clerical workers 23 10.2 10.8 
Production and transport workers 4 1.8 1.9 
Sales and service workers 24 10.6 11.3 
Labourers and related workers 1 0.4 0.5 
Homemaker 24 10.6 11.3 
Student 12 5.3 5.6 
"Retired" 28 12.4 13.1 
"Unemployed" 1 0.4 0.5 
Missing 13 5.8 
Total 226 100.0 100.0 
In terms of work status, 43 (19.0%) were working full time and 54 (23.9%) were 
working part time. The rest (n=124, 54.9%) were not working mainly due to retirement 
as reflected by the age distribution of the sample. There were five missing responses. 
3.3.1.7 Current medical conditions and prescribed medications 
Sixty eight consumers reported that they did not have any current medical conditions. 
Of the 150 consumers who did, the most common medical conditions were 
hypertension (n=47, 29.7%), arthritis (various forms) (n=27, 17.1%), 
24 An open ended question was used to collect information on participant's occupation. For 
purposes of data analysis, these occupations were categorised according to the Australian 
Standard Classification of Occupations (Australian Bureau of Statistics, 1997a). 
67 
Ch 3- CMI Study 
hypercholesterolemia (n=20, 12.7%), and diabetes (n=15, 9.5%). There were eight 
missing responses. 
In terms of current prescription medications taken by the consumers, 28 consumers 
reported that they were not taking any medications. This seemingly contradicted the 
eligibility criteria (Section 3.2.4) however as these consumers were collecting new 
medications, they did not consider themselves as currently taking the medication. 
The prescription medications currently taken by 194 consumers are shown in Table 
3.6. Four consumers did not answer the question. 
Table 3.6 Current prescription medications (by therapeutic classes) taken by participants 
(n=194) 
Current medication by therapeutic class n medications % 
Cardiovascular system 171 37.7 
Endocrine and metabolic disorders 64 14.1 
Central nervous system 49 10.8 
Musculoskeletal system 40 8.8 
Respiratory systems 26 5.7 
Alimentary system 24 5.3 
Infections and infestations 18 4.0 
Analgesia 15 3.3 
Contraceptive agents 10 2.2 
Skin 8 1.8 
Nutrition 8 1.8 
Eye 7 1.5 
Other 14 3.1 
Total number of medications 454 100.0 
3.3.2 Awareness and knowledge of CMI 
Consumers had variable understanding of CMI (Table 3.7). They most commonly 
associated CMI with written information leaflets inside the medication box (n=142, 
62.8%), a reflection of the main form of CMI available during the time of the study. 
Despite the majority having some awareness of CMI, others held inaccurate views 
(n=8, 3.4%) or were unaware of CMI (n=26, 11.5%). 
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Table 3.7 Consumers' definition of CMI (n=226) 
Definition of CMI 
Written information about prescription medications 
Written information printed by the pharmacist 
Written information leaflets or brochures 
Written information leaflets inside the medication box 
I don't know 
Other (including internet material, verbal information and advertising 
material) 
NB: Responses are not mutually exclusive. 
Ch 3- CMI Study 
n % 
107 47.3 
79 35.0 
73 32.3 
142 62.8 
26 11.5 
8 3.4 
Participants who claimed to know what a CMI was (n=200) were then asked what kind 
of medicine information a CMI contained. Nineteen consumers (9.5%) stated that it 
contained information about the medication. Most respondents, however, named 
specific items, with side effects, dosage, precautions, ingredients and indication being 
the most commonly mentioned items (Appendix D Table A 1.2). 
3.3.3 Receipt of CMI 
A total of 132 respondents (58.4%) reported receiving one or more CMI on the day of 
the interview (Appendix D Table A1.3) and 184 (81.4%) reported receiving one or more 
CMI in the past (Appendix D Table A1.4). In total, 195 CMI were received on the day of 
the interview and 290 in the past. In both cases, these medications were mainly repeat 
medications (Appendix D Table A 1.5) for a range of therapeutic classes (Appendix D 
Table A1.6). 
Forty-one consumers (18.1%) (Appendix D Table A 1.4) had not or were unsure if they 
had received a CMI in the past. However, when asked if they would like to receive a 
CMI for their prescription medications in the future, eight consumers did not respond 
(19.5%) and only 17 (41.5%) expressed a desire to do so. The latter further expressed 
their preference to receive CMI for new medications (n=8, 47.1%), repeat medications 
(n=3, 17.6%) or medications that were taken in the past (n=5, 29.4%). One consumer 
did not give a preference. 
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3.3.4 Experience of receiving CMI 
These questions were directed to consumers who had received CMI on the day of the 
interview and/or in the past (n=206). Of these, only 179 (86.9%) identified the provider 
of CMI for specific medications that they were prescribed (Table 3.8). The primary 
provider appeared to be the pharmacist followed by the manufacturer, the latter 
referring to package insert CMI found inside medication boxes. 
Table 3.8 Provider of CMI for medications received (n=179 consumers) 
Provider of CMI n medication % 
Pharmacist 110 35.0 
Manufacturer 82 26.1 
Doctor 69 22.0 
Both doctor and pharmacist 49 15.6 
Other 4 1.2 
Total number of medications 314 100.0 
When asked if the CMI was offered or requested, less than half the participants 
reported that it was given to them by a health professional and interestingly, very few 
consumers actually requested a CMI from their health professional (Table 3.9). For the 
rest, CMI was neither given nor requested, but mainly found inside the medication 
boxes (n=84, 40.8%). 
Table 3.9 Mode of receipt of CMI 
How CMI was received n % Valid% 
Given 78 37.9 43.6 
Requested 6 2.9 3.4 
Found inside medication box 84 40.8 46.9 
Other (combination of above) 11 5.4 6.1 
Missing 27 13.1 
Total 206 100.0 100.0 
Package insert CMI was by far the most common form of CMI received (Table 3.1 0). 
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Table 3.10 Type of CMI for medications received 
Type ofCMI n medication % Valid% 
Package insert 257 81.8 82.1 
Computer printout 13 4.1 4.2 
Loose leaflet 11 3.5 3.5 
Other (including combinations of above) 32 10.2 10.3 
Missing 1 0.3 
Total number of medications 314 100.0 100.0 
Although the pharmacist was cited as the primary provider, in the majority of cases the 
CMI was just found inside the medication boxes without the involvement of a health 
professional (Table 3.11 ). Hence, it seems that some consumers considered a 
package insert CMI as being provided by the pharmacist simply because they received 
their medications which contained the CMI from the pharmacy. 
Table 3.11 Consumer's experience during receipt of CMI (n=206) 
Experience when receiving CMI n % Valid% 
It was inside the medication box 154 74.8 86.0 
It was simply handed out with no further discussion 24 11.7 13.4 
My attention was drawn to the CMI document only 8 3.9 4.5 
My attention was drawn to specific sections of the CMI 19 9.2 10.6 
I was asked to read the CMI 10 4.9 5.6 
I was asked to read the CMI and come back if I had questions 12 5.8 6.7 
The content of CMI was discussed in detail 7 3.4 3.9 
The content of CMI was discussed in detail when requested 1 0.5 0.6 
Missing 27 13.1 
NB: Responses are not mutually exclusive. 
For the small proportion of consumers for whom the content of CMI was discussed in 
detail, the sections that were discussed by the health professionals are presented in 
Appendix D Table A 1. 7. 
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3.3.5 Preferred timing and provider of CMI 
These questions were directed to participants who had received CMI on the day of the 
interview or in the past as well as participants who expressed interest in receiving CMI 
in the future. Of the 198 consumers who responded to these questions, the most 
common preference was to receive a CMI at the doctor's surgery after the doctor had 
decided what medication to prescribe but before the actual prescription was written, at 
the pharmacy after the prescription was dispensed or a combination of the two (Table 
3.12). 
Table 3.12 Consumer's preferred time to receive CMI 
Preferred time to receive CMI n % Valid% 
At the doctor's surgery before the doctor writes the Rx (1) 65 30.4 32.8 
At the doctor's surgery after the doctor writes the Rx (2) 14 6.5 7.1 
At the pharmacy before the Rx is dispensed (3) 17 7.9 8.6 
At the pharmacy after the Rx is dispensed (4) 60 28.0 30.3 
(1)and(4) 20 9.3 10.1 
(1) and (3) 11 5.1 5.6 
Miscellaneous combinations of the above 11 5.1 5.6 
Missing 16 7.5 
Total 214 100.0 100.0 
Rx = prescription 
In terms of preferred provider of CMI, the doctor was nominated as the primary 
preferred provider, followed by the pharmacist, and both doctor and pharmacist (Table 
3.13). The common cited reasons for nominating the doctor were that the doctor is 
aware of the consumer's medications and medical history (Appendix D Table A1.8). 
The main reason for nominating a pharmacist was the perception that the pharmacist is 
an expert on medications (Appendix D Table A1.8). 
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Table 3.13 Consumer's preferred provider of CMI 
Preferred CMI provider n % Valid% 
Doctor 82 38.3 41.4 
Pharmacist 66 30.8 33.3 
Both doctor and pharmacist 48 22.4 24.2 
Drug manufacturer 2 0.9 1.0 
Missing 16 7.5 
Total 214 100.0 100.0 
Finally, consumers were also asked how often they would like to receive CMI for their 
repeat prescriptions (Appendix D Table A1.9). Most consumers either preferred to 
receive CMI the first time they collected a prescription (41.6%) or every time they 
collected a repeat prescription (43.9%). A variety of other preferences were also noted. 
3.3.6 Readership of CMI 
This section of the questionnaire was only applicable to consumers who had received a 
CMI in the past. A total of 184 consumers reported receiving a CMI in the past, 
however, only 153 consumers responded to this section. According to 148 of these 
consumers, the last CMI was received between 1 day to 2 years ago (median 1.5 
months, IQR 0.8-6.0 months). 
Ninety eight participants (53.3% of 184 participants) stated that they had read the CMI. 
A large proportion of these consumers (n=60, 61.2%) reported reading all sections of 
the CMI, while the others read only selected sections (n=16, 16.3%) or scanned the 
CMI (n=21, 21.4%). Consumers gave a variety of responses when asked for their focus 
while reading CMI but the main ones were side effects and dosage (Appendix D Table 
A1.10). 
The main reasons for reading a CMI reported by the respondents were to learn about 
the medication and related to their concerns about the medication's side effects 
(Appendix D Table A 1.11 ). The main reasons given for not reading the CMI were 
having taken the medication in the past or on a continuing basis (Appendix D Table 
A1.12). 
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Of those who read a CMI for themselves, approximately 60% (n=57) reported reading 
CMI for someone in their care, at varying frequencies and to different extents 
(Appendix D Table A1.13), mainly for partners, children, and elderly parents or relatives 
(Appendix D Table A1.14). 
3.3.7 Impact of reading CMI 
Becoming better informed about medications was the most commonly cited impact of 
reading CMI (Table 3.14). This was followed by greater confidence in taking 
medications and greater awareness of the importance of taking medications as 
prescribed. More than a third of consumers reported that they had not changed their 
medication-taking behaviour after reading CMI, but other consumers reported stopping 
their medications due to fear of possible side effects or drug interactions. 
Table 3.141mpact of reading CMI (n=98) 
Impact of reading CMI n % Valid% 
I am more informed about my medication 72 73.5 75.8 
I am more confident about taking my medication 55 56.1 57.9 
I am more aware of the importance of taking my medication 53 54.1 55.8 
as prescribed 
I have made no changes to the way I take my medication 36 36.7 37.9 
I have changed the way I take my medication 15 15.3 15.8 
I have stopped taking my medication because I did not want 11 11.2 11.6 
to suffer any side effects 
I have stopped taking my medication because of interactions 9 9.2 9.5 
with other medications 
I have not learnt anything new about my medication 8 8.2 8.4 
I have thought about the medication when side effect occurred 1 1.0 1.1 
Missing 3 3.1 
NB: Responses are not mutually exclusive. 
Twenty consumers (20.4%) reported that they had concerns or queries after reading 
the CMI and the majority of these reported contacting a health professional (Appendix 
D Table A1.15). After consultation with a health professional (n=16), no changes 
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occurred for about half the participants. The other half reported changing dosage, 
medication or ceasing it altogether (Appendix D Table A1.16). 
3.3.8 Use of CMI after reading 
After reading CMI, many participants kept it for a short time, that is, until they finished 
their medication (Table 3.15). Others threw it away, filed it for future reference or 
shared it with others on the same medication. 
Table 3.15 Use of CMI after reading 
Use of CMI after reading n % Valid% 
Kept the CMI in the medication box until I finished the 55 56.1 57.9 
medication (1) 
Threw the CMI away (2) 20 20.4 21.1 
Filed the CMI away for future reference (3) 13 13.3 13.7 
Shared the CMI with friends/relatives who were also on the 2 2.0 2.1 
same medication (4) 
(1)and(4) 4 4.1 4.2 
(1) and (3) 1 1.0 1.1 
Missing 3 3.1 
Total 98 100.0 100.0 
3.3.9 Attitudes towards CMI 
Using the methods outlined in Section 3.2.6, factor analysis was conducted on the 
altitudinal items (Section 4 of questionnaire) using principal axis factoring with Promax 
rotation. Initial factor analysis of the 27 attitudinal items yielded seven factors 
explaining 52.1% of the total variance (Appendix D Table A1.17). However, several 
problems were observed from the pattern matrix for this solution: two items cross-
loaded significantly (>0.3) (Pelt, Lackey and Sullivan, 2003) on multiple factors, Factors 
5 and 7 only had two items loading on each factor and overall, the factor solution did 
not provide a meaningful interpretation. 
Hence, the analysis was further refined. Based on the process mentioned in Section 
3.2.6, items that had significant cross-loading, had weak loadings on all items and/or 
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did not aid interpretation of a factor were removed one at a time. Factor analysis was 
repeated after each removal and the factor solution was inspected. 
The final factor solution contained four factors (15 items). This was considered the 
most satisfactory and interpretable solution. The Kaiser-Meyer-Oikin (KMO) test of 
sampling adequacy was 0.81 and Bartlett's test of sphericity was significant 
(l=617.72, p<0.01), both confirming that there were sufficient numbers of significant 
correlations among the items to justify undertaking factor analysis in the first place 
(Pet!, Lackey and Sullivan, 2003). 
The factors in the final solution were interpreted as: 1) perception of disease/condition, 
2) role of carer, 3) health locus of control, and 4) readability and presentation. The 
loadings of the individual items are shown in Table 3.16. With the exception of two 
items (in 'role of carer' and 'readability and presentation'), all items had good to 
excellent loading 25 (Comrey and Lee, 1992) on the respective factors. 
25 As a guideline, factor loadings> 0.71 is considered as excellent,> 0.63 as very good,> 0.55 
as good,> 0.45 as fair and< 0.32 as poor (Comrey and Lee, 1992). 
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Table 3.16 Factor loadings of the items in the "attitude to CMI" scale 
Items 
Factor 1: Perception of disease/condition 
1. I will only read the CMI if I think that my illness is 
serious. 
2. I don't read the CMI for medications prescribed for 
minor ailments. 
3. I only read the CMI for a medication which is for a 
serious medical condition. 
4. CMI is useful only for medications used in severe 
diseases. 
5. CMI should not be given out for medications used in 
minor illnesses. 
Factor 2: Role of carer 
1. It is important to read the CMI for the medications 
taken by someone in my care. 
2. As a carer, I would like to know what medication the 
person in my care is taking. 
3. The CMI is an important source of information for the 
medication taken by someone in my care. 
4. I don't believe that I should know about the 
medications taken by someone in my care. 
Factor 3: Health locus of control 
1 . I leave all the decision making about my medications 
to my doctor. 
2. I would like to be involved with my doctor in deciding 
what medications I should take. 
3. I trust the doctor to prescribe medications that are 
suitable for me. 
Factor 4: Readability and presentation 
1. The CMI is set out well, so I can always find the 
information I want. 
2. CMI contains all the medication information I need. 
3. CMI is written in a language that is easy to 
understand. 
NB: Only factor loadings "0.30 have been included in the table. 
Factor 
1 
0.82 
0.74 
0.74 
0.73 
0.63 
2 
0.85 
0.77 
0.77 
-0.50 
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3 
0.78 
-0.65 
0.58 
4 
0.68 
0.61 
0.51 
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The final factor solution explained 52.8% of the total variance. The contribution of each 
factor is shown in Table 3.17. 
Table 3.17 Eigenvalue and percentage variance explained by each factor in the "attitude 
to CMI" scale 
Factor Initial After extraction 
Eigenvalue %total Eigenvalue %total 
variance variance 
1 Perception of 4.71 31.38 4.28 28.53 
disease/condition 
2 Role of carer 1.90 12.66 1.44 9.62 
3 Health locus of control 1.75 11.66 1.26 8.39 
4 Readability and presentation 1.43 9.56 0.94 6.26 
The correlation between factors is presented in Table 3.18. The presence of 
correlations >0.3 between certain factors justified the use of oblique rotations in factor 
analysis (Pelt, Lackey and Sullivan, 2003). These correlations were also below 0.5, 
indicating that the constructs measured by each of these factors were still distinct 
enough to be considered as separate factors (Pelt, Lackey and Sullivan, 2003). 
Table 3.18 Correlation between factors 
Factor 1 Factor 2 Factor 3 Factor 4 
Factor 1 1.000 -0.448 0.430 -0.081 
Perception of disease/condition 
Factor 2 -0.448 1.000 -0.211 0.019 
Role of carer 
Factor 3 0.430 -0.211 1.000 0.105 
Health locus of control 
Factor 4 -0.081 0.019 0.105 1.000 
Readability and presentation 
The reliability of each of these factors is shown in Table 3.19. With the exception of the 
'readability and presentation' factor, all other factors demonstrated acceptable 
reliability. 
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Table 3.19 Factor reliability of the "attitude to CMI" scale 
Factor n Number of items Cronbach's alpha 
1 Perception of disease/condition 206 5 0.86 
2 Role of carer 110 4 0.85 
3 Health locus of control 220 3 0.67 
4 Readability and presentation 220 3 0.59 
As discussed in Section 3.2.6, weighted factor-based scale statistics for the factors 
were computed (Table 3.20). Median scores for factors 'role of carer' and 'readability 
and presentation' were above the mid-point, indicating that at least half or more of 
participants agreed with the items. Hence, most believed that CMI was an important 
document to aid carers in looking after their care-recipients and slightly over half 
agreed that CMI was understandable and presented in a user-friendly manner. 
Conversely, median weighted factor-based scores for 'perception of disease/ condition' 
and 'health locus of control' were below the mid-point, indicating that at least half or 
more of participants disagreed with the items. This meant that most consumers 
disagreed that their use of CMI was dependent on the severity of their condition and 
slightly more than half disagreed that decisions about their health should be left solely 
to the doctor. 
Table 3.20 Weighted factor-based scale statistics for the "attitude to CMI" scale 
Factor Range Mid- Median IQR 
point 
1. Perception of disease/condition 0.73-3.66 2.20 1.46 1.46-2.00 
2. Role of carer 1.57-3.61 2.59 3.01 2.89-3.42 
3. Health locus of control 0.67-3.16 1.91 1.78 1.34-2.29 
4. Readability and presentation 1.17-2.83 2.00 2.20 1.86-2.40 
3.3.1 0 Additional comments 
At the end of the questionnaire, participants were given the opportunity to provide 
further comments relevant to the topic area. Thirty four participants (15.0%) provided 
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comments. Several themes were identified from the comments and are summarised 
below. 
3.3.10.1 Study concept and survey design 
Positive comments were made regarding the study. Some respondents commented 
that they enjoyed being part of the study, and were happy to know that researchers 
were taking an active interest in consumers' views on CMI and related issues. 
3.3.10.2 Readability and presentation of CMI 
Most of the comments relating to the readability and presentation of CMI were 
negative. In terms of readability, participants commented that CMI was too complex 
and confusing, and felt that there was a need to simplify and summarise the 
information contained in the CMI. 
In terms of its presentation, participants requested for CMI to be printed in larger, 
darker print, and for certain sections such as the side effects to be printed in bold. 
3.3.10.3 Content of CMI 
Besides comments on the readability and presentation of CMI, several comments were 
also made regarding the content of CMI. There were suggestions to expand the list of 
interactions with other medications and food, and to include a contact number that 
consumers can use to obtain further information as well as a date indicating when the 
CMI was last updated. Some of this information was already contained in the CMI but 
may have escaped the consumers' attention when they were reading it. 
One participant also commented that the indications listed in CMI did not include the 
indication for which he/she was taking the medication, and another participant cynically 
commented that the information contained in CMI was intended to promote the product. 
3.3.1 0.4 Availability of CMI 
There were suggestions for CMI to be made available in other languages for people 
who did not speak English, and in other forms such as tape recordings for people with 
reading difficulties. There was also a request for CMI to be available as package 
inserts in all medications. 
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3.3.10.5 Role of health professionals 
Comments involving health professionals highlighted that participants viewed doctors 
and pharmacists as good sources of information about their prescription medications. 
In some cases, CMI was seen as an adjunct to advice from health professionals, in 
another case, information from health professional replaced the need for reading CMI. 
One participant's description of his/her ideal experience of CMI also highlighted the role 
of the health professional. 
''The ideal CMI is computer-generated and handed to me by the pharmacist-
this makes me take more note of the warnings and prompts me to ask 
questions." (P1800826) 
3.3.10.6 Importance of medicine information 
CMI was viewed as a source of medicine information and participants commented on 
the importance of being aware of and reading medicine information such as CMI. 
Participants also commented on other sources of medicine information that they have 
used in the past. This included information from manufacturers, health professionals, 
libraries and the internet. 
3.3.10.7 Ambivalence towards CMI 
Two comments reflected the nonchalant attitude of some participants towards CMI. 
"When you take so many medications, you become blase and stop reading 
these things." (P02014) 
Another participant commented that when he did read a CMI, he only scanned it and 
then discarded the CM I. 
"[CMI gets] in the way when I open the box." (P02004) 
26 Each participant is assigned a participant code. The alphabet 'P" and the following two digits 
refer to the particular community pharmacy in order of recruitment and the final three digits refer 
to the participant number. Hence. participant code P18008 refers to the eighth participant 
recruited in the eighteenth community pharmacy. 
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3.4 DISCUSSION 
3.4.1 Consumers' awareness and knowledge of CMI 
The results of this study indicate that most consumers had some understanding that 
CMI referred to written information about medicines, however others were unaware of it 
or held inaccurate views. In keeping with the main form of CMI available at the time of 
the study, CMI was most commonly associated with written information leaflets inside 
the medication box. While several previous studies have examined consumer 
awareness of the presence of package insert WMI (see Section 3.4.2) there seemed to 
be no published studies which have examined consumer awareness of the concept of 
WMI. 
Although the level of awareness of CMI was generally encouraging, there remained the 
possibility that consumers were influenced by the available choices read out by the 
interviewer. However, responses to the subsequent open-ended question on consumer 
knowledge of CMI indicated that this may not be the case as most consumers who 
were aware of CMI were also able to correctly name some of the specific information 
contained in a CMI. 
3.4.2 Consumers' receipt and experience when receiving CMI 
In this study, 58% of respondents reported receiving a CMI on the day of the interview 
and 81% reported receiving it in the past. It is not known, however, if the respondents 
were able to spontaneously answer the question, or if they had to look for the CMI 
before responding. Previous studies involving package insert WMI have reported that 
these inserts were noticed by approximately 80% of consumers without health 
professionals drawing their attention to it (Gotsch and Liguori, 1982; Raynor and 
Knapp, 2000). Hence, some consumers may not have actually realised that they 
received a CMI, especially if it was in the form of a package insert CMI. 
Other researchers have reported varying receipt rates for various kinds of WMI. 
Internationally, in a UK study, 78% of consumers said that they had received a patient 
information leaflet (PIL) (Bandesha, Raynor and Teale, 1996). In the US, over a twelve-
year period from 1982 to 1994, receipt of WMI by pharmacy consumers increased from 
16% to 59% (Morris, Tabak and Gondek, 1997). In a more recent study involving eight 
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states in the US, 87% of pseudo-consumers who presented with prescriptions at 
community pharmacies received a computer-generated WMI leaflet (Svarstad, 
Bultman, Mount eta/., 2003). 
In earlier studies conducted in Australia, consumers have reported WMI (not 
necessarily CMI) receipt rates of 36% in 1996 and 57% in 1999 (Quality Use of 
Medicines and Pharmacy Research Centre- University of South Australia, 2001 ). Due 
to the different WMI investigated, comparison with the current results is not possible. 
More recently, an Australian study documented receipt rates of 24% (2003) and 29% 
(2004) for computer printout CMI from pharmacists. Although still low, these receipt 
rates are an improvement compared to the 14% computer printout CMI receipt rate 
observed in the current study (conducted in 2001 ). 
Hence, overall, there is a common trend of increased receipt of WMI both 
internationally and in Australia over the past few decades (Gotsch and Liguori, 1982; 
Morris, Tabak and Gondek, 1997; Raynor and Knapp, 2000; Quality Use of Medicines 
and Pharmacy Research Centre- University of South Australia, 2001 ). A more detailed 
comparison is difficult due to differences in format as well as country-specific 
requirements surrounding the provision of WMI. 
In earlier questions in the survey, many consumers claimed that CMI were given to 
them by a pharmacist. However, later questions revealed that consumers attributed all 
CMI received while in the pharmacy to be provided by the pharmacist, including CMI 
which were placed in the medication box by the manufacturer. In fact, response to a 
subsequent question indicated that most respondents received CMI in the form of a 
package insert, largely without the involvement of a health professional, which reflects 
the findings from an earlier English study on package inserts (Bandesha, Raynor and 
Teale, 1996). Other studies have not reported whether health professionals were 
actively involved in the distribution and use of package inserts (Vander Stichele, Van 
haecht, Braem eta/., 1991; Van haecht, Vander Stichele, De Backer eta/., 1991; 
Raynor and Knapp, 2000). 
This passive provision of CMI is a cause for concern as having package inserts in 
boxes of medication does not guarantee that the consumer will be aware of its 
presence (Raynor and Knapp, 2000). Moreover, WMI alone is considered less effective 
than WMI provided in conjunction with verbal counselling (Gotsch and Liguori, 1982; 
Myers and Calvert, 1984 ). Hence, passive CMI provision without accompanying verbal 
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information may not be as beneficial for consumers. To compound this issue, since 
2001 when this study was conducted, there has been a steady decline in package 
insert CMI and a growing trend for manufacturers to make CMI available electronically 
(D. Monk, personal communication, 2 November 2004), generally via dispensing and 
prescribing software packages. 
Indeed, in a recent study, consumers reported that they resorted to the internet for 
medicine information because of the decline in package insert CMI but were unaware 
that their pharmacist could supply CMI in other formats (Peterson-Clark, Aslani and 
Williams, 2004). Given this trend, without the active involvement of health 
professionals, CMI would become more inaccessible to consumers. Although programs 
such as the MIC Program (see Section 1.3.2) have been instigated to address these 
issues, the low receipt rates of computer printout CMI in the recent MIC Program 
evaluation study (Benton, Snow and Parr, 2004) indicate that much work is still needed 
to improve the situation. 
The results of the current study, CMI Study, also indicated that individual consumers 
have distinct preferences when it comes to the provider and timing of CMI. The main 
preferred providers were doctors, pharmacists or a combination of the two. Other 
studies have similarly identified medical practitioners as the primary source of 
information for prescription medicines, followed by pharmacists, but these findings 
were not related specifically to the provision of WMI (Stergachis, Maine and Brown, 
2002; Trewin and Veitch, 2003). This finding has interesting implications. The doctor 
was preferred as he/she was aware of the medication and medical history, however it 
is not known if these consumers were also unfamiliar with the extended role of the 
pharmacists in information provision. Currently, in Australia, through the MIC Program, 
the government is encouraging the dissemination of CMI via pharmacists as it is 
considered feasible to provide CMI together with the medicine at the time of 
dispensing. Given that some consumers have other preferences, new avenues for 
providing CMI may have to be explored. 
Consumers also had different preferences for when they would like to receive CMI. The 
traditional time of receiving CMI at the pharmacy after the prescription was dispensed 
was still one of the favoured options. Interestingly, the other favoured option was to 
receive CMI at the doctor's before the prescription is written. The latter option reflects 
the increasing desire for consumers to be actively involved in their health care. Whilst 
receiving CMI at this stage of the consultation would greatly empower the consumer 
84 
Ch 3- CMI Study 
and promote concordance, the practicalities of doing so remain to be explored. Thus, 
while there are still many issues surrounding these consumer preferences that have to 
be addressed, ultimately, efforts to address these preferences will result in consumers 
having greater access to CMI in a way that best meets their needs and preferences. 
3.4.3 Consumers' readership and impact of reading CMI 
Despite issues surrounding the receipt of CMI, CMI was read fully or partially by 64% of 
consumers which concords with the average rate reported in the literature (Koo, Krass 
and Aslani, 2003). Most consumers reported increased knowledge about their 
medications, which is a commonly reported impact of reading WMI [e.g. Gibbs, Waters 
and George (1989a); Peura, Klaukka, Hannula eta/. (1993); Bandesha, Raynor and 
Teale (1996)]. A small proportion reported stopping their medications due to fear of 
potential side effects or drug interactions, which echoes the findings of several previous 
studies (Sands, Robinson and Orlando, 1984; Gibbs, Waters and George, 1989a; 
Bandesha, Raynor and Teale, 1996). However, other studies have found no 
relationship between readership of WMI and cessation of therapy due to fear of 
potential side effects (George, Waters and Nicholas, 1983; Myers and Calvert, 1984; 
Gibbs, Waters and George, 1989b). 
The low proportion of consumers ceasing their medications demonstrates that the 
reluctance of some health professionals to provide WMI to consumers for fear that they 
will not take their medications is unjustified. The challenge is for health professionals to 
ensure that consumers are equipped to understand the potential risk of a side effect or 
drug interaction by accompanying the provision of a CMI with verbal explanation. Most 
consumers in this study did not receive any guidance from health professionals when 
using CMI, and it would have been interesting to know if health professional input 
would have made a difference to the proportion of consumers who decided to cease 
their medications. 
3.4.4 Consumers' attitudes and opinions towards CMI 
The factor analysis conducted in this study was exploratory in nature and explained just 
over half of the observed variance. This is not surprising as there are other factors that 
may influence the way consumers use CMI which were not able to be covered in the 
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current study. There is the possibility that certain issues may not have been elicited in 
the focus group discussions from which the attitude statements used in this study were 
derived (Koo, Krass and Aslani, 2002) or have arisen since then. It is also possible that 
some of the issues that arose from the focus groups were not conducive to being 
explored using a survey. Further work is required to refine the items in the attitude 
scale to arrive at a more robust solution and to produce a more reliable and valid tool to 
measure consumers' attitudes toward CMI. Nevertheless, some lessons may be drawn 
from the current findings. 
The finding that consumers used CMI regardless of the severity of their condition is in 
contrast to previous findings (Koo, Krass and Aslani, 2002). It is worth noting that 
severity of condition involves very subjective assessment, hence further complicating 
research in the area. It is unclear if the observed discrepancy reflects true differences 
between the two groups or if it is due to the way the attitude statements were worded in 
this study. 
The finding that carers considered CMI a valuable information source for someone in 
their care is relatively new in relation to WMI, but is an established finding when it 
comes to carers and information in general (Fortinsky and Hathaway, 1990; Mallet and 
King, 1993; Ranelli and Aversa, 1994; Wellwood, Dennis and Warlow, 1994; Goldstein 
and Rivers, 1996; lconomou, Vagenakis and Kalofonos, 2001; Fukui, 2002; Kendall, 
Thompson and Could ridge, 2004 ). Carers are involved in a range of activities, from 
collecting and administering medicines to obtaining and relaying medicine information 
to their care-recipients (Francis, Smith, Gray et at., 2002; Gupta, Smith and Francis, 
2002). Hence, health professionals should be proactive in promoting and assisting 
carers with their information needs. 
Over half of the respondents were interested in being involved in making decisions that 
influenced their health. Although unclear from this study, an earlier study found that 
interested respondents found CMI to be a useful tool in aiding decision making (Koo, 
Krass and Aslani, 2002). In a related area, consumers with breast cancer who desired 
an active role in treatment decision also desired detailed information about their 
condition (Hack, Degner and Dyck, 1994 ). 
Lastly, consumers differed in their opinion regarding the comprehensibility and 
presentation of CMI. This was an expected finding as the user-friendliness of WMI has 
been under scrutiny for the past few decades, both by consumers and researchers 
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(Koo, Krass and Aslani, 2003). The positive opinions of more than half of the 
consumers attest to the efforts involved in the development of CMI and indicate that 
these efforts are headed in the right direction. However, it is worth noting that the free 
comments provided by consumers on this aspect of CMI were largely negative. Hence, 
there is definitely still room for improvement, and whilst it is important to continually 
improve CMI, what is more pertinent is whether negative attitudes towards the way a 
CMI is presented actually translate into negative behaviours when using CMI, as 
suggested by earlier research (Koo, Krass and Aslani, 2002). This remains to be 
explored. 
3.4.5 Study limitations 
As with all studies, the current study was associated with several limitations. The main 
limitation of the study arose due to the errors made by some interviewers. Despite the 
training session conducted prior to the commencement of the interviews, when entering 
the data, it was discovered that some interviewers had administered the questionnaire 
to consumers who were not eligible for the study and some interviewers had used the 
question skips incorrectly. Ideally, these errors should have been identified early on 
and feedback provided to the respective interviewers. However, the errors were not 
identified until the data collection process was completed. Nonetheless, these errors 
did not affect the final study results as the invalid questionnaires were discarded. 
Despite this, there were still pockets of missing data. From this experience, in the WMI 
Study Phase 1, a single data collector was used. 
Secondly, non-responders may have presented a systematic bias in the study. 
However, neither the number of non-respondents nor the reason for non-response was 
documented in this study. This limitation was noted and addressed in the WMI Study 
Phase 1. 
Lastly, despite the attempt to reach a broad cross-section of the population, the 
consumer sample was self-selected hence caution is required in generalising the 
results. 
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3.5 CONCLUSIONS 
This pilot study is one of the first studies in Australia to examine some of the issues 
surrounding the provision and use of CMI by consumers. The results indicate that most 
consumers had some awareness of CMI, and many had received CMI in the past, 
albeit without the active involvement of health professionals. Many consumers also 
read CMI. Most found it useful and beneficial but some had concerns about taking their 
medications after reading it. 
The results from this pilot study have to be confirmed in a larger study and further work 
is required to refine some of the questions used in this study. The attitudinal scales 
need to be refined in order to arrive at a more robust solution and to produce a more 
reliable and valid tool to measure consumers' attitudes toward CMI. In addition, whilst 
the attitudinal items suggest some potential factors which may influence consumers' 
attitude towards CMI and subsequently their use of CMI, there remains a need for 
research which focuses specifically on delineating the role of these factors. 
In conclusion, the results from this study form the foundation for further research in the 
area of consumer's use of CMI as well as the factors which may influence this process. 
Some of the ideas and questions from this study were incorporated in a subsequent 
study, the WMI Study Phase 1, which is reported in Chapter 4. 
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4 FACTORS INFLUENCING USE OF WRITTEN MEDICINE 
INFORMATION- PHASE 1 SURVEY 
The WMI Study Phase 1 was conducted in 2003. It consisted of the administration of a 
structured questionnaire by the researcher to patients with pain/rheumatology 
conditions recruited from Rheumatology Clinics of three major teaching hospitals in 
Sydney and patients with hypertension recruited from a random sample of community 
pharmacies in metropolitan Sydney. 
4.1 OBJECTIVES 
The overall objectives of this study were: 
• 1. To determine patients' interest and likelihood in reading and seeking WMI 
• 2. To determine patients' awareness, readership and use of CMI 
• 3. To investigate the relationship between patient factors 27 and patients' reading 
and seeking of WMI 
• 4. To investigate the influence of patient characteristics'" on patients' evaluation 
and intended use of CMI 
• 5. To determine the impact of patient CMI evaluation on their intended use of CMI 
27 Patient factors investigated in this study included disease state, health locus of control, 
coping style and various patient characteristics (demographics and health literacy). 
28 Patient characteristics investigated in this study included health literacy and various patient 
demographics (gender, age, main language spoken at home, highest level of education, 
occupation, duration of disease and number of medications). 
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4.2 METHODS 
4.2.1 Study questionnaire 
4.2.1.1 Incorporation of questions and ideas from the CMI Study 
The development of the current study, the WMI Study Phase 1 was informed by the 
results of an earlier focus group study (Koo, Krass and Aslani, 2002) and the CMI 
Study (Chapter 3). A number of the questions piloted in the CMI Study (mainly on the 
use of CMI and demographics) were incorporated into the WMI Study Phase 1. 
Several, however, needed refinement on the basis of the insight and experience gained 
from the CMI Study. The modifications are summarised in Appendix E Table A1.18. 
Other additions to the current survey included measures of patient's rating of WMI and 
health locus of control. The CMI Study results suggested that patients had differing 
attitudes and opinions with respect to the readability and presentation of CMI (Section 
3.4.4) hence the Consumer Information Rating Form (CIRF) was included to examine 
how patients evaluate the various aspects of CMI and how this in turn may influence 
their intended use of CMI (Section 4.2.1.2.2). 
Similarly, from the CMI Study (Section 3.4.4) and an earlier focus group study (Koo, 
Krass and Aslani, 2002), health locus of control (HLC) was identified as a possible 
influence on patients' use of CMI. Hence, patients' HLC was measured using the 
Multidimensional Health Locus of Control (MHLC) Scales (Section 4.2.1.2.3). 
4.2.1.2 Content 
The questionnaire (Appendix F) comprised six sections, Section A to Section F. Table 
4.1 presents a summary of the purpose of each section and the related objective(s). 
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Table 4.1 Summary of sections of the WMI Study Phase 1 questionnaire 
Section Purpose To address 
objective 
A 
B 
c 
D 
E 
F 
Examine interest in reading and seeking WMI 1 and 3 
Examine patient's awareness, readership and use of CMI 2 
and other sources of WMI 
Examine patient's perception of the comprehensibility, 
intended use, usefulness and design quality of CMI 
Determine health locus of control 
Determine coping style 
Determine health literacy level 
Collect demographic details and provide opportunity for 
further comments 
4 and 5 
3 
3 
3and 4 
3 and 4 
Each section of the questionnaire is described below in order of appearance in the 
survey form. As mentioned in Section 2.3.2, all sections in the questionnaire were 
administered by the researcher with the exception of Section E which was a self-
completion section. The questions in the questionnaire reflect the use of the general 
survey design principles discussed in Section 2.3.2.1. Some of these are elaborated 
with examples from the questionnaire. 
4.2.1.2.1 Section A 
Section A consisted of new questions constructed by the researchers and existing 
questions from the CMI Study (Section 4.2.1.1 ). 
Question 1, consisting of four horizontal rating scales (1a to 1d) examined the 
participant's interest and likelihood in reading and seeking WMI. The five-point 
horizontal rating scales ranged from 1 ('not at all') to 5 ('very'). 
The concept of CMI as a specific form of WMI was introduced in Question 2. Questions 
2 to 12 examined the participant's use of CMI including awareness and readership of 
CMI and reasons for reading or not reading CMI. Several questions also served to 
explore the influence of duration of therapy (long term or short term), status of the 
prescription (new versus repeat prescription) (Questions 4 and 5) as well as the role of 
the participant as a carer (Questions 9 and 1 0) on readership of CMI. Section A 
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concluded with two questions on other sources of WMI used apart from CMI 
(Questions 13 and 14). 
Most questions in Section A were variants of the close-ended question described in 
Section 2.3.2.1, including simple yes or no questions, multiple choice questions (some 
with an "other" option and/or with multiple answers allowed) and rating scales. The 
exceptions to this were Questions 11 and 12 (reasons for reading or not reading CMI 
respectively) which consisted of open-ended questions followed by multiple-choice 
closed-ended questions. As previously mentioned, the questionnaire was administered 
by the researcher hence it was not viewed by the participants. This allowed participants 
to express what was salient in their own minds first without being influenced by the 
available alternatives (Foddy, 1993). 
4.2.1.2.2 Section B 
Section B was included to explore patients' perceptions (that is, their evaluation) of 
various aspects of CMI and how this in turn influenced their intended use of CMI. 
Although many tools for the evaluation of WMI exist, they are associated with various 
limitations (Section 1.5.1.2). The Consumer Information Rating Form (CIRF), designed 
to provide a more direct method of quantifying patients' perceptions of different aspects 
of a patient information leaflet (Krass, Svarstad and Bultman, 2002) was chosen for the 
following reasons: it was designed to gain the patient's (and not the researcher's) 
perception of WMI, it covered multiple aspects of WMI and its validity and reliability had 
been previously established. 
An adapted form of the CIRF was included in Section B. An extra question on intended 
future use of CMI was added (see below) to examine the effect of CMI evaluation on 
intended use of CMI. Other minor changes were made to make the rating form specific 
for CMI. These consisted of changing the generic term "patient information leaflet" to 
"CMI", and adapting the different sections (Question 3 below) of a leaflet to that of a 
CMI 29 • As only minor word changes were made, these changes were not expected to 
affect the validity and reliability of the instrument. 
29 The content of most WMI is separated into different sections, such as instructions for taking 
the medication, precautions and side effects. In order to make the form applicable to CMI, the 
sections in the original CIRF were adapted to reflect the content of a standard CMI. 
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Section B consisted of five questions. The first four questions consisted of the adapted 
CIRF. Question 1, the comprehensibility subscale, explored perceived 
comprehensibility of CMI (five items on how easy/hard the CMI was to read, 
understand, remember, locate information and keep for future reference). Question 2 
(not in the original CIRF), the future use subscale, explored intended future use of CMI 
(three items on how likely the patient is to read, use or keep CMI). Question 3, the 
utility subscale, explored the perceived usefulness of CMI (eight items on the quantity 
and usefulness of information in different sections of the CMI). Question 4, the design 
quality subscale, measured the perceived design quality of the CMI (seven items on 
design aspects: organization, attractiveness, print size, tone, helpfulness, bias and 
spacing between lines). 
Responses to all questions of the adapted CIRF were scored using rating scales. All 
items in Questions 1 and 2 were scored from 1 (very hard or very unlikely respectively) 
to 5 (very easy or very likely, respectively). Items in Question 3 were scored 0 (none, 
too little or too much) or 1 (about right) for information quantity and 1 (not so useful) to 
3 (very useful) for information usefulness. Finally, items in Question 4 were scored from 
1 (negative adjective) to 5 (positive adjective). 
The last question in Section B was an open-ended question which allowed the 
participant to provide further comments on any aspect of the CMI they have read. 
4.2.1.2.3 Section C 
Section C measured patient's health locus of control (HLC) using the Multidimensional 
Health Locus of Control (MHLC) Scales; the validity and reliability of these scales had 
previously been established (Wallston and Wallston, 1978b). 
The MHLC Scales tap beliefs that an individual's health and therefore health-related 
behaviours is primarily influenced by themselves (internal HLC), by other influential 
people in their lives (powerful other HLC) or by fate and chance (chance HLC) 
(Wallston and Wallston, 1978b). 
Two equivalent forms of the MHLC, Forms A and B, were developed to cater for 
studies which may require repeated administrations. Where only a single administration 
is required (as in the current study), the authors suggested choosing either form in its 
entirety rather than choosing only some items from a given form (Wallston and 
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Wallston, 1978b). Based on this suggestion, Form A was arbitrarily chosen for this 
study. 
Six items relating to each of the three dimensions of control constituted the 18 items in 
the MHLC Scales. These dimensions of control were internal HLC, powerful others 
HLC and chance HLC. For example, agreement with the statement "If I get sick, it is my 
own behaviour which determines how soon I get well again" reflects an internal HLC. 
All items utilised a six-point Likert scale, ranging from "Strongly Disagree" (scored as 
one) to "Strongly Agree" (scored as six) (Wallston and Wallston, 1978b). As per the 
original instrument, no middle ground was provided to guard against respondents using 
an acquiescent response rnode (Polgar and Thomas, 2000). 
Where there were missing items, a coin toss determined whether an item was scored 
"Slightly Disagree" (scored as three) or "Slightly Agree" (scored as four) (Wallston and 
Wallston, 1978b). 
4.2.1.2.4 Section D 
Section D was included to examine how patients coped with stressful situations in 
order to examine whether their coping style was related to the way they used WMI. 
A shortened version of a validated instrument known as the Miller Behavioural Style 
Scale (MBSS) designed to assess an individual's coping disposition (Miller, 1987) was 
chosen as this instrument had been widely used in the health literature (Miller, 1996) 
and coping styles had been shown to influence patient behaviour including their need 
for information (Miller, 1995). 
The MBSS consists of hypothetical, relatively uncontrollable scenes that are stress-
evoking. Following each scene, there are eight descriptions of ways of coping with the 
situation, half of which involve monitoring (taking in and scanning for threat-relevant 
information) and half of which provide blunting options (ignoring or avoiding threat-
relevant information) (Miller, Brody and Summerton, 1988; Miller, 1996). The MBSS 
has been shown to possess good predictive validity, good discriminant validity and 
modest convergent validity (Rees and Bath, 2000). The monitoring subscale of the 
MBSS has also been found to have acceptable reliability (Rees and Bath, 2000). 
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The shortened version chosen for inclusion in the questionnaire (comprising two out of 
the four original scenarios, namely dental visit and possible retrenchment) had 
previously been validated in a separate study (Steptoe, 1989). The participant was 
required to tick all the responses that would best describe how he/she would have 
responded if the hypothetical scenario did arise. This version was chosen in the 
interest of time. Moreover, the other two scenarios in the MBSS (being held hostage 
and being on a turbulent flight) were considered by some critics as being too far 
removed from the everyday experience of many people, making it difficult for 
participants to hypothetically place themselves in such situations (Steptoe, 1989; Muris, 
Van Zuuren, De Jong eta/., 1994; Bijttebier, Vertommen and Vander Steene, 2001 ). 
4.2.1.2.5 Section E 
Section E aimed to assess patient's health literacy level and hence was a self-
completion section. Many tools have been developed to assess patient's health literacy 
levels, however many of these are word recognition tests that do not actually test 
comprehension of written material (Koo, Krass and Aslani, 2003) and it is known that 
the ability to read does not imply the ability to understand what is being read (Doak, 
Doak and Root, 1996). Hence, the short-form Test of Functional Health Literacy for 
Adults (S-TOFHLA), a validated test which tests both reading and comprehension skills 
was chosen (Baker, Williams, Parker eta/., 1999). 
In the interest of time, the abbreviated version of S-TOFHLA was used (Nurss, Parker, 
Williams et at., 2001 ). This consisted of a timed reading comprehension test comprising 
two passages from the health care setting, namely instructions for preparation for an 
upper gastrointestinal examination and the patient rights and responsibilities section of 
a US Medicaid application form (Baker, Williams, Parker et at., 1999). These passages 
consisted of a total of 36 items using a modified Gloze procedure 30 (Taylor, 1953). InS-
TOFHLA, four options are given for each omitted word. As per the S-TOFHLA 
administration instructions, participants were given seven minutes to complete the test 
(Nurss, Parker, Williams eta/., 2001 ). One point was given for each correct item. 
30 The Gloze procedure refers to "a test of readability or comprehension in which a person is 
required to supply words which have been deliberately omitted from a passage" (Oxford 
University Press, 1992). 
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The passages in S-TOFHLA were set in the American health care context. Hence, for 
the purposes of this study, in order to make the passages applicable to the Australian 
health care context, minor word changes were made. In the first passage, the 7 -digit 
telephone number was changed to an 8-digit number. In the second passage, the term 
'Medicaid' was changed to 'health benefits' and the term 'county' was changed to 
'government'. 
As Section E was a self-completion section, particular attention was paid to the way 
this section was laid out (see Section 4.2.1.4 ). 
4.2.1.2.6 Section F 
In Section F, demographic details were requested from participants to define the 
characteristics of the sample and to identify possible trends associating a demographic 
variable to use of WMI. Standard demographic details and other demographic details 
which were possibly associated with the use of WMI were collected: gender, age, 
country of birth, languages spoken at home, highest level of education, occupation, 
employment status, current medical conditions, duration of condition (for which 
participant was recruited into the study), current medications prescribed by the 
participant's doctor and residential postcode. The demographic details collected were 
similar to those collected for the CMI Study; however, there were some modifications 
(Appendix E Table A1.18). 
Following the request for demographic details, participants were given an opportunity 
to express any further thoughts or comments they had regarding CMI or WMI in 
general. 
4.2.1.3 Reliability and validity 
As mentioned in the preceding section (Section 4.2.1.2), the questionnaire utilised 
several validated instruments, namely the CIRF (Section B) (Krass, Svarstad and 
Bultman, 2002), MHLC Scales (Section C) (Wallston and Wallston, 1978b), MBSS 
(Section D) (Miller, 1987) and S-TOFHLA (Section E) (Baker, Williams, Parker eta/., 
1999). 
The use of previously validated questions can save time and effort as the questions 
have already been through extensive tests. Nevertheless, certain differences in the 
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design and execution of a study can affect the validity of the validated instruments 
(Czaja and Blair, 1996). The first of these is the use of different audiences; this was not 
an issue as both the validation studies and current study utilised members of the 
general public. However, consideration had to be given to the fact these 'members of 
the general public' resided in different countries. 
The second of these related to the different modes of administration. This was a 
potential problem as the validated instruments were originally designed for self-
completion but were administered by the researcher (except Section E) in the current 
study. However, this difference was minimised with the use of show cards (Section 
4.2.4) that allowed participants to visualise the questions (as in a self-completion 
questionnaire). 
Despite the use of validated instruments, to ensure the overall credibility of the survey 
results, reliability and validity of the questionnaire were assessed in the analyses. 
Two different types of reliability were assessed in this study (Section 2.3.2.2). The 
stability of the questionnaire was indirectly tested using a series of follow-up telephone 
interviews involving a sample of patients from the current study (Chapter 5). This 
allowed the responses provided in the WMI Study Phase 1 to be checked against the 
responses provided in the telephone interview. In addition, in Section A, the reliability of 
the rating scale used in Question 1 was determined using Cronbach's alpha. 
In terms of validity testing, all of the validity tests outlined in Section 2.3.2.2 were 
conducted with the exception of criterion validity as there was no gold standard 
available for comparison. 
To establish face validity, the entire questionnaire was pre-tested with a convenience 
sample (see Section 4.2.1.5). All individuals in the pre-test considered the questions to 
be clear as well as relevant to the research topic. In addition to face validity, content 
validity was also established based on the comments and feedback from two other 
researchers involved with the study. 
Construct validity tests were conducted for different sections of the questionnaire. In 
general, convergent validity was established by ascertaining if the predicted 
associations between different variables were fulfilled. This is illustrated with examples 
from different sections. In Section A, a high self-reported interest in seeking WMI was 
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expected to be correlated with the use of other sources of WMI. In Section B, computer 
printout CMI was expected to be rated better than package insert CMI in terms design 
quality. In Section E, patients with adequate levels of functional health literacy are 
expected to have better comprehension of CMI than patients with inadequate functional 
health literacy. Convergent validity was demonstrated if the expected associations 
were observed from the results. 
4.2.1.4 Layout and appearance 
The questionnaire consisted of 14 printed pages of white A4 paper. The layout of 
questionnaires personally administered by the researcher is considered less crucial 
than for self-completion surveys (Frazer and Lawley, 2000), however, care was still 
taken to ensure that the instructions and questions were clear for the interviewer. All 
pages were printed double-sided with the exception of Section E. Most questions and 
instructions to be read out to the participant were printed in bold using Arial font size 11 
whilst most responses were printed in Aria I font size 1 0 or 11. Certain instructions for 
the researcher were printed in font size 8. 
As Section E was to be completed by the participant, special attention was paid to the 
way this section was set out. The questions were printed single-sided and the back 
page contained the sentence 'this page has been left intentionally blank' to prevent any 
confusion. Arial font size 12 was used and care was taken to ensure that each page 
appeared uncluttered and contained adequate white space. 
4.2.1.5 Questionnaire pre-test 
The rationale for pre-testing has been discussed in Section 2.3.2.3. For this study, 
most of the sections have essentially been pre-tested in one form or another: the 
previously validated instruments, Sections B to E were pre-tested in other studies. 
Sections A and F were based on the CMI Study hence had been pre-tested and piloted 
at that stage (Chapter 3). Notwithstanding, some questions in the CMI Study were 
modified and improved before being incorporated into Sections A and F of the current 
study. Several new questions were also added. 
The entire questionnaire was pre-tested on a convenience sample of five individuals 
consisting of a research officer, a medical student and patients. To help establish the 
98 
Ch 4- WMI Study Phase 1 
face validity of the survey, pre-test individuals were informed of the nature and aim of 
the pre-test and were requested to provide any feedback to the researcher. 
The only issue identified was the occasional difficulty in remembering the questions as 
well as all the possible answers read out by the researcher. This difficulty was 
associated mainly with the previously validated instruments which were all designed for 
self-completion by the patient. The introduction of show cards ameliorated the difficulty. 
This is discussed in Section 4.2.4. 
As no other problems were encountered, no further pre-testing was considered 
necessary. 
4.2.2 Sampling frame and sample size 
4.2.2.1 Sampling frame 
The sampling frame for this study consisted of patients with rheumatology/pain 
conditions and patients with hypertension. This section describes the primary rationale 
for this sampling frame. 
As there is some evidence to suggest that symptoms such as pain are an important 
impetus for patients to seek medical help (Griffith and Carr, 2001 ), it was postulated 
that patients experiencing a symptomatic condition will regard and therefore manage 
their condition differently compared to patients with an asymptomatic condition. This 
difference may also extend to their use of WMI which led to the research hypothesis 
that a patient's disease state will influence their reading and seeking of WMI. 
Hence, to examine this, patients with rheumatology/pain conditions (Group 1) and 
patients with hypertension (Group 2) were chosen for inclusion in this study. Group 1 
comprised patients with a chronic condition which is usually accompanied by 
symptoms including pain, tenderness, inflammation and/or stiffness (Anonymous, 
1999b). Group 2 which comprised patients with an asymptomatic but chronic condition 
(Galton, 1973; World Health Organisation, 2003) was chosen for comparison. 
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4.2.2.2 Sample size 
As no similar studies had previously been conducted, a decision was made to base the 
sample size on the population of patients who reported reading WMI from the literature 
(40% to 89%) (Koo, Krass and Aslani, 2003) and CMI from the CMI Study (64.1 %). 
Taking an approximate value of 60% readership at a 5% degree of precision, and using 
the standard error of proportions equation (Figure 3.1) (Kalton, 1983), a total of 
approximately 400 patients was required. 
This sample size also accounted for the number of patients required in order for the 
regression models to be generalisable to the studied population. Approximately 15-20 
subjects per variable is recommended (Stevens, 1996; Hair, Anderson, Tatham eta/., 
1998). Since the maximum number of independent variables in a particular regression 
model for this study is 15, with 20 subjects per variable, a minimum of 300 patients was 
required. 
Hence, the proposed sample size of 400 was considered adequate (200 per group). 
4.2.3 Site recruitment and patient recruitment 
Participants in Group 1 were recruited from Rheumatology/Pain Clinics and participants 
in Group 2 were recruited from community pharmacies. 
In order to be eligible for the study, participants had to be: 
• over the age of 18 years 
• able to take part in the study without the help of a translator 
• currently taking at least one prescription medication for rheumatology/pain (Group 
1) (Appendix F) or hypertension (Group 2) (Appendix F). 
Although attention was paid to ensure that the sample was drawn from as wide a 
population as possible, the recruited sample from both groups was essentially a 
convenience sample. The recruitment process is described in more detail below. 
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4.2.3.1 Group 1 recruitment 
4.2.3.1.1 Group 1 site recruitment 
Rheumatology/Pain Clinics operated in most principal referral hospitals in Sydney and 
these hospitals serviced a high volume of outpatients as they were the main tertiary 
referral sites for specialist consultations. Hence, a decision was made to recruit Group 
1 participants from these specialist clinics as they offered a convenient yet large 
number of potential participants. 
The rheumatologist-in-charge of six of these principal referral hospitals in Sydney were 
approached via telephone and invited to take part in the study. St George Hospital, 
Concord Hospital and St Vincent's Hospital were the first three hospitals to grant verbal 
and written consent hence were recruited into the study. Responses from the other 
teaching hospitals were not pursued as recruitment from these three hospitals was 
deemed sufficient to meet the required sample size of 200 patients. In addition, these 
three hospitals were located geographically apart from one another and belonged to 
different area health services in Sydney, hence allowing the sample to be drawn from 
different parts of the population. 
Recruitment could only be conducted when the clinics were in session and the clinics 
were usually run as half-day clinics several times each week (depending on the 
hospital). As there were inevitable clashes between clinic times for the different 
hospitals, it was not possible to attend every single clinic in all hospitals in any given 
week. Generally, each week during the recruitment period, the researcher visited 
approximately four to six clinics at two different hospitals. 
4.2.3.1.2 Group 1 patient recruitment 
All patients waiting for their specialist appointments were approached (with the 
exception of those who were identified on the clinic list as requiring a translator and 
thus were not eligible). Patients were approached by the researcher, occasionally with 
the assistance of the nursing staff. After determining eligibility, patients were given a 
participant information sheet (Appendix G) and a brief explanation of the study. 
Patients were then requested to sign a consent form (Appendix G) if they agreed to 
participate in the study. 
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The interview was conducted in a quiet private area, usually a spare consultation or 
meeting room. The administration of the questionnaire is discussed below (Section 
4.2.4). 
From the sample size calculation (Section 4.2.2.2), a total of 200 patients were 
required for Group 1 , hence the researcher aimed to recruit approximately 70 patients 
from each of the three hospitals. 
4.2.3.2 Group 2 recruitment 
4.2.3.2.1 Group 2 site recruitment 
Despite the high prevalence of hypertension in the community31 , there were not many 
specialist clinics in the principal referral hospitals which catered specifically for patients 
with hypertension. Even if there were, many hypertensive patients become 
symptomatic by the time tertiary referral is required, which placed patients outside the 
required sampling frame for this study. Therefore, community pharmacies were 
considered the most suitable site to recruit Group 2 patients as patients with 
hypertension who were on antihypertensive medications visited community pharmacies 
regularly to collect their medications. 
For logistical reasons, the Sydney metropolitan area was used as the sampling frame 
for Group 2 and a list of community pharmacies in the area was obtained from the 
Pharmacy Board of New South Wales. 
Assuming a maximum response rate of approximately 24%, as observed in the CMI 
Study, a random sample of 100 community pharmacies were selected. As the names 
of individual pharmacy owners were not available, an information sheet addressed to 
the pharmacist-in-charge was sent to each pharmacy (Appendix G). Three copies of 
information sheet were also included for distribution to pharmacists-on-duty so that 
they were aware of the study (Appendix G). The pharmacist-in-charge was contacted 
approximately a week after mailing to determine receipt of the information sheet and to 
gauge interest in the study. 
31 In Australia, in 1999 to 2000, 30% of people aged 25 years and over had hypertension 
(Australian Institute of Health and Welfare, 2004). 
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During the course of recruitment, it became apparent that some areas of metropolitan 
Sydney were not represented in the sample of consenting pharmacies. Hence, the 
previously obtained list from the Pharmacy Board was further stratified to include only 
pharmacies in each of the under-represented 'Statistical Subdivisions (SSD)'32 
(excluding the previously approached pharmacies). From the remaining list, a random 
sample of 10 pharmacies was drawn for each under-represented SSD. The same 
protocol was followed in mailing and contacting the pharmacies. When the total number 
of participants recruited from the consenting pharmacies from each SSD was deemed 
sufficient to make up for the under-representation, the remaining pharmacies were 
considered lost to follow-up or informed that their assistance was no longer required. 
Consenting pharmacies were visited at an agreed time which was convenient for the 
pharmacies. On the first visit, the pharmacist-in-charge was requested to sign a 
consent form (Appendix G). During the recruitment period, approximately four to six 
pharmacies were visited each week. Generally, the researcher spent a full day 
(approximately six to seven hours) in each pharmacy. This was to prevent selection 
bias which can be introduced by visiting the pharmacy only during certain hours (e.g. 
capturing mainly business people during the lunch hour). 
4.2.3.2.2 Group 2 patient recruitment 
Pharmacists were requested to identify consecutive patients who were on at least one 
antihypertensive medication (based on their dispensing history) and refer them to the 
researcher. This was done for two reasons: firstly, it assisted the researcher in 
identifying eligible patients for the study; secondly, it was thought that patients would 
be more comfortable with the researcher following a referral from a pharmacist with 
whom they were familiar. 
However, this approach did not prove feasible in all pharmacies as in some pharmacies 
the pharmacist was too busy and/or neglected to refer patients to the researcher. 
Hence, the researcher requested permission from the pharmacist to personally 
approach patients while they were waiting to collect their prescriptions. 
32 
"The Statistical Subdivision (SSD) is an Australian Standard Geographical Classification 
(ASGC) defined area which represents an intermediate level, general purpose, regional type 
geographic unit"(p.256) (Australian Bureau of Statistics, 2001a). Metropolitan Sydney is divided 
into 12 such areas. 
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As the latter approach proved to be efficient and no less effective for recruitment, with 
subsequent visits to the pharmacies, both approaches were offered as options to the 
pharmacist. In most cases, the pharmacist was happy to relinquish the responsibility of 
recruitment to the researcher. 
All eligible patients were then given a participant information sheet (Appendix G) and a 
brief explanation of the study, and then requested to sign a consent form (Appendix G) 
if they agreed to participate in the study. The interview was conducted in a low-traffic, 
quieter area of the pharmacy. The administration of the questionnaire is discussed 
below (Section 4.2.4 ). 
A total of 200 patients were required for Group 2 and 40 pharmacies were involved, 
hence the researcher attempted to recruit a minimum of five patients from each 
pharmacy. 
4.2.4 Administration of the questionnaire 
After the participant had completed the consent form, the researcher commenced 
interviewing the patient using the structured questionnaire. In response to the feedback 
provided in the pre-testing stage (Section 4.2.1.5), show cards were prepared to assist 
participants in answering the questions (Frazer and Lawley, 2000) (Appendix F). 
Generally, show cards were used for all questions except those that were relatively 
simple (e.g. yes or no questions and short multiple-choice questions). 
Each section was printed on different colour A4 paper which acted as a visual 
representation to distinguish between sections. For clarity, the questions were typed in 
bold using Arial font size 16 whilst the possible answers were presented in font size 14 
or 16. All cards were individually laminated and converted into a flip chart using ring 
binders. This ensured that the cards were always presented in the correct order (Frazer 
and Lawley, 2000). 
Each participant was also shown a CMI for a particular medication that he/she was 
currently taking and was given approximately 10 minutes to read the CMI 
before completing Section B. Patients were shown a computer printout CMI unless a 
package insert CMI was also available for their specific medication. In these instances, 
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participants were alternately shown a package insert or a computer printout CMI 33 to 
ensure even numbers of each were used. 
The questionnaire took approximately 30 minutes to complete. Where possible, the 
whole questionnaire was administered to the participant by the researcher face-to-face 
in the hospital clinic or community pharmacy. However, in some cases, due to patient 
time constraints, this was not always feasible. In these instances, patients were asked 
if they would be happy for the interview to be conducted or completed by telephone. If 
so, a copy of the questionnaire was given to the patient to take home (in place of show 
cards), but the patient was requested not to look at the questionnaire until the time of 
the arranged telephone interview. If patients declined, only certain sections of the 
questionnaire were administered in the available time. The implications of these are 
discussed in Section 4.4.5. 
4.2.5 Data analysis 
All data were coded and entered into a database in SPSS (1999). The data were 
checked for incorrect entries and missing values using frequency distributions. 
4.2.5.1 Variables used in data analysis 
Besides data that were directly collected during the survey, further variables were 
created for use in later analyses. The main ones are outlined below according to 
sections in the questionnaire. 
In Section A, two scales were derived from the four items measured on a horizontal 
rating scale (Section 4.2.1.2.1). Questions 1a and 1d (which measured the participant's 
interest and likelihood of reading WMI) were summed to form the "reading" scale, while 
Questions 1 b and 1 c (which measured the participant's interest and likelihood of 
seeking WMI) were summed to form the "seeking" scale. For multivariate analysis 
(Section 4.2.5.2), the "reading" and "seeking" scales were dichotomised based on the 
33 Both types of CMI contain the same information presented in the same order but differ in their 
presentation. In order to fit inside medication boxes or around medication bottles, package 
insert CMI is typically printed double sided on lightweight paper of varying sizes, with relatively 
smaller print and limited white space. Computer printout CMI is typically printed on A4-size 
printing paper (normally in three columns), with larger print and more white space. 
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midpoint of the scale. Patients scoring above the midpoint were classified as interested 
in reading and seeking information, respectively. The remainder of patients were 
classified as not interested. 
In Section B, the individual scores assigned to tile different parts in each of the four 
subscales of the adapted CIRF (Section 4.2.1.2.2) were summed. The maximum 
possible score for each subscale was 25 (comprehension), 15 (future use), 32 (utility) 
and 35 (design quality). The utility subscale score is the sum of two scores: the quantity 
of the information and the usefulness of the information (see Section 4.2.1.2.2 for 
scoring details). In order for each subscale to have equal weighting during data 
analysis, all possible maximum subscale scores were standardised to a maximum 
score out of five. Patient scores were then standardised accordingly. 
In Section C, scores corresponding to each dimension of the MHLC Scales (Section 
4.2.1.2.3) were summed. The maximum possible score for each dimension of the 
MHLC Scales was 36. 
For Section D, the number of monitoring and blunting responses provided by the 
patient was summated separately (Section 4.2.1.2.4). The median score for each scale 
was calculated for the total sample. A decision was made to focus on the monitoring 
scale as it has been found to be more reliable (Rees and Bath, 2000) and more useful 
in predicting health behaviour (M. Rodoletz, personal communication, 14 October 
2002) than the blunting scale. Thus, based on their responses to the monitoring scale, 
participants were classified as a 'high monitor' (coped by taking in information; score~ 
median of the total monitoring score) or 'low monitor' (coped by avoiding information; 
score< median of the total monitoring score) (M. Rodoletz, personal communication, 
14 October 2002). 
For Section E, as mentioned in Section 4.2.1.2.5, one score was given for each correct 
item (maximum score of 36) in the S-TOFHLA. Based on their scores, patients were 
classified as having different levels of health literacy (Nurss, Parker, Williams eta/., 
2001 ). These are summarised in Table 4.2. 
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Table 4.2 5-TOFHLA functional health literacy levels 
5-TOFHLA Functional health Interpretation 
score literacy level 
0-16 
17-22 
23-36 
Inadequate 
Marginal 
Adequate 
Unable to read and interpret most health texts 
Has difficulty reading and interpreting health texts 
Can read and interpret most health texts 
From Nurss eta/. (2001) 
In Section F, for demographic characteristics where more than two categories existed, 
some categories were combined to facilitate data analysis. The combination was based 
on the results of analysis of variance for age groups and highest level of education, and 
existing classification for occupation (Australian Bureau of Statistics, 1997a). 
Lastly, as mentioned earlier, disease state was used to examine whether or not 
patients living with chronic symptoms (in this case pain) used WMI differently from 
those with a chronic asymptomatic disease. The two different settings presented 
feasible options for recruitment; however, it was not possible to recruit only patients 
with hypertension without any symptomatic co-morbidities (especially pain). Hence, to 
further confirm that the observed results supported the proposed theory, the groups 
were reclassified based on the presence of pain as a symptom. This was defined as 
any participant who reported taking analgesics and/or medication for musculoskeletal 
conditions. The results based on this classification were compared with the initial 
analysis. 
4.2.5.2 Statistical analysis 
Frequency distributions were compiled for categorical variables. Summary statistics 
were generated for continuous variables. The medians and IORs were reported for 
non-normally distributed continuous variables (all continuous variables in this study 
were non-normally distributed). 
Univariate analyses were conducted to determine the relationships between the 
variables using non-parametric tests; these included Chi-square test (with continuity 
correction where required), Mann-Whitney U test, Kruskai-Wallis test and Spearman's 
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correlation. Variables that were significant at the p<0.1 level 34 were included as 
predictors in multivariate analyses. 
Multiple regression analysis is a multivariate statistical technique that is used to 
analyse the relationship between a single dependent variable and several independent 
variables (Hair, Anderson, Tatham eta/., 1998). As the independent variables used in 
this study were potentially inter-related, multiple regression analysis was considered an 
appropriate statistical technique to evaluate the contribution of specific variables whilst 
controlling for other possible confounding factors (Gow, 2003). 
Standard multiple regression was performed, that is, all independent variables were 
simultaneously entered into the regression equation (Tabachnick and Fidell, 2001 ). 
This was considered the most appropriate type of multiple regression analysis to avoid 
prematurely assigning hierarchy to the independent variables (Tabachnick and Fidell, 
2001 ). The resulting regression models and the residuals were evaluated to ensure 
that they met the assumptions for multiple regression, namely normality, linearity and 
homoscedasticity35, and the absence of multicollinearity'6 and outliers37 . 
Where the assumptions for multiple regression were not met despite attempts at 
transforming the variables, the continuous dependent variables were dichotomised and 
logistic regression was conducted. Logistic regression is a special form of regression in 
which the dependent variable is a dichotomous variable (Hair, Anderson, Tatham eta/., 
1998). It is similar to multiple regression but is considered a more flexible and robust 
technique which is unrestricted by the strict assumptions of multiple regression (Hair, 
Anderson, Tatham eta/., 1998; Tabachnick and Fidell, 2001 ). 
As with standard multiple regression, direct logistic regression was performed by 
entering all predictors into the equation simultaneously (Tabachnick and Fidell, 2001 ). 
34 For interest in reading and seeking WMI, variables were included if they reached statistical 
significance for each individual scale. For the adapted CIRF, variables were included if they 
reached statistical significance for any of the subscales. 
35 Normality, linearity and homoscedasticity were assessed using visual inspection of the normal 
probability plot and residuals scatterplot (Hair, Anderson, Tatham eta/., 1g98). 
36 Tolerance values <0.2 is indicative of a problem with multicollinearity (Garson, 2005b). 
37 Outliers are defined as those with standardised residuals in excess of ±3.3 (for a sample 
n<1000 at the p=0.0011evel) (Tabachnick and Fidell, 2001). 
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This is considered the method of choice when there are no specific hypotheses about 
the importance or order of the independent variables (Tabachnick and Fidell, 2001 ). 
Despite the robustness of logistic regression, cross-tabulation was performed at the 
univariate level to ensure sampling adequacy38 , the resulting models were checked for 
potential multicollinearity39 and several diagnostic statistics40 were evaluated to identify 
potential outliers or influential cases. 
In addition to multiple regression, the relationships amongst the study variables of the 
adapted CIRF was also tested using path analysis. 
4.2.6 Response rates 
There is no universally acceptable patient response rate41 as it is dependent on many 
factors (Bowling, 2000; Jackson and Furnham, 2000). However, patient response 
rates of 65% and above (Hawe, Degeling and Hall, 1990) or 75% and above (Bowling, 
2000) are considered to provide a relatively good representation of the population. In 
this study, the overall patient response rate for both groups was 77% (n=4 79). The 
patient response rate for each group is discussed below. 
4.2.6.1 Group 1 response rate 
As mentioned earlier (Section 4.2.3.1.1 ), three hospitals were used as recruitment sites 
for Group 1. These were StGeorge Hospital (coded H01 ), Concord Hospital (H02) and 
St Vincent's Hospital (H03). The overall patient response rate for Group 1 was 81% 
(n=217). The response rates for each of these hospitals are presented in Table 4.3. 
38 To ensure sampling adequacy, when cross-tabulation is performed, all cell frequencies are" 
1 and no more than 20% of cells are <5 (Garson, 2005a). 
39 Potential multicollinearity is indicated when the correlation between two independent 
variables in a model is >0.70 (Tabachnick and Fidell, 2001). 
40 
By convention, standardised residuals >2.58 are defined as outliers at the p=0.01 level 
(Garson, 2005a). The leverage statistic identifies cases which influence the model more than 
others; leverage >0.5 is indicative of a problem (Garson, 2005b). 
41 
In this study, patient response rate is defined as the number of eligible patients who 
participated in the study and provided useable data divided by the total number of eligible 
patients who were approached. 
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Table 4.3 Patient response rate for Group 1 
Hospital Patient 
Yes (n) No (n) Response rate (%) 
St George Hospital (H01) 
Concord Hospital (H02) 
St Vincent's Hospital (H03) 
Group 1 
76 
70 
71 
217 
23 
13 
15 
51 
78 
84 
83 
81 
The reasons given by patients in Group 1 for not participating in the study is presented 
in Appendix E Table A1.19. Time constraint (e.g. due to parking, other appointments 
and transportation) was cited as the main reason for not participating. 
4.2.6.2 Group 2 response rate 
Group 2 participants were recruited from a random sample of consenting community 
pharmacies. As such, there were two response rates, pharmacy response rate and 
patient response rate. 
A total of 160 community pharmacies were invited to participate in the study. Forty 
three pharmacies agreed to participate, yielding an overall pharmacy response rate42 of 
27% (Appendix E Table A1.20). However, three of these pharmacies were eventually 
not required; hence only 40 pharmacies were used as recruitment sites. The reasons 
given by the pharmacies for not participating are presented in Appendix E Table A1.21. 
The overall patient response rate for Group 2 was 73% (Appendix E Table A1.20). The 
reasons given by patients in Group 2 for not participating in the study are presented in 
Appendix E Table A1.19. As with Group 1, time constraint was the main reason cited 
for non-participation. 
The composition of the sample was compared to the latest Australian census data 
(Australian Bureau of Statistics, 2001 b) to ensure that the proportion of recruited 
42 In this study, pharmacy response rate refers to the number of pharmacies who consented to 
participate in the study divided by the total number of pharmacies who were approached. 
Pharmacies that were lost to follow-up were considered as non-responders. 
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patients from each SSO were reflective of the actual proportion of residents residing in 
a particular SSO in the Sydney metropolitan area (Appendix E Table A1.22). 
The proportion of patients in the sample recruited from each SSO did not differ to the 
proportion of the total population residing in each SSO; however, there were several 
exceptions. In SS012, a relatively high proportion of pharmacies in the random sample 
coupled with a relatively high response rate from the pharmacies (Appendix E Table 
A 1.20) led to overrepresentation in the recruited sample. In SS002 and SS006, the 
lower proportion in the recruited sample may be attributed to language barriers 
(Australian Bureau of Statistics, 2001b). In support of this, some pharmacies in these 
areas cited this as the reason for their non-participation. The poor pharmacy response 
rate in these SSD (Appendix E Table A1.20) in turn led to reduced patient numbers in 
the study. 
4.3 RESULTS 
4.3.1 Degree and mode of completion 
Although the overall response rate was high, as previously mentioned (Section 4.2.4), 
due to time constraints, not all questionnaires were fully completed (Appendix E Table 
A1.23) and not all interviews were able to be completed face-to-face (Appendix E Table 
A 1.24 ). With the patient's consent, some of the interviews were conducted or 
completed by telephone. In other cases, only certain sections of the questionnaire 
could be completed in the time that the patient had available. 
To ensure that there were no demographic differences between the different modes of 
data collection (face-to-face and involving telephone) and different levels of completion 
(fully complete and partially complete), Chi-square statistics were computed. With the 
exception of occupation, no statistically significant differences were observed between 
the different modes of data collection (Appendix E Table A1.25 to Table A1.31 ). 
Similarly, no statistically significant differences were observed between the different 
levels of completion for any of the demographic variables (Appendix E Table A 1.32 to 
Table A1.38). 
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4.3.2 Sample demographics 
This section reports on the demographics of the whole study sample. A summary of 
patient demographics by recruitment groups (Group 1 and Group 2) is included in 
Appendix E Table A1.39. The patient demographics of both groups were similar except 
for gender, age and employment status. The higher proportion of females in Group 1 
may be attributed to the higher prevalence of rheumatology conditions in females 
compared to males (Anonymous, 1999b). The higher proportion of older patients in 
Group 2 is most likely due to the rising prevalence of hypertension with increasing age 
(Anonymous, 1999a) whereas the onset of rheumatology condition can occur at any 
age (Anonymous, 1999b). As patients in Group 2 were generally older, it is therefore 
not surprising to observe that a greater proportion of patients in this group were retired 
compared to Group 1. 
4.3.2.1 Gender 
Of the 479 participants who completed the survey, 279 (58.2%) were female and 200 
(41.8%) were male. 
4.3.2.2 Age 
The age of the participants in the sample ranged from 19 to 90 with a median of 67 
years (IQR 54-76). The age distribution by decades is shown in Table 4.4. 
Table 4.4 Frequency distribution of participants' age by groups 
Age groups n 
20 and below 1 
21-30 8 
31-40 22 
41-50 46 
51-60 103 
61-70 116 
71-80 126 
81-90 57 
% 
0.2 
1.7 
4.6 
9.6 
21.5 
24.2 
26.3 
11.9 
Total 479 100.0 
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4.3.2.3 Country of birth and language spoken 
In the sample, 307 patients (64.1%) were born in Australia. The other participants were 
born overseas in 54 different countries, the common ones being England, New 
Zealand, Egypt, China and Malta. Reflective of the countries of birth, English was the 
main language spoken at home by 391 participants (81.6%); other main languages 
spoken at home included Italian, Greek, Spanish and Cantonese. A quarter of the 
sample (n=118; 24.6%) also spoke a second or third language at home; English was 
by far the most common second language (n=64 ). 
4.3.2.4 Highest level of education 
Highest level of education varied across the sample (Table 4.5) but most respondents 
had attained at least secondary education. 
Table 4.5 Frequency distribution of participants' highest level of education 
Highest level of education n 
None 6 
Primary School 81 
School Certificate (Year 10) 145 
Higher School Certificate (Year 12) 106 
Trade or other Certificate 37 
Tertiary (Diploma, Bachelor or higher) 103 
Missing 1 
Total 479 
4.3.2.5 Occupation and employment status 
Participants' occupations are listed in Table 4.6. For data analysis purposes, the 
occupations were also reclassified into white- and blue-collar occupations43: 291 
% 
1.3 
16.9 
30.3 
22.1 
7.7 
21.5 
0.2 
100.0 
43 This classification was based on the Australian Bureau of Statistics, whereby white-collar 
occupations (managers and administrators, professionals and associate professionals, clerical 
workers, sales and service workers) are "predominantly associated with higher education and 
specific skills or with lower-skilled jobs that are mainly social rather than physical" and blue-
collar occupations (tradesperson, production and transport workers, labourers and related 
workers) are "predominantly associated with trades and lower-skilled jobs that are often 
physical" (Australian Bureau of Statistics, 1997b ). 
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(60.8%) participants held white-collar occupations and 108 (22.5%) held blue-collar 
occupations (the remainder were homemakers, student, or never worked before as 
shown on Table 4.6). 
Table 4.6 Frequency distribution of participants' occupation 
Occupation n 
Managers and administrators 48 
% 
10.0 
Professionals and associate professionals 105 21.9 
T radesperson and related workers 59 12.3 
Clerical workers 76 15.9 
Production and transport workers 28 5.8 
Sales and service workers 62 12.9 
Labourers and related workers 21 4.4 
Homemaker 75 15.7 
Student 1 0.2 
"Never worked before" 3 0.6 
Missing 1 0.2 
Total 479 100.0 
In terms of employment status, approximately half of the patients were retired, 
approximately a quarter were in full or part time employment and the rest were not 
working due to various reasons (Table 4.7). 
Table 4.7 Frequency distribution of participants' employment status 
Employment status n 
Full time 65 
Part time 41 
Retired 251 
Unable to work due to health reasons 37 
Unemployed 9 
Homemaker 75 
Missing 1 
% 
13.6 
8.6 
52.4 
7.7 
1.9 
15.7 
0.2 
Total 479 100.0 
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4.3.2.6 Current medical conditions and prescribed medications 
The most commonly reported medical conditions were hypertension (n=324, 67.6%), 
hypercholesterolemia (n=140, 29.2%), rheumatoid arthritis (n=87, 18.2%), osteoarthritis 
(n=BO, 16.7%) and diabetes (n=69, 14.4%). 
The main presenting medical conditions (for which the patients were recruited into the 
study) are presented in Appendix E Table A1.40. As expected, this comprised a range 
of rheumatology/pain conditions for Group 1 participants and hypertension for Group 2 
participants. The duration since diagnosis of the presenting condition ranged from 1 
month to 58 years with a median of 10 years (IQR 3-20 years) (41 missing data). 
The current medications taken by patients in the sample are shown in Table 4.8. The 
two main classes of medications taken were cardiovascular and musculoskeletal 
system, which reflects the eligibility criteria used in the study. The median number of 
medications taken by the patients was four (range 1-32, IQR 3-6 medications). 
Table 4.8 Current prescription medications (by therapeutic class) taken by participants 
(n=479) 
Current medication by therapeutic class n medications % 
Cardiovascular system 915 40.4 
Musculoskeletal system 315 13.9 
Endocrine and metabolic disorders 287 12.7 
Analgesia 166 7.3 
Alimentary system 139 6.1 
Central nervous system 137 6.0 
Vitamins and minerals 98 4.3 
Respiratory systems 88 3.9 
Eye 39 1.7 
Infections and infestations 25 1.1 
Other 57 2.5 
Total (for medications) 2266 100.0 
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4.3.3 Interest and use of medicine information 
4.3.3.1 Interest and likelihood in reading and seeking WMI 
Four items were used to measure patients' interest and likelihood in using WMI. As 
mentioned in Section 4.2.5, two scales, namely "reading" and "seeking" scales were 
derived from these four items. The descriptive statistics for the four individual items and 
the two scales are shown in Table 4.9. The majority of patients were interested (item 
1a) and very likely to read (item 1d) WMI about their prescription medications, 
however, the reverse was true for their likelihood (item 1b) and frequency (item 1c) of 
seeking WMI. The distribution of the "reading" and "seeking" scales mirrored this 
pattern, hence the "reading" scale had a very high median and the "seeking" scale had 
a very low median. 
Cronbach's alpha for the "reading" and "seeking" scale was 0.90 and 0.94, 
respectively, indicating very high internal consistency. 
Table 4.9 Interest and likelihood in reading and seeking WMI (n=479) 
Item Range Median 
1a How interested would you say you are in reading written 1-5 4 
information about your prescription medicines? 
1b How likely are you to seek written information about 1-5 1 
your prescription medicines? 
1c Typically, how often would you seek written information 1-5 1 
about your prescription medicines? 
1d How likely are you to read written information about 1-5 5 
your prescription medicines? 
"Reading" scale = 1 a + 1 d 2-10 9 
"Seeking" scale = 1 b + 1 c 2-10 2 
IQR 
3-5 
1-5 
1-3 
3-5 
6-10 
2-8 
When the "reading" and "seeking" scales were dichotomised (Section 4.2.5.1 ), a similar 
trend was observed. Hence, the majority of patients were classified as interested in 
reading WMI (n=336, 70.1%) but not interested in seeking WMI (n=328, 68.5%). 
4.3.3.2 Awareness, readership and use of CMI 
The majority of participants (n=398, 83.1 %) were not aware of the definition of 
'Consumer Medicine Information'. However, after a description of CMI was given by the 
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researcher, most participants (n=377, 78.7%) reported having read a CMI for their own 
medication(s). Of these, most participants reported always reading a CMI for a new 
medication, be it a short or long term medication, however, the converse was true 
when it came to repeat medications (Appendix E Table A 1 .41 ). Seventy percent 
(n=264) of participants who read a CMI reported reading all sections of the CMI, while 
the rest read most (n=39, 10.3%) or some (n=74, 19.6%) sections only. For the latter 
groups, the most popular sections were side effects, indication and how to take the 
medication (Appendix E Table A1.42). 
After reading CMI, approximately a third of participants (n=140, 37.1%) kept it for a 
short time until they finished their medication and another third (n=139, 36.9%) threw it 
away immediately. Only 52 participants (13.8%) reported filing away the CMI for future 
reference. The remainder reported a combination of the above. 
Approximately a third (n=143, 29.9%) reported reading a CMI for someone in their 
care, mainly for partners, elderly parents or relatives and children (Appendix E Table 
A1.43). Interestingly, one of these participants reported reading a CMI for her 
husband's medications but not her own. 
In response to an open-ended question about reasons for reading a CMI, the top three 
reasons given by participants were to find out about side effects (n=188, 49.7%), about 
the medication in general (n=135, 35.7%) and to be reassured that the medication is 
safe and suitable (n=70, 18.5%). A variety of other reasons were also volunteered 
(Table 4.10). When this question was followed by a multiple-choice close-ended 
question listing possible reasons for reading CMI, once again, side effects was the top 
reason (n=305, 80.7%) (Appendix E Table A1.44). 
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Table 4.10 Reasons for reading CMI (open-ended question) (n=378) 
Reason n* % 
To find out about side effects 188 49.7 
To find out general information about medication 135 35.7 
For reassurance that medication is safe and suitable 70 18.5 
To find out about interactions (drug, disease, food) 54 14.3 
Feel personally responsible for own health 47 12.4 
To know the effects of medication 45 11.9 
To find out the purpose of medication 24 6.3 
To find out about allergies 21 5.6 
To find out specific information (miscellaneous) 17 4.5 
To know how to take medication 15 4.0 
Information from health professional inadequate 8 2.1 
Due to serious/complex nature of disease condition 5 1.3 
Health professional asked to read CMI 2 0.5 
Other 11 2.9 
NB: Responses are not mutually exclusive. 
*total n=378 as the question was directed to all participants who read a CMI (for themselves 
and/or someone in their care, n=377 and for someone in their care only, n=1) 
Questions of the same style were also posed to participants who did not read CMI, but 
this time requesting their reasons for not reading CMI. In response to the open-ended 
question, trust and reliance in the doctor and/or pharmacist was by far the most 
common reason given for not reading CMI (n=63, 62.4%) (Table 4.11 ). In response to 
the close-ended question that followed, trusting the doctor and receiving adequate 
information from the doctor were the main reasons for not reading a CMI. These were 
followed by trust in the pharmacist and adequate information from the pharmacist 
(Appendix E Table A1.45 ). 
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Table 4.11 Reasons for not reading a CMI (open-ended question) (n=101) 
Reason n* 
Trust in/ rely on doctor and pharmacist 63 
Indifference or lack of interest or need 30 
Receives or asks for verbal information 24 
Difficulty in reading or understanding information 18 
Eyesight problems 10 
Unable to access information 6 
Medication taken for a long time 6 
Other (preferred) source of information 3 
Other 13 
NB: Responses are not mutually exclusive. 
*total n=101 as the question was directed only to participants who did not read a CMI for 
themselves nor for someone in their care 
4.3.3.3 Other sources of WMI 
% 
62.4 
29.7 
23.8 
17.8 
9.9 
5.9 
5.9 
3.0 
12.9 
Three quarters of the participants (n=353, 73.7%) reported not using any other sources 
of WMI other than CMI. The remaining quarter (n=126, 26.3%) reported consulting 
various sources of WMI, with reference books (e.g. annual medication guides for lay 
people) and internet being the most popular sources (Appendix E Table A1.46). 
Despite the use of other sources of WMI, CMI was still considered by many as their 
most frequently used (n=66, 52.4%) and most useful (n=54, 43.9%) source of WMI. 
4.3.3.4 Relationship between interest and likelihood in reading and seeking 
WMI and reported use of medicine information 
As part of the validation process of the "reading" and "seeking" scales, the relationship 
between the scales and various aspects of CMI and WMI use were explored. 
Statistically significant differences in both "reading" and "seeking" scores were 
observed between patients who did and did not do the following: read CMI for their own 
medications, read CMI for medications of someone in their care, and use other sources 
of WMI (Appendix E Table A 1.47). Patients who engaged in the above-mentioned 
activities had significantly higher median "reading" and "seeking" scores than those 
who did not. Hence, the "reading" and "seeking" scales demonstrated convergent 
validity. 
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Similarly, when the scales were dichotomised, there were statistically significant 
differences between patients with different levels of interest in reading and seeking 
WMI, and the behaviours reported above (Appendix E Table A1.48). 
4.3.4 Health locus of control 
The descriptive statistics for each dimension of the health locus of control (HLC) scales 
are presented in Table 4.12. Given that the possible minimum and maximum summed 
scores were 6 and 36 respectively, the ranges indicate that the scores were widely 
distributed. Nonetheless, they were negatively skewed as reflected by the median and 
IQR. Overall, patients appeared to have greater tendencies towards the internal and 
powerful other dimensions of HLC compared to chance HLC. 
Table 4.12 Descriptive statistics for dimensions of the HLC scales 
Scale Range Median IQR 
Internal HLC 12-33 26 22-28 
Chance HLC 7-31 19 15-24 
Powerful other HLC 10-35 24 20-27 
4.3.5 Coping style 
Useable data were collected from 286 respondents44 • The median score for the 
monitoring items was 5 (range 0-8, lOR 4-6). As explained in Section 4.2.5, the sample 
was split into high and low monitors based on this score. As a result, 167 participants 
were classified as monitors (score 2: median) and 119 participants were classified as 
blunters (score< median). 
44 
Although this section was attempted by 324 participants, there were missing data as some 
participants found themselves unable to relate to the presented scenarios (dental visit scenario, 
n=67; possible retrenchment scenario, n=50). 
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4.3.6 Health literacy 
Health literacy scores ranged from 0 to 36 with a median of 33 (lOR 26-35). Based on 
their scores, participants were classified into three different levels of health literacy 
(Section 4.2.5) as shown in Table 4.13 Patients' health literacy level . The majority of 
participants who had completed S-TOFHLA had adequate levels of health literacy. 
Table 4.13 Patients' health literacy level 
Health literacy level (5-TOFHLA score) n % 
Inadequate (0-16) 58 12.1 
Marginal (17-22) 13 2.7 
Adequate (23-36) 291 60.8 
Missing* 117 24.4 
Total 479 100.0 
*Not all participants completed this section due to time constraint. 
4.3. 7 Patient factors in relation to reading and seeking of WMI 
4.3.7.1 Relationship between patient factors and interest in reading and 
seeking WMI 
The univariate analyses on relationships between interest in reading and seeking WMI 
and the various patient factors (disease state, health locus of control, coping style and 
health literacy) are summarised in Appendix E Table A1.49. Variables that were 
significant at the p<0.1 level were included as predictors in multivariate analyses. For 
interest in reading WMI, qualifying predictors were disease state, coping style, health 
literacy, chance HLC and powerful other HLC (Section 4.3.7.2). For interest in seeking 
WMI, disease state, coping style, health literacy, chance HLC and powerful other HLC 
qualified as predictors (Section 4.3.7.3). 
In addition, to confirm the hypothesis regarding asymptomatic and symptomatic 
conditions (Section 4.2.5), univariate analysis was also conducted using presence or 
absence of pain as the independent variable. Statistically significant associations were 
found between pain as a symptom (pain present or pain absent) and interest in seeking 
WMI, but not interest in reading WMI (Appendix E Table A1.50). 
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Lastly, the relationships between patient demographics and interest in reading and 
seeking WMI at the univariate level are summarised in Appendix E Table A1.51. 
Variables that were significant at the p<0.1 level were included as predictors in 
multivariate analyses. These included age, main language spoken at home, highest 
level of education and occupation for both interest in reading and seeking WMI. At the 
same significance level, gender and country of birth was significant only for interest in 
reading WMI whilst employment status was significant only for interest in seeking WMI. 
4.3.7.2 Modelling predictions for interest in reading WMI 
Logistic regression was performed to determine patient variables which predicted 
interest in reading WMI (Table 4.14). The variables demonstrated sampling adequacy. 
No significant outliers were detected and no cases exerted undue influence on the 
model. Multicollinearity was not evident (all bivariate correlations were <0.51 ). 
Overall, as indicated by the model Chi-square, the model was statistically reliable 
indicating that the predictors, as a whole, reliably distinguished between patients who 
were interested in reading WMI and those who were not. The model accounted for a 
fifth of the observed variance as reflected by the Nagelkerke R2• 
The Hosmer and Lemeshow test statistic indicated that the model's estimates fitted the 
data at an acceptable level. The model performed poorly in predicting patients who 
were not interested in reading WMI (26.5% correct predictions) but performed well in 
predicting patients who were interested in reading WMI (95.3%) (Table 4.15). Overall, 
the model successfully predicted 78.7% of the cases. 
From the Wald statistics (Table 4.14), coping style, health literacy and occupation 
reliably predicted patients who were interested in reading WMI. Patients who coped by 
taking in information (monitors) were twice more likely to be interested in reading WMI 
than their counterparts. Patients with adequate health literacy levels were four times 
more likely to be interested in reading WM I than those with inadequate health literacy 
levels. Finally, patients with blue-collar occupations were approximately four times less 
likely than homemakers to be interested in reading WMI. 
Although presence of pain did not qualify as a predictor in logistic regression (Section 
4.3.7.1), to confirm the hypothesis regarding asymptomatic and symptomatic 
conditions, a separate logistic regression model for interest in reading WMI was 
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generated substituting disease state with presence of pain as one of the independent 
variables. Factors predicting interest in reading WMI were found to be identical 
(Appendix E Table A1.52). 
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Table 4.14 Logistic regression for interest in reading WMI 
Independent variables Regression Wald test p Odds 95% 
coefficient (z-ratio) ratio confidence 
interval 
Disease state - hypertension, pain/rheumatology (ind) 0.448 1.725 0.189 1.565 0.802- 3.053 
Chance HLC -0.021 0.435 0.510 0.979 0.919- 1.043 
Powerful other HLC -0.039 1.426 0.232 0.962 0.902- 1.025 
Coping style - blunter, monitor (ind) 0.801 6.137 0.013 2.228 1.182-4.200 
Health literacy - inadequate, marginal (ind) 1.708 3.277 0.070 5.518 0.868- 35.073 
- inadequate, adequate (ind) 1.409 7.918 0.005 4.091 1.533-10.913 
Gender - male, female (ind) 0.446 1.691 0.194 1.562 0.798- 3.058 
Age (years) - :s; 60, "= 61 (ind) 0.139 0.162 0.687 1.149 0.584- 2.261 
Country of birth -other, Australia (ind) 0.462 1.371 0.242 1.587 0. 733- 3.439 
Main language spoken at home -other, English (ind) -0.495 0.949 0.330 0.609 0.225- 1.651 
Highest level of education - s primary,<!: secondary (ind) 0.145 0.093 0.760 1.156 0.456 - 2.932 
Occupation - homemaker, white (ind) -0.801 2.203 0.138 0.449 0.156- 1.293 
- homemaker, blue (ind) -1.363 5.286 0.021 0.256 0.080-0.818 
n 282 
Model x2 test x2=40.519, df=13, p<o.oo1 
Hosmer & Lemeshow test x2=13.052, df=8, p=0.11 o 
Nagelkerke R2 0.200 
(ind) - indicator category 
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Table 4.15 Logistic regression classification table for interest in reading WMI 
Predicted % correct 
Not interested Interested 
Observed Not interested 
Interested 
18 
10 
50 
204 
26.5 
95.3 
Overall% 78.7 
4.3.7.3 Modelling predictions for interest in seeking WMI 
Logistic regression was performed to determine patient variables which predicted 
interest in seeking WMI (Table 4.16). As with the previous model, the variables 
demonstrated sampling adequacy. No significant outliers were detected and no cases 
exerted undue influence on the model. Multicollinearity was not evident (all bivariate 
correlations were <0.61 ). 
Overall, the model was statistically reliable and accounted for approximately a fifth of 
the observed variance. The Hosmer and Lemeshow test statistic indicated that the 
model's estimates fitted the data at an acceptable level. The model performed relatively 
well in predicting patients who were not interested in seeking WMI (88.4% correct 
predictions) but performed poorly in predicting patients who were interested in seeking 
WMI (27.6%) (Table 4.17). The predictive success of the entire model was 67.4%. 
From the Wald statistics (Table 4.16), disease state, powerful other health locus of 
control and health literacy predicted patients who were interested in seeking WMI. 
Patients with rheumatology/pain conditions were approximately two times more likely to 
be interested in seeking WMI than patients with hypertension. Increasing scores on the 
powerful other HLC scale predicted a decreasing interest in seeking WMI. Lastly, as for 
interest in reading WMI, patients with adequate health literacy levels were four times 
more likely to be interested in seeking WMI compared to those with inadequate health 
literacy levels. 
Following the substitution of disease state by presence of pain, factors predicting 
interest in seeking WMI were similar (Appendix E Table A1.53). Powerful other HLC 
and health literacy remained reliable predictors. Presence of pain displayed trends 
towards being a predictor but was not significant at the p<0.05 level. 
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Table 4.16 Logistic regression for interest in seeking WMI 
Independent variables Regression Waldtest p Odds 95% 
coefficient (z-ratio) ratio confidence 
interval 
Disease state -hypertension, pain/rheumatology (ind) 0.605 5.464 0.019 1.832 1.103-3.044 
Chance HLC 0.010 0.174 0.677 1.010 0.962 - 1.061 
Powerful other HLC -0.057 5.185 0.023 0.944 0.899- 0.992 
Health literacy - inadequate, marginal (ind) 1.503 3.749 0.053 4.495 0.982 - 20.578 
- inadequate, adequate (ind) 1.441 7.338 0.007 4.224 1.489- 11.979 
Age (years) - :s 60, ~ 61 (ind) -0.302 1.090 0.297 0.739 0.419-1.304 
Main language spoken at home - other, English (ind) 0.053 0.019 0.891 1.054 0.496- 2.242 
Highest level of education - :s primary,~ secondary (ind) 0.378 1.012 0.314 1.459 0.699 - 3.044 
Occupation - homemaker, white (ind) 0.072 0.043 0.835 1.075 0.544- 2.122 
- homemaker, blue (ind) -0.357 0.733 0.392 0.699 0.309 - 1.586 
Employment status - retired/not working, working (ind) -0.007 0.000 0.984 0.993 0.506- 1.950 
n 356 
Model x2 test l=45.253, df=11' p<0.001 
Hosmer & Lemeshow test x2=8.279, df=8, p=0.407 
Nagelkerke R2 0.165 
(ind) - indicator category 
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Table 4.17 Logistic regression classification table for interest in seeking WMI 
Predicted % correct 
Observed 
Overall% 
Not interested 
Interested 
Not interested Interested 
206 
89 
27 
304 
4.3.8 Patient evaluation of Consumer Medicine Information 
88.4 
27.6 
67.4 
The distribution of scores for each item of the four subscales is shown in Appendix E 
Table A1.54 to Table A1.57). Overall, participants rated CMI very well in all aspects. 
For the comprehension subscale, many participants agreed that CMI was easy to read, 
understand and to locate important information (Appendix E Table A1.54). However, 
when it came to remembering the information in CMI and keeping CMI for future 
reference, there was more variation in responses. 
Similarly, in the future use subscale, most participants expressed strong intentions of 
reading a CMI if the medication was a new medication (Appendix E Table A1.55) but 
less so when it came to using or referring to CMI and keeping CMI. This indicated that 
some participants viewed CMI as a source of information for new medications, but not 
as an ongoing source of reference. 
The utility subscale was divided into the quantity and usefulness of information 
contained in CMI. Although CMI contained the right quanlity of information in each 
section for most participants, it is noteworthy that up to approximately a fifth of 
participants felt that this was not the case (Appendix E Table A1.56). Nonetheless, 
generally, most participants agreed that the information contained in CMI was useful. 
All items in the design quality subscale were also rated well by participants (Appendix 
E Table A1.57). Comparatively, attractiveness and tone were rated less positively than 
the other items. 
When the individual items in each subscale were summed and weighted, the weighted 
subscale scores show a similar distribution to its constituent items (Table 4.18). 
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Despite the wide range, scores were negatively skewed indicating that generally, 
patients found CMI easy to understand, useful and well designed, and expressed 
intentions to use it in the future. 
Table 4.18 Weighted subscale scores for CIRF 
Subscale n Range Median IQR 
Comprehension 305 1.0- 5.0 4.0 3.6-4.6 
Future Use 307 1.0-5.0 4.3 3.3-4.7 
Utility 281 1.3- 5.0 4.4 3.4-5.0 
Design Quality 289 1.9-5.0 4.4 3.6-4.4 
4.3.8.1 Association of patient characteristics with evaluation of CMI 
The results of the univariate analyses for the various patient characteristics examined 
are shown in Appendix E Table A 1.58. Variables that were significant at the p<0.1 level 
for any of the subscales were included as predictors in multivariate analyses. These 
included gender, age, main language spoken at home, highest level of education, 
health literacy, occupation and number of current medications. CMI type45 and patient 
group were included to control for potential confounding effect. 
The resulting regression models met the assumptions for the absence of 
multicollinearity (tolerance values listed in individual regression tables) and outliers 
(Appendix E Table A1.59), and did not show marked evidence of heteroscedasticity 
(Appendix E Figure A 1.1 to Figure A 1.5). However, the evaluation of the residuals 
normal probability plot led to reflect inverse transformation of the weighted design 
quality subscale to reduce skewness and improve the linearity and normality of the 
residuals (Appendix E Figure A1.6 to Figure A1.11 ). 
4.3.8.1.1 Patient characteristics and perceived comprehension of CMI 
Overall, the regression model is significant as reflected by the F test of significance. 
The model explained approximately a quarter of the observed variance and was 
associated with a standard error of 0.66. 
45 Due to the decline of package inserts, only 34 (7 .1%) participants evaluated a package insert 
CMI. All other participants evaluated a computer printout CMI. 
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After adjusting for patient group and CMI type, main language spoken at home, highest 
level of education and health literacy were independently associated with weighted 
comprehension scores (Table 4.19). More specifically, patients who spoke mainly 
English at home, who had achieved at least secondary education and who had 
adequate health literacy levels had higher weighted comprehension scores than their 
counterparts. 
Table 4.19 Relationship between patient characteristics and comprehension subscale 
Predictor B 95%CI p Tolerance 
Lower Upper 
Group 
- Community (ref), hospital 0.015 -0.153 0.182 0.864 0.822 
CMI type 
- Package insert (ref), computer 0.051 -0.259 0.361 0.747 0.897 
printout 
Gender 
- Male (ref), female -0.020 -0.191 0.150 0.814 0.800 
Age group 
- :S 60 (ref),;,: 61 -0.021 -0.190 0.148 0.808 0.846 
Main language spoken at home 
- Other (ref), English 0.297 0.077 0.518 0.008 0.778 
Education 
- :S Primary (ref), ;,: secondary 0.238 0.016 0.459 0.036 0.773 
Health literacy 
- Inadequate (ref), marginal 0.165 -0.280 0.609 0.467 0.830 
-Inadequate (ref), adequate 0.592 0.347 0.837 <0.001 0.601 
Occupation 
- Homemaker (ref), white-collar 0.080 -0.144 0.303 0.483 0.478 
- Homemaker (ref), blue-collar 0.012 -0.258 0.281 0.931 0.448 
Number of medications -0.015 -0.041 0.010 0.247 0.911 
n 301 
R, 0.230 
SEE 0.664 
F 7.852 (p<0.001) 
(ref) - reference category 
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4.3.8.1.2 Patient characteristics and perceived future use of CMI 
Health literacy level was the only patient characteristic independently associated with 
the future use of CMI (Table 4.20), whereby patients with adequate health literacy 
levels scored significantly better than those with inadequate health literacy skills. 
Nonetheless, this finding needs to be interpreted with care as the overall model was 
not statistically significant (p=0.067) and explained less than 10% of the observed 
variance. 
Table 4.20 Relationship between patient characteristics and future use subscale 
Predictor B 95%CI p Tolerance 
Lower Upper 
Group 
- Community (ref), hospital 0.116 -0.150 0.382 0.392 0.822 
CMI type 
- Package insert (ref), computer 0.283 -0.210 0.777 0.259 0.897 
printout 
Gender 
- Male (ref), female 0.160 -0.112 0.432 0.249 0.800 
Age group 
- ~ 60 (ref),~ 61 0.074 -0.195 0.343 0.590 0.846 
Main language spoken at home 
- Other (ref), English 0.131 -0.220 0.482 0.464 0.778 
Education 
- ~ Primary (ref), ~ secondary 0.036 -0.318 0.389 0.843 0.773 
Health literacy 
- Inadequate (ref), marginal 0.004 -0.704 0.712 0.991 0.830 
- Inadequate (ref), adequate 0.455 0.065 0.845 0.022 0.601 
Occupation 
- Homemaker (ref), white-collar -0.181 -0.537 0.174 0.316 0.478 
- Homemaker (ref), blue-collar -0.172 -0.601 0.257 0.431 0.448 
Number of medications 0.018 -0.023 0.059 0.386 0.911 
n 303 
R> 0.061 
SEE 1.061 
F 1.726 (p=0.067) 
(ref)- reference category 
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4.3.8.1.3 Patient characteristics and perceived utility of CMI 
Weighted utility scores were associated with age whereby scores increased for older 
(61 years and over) compared to younger (60 years and under) patients (Table 4.21 ). 
The scores also increased with number of medications indicating patients on more 
medications considered the information more useful. Although the overall model was 
significant, it only explained approximately 10% of the observed variance. 
Table 4.21 Relationship between patient characteristics and utility subscale 
Predictor B 95%CI p Tolerance 
Lower Upper 
Group 
- Community (ref), hospital 0.156 -0.068 0.380 0.171 0.822 
CMitype 
- Package insert (ref), computer 0.314 -0.101 0.729 0.138 0.897 
printout 
Gender 
- Male (ref), female 0.144 -0.085 0.373 0.216 0.800 
Age group 
- s 60 (ref),~ 61 0.249 0.022 0.475 0.032 0.846 
Main language spoken at home 
- Other (ref), English 0.227 -0.069 0.523 0.132 0.778 
Education 
- s Primary (ref), ~secondary -0.016 -0.313 0.281 0.914 0.773 
Health literacy 
- Inadequate (ref), marginal -0.161 -0.757 0.434 0.594 0.830 
- Inadequate (ref), adequate 0.144 -0.184 0.472 0.387 0.601 
Occupation 
- Homemaker (ref), white-collar -0.100 -0.399 0.199 0.511 0.478 
- Homemaker (ref), blue-collar -0.154 -0.515 0.207 0.400 0.448 
Number of medications 0.036 0.001 0.070 0.042 0.911 
n 278 
R2 0.090 
SEE 0.855 
F 2.393 (p=0.008) 
(ref) - reference category 
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4.3.8.1.4 Patient characteristics and perceived design quality of CMI 
Although not a patient characteristic. type of CMI was strongly associated with 
weighted total design, with computer printout CMI scoring significantly higher than 
package insert CMI (Table 4.22). When the individual attributes that comprised the 
design subscale were compared for these two different formats of CMI, computer 
printouts were rated more favourably by patients in terms of overall attractiveness. print 
size, helpfulness and spacing (Table 4.23). 
Table 4.22 Relationship between patient characteristics and design quality subscale 
Predictor B 95"/oCI p Tolerance 
Lower Upper 
Group 
- Community (ref), hospital -0.016 -0.065 0.033 0.516 0.822 
CMI type 
- Package insert (ref). computer 0.193 0.101 0.284 <0.001 0.897 
printout 
Gender 
- Male (ref), female 0.043 -0.007 0.093 0.091 0.800 
Age group 
- s 60 (ref).~ 61 0.089 0.039 0.139 0.001 0.846 
Main language spoken at home 
- Other (ref), English -0.011 -0.076 0.054 0.730 0.778 
Education 
- s Primary (ref). ~ secondary -0.063 -0.128 0.002 0.058 0.773 
Health literacy 
- Inadequate (ref). marginal 0.101 -0.030 0.232 0.129 0.830 
- Inadequate (ref). adequate 0.063 -0.009 0.135 0.085 0.601 
Occupation 
- Homemaker (ref), white-collar -0.015 -0.081 0.050 0.647 0.478 
- Homemaker (ref), blue-collar -0.016 -0.095 0.063 0.690 0.448 
Number of medications 0.001 -0.007 0.008 0.842 0.911 
n 285 
R2 0.162 
SEE 0.190 
F 4.791 (p<0.001) 
NB: The dependent variable. weighted design quality scores, was reflected and inverse 
transformed; (ref) = reference category 
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Table 4.23 Median scores for design quality subscale by CMI type 
Attribute Package inserts Computer printouts 
n Median IQR n Median IQR 
Organisation 33 4 3.5-5.0 264 5 4.0-5.0 
Attractiveness* 33 3 3.0-4.0 264 4 3.0-5.0 
Print size* 34 3 1.8-4.0 264 5 4.0-5.0 
Tone 33 3 3.0-5.0 262 4 3.0-5.0 
Helpfulness* 33 5 3.0-5.0 264 5 5.0-5.0 
Bias 33 5 4.0-5.0 256 5 4.0-5.0 
Spacing between lines• 33 4 2.5-5.0 264 5 5.0-5.0 
*Mann-Whitney U test p<0.001 
Even after controlling for the difference arising from the two types of CMI, age was still 
independently associated with weighted design scores with the older age group giving 
more favourable scores than the younger age group. 
4.3.8.2 Association of weighted CIRF subscales with future use of CMI 
In addition to the influence of individual patient characteristics, the association between 
the original CIRF subscales (comprehension, utility and design quality subscales) and 
the future use of CMI were explored. After adjusting for patient group and CMI type, 
weighted comprehension scores and weighted utility scores were independently 
associated with future use of CMI (Table 4.24). In other words, as patients' 
understanding of CMI and their perceived usefulness of it increased, they expressed 
greater intentions to use it in the future. Interestingly, weighted design quality scores 
did not have any impact on patients' likelihood of using CMI in the future. The overall 
model was statistically significant and explained 17% of the observed variance. 
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Table 4.24 Relationship between original CIRF subscales and future use subscale 
Predictor B 95%CI p Tolerance 
Lower Upper 
Group 
- Community (ref), hospital 0.106 -0.143 0.356 0.403 0.891 
CMI type 
-Package insert (ref), computer 0.261 -0.236 0.757 0.302 0.847 
printout 
Weighted comprehension score 0.414 0.247 0.581 <0.001 0.895 
Weighted utility score 0.317 0.171 0.463 <0.001 0.840 
Weighted design quality score* -0.379 -1.041 0.283 0.261 0.760 
n 275 
R2 0.172 
SEE 0.987 
F 11.151 (p<0.001) 
*reflected and inverse transformed; (ref)= reference category 
4.3.8.3 Path analysis of associations between patient characteristics and 
adapted CIRF 
Following multiple regression, the relationships amongst the variables in the preceding 
sections (Section 4.3.8.1 and Section 4.3.8.2) were tested using path analysis (Figure 
4.1 ). Only relationships reaching statistical significance are shown. As shown, various 
patient characteristics (age, main language spoken at home, highest level of education, 
health literacy and number of medications) and CMI type at the base of the figure 
influenced the scores of each subscale of the adapted CIRF (comprehension, utility, 
design quality and future use). The original CIRF (comprehension, utility, and design 
quality) subscale scores in turn also influenced intended future use of CMI. 
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Figure 4.1 Path analysis of associations between patient characteristics and evaluation of CMI 
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4.3.9 Additional comments 
Participants were given the opportunity to make further comments in relation to the CMI 
they evaluated (Section B) and in relation to the whole study (at the end of the 
questionnaire). Other unsolicited comments were also made throughout the 
administration of the questionnaire. Themes were identified from these comments. 
These are reported under two separate headings, comments specifically relating to the 
actual CMI document (Section 4.3.9.1) and general comments (Section 4.3.9.2). 
4.3.9.1 Comments on CMI document 
4.3.9.1.1 Satisfaction with CMI 
Many patients were "pleased" and "impressed" with the information contained in CMI 
and described the information as "vety informative", "valuable", "good to read", "vety 
useful" and "vety helpful". On the whole, CMI was viewed as an essential document 
although some participants doubted if "other people will bother reading it." 
4.3.9.1.2 Presentation of CMI 
Not surprisingly, participants commented that the print in package insert CMI was too 
small although this was considered acceptable by some in order to fit everything in a 
small piece of paper. Interestingly, several participants commented that the print size in 
computer printout CMI can and should be reduced, partly to decrease the number of 
pages. However, one participant realistically pointed out, "[you] can't make evetyone 
happy regardless what is done". 
Participants appreciated the use of bold print to highlight certain sections of the CMI 
especially the different headings. Several others requested for more information in bold 
print, with description of the tablet (for methotrexate) and side effects stated as 
examples. 
There were also requests for CMI to be printed on white background (instead of the 
occasional dark grey background used on some package insert CMI) to improve its 
clarity. 
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4.3.9.1.3 Structure of CMI 
In general, patients felt that CMI was "well/aid out" and followed a "logical sequence". 
Participants also applauded the use of headings which were thought to be very clear 
and made it very easy to navigate through the CMI. 
There were several requests for important points to be placed at the start of CMI, partly 
so that patients who did not have time to read through the whole CMI can at least read 
through the important points. However, there were obvious differences in what were 
considered as important points, with how to take the medication, precautions, side 
effects, what to do if you forget to take the tablet and storage being cited by different 
participants. 
4.3.9.1.4 Content of CMI 
The length of CMI attracted numerous comments from participants. Whilst many 
participants considered CMI a very comprehensive document which covered 
"everything", equally as many complained that the length was "intimidating" and 
"ridiculous". 
"Goes on and on ... no wonder I don't read them!" (H0205546 ) 
In conjunction with that, many felt that CMI could be summarised as some of the 
information contained in CMI was common sense and "goes without saying". In 
addition, CMI was considered repetitive, contained "generic" information that were 
similar in all CMI and lacked personal relevance in some sections. 
Other participants, however, wanted more information, partly to explain and clarify 
some of the points already contained in CMI. 
Besides length, a few participants commented that CMI was written in "nice simple 
language". Many more, however, were critical on the use of technical terms 
46 Each participant is assigned a participant code. The first alphabet 'C' or 'H' denotes the 
recruitment group that is, 'community' or 'hospital', respectively. The following two digits refer to 
the particular community pharmacy or hospital in order of recruitment and the final three digits 
refer to the participant number. Hence, participant code H02055 refers to the fifty fifth participant 
recruited in the second hospital. 
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(interestingly with the ingredients list cited several times as an example) which were 
considered "bit over the top" for some patients, not necessarily the participants 
themselves. For a small minority, the difficulty with understanding CMI extended 
beyond the use of technical terms to the use of English language itself. 
Several comments were directed at particular sections of CMI. These included 
indications and side effects. In relation to indications, a few patients commented that 
they were taking the medication for indications that were not listed or not given 
emphasis in the CMI. For example, one patient commented that CMI for Salazopyrin TM 
(sulfasalazine) was biased towards bowel cancer rather than the condition he had 
which was ankylosing spondylitis. More explanation in CMI was considered necessary 
for situations such as these. 
In terms of side effects, although recognising that the information could be ''potentially 
scary" or "alarming", with the exception of a few participants who preferred to be 
unaware of the potential side effects, most participants who commented on this issue 
felt that it was necessary to be informed of the side effects so that any actual side 
effects that occurred could be appropriately attributed to the medication. A few 
participants even went to the extent of saying that it was necessary for the information 
in CMI to be slightly alarming to deter people from treating the medication lightly. 
It was also interesting to note that several participants read their CMI because they 
were experiencing an actual side effect. 
4.3.9.1.5 Comparison between package insert CMI and computer printout 
CMI 
Several participants commented on the differences between the two formats of CMI. Of 
note was the perception by several participants that computer printout CMI contained 
more information than package insert CMI although these two different formats 
contained identical information for the same medication. Whilst some found the former 
more favourable, there were others who expressed preference for the latter for its 
perceived brevity. 
The other main comparison made by participants related to the size of the two 
documents and how this impacted on ease of keeping the document for future 
reference. Some felt that the A4 computer printout CMI was a better-sized document to 
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keep but others considered the compact nature of package insert CMI as an incentive 
to keep it. 
4.3.9.2 General comments 
4.3.9.2.1 Access to CMI 
The absence of CMI from the medication box or bottle was by far the most common 
unsolicited comment made during the survey. Many participants questioned the 
absence of package insert CMI and some expressed that they were "not impressed" 
and "not happy". 
Some patients proceeded to ask the manufacturer or the pharmacist for CMI. In some 
cases, these were provided but in other cases, patients were informed that CMI was 
not available. One participant asked the doctor for verbal information. 
Other patients however only read a CMI if it came with the medication box or bottle, but 
otherwise "don't bother". 
"If I've had it, I would've read it." (H02066) 
4.3.9.2.2 Importance of emphasis on CMI document 
Some participants commented that CMI document was inadequately emphasised and 
promoted to patients. There were suggestions that more emphasis could come on the 
CMI itself (for example, "something in red that says 'Please read this document'") or 
from a health professional. 
"Perhaps doctor should encourage patient to read more." (H03060) 
Independent of the above comments but nonetheless reinforcing the importance of 
emphasising the CMI document, several other participants mentioned that they would 
read a CMI if given one or asked to by their health professionals. 
4.3.9.2.3 Patient proactiveness 
Some patients were active in seeking WMI. This was illustrated by the actions taken 
when no package insert CMI was found (Section 4.3.9.2.1 ). Further examples included 
calling the manufacturer to query a side effect or obtaining information to help the 
support group they were leading, and asking questions of health professionals. 
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4.3.9.2.4 Reliance on health professionals 
Contrary to the proactivity displayed by some patients, many participants expressed a 
heavy reliance on their doctors and pharmacists in whom they placed great trust and 
confidence. Hence, some considered reading CMI a "peripheral" activity although CMI 
was still considered a useful document. 
"The boss tells me to do it [take the medication], I do it!" (H01073) 
Others considered CMI an unnecessary document, with some patients expressing that 
patients nowadays had access to too much information and asked too many questions 
of their health professionals. 
"Don 1 give patients too much information to allow them to become their own 
doctors." (H03007) 
4.4 DISCUSSION 
4.4.1 Patients' interest and likelihood in reading and seeking WMI 
The items constituting the "reading" and "seeking" scales were used to describe 
patients' use of WMI and subsequently to form the dependent variables for other 
analyses. These scales were found to demonstrate high reliability and convergent 
validity. 
From these scales, reading and seeking WMI were two distinct activities associated 
with the use of WMI by patients. The majority of patients were interested and likely to 
read WMI but most were not prepared to actively search for it. In seeking to explain a 
lack of proactivity in information seeking, it may be that patients perceived no need to 
engage in information search because they could acquire the information passively, 
had sufficient information or that the effort involved in conducting a search outweighed 
the expected benefits (Lenz, 1984 ). It could also be that patients had been diagnosed 
with their conditions for a considerable length of time hence the information-seeking 
stage often associated with new diagnoses had passed. 
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4.4.2 Awareness, readership and use of CMI 
The interest expressed by most patients for reading WMI was supported by the finding 
that the majority (78.7%) had read a CMI for their own medication(s). It is noteworthy, 
however, that the majority of patients were not aware of the term 'Consumer Medicine 
Information'. Even after an explanation was provided, most patients only recognised 
package insert CMis and were not familiar with computer printout CMI. Interestingly, at 
the time of the study, the former were being phased out and the latter were to become 
the main form of CMI available. 
Most patients in this study were familiar with package insert CMI and many had noted 
its disappearance in recent times, notwithstanding concerns previously expressed that 
package insert WMI would go unnoticed by patients (Raynor and Knapp, 2000). Such 
awareness represents progress in the effort to inform patients about their medications. 
In contrast, the limited awareness regarding computer printout CMI, purportedly the 
main form of CMI available, is a sign that much work remains in the implementation of 
this alternate form of CMI. This notion is further supported by findings from another 
Australian study conducted at the same time which reported that less than half of 
consumers who had had a prescription filled in the past six months were aware that 
pharmacists could provide consumers with computer printout CMI (Benton, Snow and 
Parr, 2004 ). 
Whilst the majority of participants had read a CMI, in agreement with a previous study 
(Knapp and Raynor, 1999), not all participants read all the information in CMI. 
Information on side effects, indication and how to take the medication were the most 
popular amongst those who only read CMI partially, another finding which is consistent 
with the literature [e.g. Dodds and King (1989); Berry, Michas, Gillie et at. (1997); 
Dickinson, Raynor and Duman (2001 ); Raynor, Savage, Knapp eta/. (2004 )). In 
addition, it was clear from the findings that information on side effects was not only a 
popular section, but also the main reason for many to read the CMI. Given this, health 
professionals should move away from the debate about whether the provision of WMI 
and specifically side effects does more harm than good; rather, they should 
concentrate on ensuring that patients are properly equipped with the necessary skills 
and knowledge to interpret and apply such information in a beneficial way. 
Furthermore, where reading CMI was concerned, most patients read CMI for their 
medication if it was new, regardless of whether it was a long or short term medication. 
CMI for repeat medications were rarely read. After reading, CMI was generally 
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discarded immediately or kept for a short period of time. These observations may mean 
that there is a potential medication safety issue whereby patients on chronic therapy 
may not have a readily accessible CMI when there is a need to identify potential 
medication-related problems which may occur after the initiation of therapy. This 
situation is further exacerbated by the decline in package insert CMI which at least 
ensured CMI delivery with every box of medication. 
4.4.3 Relationship between patient factors and patients' reading and seeking 
ofWMI 
In addition to providing some insight into the use of WMI by Australian consumers, this 
study is also one of the first to focus specifically on potential patient factors that may 
influence the way patients read and seek WMI. Besides making a distinction between 
the reading and seeking of WMI, the study results identified several patient factors 
which influenced one or both of these activities. 
In this study, monitors expressed greater interest and likelihood only in terms of 
reading WMI, but not seeking WMI. This suggests that they do want more information 
than blunters but are unprepared to actively find it for themselves. Compared to 
previous studies, such passivity is uncharacteristic of monitors (Miller, 1995; Miller, 
1996). A possible explanation for this may be that these respondents had been 
diagnosed with their conditions for a considerable length of time hence the information-
seeking stage often associated with new diagnoses had passed. 
In addition to coping style, occupation was another patient factor associated with 
reading WMI in that patients with blue-collar occupations were found to be less 
interested and less likely to read WMI compared to homemakers. The reason for this is 
unclear but is likely to be an interaction between several factors. A previous study 
identified blue-collar occupation as one of the characteristics associated with higher 
rates of inadequate health literacy (Gazmararian, Baker, Williams eta/., 1999); this 
may be one contributing factor which explains the decreased interest and likelihood in 
reading WMI. Another contributing factor could be that homemakers are predominantly 
females, and according to Walker (Walker, 2001 ), '1he female head of household views 
herself as the family's caretaker, "owning" the well-being of her children and/or spouse" 
(p.12). Given this role of the family's carer, as suggested in the literature review 
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(Chapter 1 ), homemakers may be more interested and likely to use medicine 
information. 
Health literacy levels were found to influence both reading and seeking of WMI. There 
is a plethora of evidence to substantiate the pervasive nature of inadequate health 
literacy levels on a patient's health (Weiss, Hart and Pust, 1991; Weiss, Coyne, 
Michielutte eta/., 1998; Parker, Williams, Weiss eta/., 1999; Rudd, Moeykens and 
Colton, 2000; Tooth, Clark and McKenna, 2000; Andrus and Roth, 2002; Bernhardt and 
Cameron, 2003). However, this is one of the first studies to show, albeit not 
surprisingly, that patients with inadequate health literacy levels are less interested and 
less likely to read as well as seek WMI. This lack of motivation is most likely the direct 
result of poor literacy itself but undoubtedly, the prevalence of written material pitched 
beyond the literacy level of the general population (Weiss, Hart and Pust, 1991) further 
complicates the matter. 
Patients with rheumatology/pain conditions recruited from the hospital clinics were 
more likely to seek WMI than patients with hypertension recruited from community 
pharmacies. Similar results were observed when disease state was reclassified by the 
absence or presence of pain. Although this has not been previously reported in the 
literature, there is evidence to suggest that symptoms play a key role in the initiation of 
seeking medical care (Cameron, Leventhal and Leventhal, 1993). Moreover, it is well-
established that patients with rheumatology/pain conditions experience considerable 
physical symptoms that impinge on their ability to perform everyday tasks (Sakalys, 
1997; Griffith and Carr, 2001; Woolf, Zeidler, Haglund eta/., 2004). Hence, it is 
plausible that the presence of symptoms encouraged these patients not only to seek 
medical care but also to seek medicine information, which enabled them to understand 
their condition and participate in their care (Ryan, Hassell, Dawes eta/., 2003). 
Conversely, the asymptomatic nature of hypertension (Galton, 1973; Grueninger, 1995) 
has been cited as a major reason for non-compliance or discontinuation of therapy 
among patients with hypertension (Cummings, Kirsch!, Binder eta/., 1982; Jokisalo, 
Kumpusalo, Enlund eta/., 2001; World Health Organisation, 2003). Hence, compared 
to patients with rheumatology/pain conditions, patients with hypertension may have 
found that reading WMI sufficed, and were not as motivated or perhaps did not find it 
necessary to actively search for WMI. 
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Lastly, health locus of control was also found to influence the search for WMI. As 
scores on the powerful other HLC increased (indicating a higher reliance on powerful 
others), the interest and likelihood of seeking WMI decreased. This finding is partially 
supported by another finding in this study whereby trust and reliance in health 
professionals was stated as the most common reason for not reading CMI. Whilst it is 
not surprising that trust and reliance on health professionals mitigates the need to seek 
information, the underlying reasons for this observation seem more complicated. These 
patients seem to perceive no need to search for information due to their "belief in the 
maxim that 'doctor knows best"' (p.910) (Leydon, Boulton, Moynihan eta/., 2000) or 
because the health professional had provided sufficient verbal information (Nicholas, 
Huntington and Williams, 2004 ). However, the literature also suggests that some 
patients were concerned that health professionals might view patients' information 
seeking behaviour as violating their role as patients (Leydon, Boulton, Moynihan eta/., 
2000). 
4.4.4 Influence of patient characteristics on patient evaluation and future use 
ofCMI 
Despite the wide range of responses to each section of the adapted Consumer 
Information Rating Form (CIRF), on the whole, patients found CMI easy to understand, 
useful and well designed. Most patients expressed strong intentions to use CMI if they 
were commencing a new medication. However, consistent with earlier results which 
have already been discussed (Section 4.4.2), patients expressed less intention to refer 
back to CMI or keep it for future reference. 
Overall, the results of this section of the study highlight the need to consider patients' 
characteristics, opinions and perceptions in designing WMI. The study showed that the 
way patients evaluate WMI, and in turn, their likelihood of using the information in the 
future was associated with individual patient characteristics. This differs from previous 
findings whereby leaflet evaluation was found to be unrelated to the consumer's 
gender, age, education or current use of medication, and race only affected evaluation 
of one of the four study medications (Svarstad and Mount, 2001, 2002). A possible 
explanation for the observed difference may be that in this current study, patients 
evaluated WMI for their own medication rather than general WMI. 
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From the results, the self-reported ability of patients to comprehend CMI was related to 
their health literacy level, the main language spoken at home and their level of 
education. Adequate level of health literacy as measured by S-TOFHLA was 
associated with increasing levels of comprehension; this result was anticipated and 
provides further confirmation of the validity of the S-TOFHLA as a literacy tool that 
measures not only reading abilities but comprehension skills as well (Baker, Williams, 
Parker eta/., 1999). More importantly, the study also shows that patients with adequate 
health literacy are also more likely to use CMI in the future. Whilst this makes sense, 
the converse of this finding is a sober reminder that those with inadequate health 
literacy levels are less likely to do so. For the latter, alternative methods of patient 
education such as simplified leaflets or verbal communication may prove more 
beneficial (Davis, Meldrum, Tippy eta/., 1996; Mayeaux, Murphy, Arnold eta/., 1996; 
Weiss, Coyne, Michielutte eta/., 1998). 
Several studies have previously demonstrated the influence of main language spoken 
at home as well as highest level of education on a patient's literacy level and hence 
ability to comprehend information. In a US study, it was observed that English-speaking 
patients scored higher in TOFHLA than their Spanish counterparts (Williams, Parker, 
Baker eta/., 1995). This trend was also reflected in the International Adult Literacy 
Study worldwide where non-English language status was shown to be a significant 
determinant of literacy proficiency especially in English-speaking nations including 
Australia (OECD and Statistics Canada, 2000). 
Similarly, the role of highest level of education in influencing literacy or comprehension 
skill is well documented in the literature (Williams, Parker, Baker eta/., 1995; Parikh, 
Parker, Nurss eta/., 1996; Gazmararian, Baker, Williams eta/., 1999; OECD and 
Statistics Canada, 2000; Benson and Forman, 2002). However, highest level of 
education alone is not a reliable predictor of a patient's ability to comprehend 
information (Meade and Byrd, 1989; French and Larrabee, 1999; Wilson, Racine, 
Tekieli eta/., 2003) and the data collected in this study are consistent with previous 
findings. Hence, there will be some patients who have achieved high levels of 
education yet still have problems understanding WMI, and the converse may also be 
true. 
From the results, perceived usefulness and design quality of CMI was observed to 
increase with age. The reasons for this are unknown. It may be that older patients have 
more co-morbidities and hence are more dependent on medications and medicine 
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information. Another explanation could be that the younger age group, having grown up 
in an environment of increased interest in health-related issues and increased 
recognition of individuals' rights to information, have come to be more demanding and 
discriminatory with respect to information on medicines (Dodds and King, 1989; van 
der Molen, 1999). This was demonstrated in a study of information sources for patients 
with cancer whereby compared to older patients, younger patients used a wider variety 
of information sources more frequently but rated the quality of the information less 
favourably (Mills and Davidson, 2002). Older patients, who seem to prefer a passive 
role in their relationship with health professionals (Benbassat, Pilpel and Tidhar, 1998) 
and who tend to place greater faith in health professionals (Mills and Davidson, 2002) 
may be accustomed to the 'traditional' ways of receiving information verbally prior to 
the increasing availability of WMI. Thus, they may have had lower expectations and 
access to information. Hence, they perceived the information contained in the CMI to 
be more useful and better designed than younger patients. 
Perceived usefulness of CMI also increased with increasing number of medications. 
High number of medications may be a reflection of increased severity or complexity of 
the conditions experienced by patients. For such patients, as verbal information can be 
easily forgotten or confused, CMI may serve as an important reference source and a 
permanent record to refresh their memories and clarify any misconceptions they may 
have regarding their many medications (Mills and Sullivan, 1999). 
In terms of design quality, it is not surprising that the presentation of CMI, whether as a 
package insert or a computer printout influenced the design rating, with computer 
printouts scoring significantly better in terms of overall attractiveness, print size and 
spacing between lines. However, computer printout CMI also rated better than package 
inserts in terms of helpfulness, thus emphasising the role of design aspects in assisting 
patients as they read a document. These design aspects continue to be a challenging 
area that is attracting much discussion and research in the literature (Koo, Krass and 
Aslani, 2003). 
Finally, just as individual patient characteristics can influence their evaluation of CMI, 
their evaluation of CMI in turn can affect the likelihood of using it again in the future. 
Patients who found CMI understandable and useful were also more likely to use CMI in 
the future. These findings are expected, and further highlight the importance of taking 
account of patient characteristics not only in patient evaluation of WMI, but also in 
educating patients about the utility of WMI not only for immediate safe and effective 
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use but also for future identification of potential medication-related problems. Moreover, 
a closer examination of the path analysis in Figure 4.1 reveals that the association 
between comprehension of CMI and intended use of CMI may be attributed to the 
direct influence of health literacy levels on intended use of CMI; this further emphasises 
the importance of health literacy as a predictor of CMI use in the future. 
In contrast, the observation that design quality did not influence the intended future use 
of CMI is unexpected and seems to contradict the findings with regard to design 
aspects of CMI mentioned earlier. A plausible explanation could be that patients were 
not given a choice between the two CMI types they were asked to evaluate (package 
insert or computer printout), thus having any type of CMI albeit poorly designed may 
have been deemed better than having no CMI at all. Moreover, despite being 
recognised by a patient, poor design although frustrating may still be deemed 
"acceptable" if the patient has the motivation and desire to read CMI. Hence, it does 
not prevent a patient from reading it as long as the information is comprehensible and 
useful as discussed earlier. 
Finally, the results from this study serve as further validation for the original CIRF as an 
instrument for measuring patient perceptions of information comprehensibility, utility 
and design quality (Krass, Svarstad and Bultman, 2002). The relationship between 
patients' self-reported comprehension and their literacy levels confirms that the 
comprehension subscale of the CIRF is able to distinguish between patients of different 
literacy levels. The different design quality rating given to package inserts and 
computer printouts also reflects the subscale's ability to identify favourable or less 
favourable design characteristics as perceived by the patients. 
4.4.5 Study limitations 
Although all care has been taken to ensure the validity and generalisability of the study 
results, there are several study limitations. Non-respondents presented a limitation as 
there are possible differences between respondents and non-respondents (in terms of 
their demographics, attitudes and behaviours). The reasons for non-participation were 
able to be documented (Appendix E Table A1.19), however, due to privacy issues, no 
demographics were requested. Nonetheless, the significance of this potential limitation 
is somewhat mitigated by the high response rates (81% for Group 1, 73% for Group 2). 
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The involvement of the pharmacist during Group 2 recruitment also introduced another 
source of bias. Although pharmacists were requested and reminded to identify and 
refer consecutive eligible patients to the researcher, due to the busyness of the 
pharmacy or forgetfulness, this did not always occur. In some cases, the pharmacist 
consciously made a decision that certain patients, despite fulfilling the eligibility criteria, 
were 'not suitable' for the study. To overcome this, as mentioned in Section 4.2.3.2.2, 
the researcher requested for permission to personally approach all patients to 
determine their eligibility for the study. In most cases, permission was granted. Hence, 
the limitation was partly overcome. 
Despite the care taken to ensure that the quality of the collected data was not 
compromised, the use of a different mode of collecting the data (that is, via telephone) 
and completion of only certain sections of the questionnaire were obvious limitations in 
the study. However, as time was a major constraint for many patients, this was deemed 
to be a more satisfactory compromise than entirely excluding these patients, which 
would introduce a selection bias to the recruitment process. As presented in Section 
4.3.1, no statistically significant differences were observed between the different modes 
of data collection and the different levels of completion for the majority of the 
demographic variables. Despite having missing data, as all of the sections were highly 
subjective and dependent on the individual patient, it was deemed inappropriate to 
replace these missing pockets of data. Having said that, the available data set 
contained more than sufficient numbers to run valid and generalisable multiple 
regression analyses and produced overall significant regression equations and 
significant relationships between the dependent variables and some of the predictors. 
The last limitation associated with the methods was that the patients in the study were 
drawn from essentially a convenience sample. Although the researcher attempted to 
collect a representative sample by sampling from different geographical areas and by 
systematically recruiting all eligible patients, the generalisability of the data to the main 
population remains limited. The eligibility criteria also excluded patients with insufficient 
command of the English language hence the current results are probably an 
underestimation of the actual extent of the influence of patient literacy levels and 
primary language spoken at home in the community. 
In terms of the study results, all multivariate analyses only managed to explain some of 
the variance observed in the data. This is not surprising as there are many other 
potential factors, some of which were mentioned in Chapter 1, which can influence the 
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way a patient uses WMI. Moreover, although statistically significant results were 
observed in this study, the magnitude of some of the relationships was small; also, the 
clinical significance of these results was outside the scope of this study and is largely 
unknown. Hence, further work is needed to clarify some of the findings in this study as 
well as to identify other factors that contribute to the way a patient uses WMI. 
4.5 CONCLUSIONS 
This study revealed that the majority of patients are interested in reading but not 
seeking WMI. This interest in reading WMI is supported by the finding that the majority 
of patients have read CMI in the past. Nonetheless, despite a high reported readership, 
there is still room for improvement in terms of patients' awareness of different forms of 
CMI and the role of CMI as an ongoing reference source. 
This is also one of the first studies to establish the influence of certain patient factors 
on reading and information-seeking behaviour. More specifically, coping style, health 
literacy and occupation were predictors of the way patients read WMI whilst disease 
state, health literacy and health locus of control influenced information-seeking 
behaviour. Furthermore, reading and seeking WMI were treated as two distinct 
independent activities that did not necessarily occur in tandem. 
Finally, the results provide an additional aspect for consideration when involving 
patients in the design and evaluation of WMI. Not all patients will evaluate the same 
information in the same way and certain patient characteristics may influence a 
patient's preferences and need for medicine information. 
In conclusion, further research is needed to confirm the validity and reliability of the 
current results as well as clarify the findings in this study. Hence, a follow-up qualitative 
study, the WMI Study Phase 2, was conducted, the results of which are reported in 
Chapter 5. In addition to this, the results from this study provide other directions for 
future research. At the forefront of this is the need for studies which determine the 
clinical significance of some of these observed associations as well as studies to 
identify other potential factors that may influence the way a patient uses WMI. 
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5 FACTORS INFLUENCING USE OF WRITTEN MEDICINE 
INFORMATION- PHASE 2 FOLLOW-UP INTERVIEWS 
This study was conducted in 2003 and comprised a series of follow-up semi-structured 
telephone interviews administered to a sub-sample of respondents from the WMI Study 
Phase 1 to meet the objectives stated below (Section 5.1 ). 
5.1 OBJECTIVES 
The overall objectives of this study were: 
• 1. To triangulate the results of the WMI Study Phase 1 by comparing patient 
responses from the WMI Study Phase 1 and this study 
• 2. To gain more in-depth information on factors influencing patients' reading and 
seeking of WMI 
• 3. To explore further issues surrounding the use of CMI and WMI in general. 
5.2 METHODS 
5.2.1 Interview guide 
An interview guide mainly consisting of open-ended questions (some with prompts) 
was used for the semi-structured interviews (Appendix H). The themes covered in the 
interview guide and the related objectives are summarised in Table 5.1 . 
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Table 5.1 Summary of questions in the interview guide 
Theme Purpose To address 
objective 
1 Explore how patients cope with diagnosis and the role of 1 and 2 
information in the coping process 
Examine the impact of symptoms (or lack there of) on the 1 and 2 
coping process 
2 Examine interest in medicine information, especially WMI 1 and 3 
3 Examine perceived access and perceived role of health 3 
professionals in relation to medicine information 
4 Explore opinion about format and presentation of CMI and 2 
its impact on CMI use 
5 Explore ease of understanding content of CMI 1 and 2 
6 Examine perceived HLC and its influence on use of 1 and 2 
medicine information 
7 Provide opportunity for further comments 3 
5.2.2 Reliability and validity 
In qualitative research, validity refers to the accuracy of findings from the perspective of 
the researcher, participant or readers (Creswell, 2003). Hence, in order to establish the 
credibility of the study, the validity of the interviews was assessed in several ways 
(Maxwell, 1996; Minichiello, Aroni, Timewell eta/., 2000; Polgar and Thomas, 2000; 
Creswell, 2003). Firstly, validity was examined by probing and cross-checking patient 
responses where applicable during the interview (Minichiello, Aroni, Timewell eta/., 
2000). This enabled the interviewer to discover any discrepancies in the participant's 
responses. Secondly, validity was enhanced by identifying and reporting negative or 
discrepant information that ran counter to the themes (Maxwell, 1996; Creswell, 2003). 
Perspectives presented in real life do not necessarily concur, hence the discussion of 
contrary information adds to the credibility of the data (Creswell, 2003). Finally, 
triangulation of findings from this study with data from the WMI Study Phase 1 was also 
carried out to support the validity of the study (Maxwell, 1996; Polgar and Thomas, 
2000; Creswell, 2003). 
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To establish the reliability of patient responses in both studies, some of the participant's 
responses in the interview were compared to his/her responses to the same questions 
in the WMI Study Phase 1. 
5.2.3 Sampling frame and sample size 
The sampling frame consisted of all participants in the WMI Study Phase 1 who 
consented to be contacted for a follow-up telephone interview. 
From this sampling frame, a purposive sample was chosen for inclusion in the study. 
Purposive sampling is considered appropriate when the researcher wishes to select 
unique cases that are especially informative and to identify particular types of cases for 
more in-depth investigation (Neuman, 2003). 
The sample size in a qualitative study is not considered as critical as a sample size in a 
quantitative study. Where the qualitative study is conducted to inform the development 
of a quantitative study, the sample size is usually dependent on the number taken to 
reach saturation, that is, the study is ceased when no new concepts emerge (Creswell, 
1998). However, the current study was conducted mainly for the purposes of 
triangulation and there were no set guidelines for determining the sample size for such 
a study. Hence, initially, approximately 40 interviews were conducted. After the initial 
interviews were conducted, the data were reviewed and judged adequate for the 
purposes of triangulation, hence no further interviews were considered necessary. 
5.2.4 Patient selection 
At the end of the WMI Study Phase 1, all patients were informed of the plan for a series 
of follow-up telephone interviews. Patients were given an information sheet (Appendix 
I) and a brief explanation of the follow-up interviews. They were informed that the 
telephone interviews would last approximately 30 to 45 minutes and would be 
conducted at a convenient time. As not all the WMI Study Phase 1 participants were 
required for interviews, patients were asked if they would consent to be contacted if 
necessary. Consenting patients were requested to fill in a consent form which also 
included a request for telephone contact details and the best time of day for contact 
(Appendix 1). 
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Of the 4 79 participants of the WMI Study Phase 1 , 112 participants (23.4%) [n=85 from 
Group 1 (pain/rheumatology) and n=27 from Group 2 (hypertension)] consented to be 
contacted if necessary for the follow-up telephone interviews. 
As one of the objectives was to triangulate patient responses provided in both studies, 
a heterogeneous group of patients representing a mix of recruitment groups, 
geographic locations, demographics and reported interest in WMI were selected. 
Furthermore, as another objective was to gain more in-depth information and to clarify 
the factors influencing patient's use of WMI, patients who were observed to be 
especially informative in terms of their previous experience with WMI (based on their 
comments in the WMI Study Phase 1) were selected (Neuman, 2003). 
Selected patients were then contacted by telephone twice. The first call was made to 
establish contact and arrange a time for the interview. The second call was the actual 
telephone interview. 
The first call was made at the time specified on the consent form. As this study 
commenced at the completion of the WM I Study Phase 1, in most cases, 
approximately one to three months had lapsed between the initial contact for the WMI 
Study Phase 1 and the follow-up telephone call. Hence, when patients were contacted 
by telephone, they were reminded about the study and the consent they had given for 
further contact, and were asked if they were still willing to participate in the follow-up 
interviews. Patients were also told that with their consent, the interviews would be 
recorded to ensure accuracy and to ease analysis of the interviews. A suitable time for 
the actual interview was then arranged with consenting patients. 
Of the 112 participants who consented to be contacted for follow-up telephone 
interviews, 44 were contacted (n=22 from both Group 1 and Group 2) and 39 were 
interviewed. Of the five patients who did not participate in the interviews, three were 
uncontactable after several attempts and therefore lost to follow-up (from Group 1) and 
two changed their minds about participating (one from each group). 
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5.2.5 Conducting the interview 
The telephone interviews were conducted at the Faculty of Pharmacy. With the 
patient's consent, the interviews were recorded using a digital recorder; a tape recorder 
was also simultaneously used as a backup. The interview procedure is outlined in 
Appendix H. 
5.2.6 Data analysis 
Following verbatim transcription of all interviews, NVivo Version 2.0.161 (QSR, 2002) 
was used to facilitate content analysis of the data. According to Holsti [in Bauer (2000)], 
content analysis is defined as "any technique for making inferences by objectively and 
systematically identifying specified characteristics of the messages" (p.133). Thematic 
content analysis was conducted. The main themes set out in the interview guide 
formed the basis of the analysis. Other emergent themes were also elucidated and 
explored. 
5.3 RESULTS 
The structure of the results section is summarised in Figure 5.1. The left column lists 
the themes in the current study that are discussed in this results section in order of 
appearance. The right column lists the different aspects examined in the WMI Study 
Phase 1 (Chapter 4 ). The links between the two columns represent the triangulation 
points between the two studies. 
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Figure 5.1 Outline of study results and triangulation points with the WMI Study Phase 1 
WMI Study Phase 2 
Interest in medicine 
information 
Access to information and role 
of health professionals 
CMI 
WMI Study Phase 1 
Interest in WMI 
Use ofCMI 
Evaluation of CMI 
(format and presentation, ease l..:::::::::e:::::::....._ _ _.-----:-:---:-:-:-~-----, 
of comprehension, availability) r , Health literacy I 
Health locus of control 
Coping with diagnosis 
(and impact of symptoms) 
Other issues 
5.3.1 Sample demographics 
Health locus of control 
Coping style 
Presence of symptoms in 
disease 
Demographics 
The demographics of the interviewees are summarised in Table 5.2. 
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Table 5.2 Demographic characteristics of Interviewees (n=39) 
Demographic characteristic 
Gender 
Age 
Country of birth 
Main language spoken at home 
Highest level of education 
Occupation 
Employment status 
Number of medications 
Duration of disease (years) 
Male 
Female 
60 years and below 
61 years and above 
Australia 
Overseas 
English 
Other 
Primary or below 
Secondary or above 
White-collar 
Blue-collar 
Homemaker 
Working (full- or part-time) 
Not working (including retired) 
Range= 1-32; Median= 5; lOR= 4-7 
Range= 0.1-40; Median= 7; lOR= 1-13 
(1 missing data) 
5.3.2 Interest in medicine information 
The majority of participants expressed interest in obtaining information about their 
prescription medications to find out about particular aspects of the medication (e.g. 
benefits or side effects) and for their own safety and well-being. 
n 
19 
20 
18 
21 
32 
7 
37 
2 
8 
31 
28 
9 
2 
10 
29 
"Gives you more information and you know, you feel more relaxed by knowing 
what you're taking." (C05004) 
"I am interested in getting information about my medicines. Yes, I am. I think I 
have the responsibility these days to really be aware and to look after one self." 
(C09002) 
"Oh yeah ... if you don't know what you're taking, you know, you might be taking 
Fred's tablets instead of my tablets, you know?" (H02022) 
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There were several interviewees, however, who were not interested in obtaining 
information about their medications. 
"I don't worry about any of those [information], like when I've got cancer, I've 
never looked into it. I just take the treatment and that's it, you know, and just ... 
I'm alright. As far as I'm concerned I'm good." (C39005) 
"Well, I'm not that interested. As I say, I just go along with what [doctors] 
recommend because I think, well, they know and I don't." (H03015) 
Interestingly, some participants, especially those who were very interested in medicine 
information also commented on the general public's lack of interest in medicine 
information. 
"It's ... it's the same as people putting their hands up to help at preschool or 
school. You'll have some people who do everything and some that would do 
nothing. And same as the people who are aware, and the people who are 
unaware. You'll have some that will try to be aware of much information, and 
others don't care." (C34004) 
Overall, the general level of interest expressed by the majority of interviewees was 
similar to that expressed in the WMI Study Phase 1 (Section 4.3.3.1 ). 
5.3.2.1 Preference for verbal or written medicine information 
Participants were also asked to express preferences for written or verbal information. 
Written information was favoured by some mainly because verbal information was 
considered easily forgotten. Moreover, written information was a handy reference for 
the future and allowed participants to digest the information in their own time. 
"Well you can refer back to it, cos sometimes you can't remember everything 
and you can refer back to it." (C14002) 
"And sometimes if people are stressed or a little bit shocked if they're being 
introduced to something, and they're a bit ... you know, hard to take everything 
in, but if it's written, it's something that they can go back and read later on." 
(C34004) 
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Those who preferred verbal information considered it a more user-friendly, clearer, 
personal and relevant way of obtaining information. Interestingly, in Phase 1, receiving 
verbal information was one of the reasons cited for not reading WMI (Section 4.3.3.2). 
"I find it better to have it, something clearly spoken to me, and explained 
thoroughly, than to try and read all the little bits in all different packages, and 
you haven't got a clue as to what they're really saying." (H02008) 
"It's just because I, I am going to the doctor, having that time put aside. That is 
just part and parcel of the time put aside to see the doctor. Reading the great 
long leaflets, one doesn't always have the time or inclination." (C09002) 
"I haven't found the information that comes with the medication completely 
accurate. A lot of it is generalised ... Your pharmacist knows you, your doctor 
knows you, and they are better sources." (H01 040) 
Finally, some participants preferred a combination of both written and verbal 
information. 
"I actually would like to be told by the doctor, and follow up with brochure on the 
product ... in like inside the packet ... I think they're both necessary." (C30005) 
5.3.2.2 Use of written medicine information 
The range of different sources of WMI used by the interviewees was similar to that 
reported in the earlier study (Section 4.3.3.3). Package insert CMI was by far the most 
common source of WMI. Other sources included the internet, patient medication 
handbooks/encyclopaedias, computer printout CMI and various other printouts from 
pharmacies, health professional medical references as well as support group 
newsletters, magazines and newspaper articles. 
Some participants were content to use the information if it happened to be there (e.g. 
package insert CMI), but would not go out of their way to look for information. This 
relatively passive use of information was characteristic of the majority of participants in 
the WMI Study Phase 1 (Section 4.3.3.1 ). However, as found in Phase 1, there were 
also those who avidly searched for medicine information, including WMI. 
"Well, I don't go looking for 'em you know. If they're not in the box, I don't worry 
about it and I don't, as I've said, I don't very often read them anyway. Now and 
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again, if I think I am going to find out anything I'm not sure, I'll read them, but 
uhm, no, I'm happy with them as it is." (H02066) 
" ... Again I stress the point if I find the print in the box or the sheet in the box 
not to my satisfaction /look elsewhere to get the answer." (H01 040) 
Regardless of their information seeking behaviour, CMI was read by most participants. 
Some participants reported always reading it whilst others reported reading it only for 
new medications. Certain sections appeared to be of particular interest, including drug 
interactions, side effects, benefits and how to take the medication. 
A handful of participants claimed that they seldom or never read WMI. Of these, some 
were aware of the benefit of keeping the information for future reference, but the 
majority of non-readers reported discarding the CMI. 
"No, [I don't normally read it}. I just accept what the doctor tells me. When I get 
my script, sometimes I'll read the little pamphlets that's inside with the 
medication, sometimes I don't, if I'm, you know ... the only thing that I know 
there might be information there I can make use of when I need it." (H02066) 
"Chuck [GMt] straight in the garbage tin." (C34005) 
When interviewees' reported readership of CMI was compared to their response to an 
identical question in the earlier study (Section 4.3.3.2), the answers were consistent in 
all cases with the exception of one interviewee. In Phase 1, this interviewee stated that 
he did not read CMI; the opposite response was provided in Phase 2. 
5.3.3 Access to information and role of health professionals 
5.3.3.1 Receipt of and access to medicine information 
Interviewees reported that they received a mixture of solicited and unsolicited medicine 
information from their pharmacist, doctor and/or WMI such as package inserts and 
printouts. Pharmacists more commonly gave a combination of verbal and written 
information whilst doctors by and large provided only verbal information. Hence in 
general, many felt they had no trouble accessing information when it was needed, 
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using a combination of CMI and advice from health professionals plus the occasional 
extra source. 
Although many were satisfied with the information they were able to obtain, several 
issues were identified with the information provision process, including inadequate 
information, provision of contradictory information by different health professionals, 
inappropriate timing of information and lack of proactiveness from health professionals. 
The latter point is further discussed in Section 5.3.3.3. 
"It's in and out. So getting information on your pills, they're not prepared to sit 
down and talk about that." (C20003) 
"What I have found in practice though is that sometimes they give you 
contradictory information ... If I get contradictory information from the doctor and 
the chemist usually it's more to do with what the doctor's left out telling me." 
(H01020) 
"(The pharmacist] will attempt to give me some explanation if I want it, but I 
actually think that's a bit far down the track ... Before you actually go and buy 
the drug and actually put your prescription in, you should know what you're ... 
why you're getting this particular drug." (H03043) 
"Well, health care professionals never seem very ... willing to ... provide 
information. I think they're not forward in providing it." (H02002) 
Moreover, where information seeking was concerned, several individuals felt that 
information was not that easily accessible and that the information seeking process 
required initiative and perseverance. 
"Well, it's not, it's not out there looking at you in the face. You have to actually 
investigate for yourself ... It's not what I'd say freely available in ... in any shape 
or form." (H03043) 
5.3.3.2 Perceptions of health professionals 
Patients' perceptions of health professionals varied widely. Many had high regard and 
spoke well of the health professionals. However, a minority also expressed negative 
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perceptions and comments about doctors and pharmacists. One of the quotes also 
highlighted the participant's perceptions of the difference between the role of doctors 
and pharmacists. 
"If [doctors are] arrogant and big-headed and oh ... so ... "I'm God and you're 
nothing, just lie there like a piece of meat on a hook" ... no, I have no confidence 
in that variety at all ... the rheumatologist that I go under ... an excellent person, 
because he not only thinks of your complaints, he talks to you. He is 
understanding of your complaint, and he listens to you when you talk to him." 
(H02008) 
"The pharmacist is very important because the average person relies a great 
deal on their pharmacist. Quite often they do develop a personal relationship 
with the pharmacist over a number of years. If you don't have a good 
pharmacist that you can go to and rely on, then you know, it's quite 
unfortunate ... " (H01 040) 
"Doctors are alright and chemists are alright if you need them, but if you don't 
need them, I sort of don't bother with them. I didn't need to go to a doctor for 
years, and I didn't. And so ... I don't ... see the need to ... have them as a prop in 
your life sort of thing." (H02013) 
"I don't think [doctors] understand that you NEED a bit of information, but the 
ways surgeries are run today ... it's absurd! More business than there ever was, 
and you only get a time limit!" (C20003) 
"I suppose I just see a doctor as a professional, and to me a pharmacist just 
sells the drug, it's almost like I think, the difference between the bar manager 
and the barmen. You know, the bar manager sets the rules and everything, the 
barmen's just there to sell the alcohol." (H03007) 
5.3.3.3 Role of health professional in medicine information provision 
Regardless of their perceptions of health professionals, most respondents felt that 
health professionals played a crucial role in the provision of medicine information and 
were responsible in educating the public about their medications. 
"I think it's paramount that they know exactly what they're talking about and 
they're able to impart that knowledge on to you in a layman's term."(C15007) 
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Some felt that the onus should fall on the doctor, the prescriber of the medication. 
"As soon as he writes that first script, and if he has to write uh three, four ... how 
many medications when you first have ... something diagnosed, he should give 
you a full page covering that medication." (C20003) 
Others argued that the pharmacist should be responsible. 
"Oh, pharmacists should always give a printout to the patient, and I know that 
doctors can't always go through all the side effects 'cos they just haven1 got 
enough time." (C03009) 
However, most felt that it should be a shared role between the doctor and the 
pharmacist. 
"Because like if the doctor gives me a script, he knows if it's going to muck up 
with another script that I'm taking ... and then /'II go ... to the chemist and he'll 
say, "look, be careful with this one, this one, this one" sort ofthing ... "(C30001) 
Still others felt that ideally the information should come directly from the drug 
manufacturer, although some were sceptical of the credibility of such information. 
''The manufacturer I'd say ... well, saves everybody a lot of mucking about. You 
receive the packet, you got the information there!" (C14002) 
"Well anything is better than nothing [referring to information from 
manufacturers]. But if it came from an independent source I think it'll probably 
be more trustworthy."(H01031) 
Despite their preferences as to who should provide the information, with the exception 
of a few individuals, all interviewees agreed that health professionals needed to be 
proactive in offering medicine information to patients. 
"I think they should offer information, because some people are a bit reluctant to 
er, ask- they're you know a little bit apprehensive where as the doctor or the 
chemist approaches them in a pleasant manner, I think it's better for the 
patient." (C05004) 
In addition, interviewees were also asked for their suggestions of strategies for patients 
who were not interested in medicine information and WMI in particular. Participants 
conceded that patients cannot be forced to read WMI, but emphasised that health 
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professionals should at least offer the information to patients, and actively ask the 
patient to read the WMI. 
"I think when a person gets the medications from the pharmacist, well, if they 
give the printout as I think our pharmacist would, say, "Now, here's the printout, 
read it carefully, if there's anything there that's a problem, speak to me, I'll help 
you, or ring your doctor." People have got to be guided." (H01 040) 
In response to a similar suggestion, one participant commented that she would 
possibly have read the CMI had she been asked to do so by a health professional. 
Another participant, however, felt that asking a patient to read a CMI implied disinterest 
on the health professional's part to spend time with the patient and counsel them with 
verbal information. 
Some participants also suggested that WMI should be provided regardless of the 
patient's interest in the information as it may be a handy resource for family members 
and carers, as well as for the patients themselves should the need arise to consult WMI 
in the future. 
Despite these suggestions, it was acknowledged that there was no guarantee of WMI 
being read. Therefore, several participants highlighted the importance for health 
professionals to provide adequate verbal counselling to all patients. 
5.3.4 Consumer Medicine Information 
As the main form of available WMI, CMI attracted a lot of discussion during the 
interviews. CMI was mainly found as a package insert or provided as a printout by the 
pharmacist. Participants were by far more familiar with the former format than the latter. 
Many participants first encountered computer printout CMI during the WMI Study 
Phase 1 when they were asked to evaluate a CMI. 
5.3.4.1 Format and presentation of CMI 
Overall, the comments on the format and presentation of CMI made by interviewees 
were very similar in scope to those provided by participants in the WMI Study Phase 1 
(Section 4.3.9.1 ). Nonetheless, some comments made during these interviews were 
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more detailed and thus served to elaborate some of the points raised in the earlier 
study. 
5.3.4.1.1 Presentation of CMI 
Approximately half the participants found package insert CMI acceptable or well set out 
and presented. These participants understood the need for the print size to be smaller 
in order to fit into the medication box or around bottles, and to avoid having a leaflet the 
size of a 'toilet roll". 
"Most of them are pretty good ... They sort of. .. clearly indicate each paragraph, 
and you could skip to what you want to know ... " (C19003) 
"Oh well, I think if the box isn't big enough to hold it ... so they have to squash it 
a bit." (C03009) 
By the same token, small print size was by far the biggest complaint of participants who 
were dissatisfied with the current package insert CMI. Interestingly, several people 
expressed concern about the small print not for themselves, but for older people and 
people with impaired vision in general. 
"Oh, for one thing, the thing inside the boxes gets creased and they're in 
smaller print ... and if the crease mark goes across the actual wording, you 
know, it can become a bit difficult to read ... "(C15007) 
"Sometimes the print's very small ... you know, sort of older people may find it 
hard to read." (C39004) 
In contrast, the larger print size of the computer printout CMI was a welcomed change 
from package insert CMI. Nonetheless, some participants commented that computer 
printout CMI was unattractive and less user-friendly. 
" ... doesn't necessarily attract the eye to things. It's usually on an A4 sheet of 
paper, it's big and it's cumbersome ... "(H01020) 
" ... Something that looks like a sort of uh, a medical textbook, where it's fairly 
bland, and sort of research papery like, you know, isn't that appealing ... Needs 
to be something that is actually manageable to put into your handbag or to carry 
home ... without having to fold it ten times ... "(H03043) 
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5.3.4.1.2 Comprehensiveness of CMI 
In terms of the comprehensiveness of package insert CMI, whilst many were satisfied 
with the current length of CMI, others were not. Some participants felt it was too 
lengthy, and wanted something more concise; others felt that it was too brief, and 
wanted something more detailed. 
"It's generally very comprehensive, you know, covers a lot of areas ... " (C39004) 
"Sometimes it can be long winded ... " (H01009) 
"They are probably a little bit brief I think ... " (C03008) 
Interestingly, some participants perceived computer printout CMI to be more 
comprehensive than package insert CMI although these two formats are identical in 
terms of content for the same medicine. 
''[That computer printout CMI] I thought had more information probably than the 
one /looked at in the box, cos it's very small ... but I would like again, even 
more information or at the bottom of that somewhere that I could get more 
information ... " (H03028) 
There were also comments that CMI was too general and not relevant for a particular 
individual, or too repetitive. Some interviewees also expressed cynicism that CMI was 
included to protect manufacturers from litigation than to benefit consumers. 
"It tends to be a bit stereotype ... [the manufacturers] seem to include a lot of 
information that just sort of covering themselves you know ... probably not even 
relevant to what you're doing or what you're taking ... it's not to my benefit ... " 
(C14002) 
5.3.4.1.3 Influence offormat and presentation on use of CMI 
Despite identifying shortcomings with the presentation of CMI, some participants 
commented that these did not influence their use of CMI. For example, one participant 
who complained about the small print size mentioned that he "[needed) glasses to read 
it properly, that's all. "This concurs with the findings in the WMI Study Phase 1 whereby 
design quality did not influence intended future use of CMI (Section 4.3.8.2). 
In contrast, there were others who felt that whilst the presentation of CMI did not 
influence their own use, it may affect its use by the general population. 
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''As a marketing professional, I find it irritating when I see things that are not 
well-presented that I know mean that most people will be turned off by it." 
(H03043) 
5.3.4.2 Comprehension of CMI 
At least half of the participants found CMI "very easy to understand" and "pretty simple 
and straightforward". A minority, however, commented that there was too much 
medical jargon and requested "down-to-earth language that normal people can 
understand". Once again, some participants expressed concern not for themselves, but 
for others. 
"Put it in our lingo ... not in the expert's lingo, they KNOW all about it already!" 
(H02008) 
" ... You gotta remember when you write this stuff, that you're writing to people 
that are ... don't have any medical knowledge at all, and you're writing to people 
with various uhm education level, so you've gotta sort of bring it down so that 
everybody can understand." (H01 002) 
5.3.4.2.1 Influence of comprehension on use of CMI 
Although participants' health literacy levels influenced their interest in reading and 
seeking WMI in the WMI Study Phase 1 (Sections 4.3.7.2 and 4.3.7.3, respectively), in 
the current study, it was more difficult to ascertain whether interviewees' health literacy 
level affected their understanding and hence their use of CMI. All participants who 
commented on the comprehensibility of CMI, including those who felt CMI was not that 
easily understood, had adequate health literacy levels (as determined during the WMI 
Study Phase 1 ). Moreover, there were no apparent differences in terms of ease of 
understanding CMI between participants who did not usually read CMI and those who 
usually read them. 
The only interviewee who had inadequate health literacy level was unable to comment 
on his comprehension of CMI as he had never read it before. However, there was no 
indication as to whether poor literacy was the reason for not reading CMI. Rather, a 
preference for being told "face to face" and faith in the doctor were the cited reasons. 
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5.3.4.3 Availability of CMI 
As was the case in the WMI Study Phase 1 (Section 4.3.9.2.1 ), many participants 
noticed the disappearance of package insert CMI in recent times. 
"Well, to tell you a fact, in all of the last few months, a lot of the medications I 
received, not one, but from several chemists ... have had no information inside." 
(C13005) 
Many participants expressed dissatisfaction when they were informed that package 
insert CMI was being phased out and being replaced by computer printout CMI that 
could be obtained from their pharmacists. Participants viewed package insert CMI as a 
convenient and reliable source of WMI. Moreover, some interviewees added that it may 
be the sole form of WMI available to some patients. 
" ... Most other consumer products the instructions come with it ... my new dryer 
came with an instruction manual. Drugs should come with their, you know, the 
equivalent, which is the instruction manual. If it's left out then you're less likely 
to see it." ( H01 020) 
"I don't think that's a good idea to be honest with you ... You know, the 
information in the box is vital because ... you won't always think to ask the 
pharmacist "Can I have information on this tablet?"" (C39004) 
"For the couple of times that I've actually read the pamphlet, I've only read it 
cos it was there. If it hadn't been in the packet, I wouldn't have gone out of my 
way to ask for it ... so I find it much better of an idea being in the packet." 
(H03007) 
Even participants who did not normally read CMI conceded that package insert CMI 
"can be helpful to people who do want some knowledge about it." 
Just as many were unaware that package insert CMI was being phased out, many 
were also unaware of the availability of an alternative version of CMI. 
"Oh, I thought that was the only way they come, in the box." (C17009) 
Only one participant mentioned that the pharmacist had advertised the availability of 
computer printout CMI. Other participants felt that it was important for pharmacists to 
promote this alternative version of CMI. 
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"Yes, they have a sign up near the counter saying that the information is 
available." (H02002) 
Although some participants felt that it was a good idea for health professionals to be 
able to provide computer printout CMI, there was some scepticism regarding how well 
health professionals could maintain this practice in an everyday setting. 
"What I worry about when the information isn't [with the medication], is that 
although in an ideal world, the doctor or pharmacist would tell you that you have 
this option of getting it or actually give you the information anyway ... they're 
often too busy to do so."(H01020) 
5.3.4.4 Suggestions for improvement of CMI 
Besides the suggestions that were voiced in the preceding paragraphs, other 
suggestions were made regarding measures that could be taken to improve the current 
CMI. These are summarised in Appendix J. 
5.3.5 Health locus of control 
5.3.5.1 Dimensions of control in relation to health 
From their comments, interviewees exhibited traits reflective of one or more of the 
three dimensions of the MHLC scales: internal HLC, powerful other HLC and chance 
HLC (Section 4.2.1.2.3). Patients with internal HLC viewed themselves as being 
personally responsible for decisions that affected their health, with the assistance of 
health professionals when required. 
"I guess the individual. For me it's me ... Well ... it's up to me to ... if I have a ... 
an unusual ... Then I go to the doctor. So it's me to take the first move ... " 
(C33005) 
"Well, I should be ... if the doctor actually makes a comment about a particular 
aspect of my health ... if he said to me "well, look, you really do need to lose 
10kg", I mean, I don't need him to tell me that, I know I should lose 10kg, so I 
suppose I am controlling my health ... 'cos like I know my body, so I know when 
something's not right." (C30005) 
168 
Ch 5- WMI Study Phase 2 
"/listen to the information and make a decision for myself. And that may well be 
that I do what [the health professionals] ask me to do ... but, because 
information is not always consistent, sometimes you're forced to make that 
decision yourself." (H01 020) 
On the other hand, patients with powerful other HLC viewed themselves "as a patient" 
and saw their role as just being aware of the symptoms and presenting themselves to 
the doctor when they were unwell. Although the doctor was deemed as the 'powerful 
other' individual in most cases, one participant saw her parents in the decision-making 
role. 
"/ rely on my doctor to explain things to me and he makes the decision what I 
take and what I do, and I just go and do what he says, you know." (C28001) 
"Well, I'm not the sort of person that would go out to seek all I know about the 
disease you know. I mean, I sort of take the view that the doctors have gone a 
long time to university to get the qualifications that they have and I couldn't help 
to match it in ... with them as far as knowledge is concerned, so I don't even 
bother ... I sort of just leave it to them ... I rely on the doctor." (H01002) 
"Well, if I wanted to take a medication ... I would obviously speak to my parents 
first rather than have a doctor give it to me as to what he thinks ... and parent's 
decision would always have [an] overriding effect." (H01 009) 
Several participants deemed their health as being jointly controlled by themselves and 
by powerful other individuals in their lives. Some of them still viewed themselves as the 
main driver, others viewed the health professional as the main driver, and still others 
saw it as an equal partnership. 
"Well, it's not an equal partnership, I have to get a bit pushy ... just so that I can 
function and so that's why I sort my pills out myself and then next time I go to 
the doctor, I say, "Now, I've done this. /s this OK?" ... it's a bit arrogant but I'm 
the only one who knows how I'm feeling." (C20003) 
"Well, of course you've got your own thoughts on the matter, and you've got 
to ... work out your own ... capabilities with what you're going to do about it. But 
my wife's very good, she assists me in lots of ways and of course you go to the 
chemist and of course the doctor's the ... the final say." (C05004) 
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"I think it's a joint thing, and I take responsibility for, you know, for actually 
involving myself and understanding what's best for me. I mean, rheumatoid 
arthritis to a large extent is self-management. Unless you learn that, you really 
aren't going to, and you need to be able to monitor your own condition, and 
therefore it's a partnership." (H03043) 
Only one individual held a chance HLC, namely a trust and belief in God, but at the 
same time acknowledged the role of health professionals. 
"I just ... accept the advice people give me, uh ... but I don't go looking for it, 
and that's maybe different from other people. Other people might need to know 
the ifs and buts and ... everything else, uhm ... by firstly, my trust in God, and 
secondly, my trust in humans, being doctors or whatever ... " (H02013) 
5.3.5.2 Influence of health locus of control on use of medicine information 
For some participants, there appeared to be an association between HLC and their use 
of information. As expected, interviewees exhibiting internal HLC were more active in 
using and seeking medicine information whilst those with powerful other HLC were less 
inclined to do so, the latter confirming the findings from the WMI Study Phase 1 
(Section 4.3.7.3). 
"Most other people that I see or talk to don't as much as I do. Yeah, generally, I 
research everything and find out what I want to do, and then find you know, and 
then go and get a few opinions." (H03028) 
"Yes, I do, because I often will find something ... independently ... and I will then 
discuss that with my rheumatologist. I'll take up those issues or thoughts and 
talk about you know, potential treatments." (H03043) 
"I think well, [the doctors are] prescribing and they know what's best and ... 
what's the point of reading what's inside [the boxes} ... ?" (H03015) 
However, for most participants, there seemed to be no apparent link between HLC and 
use of medicine information. Medicine information was an important means of acquiring 
knowledge and information, but did not necessarily influence the health decision-
making process. 
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Nonetheless, it is noteworthy that trust and confidence in health professionals seemed 
to be common to both interviewees with powerful other HLC (current study) and 
participants who did not read CMI (Section 4.3.3.2). 
5.3.6 Coping 
5.3.6.1 Reaction and coping with diagnosis 
Patients reacted to the diagnosis of their conditions in different ways. For patients with 
symptomatic conditions (Group 1- patients with rheumatology/pain conditions), many 
were surprised, frightened or worried. 
"I was a bit surprised and then when I found out how bad it was I was a bit 
devastated." (H01 002) 
"I've been healthy all my life so ... it's quite a ... disturbing thing. And ... I knew 
nothing about [giant cell arthritis], not even how to spell the name actually! So, it 
was quite a shock." (H02013) 
''The specialist told me that because lupus is difficult to diagnose he wanted to 
wait for a conclusive diagnosis ... before he answered my questions because he 
didn1 want to frighten me, which of course was quite frightening." (H01 020) 
However, some others were relieved that the diagnosis "had a name" and that it 
"wasn't something worse"whilst others just accepted the diagnosis or were 
unperturbed. 
''There's not a great deal you can do about ... [osteoarthritis] was in the family ... 
it was just a possibility and it came to be. So I just accept it. I didn't really like 
the pain that goes with it, all the inconveniences, things you can1 do, but... as 
for actually having it ... you just accept it." (H02008) 
A few individuals were unsure or ignorant of what the diagnosis meant, and one patient 
viewed her osteoarthritis diagnosis as 'just a nuisance". 
The spectrum of reactions for patients with the asymptomatic condition (Group 2-
patients with hypertension) was similar; however, there were several distinct 
differences. Firstly, the fear and shock expressed by a small number of individuals was 
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linked to the presence of past family history of cardiovascular complications or 
diagnosis at a very young age. Secondly, whereas fear or anxiety was the common 
reaction by Group 1 patients, the majority of Group 2 patients were unperturbed with 
the diagnosis or accepted it as an inevitable part of ageing. 
"Well, I didn't really react to it at all. I just got high blood pressure ... " (C39005) 
"I tend to be the sort of person who accepts these things as inevitable as one 
gets older ... part and parcel of life's great canvas." (C09002) 
Thirdly, a small number of Group 2 patients also expressed denial or shock at the 
diagnosis possibly due to the absence of symptoms. 
"Stupidly, because I said to the doctor ... before I had any [cardiovascular 
complications], I said to the doctor, "Well, I'm not sick. I'm still walking about." 
(C20003) 
"It surprised me a bit, because I didn't know. I mean, you had no effects ... " 
(C17009) 
In relation to the absence of symptoms, one participant also commented on the 
deceptive nature of an asymptomatic condition such as hypertension. 
"So many people have high blood pressure, but don't relate it so much as how 
much damage and what damage it can cause the heart." (C34004) 
Following their diagnosis, the coping strategies of each group of patients reflected their 
general reaction to their diagnosis. Group 2 patients who were largely unperturbed at 
their diagnosis proceeded to take medications with advice from their health 
professionals. 
"Well, I went on the medication that was prescribed for me and just took advice 
of what to do with it and ... follow the procedures." (C15007) 
In contrast, although some Group 1 patients proceeded to follow instructions from 
health professionals and took medications as prescribed, many patients sought 
information about their condition from health professionals, family, friends and different 
sources of written information. 
"I asked around about ... I asked my mom ... and my ... people I knew, and I 
looked on the internet, I read things to find out if you know ... if I've got ... you 
know what... oh ... to find out everything about it." (H03028) 
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Others queried the necessity of certain medications, especially "heavy" medications 
like prednisone, whilst others tried to be optimistic and put things into perspective. 
" ... possibly not have it severely, I was hoping that that would be the case. So I 
set off with sort of a degree of optimism that I wouldn't be in the too-hard 
basket ... " (H03043) 
"Probably I realised that there were so many people worse off than me, so ... 
that made it easier I suppose." (H01 002) 
5.3.6.2 Role of information in the coping process 
Most participants in Group 1 received information from their doctors as well as from 
family and friends. One patient complained that the doctor refused to provide any 
information yet another was satisfied with the very basic information she had received. 
"He didn't want to give me any information, so then I set about finding 
information for myself and eventually changing doctors." (H01 020) 
"I'm quite happy with what they've said because I've never been one to sort 
of ... I've never been one for asking a lot of questions because I think ''well, they 
know better than what I do" and you ask a lot of questions and half the time, 
you don't know what it's about anyway, you know ... " (H03015) 
To a lesser extent, a few participants in Group 2 also mentioned that they were given 
information. In contrast, a few said they did not receive any information. 
Overall, although many interviewees felt that the information was useful to help them 
cope with their condition, others were unsure or felt that the information did not make 
any difference. Interestingly, one participant in particular felt that she coped best 
without information. 
" ... Once you realised what you've got and where you're going you're more 
settled and a bit more probably confident about the treatment you're getting ... if 
you've got some knowledge of it." (H01017) 
"Well, I think it helped ME because I'm the sort of person who likes to get to the 
bottom of everything and I've got a research mind ... I've been an academic in 
the past and ... I've obviously got that desire to know as much as possible. So it 
helped me to understand what was happening to my body and the way in which 
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the drugs may or may not help, and to have a realistic appraisal of the 
situation." (H03043) 
"Well, I don't know [if the information would have made a difference], because I 
think, well, once you get this sort of thing, you just gotta learn to live with it I 
think, haven't you? (H03015) 
"What works or how I got it, it wouldn't make any difference. I will be still none 
the wiser." (H02023) 
"Yes, I can cope very well with the less I know of it, and about it..." (C39005) 
When the responses of the interviewees were compared to their coping style 
determined in the WMI Study Phase 1 (monitor or blunter- Section 4.2.5.1 ), many of 
the interviewees who were monitors found medicine information useful in the coping 
process, thus supporting the definition that monitors were those who coped by taking in 
information. Moreover, interviewees who were monitors were generally interested in 
medicine information, thus supporting the finding of the earlier study whereby monitors 
were more interested in reading WMI (Section 4.3.7.2). Nonetheless, from the 
interviews, some blunters also found medicine information useful to aid with the coping 
process. 
5.3.6.3 Impact of symptoms 
The presence of symptoms affected the way patients perceived and dealt with their 
condition (Section 5.3.6.1 ). Although the range of reactions to their diagnoses were 
similar in both groups, Group 1 patients appeared more negatively affected by their 
diagnoses and were more interested in seeking information about their conditions. This 
was not surprising as participants had to learn to cope with symptoms that had a 
debilitating impact on their daily lives. This also concurred with the findings in the WMI 
Study Phase 1 whereby patients with symptomatic conditions were more interested in 
seeking WMI (Section 4.3.7.3). 
"I'm still finding there's a part of me fighting it and that's because I've grown up 
for 28 years with full mobility, and now coming up year and a half without, it's 
like yeah, just hitting your head against a brick wall." (H03007) 
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"I'm a very active person ... I'm with a few little groups that I'm involved with, uh, 
and we go on little trips ... Well, now I find that I can't get involved in anything!" 
(H03015) 
"Oh well the [pain] certainly annoys you but I mean, you learn to accept these 
things." (H01 002) 
5.3.7 Other issues 
5.3. 7.1 Side effects 
The issue of side effects was brought up in several interviews. A few participants 
expressed alarm over the list of side effects found in CMI. Nonetheless, all except one 
felt that it was still important to be aware of these. The participant who was the 
exception to this rule avoided reading CMI due to the side effects. 
"I think [medicine information should be given] once you started on the 
medication ... rather than right at the beginning ... just so not to freak us out ... 
Yeah you haven't taken it and ... then you're like bombarded with all these side 
effects ... " (H01009) 
"That's right [I don't want to know], not as far as in the pamphlets. I mean 
sometimes, it's got that many things that could happen, that it's frightening you 
know. You think, "oh my god!"" (C39005) 
On the contrary to the side effect list causing alarm, several participants found it 
reassuring to know of the possible side effects so that if it were to occur, they would 
know that "it's the drugs and not you going nutty". 
"I do like to know if something's happening to me ... I can put it down to the 
medication because I've read about the side effects, and not ... be worry about ... 
why I'm having that particular side effect." (H02002) 
One participant proposed that health professionals' reluctance in providing information 
may be linked to their fear of "[scaring] their patients about ... side effects". Another 
participant however felt that this was unjustified, and along with several other 
participants felt that it was the responsibility of health professionals to provide patients 
with a balanced perspective on potential side effects. 
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"/think worrying about patients getting scared ... is garbage. I think that patients 
are more likely to be scared when they're given no information. And the job of the 
hea/thcare professional no matter what the ... you know pharmacist, doctor, 
whatever, is ... is to let people know that it's not necessary to be upset about [side 
effects]." (H01 020) 
In addition to the role of health professionals, one participant felt that current CMI was 
lacking in positive information about the medication and expressed the need for CMI to 
"express the benefits as well as the ... potential side effects". 
5.3.7.2 Other factors influencing interest in WMI 
Other potential factors influencing interest and use of WMI emerged during the 
interviews. These included personality, past experience, timing of information and 
background or career. Quotes illustrating these points are included in Appendix J. 
5.4 DISCUSSION 
5.4.1 Triangulation with the WMI Study Phase 1 results 
The current study provides greater insight into some of the issues examined in the WMI 
Study Phase 1. On the whole, the interview data supports the reliability of the 
responses provided by participants and the validity of the findings from the WMI Study 
Phase 1. 
In terms of interest in medicine information, as in Phase 1, most respondents in the 
current study expressed interest in obtaining information about their prescription 
medicines. This interest has been evident in previous studies on medicine information 
conducted both in Australia [e.g. Allen and Alderman (1995); Newby, Hill, Barker eta/. 
(2001)] and internationally [e.g. Baksaas and Helgeland (1980); Trewin and Veitch 
(2003)]. However, in contrast to the active search for information displayed by 
respondents in the Australian studies, in both phases of the WMI Study, many patients 
were relatively passive in the way they used information, especially WMI. The factors 
that may have contributed to this passivity are explored below. 
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Nonetheless, many participants read WMI. Consistent with the findings in the WMI 
Study Phase 1, package insert CMI was the most common source of WMI. The 
interview data also provided confirmation that many participants had noticed the 
disappearance of package insert CMI in recent times. With the exception of one 
interviewee, all participants were found to provide reliable responses (compared to 
Phase 1) when asked if they had read CM I. The reason for the exception was 
unknown. 
Consistent with the findings in WMI Phase 1, patients experiencing symptomatic 
conditions were more proactive and inclined to search for information. In Phase 1, it 
was postulated that the physical symptoms experienced by these patients served as an 
impetus to seek information. The interview data revealed that the inconveniences 
associated with the symptoms of the disease do play a role. In addition, other factors 
including anxiety with the diagnosis and lack of familiarity with the disease also 
motivated these patients to seek information. Conversely, with the exception of the few 
who had past family history of cardiovascular complications or were diagnosed at a 
very young age, most of the patients with hypertension were either somewhat surprised 
at the diagnosis (due to the absence of symptoms) or unperturbed. 
Where health locus of control was concerned, the interview data produced mixed 
observations compared to the WMI Study Phase 1. As predicted in Phase 1, some 
patients with powerful other HLC were less interested in seeking information and 
entrusted their health and well-being in the hands of health professionals, especially 
doctors. However, in the interviews, some patients with internal HLC were also more 
active in using WMI; this was an expected trend but it was not evident in Phase 1. The 
discrepancy between these two phases may be explained by the overarching finding 
that for the majority of interviewees, there seemed to be no apparent link between HLC 
and use of medicine information. Medicine information served as a means of gaining 
knowledge and information but an interest in medicine information did not necessarily 
translate into internal HLC. This is similar to a previous finding by Beisecker and 
Beisecker (1990). They reported that patients wanted to be well-informed without 
necessarily wanting to assume responsibility for health-related decisions. 
The interview data also confirmed that monitors were generally interested in medicine 
information and found information useful in the coping process. Whilst this concurs with 
findings from Phase 1, there were several blunters who also found medicine 
information useful in aiding the coping process. A plausible suggestion may be that an 
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individual's coping style may be positioned somewhere along a spectrum between the 
two opposite polarities, monitors and blunters, rather than distinctly at either end of the 
polarities. Hence, it is possible that some blunters may still be interested in general and 
basic information about their medicines. 
In terms of health literacy, it was difficult to confirm the associations observed in the 
WMI Study Phase 1 between health literacy and use of WMI as only one interviewee 
with inadequate health literacy levels was available for interview. However, many 
respondents with adequate health literacy levels complained about the use of medical 
jargon in WMI. This suggests a need to re-evaluate the readability of CMI. 
5.4.2 Other issues surrounding use of CMI and WMI 
Besides allowing the triangulation of data with the WMI Study Phase 1, the interviews 
also provided an opportunity to explore participants' opinions on other issues 
surrounding the use of CMI and WMI. 
In addition to clarifying the roles of some of the patient factors that were examined in 
the WMI Study Phase 1, several other factors which potentially influenced participants' 
interest in reading and seeking WMI emerged during the interviews. Past experience 
appeared to be a notable one, with positive experiences in using medicine information 
as well as negative experiences with the medication or treatment both serving as 
impetus to seek and use medicine information. This lends support to one of the factors, 
'experience', which was identified in the literature review (Section 1.5.2.2). The finding 
that negative experiences with medication or treatment encouraged use of medicine 
information also concurred with previous findings (Koo, Krass and Aslani, 2002). 
The availability of package insert CMI, or rather, the lack there of, was another issue 
discussed during the interviews. As mentioned earlier, in both phases of the WMI 
Study, many participants noticed the recent disappearance of package insert CMI. As 
reported in the results section, many participants expressed their dissatisfaction when 
they were informed that there was an intentional move to phase out package insert 
CMI and make them available as computer printout CMI via pharmacies and other 
providers. Despite its small font size, package insert CMI was viewed as a convenient 
and reliable source of WMI, and for some people, the sole source of WMI. This 
sentiment was echoed in another study whereby concern was expressed that the shift 
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from package insert to computer printout CMI meant that "consumers were no longer 
automatically provided information, but instead were subject to the vagaries of a health 
professional's approach." (p. 37) (Benton, Snow and Parr, 2004 ). 
Indeed, in the current study, this concern was further compounded with the perceived 
lack of proactiveness from health professionals. Some participants perceived that 
health professionals were unwilling to provide information about medicines. Whilst 
many others had received solicited and unsolicited advice from health professionals, 
they still agreed that health professionals should be proactive in offering medicine 
information to patients. The importance of this is underscored by the transition from 
package insert to computer printout CMI. Although the MIC Program was established 
as an incentive for pharmacists to provide CMI to patients, based on the responses 
provided by participants in both phases of the WMI Study, it is clear that there is much 
room for improvement. 
Whilst it is important for health professionals to actively encourage the use of WMI by 
patients, it is prudent to bear in mind that not all patients have a preference for WMI. As 
in previous studies (Harvey and Plumridge, 1991 ), in terms of medicine information, 
participants expressed preference for verbal information, written information or a 
combination of the two. Hence, whilst many participants in the current study preferred 
WMI and extolled its benefits, others perceived verbal information as more user-
friendly, clearer and more personal than WMI. The latter had been reported in a 
previous study (Raynor, Savage, Knapp eta/., 2004 ). Thus, in addition to being 
sensitive to individual patient preferences, the provision of verbal counselling 
accompanied by written information may aid health professionals to meet a variety of 
patient needs. 
Last but not least, the issue of side effects was raised. There were comments that the 
current CMI lacked positive information about the medication and that the list of side 
effects was slightly alarming, the latter echoing the findings of some studies in the 
literature (Dodds and King, 1989; Gibbs, Waters and George, 1989a; Bandesha, 
Raynor and Teale, 1996; Livingstone, Pugh, Winn eta/., 1996; Benton, Snow and Parr, 
2004 ). There were also comments that the side effects list was reassuring, a finding 
which is consistent with another previous study (Baker, Roberts, Newcombe eta/., 
1991 ). However, regardless of their comments, most interviewees felt that it was 
important for them to be aware of potential side effects and felt that the responsibility of 
providing a balanced perspective on side effects fell on health professionals. This need 
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for information on side effects has been demonstrated in the literature (e.g. Dodds and 
King (1989); Berry, Michas, Gillie et at. (1997); Dickinson, Raynor and Duman (2001); 
Raynor, Savage, Knapp eta/. (2004 )]. Hence, in conjunction with the low proportion of 
consumers observed to cease their medications due to side effects in the CMI Study 
(Section 3.3.7), the current findings provide further confirmation that health 
professionals should be actively informing patients about the benefits as well as the 
potential side effects associated with the medications. 
5.4.3 Study limitations 
Several limitations were evident in the study. Firstly, the time that had lapsed between 
the initial meeting and the follow-up interview allowed for the possibility that patients 
may have forgotten about the study. However, when the researcher contacted patients 
for the follow-up telephone interviews, most patients remembered and no problems 
were encountered. Moreover, the consistency of the responses provided by the 
participants in spite of the lapsed time between the two phases of the study further 
strengthened the reliability of their responses. 
Secondly, only approximately 10% of participants in Group 2 consented to be 
contacted for this study (as opposed to approximately 40% from Group 1 ). This is 
reflective of the issues encountered with Group 2 recruitment outlined in the limitations 
in Chapter 4. Although this limitation could not be overcome per se, from the 
consenting list, the researcher attempted to select a heterogeneous group of 
participants (Section 5.2.4 ). 
Lastly, saturation of responses was reached for some of the topics covered in the 
interviews but not for others. As generation of new ideas or issues was not the primary 
aim of this study, forty interviews were considered a feasible number for this study. 
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5.5 CONCLUSIONS 
This study served to confirm the reliability and validity of some of the findings from 
Phase 1. The general level of interest exhibited by patients in terms of reading and 
seeking WMI in both phases of the studies was found to be similar. The interview data 
directly supported some of the factors influencing use of WMI identified in Phase 1 but 
not others. For the latter, the findings from this study provided some insight into the 
complexities of some of these associations. 
Furthermore, this study provided the opportunity to explore several other issues 
surrounding the use of CMI and WMI including other potential factors which influence 
the use of CMI and WMI, availability of CMI, patient preferences for information, role of 
health professionals and information on side effects. Participants' opinions and 
perceptions on these issues can inform future practice and are discussed in Chapter 6. 
In conclusion, the WMI Study Phase 2 served as a means of triangulating study results 
and gaining insight into participants' perceptions on issues surrounding the use of WMI. 
In doing so, it also emphasised the value of complementing quantitative with qualitative 
research. 
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6 CONCLUSIONS AND RECOMMENDATIONS 
This thesis comprised of three studies which focussed on examining various aspects of 
WMI from the perspective of medication users, the consumers. The studies provided a 
description of how Australian consumers use CMI and contributed to the current 
understanding of consumer factors which may influence the use of WMI by consumers. 
Overall, consumers are interested in obtaining information about their prescription 
medications and the results support the ongoing use of WMI in consumer education. 
However, in order to ensure consumers gain maximum benefits from the use of WMI, 
much remains to be done. 
The recommendations arising from these findings may have implications at various 
stages associated with WMI as it progresses from development to use by consumers. 
These stages are the development of WMI, availability and dissemination of WMI, use 
of WMI during consultation and use of WMI after consultation. 
6.1 DEVELOPMENT OF WMI 
The findings from this research highlighted that consumers have varying opinions 
about the content of WMI and the way it is presented. Many consumers expressed 
satisfaction with the current CMI. However, others indicated preferences for increased 
font size (for package inserts) and the use of simpler language. In regard to 
presentation, the results suggested that consumers were capable of discriminating 
between well designed and poorly designed WMI. Although the way CMI was 
presented was not found to influence readership and use, it did influence consumers' 
perceptions of its helpfulness, with better designed CMI considered more helpful. Thus, 
it is important for developers of WMI to consider the comments from consumers and 
strive to improve the content and presentation of CMI. However, as there seemed to be 
no consensus from consumers on what constituted an ideal CMI, predicting a single 
universal version of CMI that meets all consumers' needs is likely to be impossible. 
In addition to improving current CMI based on consumers' comments, the results also 
revealed another aspect for consideration by developers of WMI. As mentioned in the 
literature review, the involvement of consumers in the development and evaluation of 
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written information has been advocated. Findings from this research established that 
consumer characteristics including age, main language spoken at home, highest level 
of education and health literacy levels can influence their evaluation of WMI and should 
be taken into consideration in the design and evaluation of WMI. Hence, when 
conducting evaluation of WMI, it is crucial to involve consumers who will be 
representative of the intended users of a particular medication. 
Furthermore, from the current research, it was also observed that consumers may have 
different information needs depending on the stage of their therapy. For example, 
different information regarding the medication may be required when the consumer is 
deciding to start on a medication compared to when the consumer has already been 
taking the medication for a period of time. Whilst standardised WMI such as CMI 
serves as an important tool in consumer education, its content and presentation are 
essentially rigid in order to comply with current legislations. As such, in its current form, 
it is informative but not necessarily consumer-centred. Hence, there is a need for 
further research which explores the development of WMI which can cater to different 
consumer needs associated with different stages in the medicine-taking process. 
6.2 AVAILABILITY AND DISSEMINATION OF WMI 
Once WMI has passed the development stage, the next challenge lies in ensuring that 
consumers are aware of it and have ready access to it. While this may sound 
straightforward in principle, awareness and access to WMI was a recurrent issue 
during this research. Most consumers were able to identify with package insert CMI 
when a description was provided but the majority were generally unaware of the term 
'Consumer Medicine Information', the concept of CMI and other forms of CMI available. 
This lack of awareness was further accentuated by consumers' ignorance of the 
current transition from package insert CMI to computer printout CMI. In addition, whilst 
some consumers had noticed the recent disappearance of package insert CMI from 
medication boxes, most consumers were not avid seekers of WMI, hence would not 
necessarily make the effort to seek CMI if it was not in the medication box. Thus, 
consumers' access to WMI especially CMI may be compromised. 
One possible solution to this problem is to re-introduce package insert CMI. Many 
consumers were in favour of this option. Nonetheless, according to manufacturers, one 
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of the main reasons for phasing out package insert GMI was that it was not easily 
updated. Given this, other possible solutions have to be considered. 
Programs such as the MIG Program have been instigated to address this issue, but 
from its recent evaluation, it is clear that there is still much room for improvement 
(Benton, Snow and Parr, 2004 ). Recently, the Therapeutics Goods Administration 
initiated a discussion forum to improve access of prescription medicine information, 
namely GMI and PI, to consumers (mpconsulting, 2005). 
In conjunction with these government policies and programs, at the practice level, 
much can be done by health professionals. During the evaluation of the MIG program, 
many pharmacists indicated that the greatest impetus for widespread provision of GMI 
will be consumer demand (Benton, Snow and Parr, 2004). Ironically, consumers cannot 
demand for GMI unless they are aware of it and they would not be aware of it unless it 
is actively promoted. Whilst public awareness campaigns would be desirable, health 
professionals also need to assume responsibility in educating the public about the 
availability of GMI. Hence, as suggested by some participants in the study, health 
professionals can help to increase consumer awareness of the availability of alternate 
forms of GMI by offering it to them and incorporating it in their counselling. 
In addition to the efforts of health professionals, changes can be made to prescribing 
and dispensing softwares used by doctors and pharmacists to facilitate the process. 
This can include the appearance of an automatic reminder which prompts the health 
professional to offer and print a GMI before the health professional is able to complete 
the prescribing or dispensing process. The system can be set up in such a way that 
this reminder is automatically triggered for new prescriptions and/or is triggered at a 
specified interval for repeat prescriptions. There can also be an additional function that 
allows the health professional to document when a GMI has been offered and/or 
provided. 
6.3 USE OF WMI DURING CONSULTATION 
Of all the stages involving consumers and WMI, results from this research have the 
largest implications for the use of WMI during consumer interaction with health 
professionals. The results highlight the need for a more holistic and integrated 
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approach by health professionals when using WMI for consumer education. Rather 
than viewing consumer education from the perspective of ticking off a 'to do' list (e.g. 
offered WMI, counselled consumer), consumer education should be approached from a 
consumer-centred perspective, where meeting the information needs of the consumer 
is the main priority. 
In meeting information needs of consumers, there is evidence in the general health 
information literature to suggest that tailored information, often with the assistance of 
computer programs and software, is more effective than non-tailored information 
(Skinner, Siegfried, Kegler eta/., 1993; Bental, Cawsey and Jones, 1999; Dijkstra and 
De Vries, 1999). For WMI, working towards an information system for providing tailored 
information would be a worthwhile albeit challenging endeavour, notwithstanding the 
potential legal ramifications of altering standardised and regulated WMI such as CMI. 
Meanwhile however, much can be done on a personal level by health professionals. 
The results from this study reveal some of the issues for consideration and may assist 
health professionals in understanding consumers' perspectives and needs and thus 
assist health professionals to tailor information to meet these needs. 
It is clear from the study results that not all consumers will utilise WMI in the same way. 
Hence, it is important to take account of this variation. First and foremost, there is a 
need to identify the individual's information preferences. This may involve asking 
appropriate questions, making inferences from existing consumer medication/medical 
history or being observant during the interaction with the consumer. In addition, as the 
results suggested that several consumer factors may influence reading and/or 
information-seeking behaviour, it is also crucial to identify these traits in the individuals. 
Once these are identified, health professionals may then tailor the delivery of medicine 
information to suit the individual. The following paragraphs suggest strategies for health 
professionals corresponding to each of the influential consumer factors identified from 
this research. 
Consumers with adequate functional health literacy levels, homemakers and monitors 
may be more interested than their counterparts in reading WMI but may not be 
prepared to actively look for it. Hence, health professionals can encourage use of WMI 
in these groups of consumers by actively offering WMI and ensuring access to reliable 
and appropriate sources of WMI. Adequate health literacy levels and presence of a 
symptomatic disease may indicate consumers who are interested in seeking WMI. 
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Health professionals can further assist these consumers by referring them to credible 
sources of WMI and being prepared to answer potential questions which may arise 
from their information search. 
Consumers who are less motivated in reading and/or seeking WMI pose a greater 
challenge to health professionals. Understanding the reasons underlying the disinterest 
in WMI may help health professionals decide the best way to tailor information for 
these consumers. The disinterest may be due to consumers' own beliefs and 
perceptions. As an example, some consumers such as those with asymptomatic 
diseases may view their conditions as innocuous. Hence, health professionals may be 
able to encourage these consumers to use WMI by providing them with a realistic and 
balanced appraisal of their condition. Other consumers may perceive the amount of 
information in WMI to be overwhelming and may benefit from small doses of subtle and 
initially non-threatening information. Yet others may not perceive a need for or realise 
the usefulness of WMI. Health professionals may assist these individuals by promoting 
WMI and taking the time to explain the information and how it may serve as a useful 
reference for the duration of their medication therapy. 
Besides being related to a consumer's own beliefs and perceptions, disinterest in WMI 
may be related to difficulty in understanding WM I. This is certainly the case for 
consumers with inadequate health literacy levels. Of all the factors identified from this 
research, this is arguably the most pervasive. However, it is difficult to identify 
consumers with inadequate health literacy levels as it is associated with shame and 
embarrassment hence is often concealed (Parikh, Parker, Nurss eta/., 1996; Brez and 
Taylor, 1997). As mentioned earlier, appropriate questions or astute observation may 
help health professionals in identifying these consumers. Several questions proposed 
by Chew eta/. (2004) including "how often do you have problems learning about your 
medical condition because of difficulty understanding written information?" were found 
to be effective in predicting inadequate health literacy. However, these questions need 
to be used with care as they are very direct and may be considered offensive to some 
consumers. Praska eta/. (2005) proposed more indirect methods which involved 
observing consumer behaviours that may flag a literacy problem such as identifying 
medications by pill colour and shape rather than by name. 
Myriad strategies and tips for identifying and managing poor health literacy in practice 
suggested in the literature may provide a helpful starting point in addressing this crucial 
yet challenging issue (Meade, McKinney and Barnas, 1994; Plimpton and Root, 1994; 
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Davis, Meldrum, Tippy et at., 1996; Mayeaux, Murphy, Arnold et at., 1996; Nichols-
English, 2000; Tooth, Clark and McKenna, 2000). It is clear that current CMI will not 
adequately serve the needs of these consumers. Whilst an emphasis on oral 
communication seems to be the obvious solution, there is evidence to suggest that 
consumers with low literacy levels do not only struggle with written information but also 
have poorer oral communication skills (Williams, Davis, Parker et at., 2002; Schillinger, 
Bind man, Wang et at., 2004). However, a combination of techniques tailored to suit 
consumers with poor health literacy such as verbal information, simplified explanations, 
'teach-back' and picture-based materials have been shown to improve health outcomes 
(Rothman, DeWalt, Malone et at., 2004). In addition, on a more general level, it may 
also be worthwhile to consider educational strategies which engage the interest of 
these consumers and work interactively with them to improve their health literacy 
levels. 
As mentioned earlier, not all consumers will utilise WMI in the same way and consumer 
preferences and needs should be taken into consideration when using WMI as an 
education tool. Some of these preferences were highlighted during the project. 
Notwithstanding the efficacy of WMI as an effective education tool, some consumers in 
the study had a preference for verbal information; hence health professionals need to 
be mindful of this preference when counselling consumers. A combination of verbal 
and written medicine information, perhaps with an emphasis on the consumer's 
preferred mode, may be the ideal way to meet a variety of different consumer needs. 
Consumers also had individual preferences regarding when (e.g. before prescription is 
written, after medication is dispensed) and from whom (e.g. doctor, pharmacist) they 
wanted to receive WMI. While it may not always be feasible to meet consumer 
preferences due to logistics constraints such as work practice and time, these 
preferences should be acknowledged and accommodated where possible. However, 
meeting these preferences may involve changes in work practice and training sessions 
for health professionals to ensure they are competent in delivering CMI. 
Finally, consistent with existing literature, the findings in this research confirmed that 
consumers particularly want to know what the medicine is for, how to take the medicine 
properly and the potential side effects. In relation to the latter, despite some 
participants finding information about side effects alarming, an overwhelming 
proportion of participants wanted to be informed about these and felt that the onus was 
on health professionals to provide a balanced perspective. 
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A series of research studies in the UK have indicated that the way side effects of 
medications are described and communicated to consumers can influence their 
perception of the likelihood of the side effects occurring (Berry, Knapp and Raynor, 
2002; Berry, Raynor and Knapp, 2003; Berry, Raynor, Knapp eta/., 2003; Knapp, 
Raynor and Berry, 2004). Recently, the MHRA Patient Information Working Group 
(Patient Information Working Group, 2005) made some recommendations for 
improvements to the side effects information in existing Plls. Other countries including 
Australia have yet to evaluate the side effects information in their standard WMI. 
Meanwhile, health professionals should embrace the challenge of equipping 
consumers with the necessary skills to interpret and apply potentially alarming 
information in a beneficial and positive way. However, this should usually be done in 
conjunction with the benefits of the medication. Several strategies have been 
suggested by Paling (2003) to assist health professionals in communicating risks to 
consumers, especially the numerical likelihood of a certain risk occurring. These 
include framing the message in both positive and negative forms (and not only the 
negative form). using absolute numbers rather than relative risks and using 
standardised vocabulary. 
6.4 USE OF WMI AFTER CONSULTATION 
Although the majority of participants read CMI, it was observed that most only read it 
for new medications and generally discarded CMI straight after reading it or kept it for a 
short duration after commencing a new medication. From this it seemed that most 
consumers failed to realise the potential benefit of keeping CMI as a source of ready 
reference for their medications after commencing therapy. Health professionals can 
thus play an important role in enlightening consumers on the usefulness of CMI beyond 
the initial stages of therapy and encourage consumers to keep CMI. This is particularly 
important as CMI is no longer available with each repeat box of medication received by 
the consumer. 
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6.5 FUTURE DIRECTIONS 
The results from this research provide a myriad of suggestions for ongoing work in the 
area of WMI. These suggestions focus on CMI as it is the standard form of WMI 
available in Australia but some of these ideas may be transferable to other forms of 
WMI internationally. 
There is clearly room to improve on the current CMI. Whilst the current study highlights 
this need, due to wide variations in consumer perceptions of CMI, a wider national 
consultation may be helpful to clarify consumers' perceptions on CMI. This can then 
inform a process to develop a more consumer-friendly CMI. In conjunction with this, 
CMI can be improved by increasing the emphasis on the benefits of the medication to 
balance against the current list of side effects. Research on consumer's understanding 
of their perceived risk of experiencing a side effect list in the CMI is also needed to 
inform the best approach to describing side effects in CMI. 
Besides improving the actual CMI document, access to CMI was a pertinent discussion 
point that was raised throughout the entire research project. Whilst some 
recommendations have been made in the preceding sections, there may be a need for 
a study which specifically focuses on delineating the issues surrounding access to CMI 
and identifying feasible solutions to the problem. All stakeholders including 
manufacturers, health professionals and most importantly, consumers, will have to be 
consulted. 
As mentioned in the preceding sections, prior to delivering consumer education on 
WMI, it is important for health professionals to assess a consumer's specific needs and 
preferences, taking into consideration the influence of consumer factors and 
characteristics. The effectiveness of these approaches could be evaluated using a 
randomised controlled trial whereby consumers are provided medicine information by 
health professionals with or without prior assessments of their preferences and needs. 
Possible outcome measures would be consumer comprehension of the information 
provided and consumer satisfaction with the information provision process. 
A more in-depth study investigating the preferred timing and provider for CMI will also 
be beneficial. Some of the preferences expressed in this research were somewhat 
novel and have the potential to empower consumers to make informed decisions about 
their medications. In addition to the preferences that were stated during the survey, 
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there may be other preferences that were not mentioned. Moreover, little is known 
about the reactions or attitudes of health professionals towards these preferences, for 
example, it is unknown if doctors are willing or consider it feasible to provide a CMI 
prior to prescribing a medication. All these unanswered questions present avenues for 
future research. 
If consumers do have distinct preferences in terms of providers of CMI, then it stands 
to reason that these providers should be well equipped and trained to provide CMI. 
Hence, educational programs on information delivery targeted at health professionals 
should also be encouraged. In the pharmacy profession, for example, educational 
programs are already in place (e.g. CMI training by the Pharmaceutical Society of 
Australia) but more remains to be done. Whilst this program is beneficial, due to its 
voluntary nature, in most cases, the uptake remains limited to pharmacists who are 
already motivated to provide information to consumers. Hence, any programs targeting 
health professionals developed in the future should aim to reach most of the target 
audience. The training should focus on increasing health professional awareness of 
consumer demand for information, educating health professionals to provide 
consumer-centred information, improving the attitudes of health professionals towards 
CMI and emphasising the important role of health professionals in providing and 
informing consumers about their medicines. 
There is also great opportunity for some training programs to be incorporated into the 
university curriculum where future health professionals are trained. While many 
courses already include general programs on information provision and counselling, 
there may be a possibility of incorporating specific training programs based on 
research evidence. For example, a module on health literacy has been trialled at a 
university to teach students to develop sensitivity to the needs of consumers with low 
health literacy, assess health literacy levels and counsel consumers with low health 
literacy levels appropriately (Dolinsky, Dhing, Lonie et at., 2001 ). 
In conjunction with health professional education, educational programs targeted at 
consumers are also needed. While it is clear that consumers are interested in reading 
CMI, it is also apparent that many lacked the essential knowledge to use WMI optimally 
and may not be aware of the full extent of the usefulness of CMI. A public education 
program which equips consumers with a set of generic skills applicable to all CMI may 
assist consumers to realise the full benefits of CMI. The content of such programs may 
include educating consumers about the benefits of CMI, where and how they may 
190 
Ch 6- Conclusions & Recommendations 
access CMI, the way CMI is set out, the differences between CMI and other forms of 
WMI, and how to interpret side effects information. These programs may be targeted at 
all levels of society and conducted in different settings including community centres, 
schools and recreational settings such as lawn bowling clubs. 
Special attention needs to be given to consumers who find it difficult to understand 
standard WMI such as CMI. These include consumers with poor health literacy levels 
and those who struggle with the official language of their country of residence. Different 
strategies for engaging these consumers and helping them to understand information 
about their medicines should be trialled. However, for these strategies to be integrated 
in the existing system, it is paramount that they are able to be implemented in everyday 
practice, and be sustainable. 
Lastly, in addition to testing the effectiveness of tailored interventions by health 
professionals, there is also an opportunity to explore the possibilities of tailoring 
information for consumers using computer programs and software. As mentioned 
previously, this strategy has been utilised successfully in the area of general health 
information. In the area of WMI, this strategy has been used for non-legislated WMI. 
The main challenge with applying this strategy to standard WMI such as CMI is 
circumventing the legal ramifications of 'altering' the document. Other issues to 
consider include the parameters to which the information will be tailored. 
In conclusion, the research described in this thesis contributes to the current 
understanding in the area of WMI from the perspective of the consumer. It has 
provided a description of Australian consumers' perceptions and use of CMI. In doing 
so, it has emphasised the importance and value of including consumers as informative 
stakeholders who have much to contribute to the area. This research has also 
identified several consumer factors which may influence the way consumers read, seek 
or evaluate WMI. These findings have highlighted the need to consider individual 
consumer factors to ensure that information about medicines is tailored to meet 
individual needs and preferences. The overall findings from this research have 
provided important insights which may be used to inform the development of strategies 
to enhance consumers' medicines use and as a consequence, improve consumer 
health outcomes. 
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Section 1- Knowledge a bout and receiving CMI 
Interviewer: To begin, I would like to ask you some general questions about consumer medicine 
information: 
1. What do you think consumer medicine information is? (you may tick more than on 
o Written information about prescription medications. 
o Written information printed by the pharmacist. 
o Written information leaflets or brochures. 
o Written information leaflets inside the medication box. 
o Other (please specify) 
o I don't know. 
+ 
Interviewer to provide the following information to consumer: 
Consumer Medicine information (or CMI as it is called for short), is written 
information about medications, that comes with most prescription medications. 
CMI provides you with information about your medications, such as telling you 
2 . What kind of drug information do you think a CMI contains? 
3. Did you receive a consumer medicine information for any of your prescription 
medications you collected from the pharmacy today? 
o Yes 
o No 
GOTO 04 
GOTO 06 
o Don't know (Interviewer to check by writing the name of the medication 
.. . .) 
4. Which medication(s) did you receive the consumer medicine information for? 
5 . I s (ar-e) the med•caUon(s). new, rep~nt or- hnvo you had it (th em) •om•um• tn tho P•••·, ~ 'P"11 
Name of medication (please write): 
New 0 0 0 
Repeat 0 0 0 
Had it sometime in the past 0 0 0 
Other medications (please specify) 
6. Have you ever received consumer medicine information for any of your prescription 
medications you have collected from a pharmacy? 
o Yes 
o No 
o Don't know 
GO TO 0 7 
GO TO 0 9 
GO TO 09 
7. Which medication(s) did you receive the consumer medicine information for? 
8. Was (were) the medication(s), new, repeat or have you had it (them) sometime in the 
past? 
Name of medication (please write): 
New 0 0 0 
Repeat 0 0 0 
Had it sometime in the past 0 0 0 
Other medications (please specify) 
GO TO SECTION 2 
0 
0 
0 
0 
0 
0 
9. Would you like to receive consumer medicine information for any of your prescription 
medications wh ich you have collected from a pharmacy? 
o Yes GO TO 010 
o No 
o Don't know 
GO TO SECTION 4 
GO TO SECTION 4 
10. Which medication(s) would you lfke to roce ivo the consumer rnedicino information fo r ? 
11. Would you like to receive Consumer Medicine Information for your new or repeat 
medications? 
0 New 
0 Repeat 
Other (please specify) 
GO TO QUESTION 17 
Section 2- CMI Experience and Provider 
In terviewer: We are now going to look at who gave you a CMI and what happened when you 
received it. 
Please note that questions 12-16 are applicable to consumers who have received a CMI 
today or for those who have received a CMI in the past. 
12. Who provided you with the consumer medicine information for your prescription 
medication(s)? 
Name of medication (please write): 
Doctor 
Pharmacist 
Other (please specify) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
13. Was the consumer medicine information given to you or did you ask for it? 
o Given 
o Requested. 
o Neither, found it inside the medication box 
o Other (please specify) _______________ _ 
• 
14. W hat type o f C MI did you r eceive? 
Name of medication (please write): 
Package inserts 
Computer generated print-outs 
Loose leaflets I brochures 
Other (please specify) 
········· ········ 
0 0 
0 0 
0 0 
0 0 
15. How was the CMI given out to you? (More than one box may be ticked) 
o It was inside the medication box 
o Simply handed out with no further discussion. 
o My attention was drawn to the CMI document only. 
o My attention was drawn to specific sections of the CMI. 
o I was asked to read the CMI. 
o I was asked to read the CMI and come back if I had any questions. 
o The content of the CMI was discussed in detail. -+ GO TO Q16 
0 
0 
0 
0 
1 
GOTO Q17 
16. Which sections of the consumer medicine information did the pharmacist (or doctor) 
discuss with you? 
Doctor Pharmacist Other 
How and when to take the medication 0 0 0 
Dosage 0 0 0 
Ingredients 0 0 0 
When not to take the medication 0 0 0 
How the medication works 0 0 0 
Drug I food interactions 0 0 0 
Side effects 0 0 0 
What to do if you take too much medication 0 0 0 
What to do if you miss a dose of medication 0 0 0 
Storage 0 0 0 
Disposal 0 0 0 
Manufacturer 0 0 0 
Other (please specify) 0 0 0 
1 7 . Whe n do you think I• tho b est time to receive a C Mt? 
o At the doctor's surgery before the doctor writes the prescription 
o At the doctor's surgery after the doctor has written the prescription 
o At the pharmacy before I get the prescription dispensed 
o At the pharmacy after I get the prescription dispensed (with medication) 
o Other (please specify) ___________ _ 
18. Who do you feel is the best person to provide you with CMI? 
o Doctor 
o Pharmacist 
o Neither 
o Other (please specify)------ ------
19. Why do you think a pharmacist (or a doctor) is the best person to provide you with CMI? 
(you may tick more than one box) 
Doctor Pharmacist Other 
Is aware of the medication(s) I am taking 0 0 0 
Is an expert on medication(s) 0 0 0 
Sees me on a regular basis 0 0 0 
Has prescribed my medication(s) 0 0 0 
We have a good relationship 0 0 0 
Is aware of my medical history 0 0 0 
I can decide whether to take the medication(s) 0 0 0 
Other (please specify) 0 0 0 
20. How often do you think you should receive CMI for your repeat prescriptions? 
o The first time I get the prescription 
o Every time I collect a repeat prescription 
o Every _ repeats 
o Every_ months } Please fi ll in blanks 
o When new information about the medication becomes available 
o Only when I ask for it 
o Other (please specify), ______ _________ _ 
GO TO SECTION 3 
Interviewer: Please note that this section is only applicable to the CMI document which has been 
received in the past (NOT today). Please focus on the most recent experience and only select one 
prescription medication. 
Now I would like to ask you about what you did with the CMI you have received in the past. 
21. If you think back to the last time you received a CMI for your prescription medication(s), 
how long ago was that?--------------
22. Did you read the CMI for your prescription medication(s)? 
o Yes 
o No 
GO TO 023 
GOTO 024 
23. How much of the CMI did you read? 
o All sections 
o Some sections 
o I scanned the CMI } GO TO 025 
24. Here are some reasons other consumers have provided for not reading CMI. Which of 
the following applies to you? (More than one box may be ticked) 
o I receive all the information I need from my doctor. 
::1 I receive all the information I need from my pharmacist. 
o I trust my doctor to prescribe a medication that is suitable for me. 
o I trust my pharmacist to provide a suitable medication for me. 
o I find the CMI too difficult to understand. 
o I find the CMI too long to read. 
o The print in the CMI is too small to read. 
o I don't have time to read the CMI. 
o I don't think the CMI is important. 
o My illness is not serious. 
o I have been taking my medication for a long time. 
o I am not interested in the information in the CMI. 
o I have taken this medication in the past. 
o Other (Please specify)------------
GO TO SECTION 4 
25. H e r e a r e som e reason s o the r consume r • h a v e p rovided t or r eadin g CMI~ W'hfch o f • he 
following a p p lies t o you? (More than one box may be ticked) 
a I want to know about my medication. 
a I am concerned about the medication's side effects. 
a I have allergies and so like to check that I am not allergic to the medication. 
a I have other disease conditions and would like to know if the medication is suitable for me. 
a I want to check that the doctor didn't forget anything. 
a I want to check that the pharmacist didn't forget anything. 
a My doctor I pharmacist asked me to read the CMI (circle doctor or pharmacist). 
a I have had bad experiences with my medications in the past. 
a Do not trust my doctor I pharmacist (circle doctor or pharmacist). 
a Other (Please specify)---- --------
26. Which specific items of medication information did you focus on when you read the 
CMI? 
27. What have you learnt from reading your CMI(s)? 
GO TO QUESTION 28 
- -28. H o w has read i n g •ho C MI lntluon cod the woy you t.oke your m o dh::ation? (you rnoy tick 
more than one box) 
Since reading the CMI: 
a I am more informed about my medication. 
a I am more aware of the importance of taking my medication as prescribed. 
a I am more confident about taking my medication. 
a I have stopped taking my medication, because of interactions with other medications. 
a I have stopped taking my medication, because I did not want to suffer any Side effects. 
a I have changed the way I take my medication. 
•:• Please specify how------------------
a I have not learnt anything new about my medication. 
a I have made no changes to the way I take my medication. 
a Other (please specify), _____________ ___ _ 
29. Did you have any concerns or queries with the information you read in the CMI? 
a Yes GO TO Q30 
a No GO TO Q32 
30. What did you do to address your concerns or queries with the information you read in 
the CMI? (You may lick more than one box) 
a I contacted my pharmacist 
a I contacted my doctor 
a I contacted another health care professional (Please 
specify), _____________ _ } GO TO Q31 
a I consulted a friend or relative. t 
a I searched for more information (please specify the source -------
a I made changes to the way I take the medication (please specify 0 TO Q32 
a Other (please specify·- ------ ---- ------ ---
31 . What further action was taken after consultat ion with the pharmacist (or doctor or other 
health care professional)? (Please tick one box only) 
a There was no change in the way I take my medication. 
a My medication was changed. 
a There was a change in the dosage. 
a The medication was stopped altogether. 
a A new medication was given to me. 
a Other (please specify) _ ______ ______ _ 
32. Afte r reading the CMI. -hat c:lld you do -ttlh It ? 
c.J Foled the CMI away for futuro reference (ho w long dod you keep the C MI for?--------' 
o Kept the CMI in the medication box until I finished the medication 
o Shared the CMI with friends I relatives who were also on the same medication 
o Threw the CMI away 
o Other (Please specify --------------------~ 
33. Have you read the CMI for anyone else's medication (eg. your child, parent, partner)? 
o Yes, always 
o Yes, sometimes 
o Yes, I scan the CMI and do not read it in-<lepth 
} GoToQ34 
o No 
34. Whose CMI have you read? 
o Child 
CJ Partner 
o Elderly parent I relative 
o Other (please specify) ___________ _ 
GO TO SECTION 4 
~-S!!On .. _ ..-..!s!lydw •latv•nyr!lft 
Interview er: Below are a number of opinions of consumers about consumer medicine informot,on. 
Please read each statement carefully and show whether you, as a consumer, agree or disagree . 
with these statements. If you strongly disagree please circle SO; if you disagree please circle D; If 
you neither agree nor disagree please circle U; if you agree please circle A; if you strongly agree 
please circle SA; if the statement is not applicable to you please circle NA 
SO= Strongly Disagree 
D= Disagree 
U= Neither agree nor disagree 
A= Agree 
SA= Strongly agree 
NA= Not applicable 
. I would like to know all about the medications I am takmg 
. I only read CMI for a medication which is for a serious medical condition 
. I read the CMI because I have experienced problems with my 
medication(s) in the past 
. The CMI is an important source of information for the medocatlon taken by 
someone in my care 
. I am not interested in learning about my medications 
. I don't believe that I should know about the medications taken by someone 
in my care 
. CMI contains too much drug information 
. CMI is useful only for medications used in severe diseases 
. I don't read a CMI beacuse I have never had any problems with my 
medications in the past 
. I would like to be onvolved with my doctor in deciding what medications 1 
should take 
. CMI should not be given out for medications used in minor illnesses 
. As a carer, I would like to know what medication the person in my care is 
taking 
. CMI is useful for consumers who experience problems with their 
medications 
. I leave all the decision making about my medications to my doctor. 
. CMI contains all the medication information I need. 
. I find the print on CMitoo small to read 
. I will only read the CMI, if I think that my illness is serious 
. The CMI is set out well, so I can always find the information I want 
. CMI is useful as I can check if I am allergic to the medocation and 1ts 
ingredients 
. I do not read the CMI for medocations taken by my children or someone 
under my care 
. CMI uses words that I find difficult to understand 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
so 0 u A SA 
NA 
NA 
NA 
NA 
NA I 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
.. 
, ~odo.n"l "r•.ci .. ffMt"CMi h::H ~tcalton• Pf'e~ fo" notno •ttrnenta S O U U A 6A N A 8 . YYh a l I• y o t.." 
-~t the "docto r to pr-e scnt>o m ec:hcaho n (s) that ts ( ore) su rlable fo r m e So D U A SA N A 
e) occ upation'' 
b) type of business or work? 
• I read a CMI because I have experoenced sode effects with my previous SO 0 U A SA NA 
medicatoons. 9. Which of the following best describes your current work situation? 
Working • It is important to read the CMI lor the medications taken by someone in my SO 0 U A SA NA 0 No 
~ 0~ rt TimeWork 
TimeWork 
• I like to take control of my medication taking so 0 U A SA NA 0 Fu 
• CMios written 1n a language that os easy to understand SO 0 U A SA NA 
Section 5- Demographic Characteristics 
Interviewer: The following questions collect some demographic details about you. Please 
answer all questions. 
1. Sex: 
0 Male 
0 Female 
2. How old are you? ............ years 
3. In what country were you born? 
0 Australia 
0 Overseas- please state country of birth 
4. Do you speak a language other than English at home? 
0 No 
0 Yes- please state language spoken 
5. Which of the following best describes your current marital status? 
0 Never Married 0 Separated 
0 Married 0 Divorced 
0 De Facto 0 Widowed 
6. Do you have any children? 
0 No 
0 Yes- please state number of children ..... .. .............. . 
7. What is the highest educational qualification you have obtained? 
0 None 
0 School Certificate (Year 10) 
0 Higher School Certificate (Year 12) 
0 Associate Diploma 
0 Undergraduate Diploma 
0 Bachelor Degree 
0 Postgraduate Diploma 
0 Higher Degree 
10. What postc de is your residence in? 
11 . Do you have any medical conditions? 
0 No 
0 Yes- please state your medical conditions 
12. Do you currently take any medications prescribed by your doctor? 
0 No 
0 Yes- please state your medications . ..... ..... ....... . 
Thank you for participating in this study, your input is highly valued, 
are there any other comments, relevant to the topic area which you 
Comments: _____________ ________ ________ ___ _ 
£ZZ 
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Training protocol 
Aim and objectives of the study: The interviewers were informed of what the 
researchers were trying to achieve. 
Introduction and background to CMI: The interviewers were given a brief 
introduction to CMI, covering aspects such as the definition of CMI, the available 
formats, its contents and its availability from different health professionals. 
CMI and community pharmacy practice: The interviewers were briefed on the 
differences between a typical dispensing scenario (limited verbal counselling when 
medication is dispensed) and an ideal dispensing scenario (verbal counselling 
accompanied by written information). They were also informed of the different ways a 
CMI could be provided in the community pharmacy (e.g. through package inserts, 
simply handed out, accompanied by detailed counselling and discussion of CMI 
content). 
Difference between CMI and other WMI: The interviewers were taught the 
differences between CMI and other forms of WMI so that they were able to double-
check whether patients were referring to CMI or not during the administration of the 
survey. Some examples of CMI were shown. 
Recruitment process: The recruitment process and the responsibility of each 
interviewer were explained (see Section 3.2.4). 
Questionnaire administration: Each question in the questionnaire was explained to 
the interviewers. All the different possible combinations of question skips were explored 
and explained. The interviewers also had a trial run of administering the questionnaire 
on one another. 
Questions: Interviewers were encouraged to ask questions at any time during the 
training session. 
This area has been left intentionally blank 
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• CMI Study patient information sheet 
• CMI Study patient consent form 
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Telephone: (02) 935 I 67 II 
Fax: (02) 9351 4391 
InternaL Fax: 61-2 9351 4391 
e-mail: parisa@pharm.usyd.edu.au 
Pharmacist Subject Information Sheet- Phase 2 of the Project 
Information for Participants 
Title of Research Project: The Use of Consumer Medicine Information by Consumers 
The above named research study is being conducted by Dr Porisa Aslani (Tel: 9351 6711) and Dr 
Ines Kross (Tel: 9351 3507). at the Faculty of Pharmacy. University of Sydney. This study aims to 
investigate consumers' opinions of Consumer Medicine Informat ion (CMI) and how they use CMi s 
received with their prescription med1cotions. 
The study sample will consist of consumers who hove collected o prescription medication for 
t hemselves from the part icipat ing community pharmacy. A researcher 
............................ 9351 6711) will visit your community pharmacy for 
three days t o recruit and interview consumers. Consumers will be approached by the researcher 
on leaving t he dispensary and invited to part icipate in t he study. A brief explanation of the 
research will be provided and the consumer inclusion criteria will be checked. The criteria include: 
being 18 years of age or over; not requiring a translator to respond to the survey; and collecting a 
prescription medication for themselves. Eligible and consenting consumers will be requested t o 
sign o consent form. The int erviews will be approximately 15 minutes in durat ion. The quest ionnaire 
will focus on awareness of and att itudes to CMI for prescription medications and how CMis ore 
used by consumers. 
All data collected during t he research s tudy will be confident ial. Only group data will be used in 
reporting and publishing the results of t he research. Part icipat ion in t he s t udy is voluntary. You 
and your consumers con withdraw from t he study at any t ime. 
Any person with concerns or complaints about the conduct of a research study can contact 
the Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 9351 
4811 
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Porisa As/ani 
BPharm (Hons), MSc, PhD 
MPS. MRPhamtS 
Lecturer in Phamwcy Practice 
The University of Sydney 
Telephone: 
Fax: 
Faculty of Pharmacy 
NSW 2006 Australia 
ImemaL Fax: 
(02) 9351 67 II 
(02) 935 I 439 I 
61-2 9351 4391 
e-mail: pansa@phamt.usyd.edu au 
Pharmacist Consent Form- Phase 2 of the Project 
Title of Research Project : The Use of Consumer Medicine Information by Consumers 
I. 
(nome) 
of ............... . 
(address) 
hove read and understood t he "Informat1on for Participants• on the above named research study 
and hove discussed it with one of the researchers(. ............................. Tel (02) 9351 6711). I om aware 
of t he procedures involved and underst and what is expect ed of me. 
I hereby voluntarily consent to participate in t he s t udy, and understand that I con withdraw from 
the study at any t ime. 
I also understand that all data obtained from this study will be treated confidentially and only 
group data will be used in future research or publ1shed. No personal details will be revealed at any 
time dunng or after the study. 
Signat ure: 
Nome (please print): 
Dote: 
Nome of Wit ness: 
Signature of Witness: 
Dote: 
Any person with concerns or complaints about the conduct of a research study can contac t 
the Manager o f Ethics and Biosafety Administration, University of Sydney, on (02) 9351 
4811 
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MPS.MRPhannS 
Lecturer in Pharmacy Practice 
The University of Sydney 
Telephone: 
Fax: 
Faculty of Phannacy 
NSW 2006 Australia 
Internal. Fax: 
(02) 93516711 
(02) 9351 4391 
61-2 93514391 
e-mail: parisa@pharm.usyd.edu.au 
Consumer Subject Information Sheet- Phase 2 of the Project 
Information for Participants 
Title of Research Project : The Use of Consumer Medicine Information by Consumers 
The above named research study is being conducted by Dr Parise Asloni (Tel: 9351 6711) and Dr 
Ines Kross (Tel: 9351 3507). at the Faculty of Pharmacy, University of Sydney. 
This study aims t o investi90te consumers' opinions of Consumer Medicine Information (CMI) and 
how they use CMis received with their prescription medications. 
It you consent to participate in the study. you will be interviewed by the researcher using a 
structured questionnaire. The interview will be approximately 15 minutes in duration and will be 
conducted in a quiet area of the pharmacy. The questionnaire will focus on awareness of and 
attitudes to CMI for prescription medications; experiences when receiving CMI for prescription 
medications from community pharmacists; and how CMis ore used by consumers. 
All data collected during the research study will be confidential. Only group data will be used in 
reporting and publishing the results of the research. Participation in the study is voluntary and you 
con withdraw from the study at any time. 
Any person with concerns or complaints about the condtJCt of a research study con contact 
the Manager of Ethics and Biosafety Adminis tration, University of Sydney, on (02) 9351 
4811 
Page I of I 
Parisa As/ani 
BPhann (Hons), MSc, PhD 
MPS. MRPharmS 
Lecturer in Phamracy Practice 
The University of Sydney 
Telephone: 
Fax: 
Faculty of Pharmacy 
NSW 2006 Australia 
llllemaL Fax: 
(02) 9351 6711 
(02) 93514391 
61-2 9351 4391 
e-mail: pal'isa@pharm.usyd.edu.au 
Consumer/ Patient Consent Form- Phase 2 of the Project 
Tit le of Research Project : The Use of Consumer Medicine Information by Consumers 
! , 
(nome) 
of . ........... . 
(address) 
hove read and understood the "Informotoon for Participants" on the above named research study 
and hove discussed it with one of the researchers(. ............................ , Tel (02) 9351 6711). I om aware 
of the procedures involved and understand what is expected of me. 
I hereby voluntarily consent to participate in the s t udy, and understand that I con withdraw from 
the study at any time. 
I also underst and that all data obtained from this study will be treated confidentially and only 
group data will be used in future research or published. No personal details will be revealed at any 
time during or after the study. 
Signature: 
Nome (please print): 
Dote: 
Nome of Witness: 
Signature of Witness: 
Date: 
Any person with concerns or complaints about the condtJCt of a research study can contact 
the Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 9351 
4811 
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Table A1.1 Number of questionnaires from each pharmacy 
Pharmacy code Questionnaire administered Useable questionnaire 
P01 20 20 
P02 20 18 
P03 20 18 
P04 3 3 
P05 2 2 
P06 19 16 
P07 9 9 
P08 20 20 
P09 20 19 
P10 10 10 
P11 20 18 
P12 
P13 19 18 
P14 7 7 
P15 16 13 
P16 10 9 
P17 5 5 
P18 20 20 
Total 241 226 
Table A1.21nformation contained in CMI as reported by patients {n=200) 
Information contained in CMI"' 
Side effects 
Dosage/ how to take 
Warning/ precaution/ contraindication 
Content of drug/ ingredients 
Indication 
Drug interactions 
Information about medication 
Other 
NB: Responses are not mutually exclusive. 
•Question was only directed to patients who knew what a CMI was. 
Table A1.3 Receipt of CMI on the day of interview 
Received CMI on day of interview 
Yes 
No 
Don't know 
Total 
Table A1.4 Receipt of CMI in the past 
Received CMI in the past 
Yes 
No 
Don't know 
Missing 
Total 
n 
184 
26 
15 
1 
226 
n 
132 
91 
3 
226 
% 
81.4 
11.5 
6.6 
0.4 
100.0 
n 
108 
94 
54 
45 
35 
19 
19 
67 
% 
54.0 
47.0 
27.0 
22.5 
17.5 
9.5 
9.5 
33.5 
% 
58.4 
40.3 
1.3 
100.0 
Valid% 
81.8 
11.6 
6.7 
100.0 
Table A1.5 Status of prescription medications for which CMI was received Table A1.7 Sections discussed in detail by doctor and pharmacist 
Status of prescription Day of interview In the past Sections discussed Doctor (n=8) Pharmacist (n=6) 
n % n % {n=135 ~atients) {n=184 ~atients) 
n medications % n medications % 
New 43 22.1 39 13.4 How and when to take the medication 6 75.0 5 83.3 
Repeat 144 73.8 197 67.9 Dosage 8 100.0 3 50.0 
Had before 8 4.1 39 13.4 Ingredients 4 50.0 0 0.0 
Unspecified 0 0.0 15 5.2 When not to take the medication 3 37.5 2 33.3 
Total number of medications 195 100.0 290 100.0 
How the medication works 5 62.5 2 33.3 
Drug/food interaction 5 62.5 2 33.3 
Side effects 7 87.5 3 50.0 
Table A1.6 Medications (by therapeutic classes} for which CMI was received What to do if you take too much medication 2 25.0 1 16.7 
Medication by therapeutic class Day of interview In the past What to do if you miss a dose of medication 5 62.5 1 16.7 
Storage 1 12.5 1 16.7 {n=135 ~atients) {n=184 eatients) 
n medications % n medications % 
Disposal 0 0.0 1 16.7 
Manufacturer 0 0.0 1 16.7 
Cardiovascular system 53 27.2 88 30.3 
Central nervous system 31 15.9 36 12.4 
Infections and infestations 21 10.8 25 8.6 
NB: Responses are not mutually exclusive. 
Endocrine & metabolic disorders 20 10.3 27 9.3 
Musculoskeletal system 17 8.7 23 7.9 
Analgesia 10 5.1 12 4.1 
Respiratory system 10 5.1 10 3.4 
Alimentary system 8 4.1 19 6.6 
Eye 7 3.6 5 1.7 
Skin 6 3.1 6 2.1 
Contraceptive agents 5 2.6 4 1.4 
~cannot recall" 0 0.0 19 6.6 
Other 7 3.6 16 5.5 
Total number of medications 195 100.0 290 100.0 
Table A1.8 Reasons for preferred provider of CMI Table A1.9 Patient's preferred frequency of CMI receipt (n=214} 
Reason for preference Doctor Pharmacist Manufacturer Preferred frequency of receiving CMI n % Valid% 
(n=130) (n=114) (n=2) 
First time I get the prescription 89 41.6 44.9 
n % n % n % 
Is aware of the medication(s) I 101 77.7 60 52.6 Every time I collect a repeat prescription 94 43.9 47.5 
am taking 
When new information about the prescription becomes 31 14.5 15.7 
Is an expert on medication(s) 81 62.3 87 76.3 2 available 100 
Sees me on a regular basis 89 68.5 40 35.1 
Only when I ask for it 5 2.3 2.5 
Has prescribed my 86 66.2 0.9 Every few repeats 6 
2.8 3.0 
medication(s) Every few months 2 0.9 1.0 
When there are changes to the dose or the medication 2 0.9 1.0 
We have a good relationship 77 59.2 44 38.6 
Never 2 0.9 1.0 
Is aware of my medical history 100 76.9 28 24.6 
I can decide whether to take 31 23.8 15 13.2 Missing 16 
7.5 
the medication NB: Responses are not mutually exclusive. 
Doctor can outline important 1 0.8 
relevant points Table A1.10 Items offocus when reading CMI (n=98) 
Focus while reading CMI n % Valid% Convenience 1 0.9 
Has the time 4 3.5 None in particular 7 7.1 7.4 
Dispenses my medications 4 3.5 Side effects 46 46.9 48.4 
Missing 3 2.6 Dosage 28 28.6 29.5 
NB: Responses are not mutually exclusive. Warning/contraindication 10 10.2 10.5 
Drug interactions 8 8.2 8.4 
Ingredients 6 6.1 6.3 
Indication 5 5.1 5.3 
Dieutood while on medication 5 5.1 5.3 
Other 36 36.7 37.9 
Missing 3 3.1 
NB: Responses are not mutually exclusive. 
Table A1.11 Patient's reasons for reading CMI (n=95) 
Reason for reading CMI 
I want to know about my medication 
I am concerned about the medication's side effects 
I have other disease conditions and would like to know if the 
medication is suitable for me 
I want to check that the doctor didn't forget anything 
I have allergies and so like to check that I am not allergic 
to the medication 
I want to check that the pharmacist didn't forget anything 
I have had bad experiences with my medications in the past 
My doctor asked me to read the CMI 
My pharmacist asked me to read the CMI 
I do not trust my doctor 
Other 
Missing 
NB: Responses are not mutually exclusive. 
Table A1.12 Patient's reasons for not reading CMI (n=55} 
Reason for not reading CMI 
I have taken this medication in the past 
I have been taking my medication for a long time 
I trust my doctor to prescribe a medication that is suitable for me 
I receive all the information I need from my doctor 
I receive all the information I need from my pharmacist 
I find the CMI too long to read 
I trust my pharmacist to provide a suitable medication for me 
The print in the CMJ is too small to read 
I find the CMI too difficult to understand 
I don't have time to read the CMI 
My ~lness in not serious 
Other 
NB: Responses are not mutually exclusive. 
n % 
78 79.6 
76 77.6 
25 25.5 
22 22.4 
21 21.4 
15 15.3 
13 13.3 
8 8.2 
8 8.2 
2 2.0 
3 3.1 
3 3.1 
Valid% 
82.1 
80.0 
26.3 
23.2 
22.1 
15.8 
13.7 
8.4 
8.4 
2.1 
3.2 
n % 
37 67.3 
29 52.7 
22 40.0 
18 32.7 
11 20.0 
8 14.5 
7 12.7 
5 9.1 
2 3.6 
2 3.6 
2 3.6 
3 5.5 
Table A1.13 Third party readership of CMI (n=95} 
Read CMI for someone else 
Yes, always 
Yes, sometimes 
Yes, I scan the CMI and do not read it in depth 
No 
Missing 
Total 
Table A1.14 Third party for whom CMI was read (n=57) 
Third party 
Partner 
Child 
Elderly parent/relative 
Friend 
n 
34 
21 
2 
38 
3 
98 
Other (others with same condition, grandchild, neighbour, patient) 
NB: Responses are not mutually exclusive. 
% 
34.7 
21.4 
2.0 
38.8 
3.1 
100.0 
Table A1.15 Action taken to address concern after reading CMI (n=20) 
Action taken to address concern 
I contacted my doctor 
I contacted my pharmacist 
I made changes to the way I take the medication 
I consulted a friend or relative 
I searched for more information 
NB: Responses are not mutually exclusive. 
Valid% 
35.8 
22.1 
2.1 
40.0 
100.0 
n % 
31 54.4 
25 43.9 
18 31.6 
4 7.0 
6 10.5 
n 
14 
5 
3 
% 
70 
25 
15 
5 
5 
Table A1.16 Further action taken after consultation with health professional to discuss 
concerns 
Action taken after consulting health professional n % 
There was no change in the way I take my medication 8 50.0 
My medication was changed 3 18.8 
There was a change in the dosage 2 12.5 
The medication was stopped altogether 2 12.5 
l was reassured and more confident to take my medication 1 6.3 
Total 16 100.0 
This area has been left intentionally blank 
Table A1.171nitial factor analysis 
Items 
The CMI is an important source of information for the medication taken by someone in 
my care. 
It is important to read the CMI for the medications taken by someone in my care. 
As a carer, I would like to know what medication the person in my care is taking. 
I would like to know all about the medications I am taking. 
I don't believe that I should know about the medications taken by someone in my care. 
CMI is useful for consumers who experience problems with their medications. 
I like to take control of my medication taking. 
I am not interested in learning about my medications. 
CMI is useful as I can check if 1 am allergic to the medication and its ingredients. 
I don't read the CMI for medications prescribed for minor ailments. 
I only read CMI for a medication which is for a serious medical condition. 
I will only read the CMI if I think that my illness is serious. 
I don't read a CMI because I have never had any problems with my medications in the 
past. 
I do not read the CMI for medications taken by my children or someone under my care. 
I leave all the decision making about my medications to my doctor. 
I would like to be involved with my doctor in deciding what medications I should take. 
I trust the doctor to prescribe medications that are suitable for me. 
Items 
CMI is written in a language that is easy to understand. 
CMI uses words that I find difficult to understand 
I find the print in CMI too small to read 
I read a CMI because I have experienced side effects with my previous medications. 
I read the CMI because I have experienced problems with my medication(s) in the past. 
CMI is useful only for medications used in severe diseases. 
CMI should not be given out for medications used in minor illnesses. 
CMI contains too much drug information. 
The CMI is set out well, so I can always find the information I want. 
CMI contains all the medication information I need. 
Extraction method: Principal Axis Factoring 
Rotation method: Promax with Kaiser Normalisation 
NB: Only factor loadings 2: 0.30 have been included in the table. 
Factor 
0.87 
0.81 
0.72 
0.58 
-0.56 
0.53 
0.46 
-0.42 
0.42 
-0.46 
Factor 
2 3 4 5 6 7 
0.31 
0.81 
0.75 
0.74 
0.51 
0.49 -0.30 
0.87 
-0.56 
0.48 
2 3 4 5 6 7 
-0.77 
0.62 
0.33 
0.86 
0.69 
0.80 
0.46 
0.39 
0.88 
0.46 
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Table A1.18 Changes made to questions from CMI Study before Incorporation into WMI Study Phase 1 
CMI Study WMI Study Phase 1 Rationale for change 
Question Description Question Description 
Awareness of CMI 
Sect 1, 
01 
MCO listing various 
definitions of CMI (~ 1 
response allowed) 
Sect A, 
02 
Focus! sections of interest when reading CMI 
Sect 3, 
026 
Open-ended question 
examining focus while 
reading CMI 
CMI readership for third party 
Sect A, 
07 
Sect 3, 
033 
MCO with separate options Sect A, 
for different extents of 
readership 
09 
Reasons for reading and not reading CMI 
Simple yes/no question, with interviewer 
checking understanding of participants 
who responded 'yes' 
MCQ on the sections of CMI usually 
read (options included all sections in 
CMI; ~ 1 response allowed) 
Simple yes/no question 
Simpler and clearer way of ascertaining 
awareness of CMI 
Simpler and more direct way of 
ascertaining sections of interest 
(sections in CMI are standardised hence 
feasible to include all possible options) 
Distinctions between different extents of 
third party readership did not prove 
useful, hence question was simplified 
Sect 3, MCQ listing reasons for Sect A, Open ended question, followed by MCQ Allowed participants to express what was 
024 & 25 reading or not reading CMI 011 & 12 listing various reasons for reading or not salient in their own minds first without 
(~ 1 response allowed) reading CMI; some choices from CMI being influenced by the available 
CMJStudy 
Question Description 
Demographics 
Sect 5, - Patients asked if they 
04 spoke a language other 
than English at home 
Study were removed 
WMI Study Phase 1 
Question Description 
Sect F, 
04&5 
- Main language spoken at home was 
requested, followed by other languages 
spoken at home 
alternatives; some choices in CMI Study 
were found to be not applicable to many 
participants hence were removed 
Rationale for change 
- Original question did not provide 
indication of participant's main language 
which could influence their use of WMI 
05 & 06 - Marital status and number Nil 
- Marital status and number of children 
were not requested 
- Information was not found to be useful 
07 
08 
of children were requested 
- Eight options were 
provided when requesting 
for highest level of 
education 
-Open-ended question 
requesting for occupation 
followed by type of 
business or work 
06 
07 
- Only six options were provided when - The more detailed differentiation 
requesting for highest level of education between levels did not prove useful, 
hence categories were condensed 
- MCQ requesting for occupation only• - Open-ended question produced 
inaccurate response from participants 
(e.g. "retired"); request for type of 
business/work was confusing and 
therefore removed 
*based on ABS ASCO (Australian Bureau of Statistics, 1997a) 
Sect= section, Q= question, MCQ= multiple choice question, ABS= Australian Bureau of Statistics, ASCO= Australian Standard Classification of 
Occupations 
Table A1.19 Group 1 and Group 2 patient reasons for not participating 
Reason for not participating Group 1 Group 2 
n % n % 
Time constraints 24 47.1 57 60.0 
Not interested 9 17.6 15 15.8 
Not feeling well 8 15.7 4 4.2 
Not comfortable with English 0 0.0 6 6.3 
Other 5 9.8 2 2.1 
No reason given 5 9.8 11 11.6 
Total 51 100.0 95 100.0 
Table A1.20 Pharmacy and patient response rate for Group 2 
SSD Pharmacy Patient 
Yes (n) No (n) Response rate Yes (n) No (n) Response rate 
(%) (%) 
55001 3 8 27 20 4 83 
55002 2 16 11 12 2 86 
55003 4 4 50 27 5 84 
55004 3 11 21 14 9 61 
55005 4 8 33 19 6 76 
55006 1 6 14 9 3 75 
55007 5 16 24 23 10 70 
55008 2 7 22 11 11 50 
55009 5 21 19 21 5 81 
55010 3 5 38 16 6 73 
55011 2 3 40 17 3 85 
55012 9 12 43 73 31 70 
Overall 43 117 27 262 95 73 
Table A1.21 Pharmacy reasons for not participating 
Reason 
No reason provided 
Not contactable or lost to follow-up 
Mainly non-English speaking clientele 
Too busy (e.g. with OCPP accreditation•) 
Fear of pressurising clients/ deem clients unsuitable/ disinterested 
Low prescription volume 
Not interested 
Low walk-in clientele (mainly deliveries) 
Space restriction in pharmacy 
Involved in other research studies 
Pharmacy undergoing relocation 
Pharmacy undergoing change of ownership 
Other 
n 
33 
21 
15 
11 
5 
5 
5 
4 
4 
3 
3 
3 
5 
Total 117 
*Quality Care Pharmacy ProQriili (QCPP) accreditation is a national quality assurance program for 
community pharmacies: pharmacies receive incentive payments for accreditation before certain 
deadlines (The Pharmacy Guild of Australia, 1998). 
Table A 1.22 Chi-square statistics for the comparison between recruited sample and 
population of metropolitan Sydney 
Sydney (n= 3.4 million) Sample (n=262) Chi square statistics 
% n % 
·l df P-value 
SSD01 7.6 20 7.6 0.00 1 0.98 
SSD02 8.8 12 4.6 5.85 1 0.02 
SSD03 11.5 27 10.2 0.36 1 0.55 
SSD04 8.5 14 5.3 3.38 1 O.Q7 
SSD05 6.9 19 7.3 0.05 1 0.83 
SSD06 10.0 9 3.4 12.55 1 <0.001 
SSD07 9.2 23 8.8 0.06 1 0.81 
SSD08 4.7 11 4.2 0.14 1 0.70 
SSD09 8.3 21 8.0 0.03 1 0.88 
SSD1 0 6.5 16 6.1 0.06 1 0.80 
SSD11 5.6 17 6.5 0.38 1 0.54 
SSD12 12.3 73 27.9 58.94 1 <0.001 
Total 100.0 262 100.0 
Table A1 .23 Completion rate by section of questionnaire 
Section Group 1 (n=217) Group 2 (n=262) Overall (n=479) 
n % n % n % 
A 217 100.0 262 100.0 479 100.0 
B 217 100.0 104 39.7 321 67.0 
c 217 100.0 251 95.8 468 97.7 
0 217 100.0 104 39.7 321 67.0 
E 217 100.0 152 58.0 369 77.0 
F 217 100.0 262 100.0 479 100.0 
NB: These figures 1nd1cate the number of participants who attempted each section of the 
questionnaire. 
Table A1 .24 Mode of administration of questionnaire 
Administration of questionnaire Group 1 Group 2 Overall 
n % n % n % 
Face to face 175 80.6 230 87.8 405 84.6 
Completed or conducted by telephone 42 19.4 32 12.2 74 15.4 
Total 217 100.0 262 100.0 479 100.0 
Table A1.25 Comparison of participants' gender for surveys conducted face-to-face or 
by telephone 
Gender 
Male 
Female 
n 
173 
232 
405 
Face-to-face 
Within column % 
42.7 
57.3 
100.0 
n=479, x2=0.759, df=1, p=0.384 
Completed or conducted by telephone 
n 
27 
47 
74 
Within column % 
36.5 
63.5 
100.0 
Table A1 .26 Comparison of participants' age for surveys conducted face-to-face or by 
telephone 
Age Face-to-face Completed or conducted by telephone 
n Within column % n Within column % 
18 to 40 24 5.9 7 9.5 
41 to 60 118 29.1 31 41.9 
61 to 80 214 52.8 28 37.8 
81 and above 49 12.1 8 10.8 
405 100.0 74 100.0 
NB: Certain categories with small frequenc1es were comb1ned to allow meaningful and valid statistical 
analyses to be conducted. 
n=479./=7.354, df=3. p=0.061 
Table A1 .27 Comparison of participants' country of birth for surveys conducted face-
to-face or by telephone 
Country of 
birth 
Australia 
Overseas 
n 
263 
142 
405 
Face-to-face 
Within column 
% 
64.9 
35.1 
100.0 
n=479, :?=0.595, df=1. p=0.440 
Completed or conducted by 
telephone 
n Within column % 
44 59.5 
30 40.5 
74 100.0 
Table A1 .28 Comparison of participants' main language spoken at home for surveys 
conducted face-to-face or by telephone 
Main language Face-to-face 
n Within column % 
English 
Non-English 
332 
73 
405 
n=479, /=0.087, df=1 , p=0.768 
82.0 
18.0 
100.0 
Completed or conducted by telephone 
n 
59 
15 
74 
Within column % 
79.7 
20.3 
100.0 
Table A1 .29 Comparison of participants' highest level of education for surveys 
conducted face-to-face or by telephone 
Highest level 
of education 
Face-to-face 
n Within column % 
Primary or below 75 
Secondary 217 
Tertiary 112 
404 
18.6 
53.7 
27.7 
100.0 
n=478 (1 missing value), x7=3.093. df=2, p=0.213 
Completed or conducted by 
telephone 
n Within column % 
12 16.2 
34 45.9 
28 37.8 
74 100.0 
Table A 1.30 Comparison of participants' occupation for surveys conducted face-to· 
face or by telephone 
Occupation Face-to-face Completed or conducted by telephone 
n Within column % n Within column % 
White-collar 246 60.7 45 60.8 
Blue-collar 98 24.2 10 13.5 
Other 61 15.1 19 25.7 
405 100.0 74 100.0 
n=479, /=7.388, df=2, p=0.025 
Table A1 .31 Comparison of participants' current employment status for surveys 
conducted face-to-face or by telephone 
Employment status Face-to-face 
n Within column % 
Working 84 
Retired or not working 320 
404 
n=478 (1 m1ssing value), x1=2.400, df=1, p=0.121 
20.8 
79.2 
100.0 
Completed or conducted by 
telephone 
n 
22 
52 
74 
Within column % 
29.7 
70.3 
100.0 
Table A 1.32 Comparison of participants ' gender for fully and partially completed 
surveys 
Gender 
Male 
Female 
n 
126 
195 
321 
Fully completed 
Within column % 
39.3 
60.7 
100.0 
n=479, /=2.201. df=1. p=0.138 
n 
74 
84 
158 
Partially completed 
W ithin column % 
46.8 
53.2 
100.0 
Table A1.33 Comparison of participants' age for fully and partially completed surveys 
Age Fully completed Partially completed 
n Within column % n Within column % 
18 to 40 26 8.1 5 3.2 
41 to 60 106 33.0 43 27.2 
61 to 80 154 48.0 88 55.7 
81 and above 35 10.9 22 13.9 
321 100.0 158 100.0 
NB: Certain categones with small frequencies were combined to allow meaningful and valid statistical 
analyses to be conducted. 
n=479, /=7.194. df=3, p=0.066 
Table A1.34 Comparison of participants ' country of birth for fully and partially 
completed surveys 
Country of birth Fully completed Partially completed 
n W ithin column % n Within column % 
Australia 
Overseas 
213 
108 
321 
n=479, ;t2=1.878, df=1. p=0.171 
66.4 94 
33.6 64 
100.0 158 
59.5 
40.5 
100.0 
Table A1 .35 Comparison of participants' main language spoken at home for fully and 
partially completed surveys 
Main language 
English 
Non-English 
n 
264 
57 
321 
n=479, /=0.137. df=1, p=0.712 
Fully completed Partially completed 
Within column % n 
82.2 127 
17.8 31 
100.0 158 
Within column % 
80.4 
19.6 
100.0 
Table A 1.36 Comparison of participants' highest level of education for fully and 
partially completed surveys 
Highest level of 
education 
Fully completed Partially completed 
Primary or below 
Secondary 
Tertiary 
n 
64 
171 
86 
321 
Within column % n 
19.9 23 
53.3 80 
26.8 54 
100.0 157 
n=478 (1 miss1ng value), /=3.809, df=2, p=0.149 
Within column % 
14.6 
51.0 
34.4 
100.0 
Table A 1.37 Comparison of participants' occupation for fully and partially completed 
surveys 
Occupation Fully completed Partially completed 
n With in column % n Within column % 
White-collar 
Blue-collar 
Other 
195 
69 
57 
321 
n=479, :?=1.127. df=2. p=0.569 
60.7 
21.5 
17.8 
100.0 
96 
39 
23 
158 
Table A1.38 Comparison of participants' current employment status for fully and 
partially completed surveys 
60.8 
24.7 
14.6 
100.0 
Employment status Fully completed Partially completed 
Working 
Retired or not working 
n 
78 
242 
320 
Within column % n 
24.4 28 
75.6 130 
100.0 158 
n=478 (1 miss1ng value).l=2.341, df=1, p=0.126 
With in column % 
17.7 
82.3 
100.0 
Table A1 .39 Group 1 and Group 2 sample demographics Table A 1.40 Presenting medical conditions 
Patient characteristics Group 1 Group 2 Presenting medical condition 
(n=217) {n=262) 
n % 
n % n % Hypertension 262 54.7 
Gender Male 73 33.6 127 48.5 Rheumatoid arthritis 73 15.2 
Female 144 66.4 135 51.5 Musculoskeletal pain (unclassified*} 38 7.9 
Age s 60 years 105 48.4 75 28.6 Osteoarthritis 34 7.1 
~ 61 years 112 51.6 187 71.4 Arthritis (unclassified*} 20 4.2 
Country of birth Australia 142 65.4 165 63.0 Back problems 13 2.7 
Overseas 75 34.6 97 37.0 Systemic lupus erythematosus 7 1.5 
Main language spoken at English 179 82.5 212 80.9 Psoriatic arthritis 5 1.0 
home Other 38 17.5 50 19.1 Polymyalgia rheumatica 5 1.0 
Highest level of education s Primary 40 18.4 47 17.9 Other 22 4.6 
~Secondary 177 81.6 214 81.7 Total 479 100.0 
Missing 1 0.4 ·some patients were unable to specifically name their medical conditions, hence these were put under broad headtngs. 
Occupation White-collar 125 57.6 166 63.4 
Blue-collar 47 21.7 61 23.3 Table A1.41 Readership by duration of therapy and status of prescription (n=377) 
Homemaker 40 18.4 35 13.4 New Repeat 
Miscellaneous 4 1.8 Short term Long term Short term Long term 
Missing 1 0.5 
n % n % n % n % 
Employment status Working 62 28.6 44 16.8 
Not working 154 71.0 218 83.2 
Always 271 71 .9 338 89.7 7 1.9 16 4.2 
Sometimes 48 12.7 39 10.3 7 1.9 84 22.3 
Missing 1 0.5 
Never 54 14.3 357 94.7 276 73.2 
Number of medications median; IQR (n) 5; 3-7 (217) 4; 2-6 (262) 
Duration of disease (years) median; IQR (n) 10; 3-20 (177) 10; 3-18 (261} 
Not applicable 4 1.1 6 1.6 1 0.3 
Total 377 100.0 377 100.0 377 100.0 377 100.0 
Table A 1.42 Sections of CMI read (n=113) 
Section (in order of appearance in CMI) n* 
What is in the leaflet 52 
What the medication is for 86 
Points to note before starting the medication 71 
How to take the medication 82 
Drug interactions 62 
Side effects 103 
Storage 34 
Disposal 16 
Description of medication 17 
Ingredients 22 
Manufacturer 15 
NB: Responses are not mutually exclusive. 
·Applicable to participants who reported reading only certain sections of a CMI (1 missing case). 
Table A1 .43 Third party for whom CMI was read (n=143) 
Third party 
Partner 
Elderly parenVrelative 
Child 
Friends/colleagues 
Other (grandchild, patients, members of support group, neighbours) 
NB: Responses are not mutually exclusive. 
n 
81 
36 
28 
11 
12 
% 
46.0 
76.1 
62.8 
72.6 
54.9 
91 .2 
30.1 
14.2 
15.0 
19.5 
13.3 
% 
56.6 
25.2 
19.6 
7.7 
8.4 
Table A1 .44 Reasons for reading CMI (multiple-choice question) (n=378) 
Reason 
I am concerned about the medication's side effects. 
I take other medications and would like to make sure there are no drug 
interactions. 
n* % 
305 80.7 
166 43.9 
I have other disease conditions and would like to know if the medication 132 34.9 
is suitable for me. 
I have allergies so I like to check to make sure I am not allergic to the 
medication. 
I want to check that the doctor did not forget anything. 
I have had bad experiences with my medications in the past. 
I want to check that the pharmacist did not forget anyth ing. 
NB: Responses are not mutually exclusive. 
126 33.3 
93 24.6 
85 22.5 
59 15.6 
'n=376 as the question was directed to all participants who read a CMI (for themselves and/or 
someone in their care, n=377 and for someone in the1r care only, n=1 ). 
Table A1 .45 Reasons for not reading a CMI (open-ended question) (n=101 ) 
Reason n* % 
I trust my doctor to prescribe a medication that 1s su1table for me. 92 91.1 
I receive the information I need from my doctor. 89 88.1 
I receive the information I need from my pharmacist. 66 65.3 
I trust my pharmacist to provide a suitable medication for me. 59 58.4 
I have been taking my medication for a long time. 38 37.6 
I have taken this medication in the past. 4 4.0 
NB: Responses are not mutually exclusive. 
·n=101 as the question was directed only to participants who did not read a CMI for themselves nor for 
someone in their care. 
Table A1.46 Other sources of written medicine information (n=126) 
WMI sources 
Reference book 
Internet 
Journal or magazine 
Printout 
Other 
NB: Responses are not mutually exclusive. 
n 
76 
59 
20 
17 
18 
% 
60.3 
46.8 
15.9 
13.5 
14.3 
Table A1 .47 Relationship between " reading" and "seeking" scales and use of CMI 
n " Reading" scale " Seeking" scale 
Median IQR Median IQR 
Read CMI (for self)* Yes 377 10 8- 10 5 2-9 
No 102 2 2-4 2 2-2 
Read CMI (for someone in Yes 143 10 9-10 6 2-10 
care)* No 336 8 4-10 2 2-6 
Used other sources of WMI* Yes 125 10 9-10 9 6-10 
No 354 8 4-10 2 2-5 
·Mann-Whitney U test p<0.001 for all variables. 
This area has been left intentionally blank 
Table A1.48 Relationship between interest in reading and seeking WMI and use of CMI 
Read CMI (for self)' Read CMI (for someone in care)* Used other sources of WMI* 
Yes No Yes No Yes No 
n % n % n % n % n % n % 
Reading Interested 328 87.0 8 7.8 134 93.7 202 60.1 219 61.9 117 93.6 
Not interested 49 13.0 94 92.2 9 6.3 134 39.9 135 38.1 8 6.4 
Total 377 100.0 102 100.0 143 100.0 336 100.0 354 100.0 125 100.0 
Seeking Interested 150 39.8 1 1.0 71 49.7 80 23.8 61 17.2 90 72.0 
Not interested 227 60.2 101 99.0 72 50.3 256 76.2 293 82.8 35 28.0 
Total 377 100.0 102 100.0 143 100.0 336 100.0 354 100.0 125 100.0 
NB: Percentages refer to within column percentages. 
•chi-square test p<0.001 
Table A1.49 Relationship between patientfactors and "reading" and "seeking" scales 
Reading Seeking 
Interested Not Statistics Interested Not Statistics 
interested interested 
n % n % n % n % 
Disease state8 Hypertension 168 64.1 94 35.9 x2=9.40 61 23.3 201 76.7 x2=18.20 
Pain/rheumatology 168 77.4 49 22.6 p=0.002 90 41.5 127 58.5 p<0.001 
Coping style' Blunter 83 69.7 36 30.3 x2=4.12 43 36.1 76 63.9 x'=0.44 
Monitor 135 80.8 32 19.2 p=0.042 68 40.7 99 59.3 p=0.509 
Health literacy' Inadequate 25 43.1 33 56.9 x2=32.74 6 10.3 52 89.7 x2=19.05 
Marginal 10 76.9 3 23.1 p<0.001 4 30.8 9 69.2 p<0.001 
Adequate 231 79.4 60 20.6 117 40.2 174 59.8 
Health locus of Internal Z=-0.066 Z--1.075 
controlb p=0.948 p=0.282 
Chance Z=-1.940 Z=-2.126 
p=0.052 p=0.033 
Powerful other Z=-2.589 Z=-3.977 
p=0.010 p<0.001 
aChi-square test; 6Mann-Whitney U test 
Table A1.50 Relat ionship between pain as a symptom and interest in reading and 
seekingWMI 
Pain as a symptom 
Absent Present 
n % n 
Reading* Interested 120 67.8 216 
Not interested 57 32.2 86 
Total 177 100.0 302 
Seeking•• Interested 40 22.6 111 
Not interested 137 77.4 191 
Total 177 100.0 302 
NB: Percentages refer to withtn column percentages. 
'x2=0.573, dt=1 , p=0.449; " x2=9.714, dt=1, p=0.002 
% 
71 .5 
28.5 
100.0 
36.8 
63.2 
100.0 
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Table A1.51 Relationship between patient demographics and " reading" and "seeking" scales 
Gender" 
Age• 
Country of 
birth" 
Main language 
Male 
Female 
s 60 years 
~ 61 years 
Australia 
Overseas 
English 
spoken at home" Other 
Highest level s Primary 
Reading Seeking 
Interested Not Statistics Interested Not Statistics 
n % 
122 61.0 
214 76.7 
138 76.7 
198 66.2 
228 74.3 
108 62.8 
285 72.9 
51 58.0 
51 58.6 
interested 
n % 
78 39.0 x 2=12.98, p<0.001 
65 23.3 
42 23.3 x~=5.37, p=0.021 
101 33.8 
79 25.7 x~=6.40, p=0.011 
64 37.2 
106 27.1 / =6.96, p=0.008 
n 
56 
95 
77 
74 
103 
48 
132 
37 42.0 19 
36 41.4 / =5.87, p=0.015 15 
% 
28.0 
34.1 
42.8 
24.7 
33.6 
27.9 
33.8 
21.6 
interested 
n % 
144 72.0 
184 65.9 
103 57.2 
225 75.3 
204 66.4 
124 72.1 
259 66.2 
69 78.4 
x2=1. 705, p;0.192 
x~=16.09, p<0.001 
/ =1.38, p=0.241 
/=4.38, p=0.036 
72 82.8 /=8.76, p=0.003 
of education" 2: Secondary 282 72.5 107 27.5 133 
17.2 
34.2 256 65.8 
Occupation• White-collar 
Blue-collar 
Homemaker 
213 73.2 
58 53.7 
61 81.3 
78 26.8 /=19.68, p<0.001 103 35.4 
20.4 
32.0 
188 64.6 /=8.26, p=0.016 
50 46.3 22 86 79.6 
14 18.7 24 51 68.0 
Employment Working 75 71.4 30 28.6 /=0.042 , p=0.838 45 60 57.1 / =7.34, p=0.007 
status" Not working 261 69.8 113 30.2 106 
42.9 
28.3 268 71.7 
Number of medications0 
Duration of disease of interestb 
8Chi-square test: "Mann-Whitney U test 
Z=-0.282, p=0.778 
Z=-1 .279, p=0.201 
Table A1 .52 Logistic regression of interest in reading (using presence of pain) 
Z=-0.860, p=0.390 
Z=-1 .385, p=0.166 
Independent variables Regression Wald test p Odds ratio 95% confidence 
interval 
Presence of pain 
Chance HLC 
Powerful other HLC 
Coping style 
Health literacy 
Gender 
Age (years) 
Country of birth 
Main language spoken at home 
Highest level of education 
Occupation 
n 
Model y} test 
Hosmer & Lemeshow test 
Nagelkerke R2 
(ind) = indicator category 
-no, yes (ind) 
- blunter. monitor (ind) 
-inadequate, marginal (ind) 
-inadequate, adequate (ind) 
- male, female (ind) 
- s 60, 2: 61 (ind) 
- other, Australia (ind) 
-other, English (ind} 
- s primary, 2: secondary (ind) 
- homemaker. white (ind) 
- homemaker, blue (ind) 
coefficient 
0.336 
-0.019 
-0.042 
0.816 
1.782 
1.396 
0.465 
0.114 
0.435 
-0.518 
0.226 
-0.872 
-1.408 
282 
(z-ratio) 
0.900 
0.362 
1.617 
6.372 
3.559 
7.857 
1.834 
0.110 
1.213 
1.003 
0.231 
2.598 
5.585 
x2=39.697, df=13. p<o.oo1 
x2=8.838, df=8, p=0.356 
0.196 
0.343 1.442 
0.548 0.981 
0.203 0.959 
0.012 2.262 
0.059 5.941 
0.005 4.041 
0.176 1.591 
0.740 1.121 
0.271 1.544 
0.317 0.596 
0.631 1.253 
0.107 0.418 
0.018 0.245 
0.677- 3.072 
0.921 - 1.045 
0.899- 1.023 
1.200-4.262 
0.933-37.827 
1.522- 10.728 
0.812-3.117 
0.570- 2.205 
0.713-3.347 
0.216 - 1.642 
0.499-3.146 
0.145- 1.207 
0.076-0.786 

Table A1.54 Summary of scores for items in the comprehension subscale Table A1 .56 Summary of scores for items in the utility subscale 
How easy or hard the information in CMI is to ... ? n Median IQR Opinion on the quantity Quantity• Usefulness 
Read 309 4 4-5 and usefulness of the Too much/ too About right n Median IQR 
Understand 309 4 4-5 information provided little/ none at all 
Remember 307 4 3-4 on .. . in the CMI n % n % 
Locate important information 307 4 4- 5 Benefits of taking the 52 18.0 237 82.0 291 3 2-3 
Keep for future reference 307 4 3-5 medication 
Who should not use the 40 13.9 248 86.1 290 3 2-3 
medication 
Specific directions on how 32 11 .1 256 88.9 290 3 2-3 
to take the medication 
Table A1 .55 Summary of scores for items in the future use subscale 
How likely is it that you would ... the CMI? n Median IQR 
Read 307 5 5-5 
Precautions while using 32 11.0 258 89.0 291 3 2-3 
Use/refer 307 4 1-4 
the medication 
Keep 307 5 2-5 
Possible side effects 41 14.1 249 85.9 290 3 2-3 
What to do about side 37 12.8 253 87.2 291 3 2-3 
effects 
How to store the 35 12.1 255 87.9 291 3 2-3 
medication 
General information 44 15.3 243 84.7 291 2 2 - 3 
"Quantity of information was scored 0 (too much/ too little/ none at all) or 1 (about right) hence was 
summarised in a different format to make it more informative. 
NB: The utility subscale score is the sum of the quantity of information score and the usefulness of 
information score. 
Table A1 .57 Summary of scores for items in the design quality subscale 
Opinion on ... of CMI n Median IQR 
Organisation 297 5.0 4.0-5.0 
Attractiveness 297 4.0 3.0-5.0 
Print size 298 5.0 3.8 - 5.0 
Tone 295 4.0 3.0 - 5.0 
Helpfulness 297 5.0 4.0-5.0 
Bias 289 5.0 4.0-5.0 
Spacing 297 5.0 5.0 - 5.0 

Table A1 .59 Outliers in the adapted CIRF regression models 
Regression model Outlier• Standardised 
residual 
Comprehension # 1 -3.490 
Future use (patient characteristics Nil 
as predictors) 
Utility # 1 -3.354 
#2 -3.368 
#3 -3.304 
#4 -3.735 
Design quality Nil 
Future use (CIRF subscales as #1 -3.34 
predictors) 
'Outliers are numbered arbitrarily. 
Observed Predicted 
value value 
1.80 4.12 
1.25 4.12 
1.25 4.13 
1.25 4.07 
1.25 4.44 
1.00 4.30 
Figure A 1.1 Scatterplot of the 
regression standardised residuals for 
the comprehension subscale 
Figure A 1.2 Scatterplot of the 
regression standardised residuals for 
the future use subscale (with patient 
characteristics as predictors) 
Figure A 1.3 Scatterplot of the 
regression standardised residuals for 
the utility subscale 
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Figure A 1.4 Scatterplot of the 
regression standardised residuals for 
the design quality subscale 
Figure A1 .5 Scatterplot of the 
regression standardised residuals for 
the future use subscale (with CIRF 
subscales as predictors) 
Figure A1 .6 Normal probability plot of 
the regression standardised residuals 
for the comprehension subscale 
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Figure A1 .7 Normal probability plot of 
the regression standardised residuals 
for the future use subscale (with patient 
characteristics as predictors) 
Figure A1 .8 Normal probability plot of 
the regression standardised residuals 
for the utility subscale 
Figure A1.9 Original normal probability 
plot of the regression standardised 
residuals for the design quality 
subscale 
Figure A1 .10 Reflect inverse 
transformed probability p lot of the 
regression standardised residuals for 
the design quality subscale 
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Figure A1 .11 Normal probability plot of 
the regression standardised residuals 
for the future use subscale (with CIRF 
subscales as predictors) 
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Consumer Medicine Information (CMI} Questionnaire 
Section A 
1. (a) How interested would you say you are in reading written information about your 
prescription medicines? 
2 3 4 5 
Not interested at all Very interested 
(b) How likely are you to seek written information about your prescription medicines? 
2 3 4 5 
Not likely at all Very likely 
(c) Typically, how often would you seek written information about your prescription 
medicines? 
2 3 4 5 
Not often at all Very often 
(d) How likely are you to read written information about your prescription medicines? 
2 3 4 5 
Not likely at all Very likely 
One form of written information about medicines is known as Consumer Medicine 
Information. Below are some general questions on Consumer Medicine Information and 
how you use them. 
2. Are you aware of what Consumer Medicine Information (CMI for short) is? 
Yes 
No 
o , 
0 2 
golo03 
please explain what CMIIs. then go to 0 3 
Consumer Medicine Information (or CMI as it is called for short). is written information about 
medications produced by the manufacturer that comes with prescription medications. CMI provides 
you with information about your medications. such as how and when to take it. and what to expect 
alter taking it. CMI comes in three different forms: a printed sheet that comes inside your medication 
box. a loose leaflet given to you with the medication or a computer print out given to you at the 
pharmacy. 
Consumer Medicine Information (CMI) Ouastionnolre· Varslon 2 (19.12.02} 
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3. Have you ever read CMI for any of vour own medications? 
Yes 
No 
o, 
0 2 
goto04 
goto09 
4. Typically, how often would you say you read a CMI for a !l!l.l!! medication that was 
prescribed for ... ? 
Always Sometimes Never 
0 0 0 Short lerm use (less than 2 weeks) 
0 0 0 
f.----.--- go to 0 5 
Long term use (2 weeks or more) 
5. Typically, how often would you say you read a CMI for a repeat medication or a 
medication that you have had In the past that was prescribed for ... ? 
ANioys Sometimes Never 
0 0 0 Short term use (less than 2 weeks) 
~goto06 
Long term use (2 weeks or more) 0 0 0 
6. Typically, when you read CMI, how much of the CMI would you read? 
All sections 
Most sections 
Some sections 
o, 
0 2 
O J 
go to08 
go to07 
go IO 0 7 
7. What sections of the CMI would you usually read? (you may tick more than one box) 
What is in the leaflet 
What the medication is for 
Points to note before starting the medication 
How to take the medication 
Drug interactions 
Side effects 
Storage 
Disposal 
Description of medication 
Ingredients 
Manufacturer 
Others (please specify)---- ---------
01 
0 2 
0 3 
0 4 
Os 
Os 
0 7 
Oa 
De 
Oto 
0 11 
0 12 
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8. What did you do with the CMI after you read it? 
Kept it until I finished the medication 
Filed it away for future reference 
Shared it with someone else on the same medication 
Threw it away 
Other (please specify)-------------
go to09 
9. Have you ever read CMI for the medications of someone in your care (e.g. child, elderly 
parent, partner)? 
Yes 
No 
0 1 go to010 
0 2 If from 0 8. go to 0 11; If from 0 3. go toO 12 
10. Whose CMI did you read? (you may lick more than one box) 
Child 
Grandchild 
Partner go toO 11 
Elderly parent/ relative 
Other (please specify)-------------
11. What are your reasons for reading a CMI? 
Below are some reasons that other people have given for reading the CMI. Do any of the 
following apply to you? (you may lick more than one box) 
I am concerned about the medication's side effects. 
I have allergies so I like to check to make sure I am not allergic to 
the medication. 
I want to check that the doctor did not forget anything. 
I want to check that the pharmacist did not forget anything. 
I have had bad experiences with my medications in the past. 
I have other disease conditions and would like to know if the medication 
is suitable for me. 
I take other medications and would like to make sure there are no drug 
interactions. 
0 1 
0 2 
Con&umer Medicine Information (CMI) Questionnaire· Version 2 (19.12.02) 
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12. What are your reasons for not reading a CMI? 
Below are some reasons that other people have given for not reading the CMI. Do any of the 
following apply to you? (you may lick more than one box) 
I receive the information I need from my doctor. 
I receive the information I need from my pharmacist. 
I trust my doctor to prescribe a medication that is suitable for me. 
I trust my pharmacist to provide a suitable medication for me. 
I have been taking my medication for a long time. 
I have taken this medication in the past. 
go to 013 
13. Apart from the CMI, where do you find written information about your prescription 
medicines? (you may lick more than one box) 
Internet 
Reference books (please specify)-------------
Print-outs (from ___________ _] 
Journals or magazines (please specify) ----------
Other (please specify)----------------
I don't (because -------------------' 
go to 014 
O s go to Section 8 
14. Consider all the different types of written medicine information that you have used in 
the past. Please rank your top 3 choices in terms of how often you use them and then in 
terms of usefulness (with '1 ' being the most frequently used or the most useful). 
CMI 
Internet 
Reference books 
Print-outs 
Journals or magazines 
Other 
How often you used it? 
o ,. 
D 2a 
D 3a 
04a 
DSa 
D6a 
How useful you found it? 
Otb 
0 2b 
0 3b 
04b 
0 5b 
06b 
Consumer Medicine Information (CMI) Questionnaire· Version 2 (19. 12.02} 
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Section 8 
You will now be shown a CMI for one of your medications and given about 10 minutes to 
read it. After that, we would appreciate it if you could give us your opinion about this 
particular CMI by answering the questions below. 
1. Overall, how easy or hard would you say the info rmation in the CMI is to ......... ? 
Very easy Quite easy In between Oolte hard Very hard 
• Read 0 0 0 0 0 1 
• Understand 0 0 0 0 0 2 
• Remember 0 0 0 0 0 3 
• Locale lmporlanl informalion 0 0 0 0 o. 
• Keep for future reference 0 0 0 0 0 5 
2. If you were taking this medication for the first time and found this CMI in the 
medication box (for package Inserts)/ received this CMI from the pharmacist (for 
computer print out) (delete whichever is not applicable), how likely is it that you would 
......... the CMI? 
Very likely Somewnatllkely Unsure Somewllat unlikely Very unlikely 
• Read 0 0 0 0 0 1 
• Use 0 0 0 0 0 2 
• Keep 0 0 0 0 0 3 
3. Below is a list of topics. Please indicate your opinion about how much information was 
provided on each topic and how useful you think this information would be if you were 
taking this medicine for the first time. 
How much information? How useful is the info? 
Too About Too None Very 
much right tittle at all useful 
• The benefits of taking the medication 0 0 0 0 1a 0 
• Who should not use the medication 0 0 0 0 2e 0 
• Specific directions about how to take 0 0 0 0 Ja 0 
the medication 
• Precautions that need to be taken 0 0 0 04a 0 
while using the medication 
• Possible side effects 0 0 0 Os. 0 
• What to do about side effects 0 0 0 0 Sa 0 
• How to store the medication 0 0 0 0 7a 0 
• General information 0 0 0 0 88 0 
(e.g. description of medication) 
Consumer Medicin<J Information (CMI) Questionnaire· Version 2 (19. 12.02) 
Pege 5 of 14 
Fairly Not so 
useful useful 
0 0 1b 
0 0 2b 
0 0 Jb 
0 04b 
0 O Sb 
0 0 6b 
0 0 7b 
0 0 8b 
Code: Date:_!_!_ 
4. Below is a list of words on a scale of 1 - 5 describing the design, layout and tone of the 
CMI. Which best describes your opinion? 
2 3 4 5 
poorly organized well organized 
2 3 4 5 
unattractive attractive 
2 3 4 5 
poor print size ideal print size 
2 3 4 5 
alarming in tone encouraging in tone 
2 3 4 5 
unhelpful helpful 
2 3 4 5 
biased unbiased 
2 3 4 5 
poor spacing ideal spacing 
between lines between lines 
5. Do you have any other comments about this particular CMI? 
Consumer Medicln<~ Information (CMJ) Quest/onnolre· Version 2 (19.12.02) 
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Section C Section D 
B elow are a series of statements which describe how people view their health. Please In the section below, you will be asked to imagine that you find yourself in a particular 
read each s tatement carefu lly and show whether you agree or disagree with these scene. This is followed by eight responses. Please tick all responses that might apply to 
statements by ticking the appropriate box. you. You can tick more than one response. 
Strongly Disagree Slightly Slightly Agree Strongly 
disagree disagree ag•ee agree 1. Vividly imagine that you are afraid of the dentist and have to get some dental work 
• If I gel sick, it is my own behaviour which determines 0 0 0 0 0 0 done. Which of the following would you do? Tick all of the statements that might apply how soon I get well again. to you. 
• No matter what I do, if l am going to gel sick, I will 0 0 0 0 0 0 0 get sick. t I would ask the dentist exactly what work was going to be done. 
t I would take a tranquilizer or have a drink before going. 0 
• Having regular contact with my physician is the best 0 0 0 0 0 0 t I would try to think about pleasant memories. 0 
way for me to avoid illness. 
t I would want the dentist to tell me when I would feel pain. 0 
• Most things that affect my health happen to me by 0 0 0 0 0 0 t I would try to sleep. 0 
accident. • 1 would watch all the dentist's movements and listen for the sound of the drill. 0 
• Whenever I don't feel well, I should consult a 0 0 0 0 0 0 • I would watch the now or water from my mouth to see if it contained blood. 0 
medically trained professional. t I would do mental puzzles in my mind. 0 
• I am in control or my health . 0 0 0 0 0 0 
• My family has a lot to do with my becoming sick or 0 0 0 0 0 0 2. Vividly imagine that, due to a large drop in sales, it is rumoured that several people in 
slaying healthy. your department at work will be laid off. Your supervisor has turned In an evaluation of 
0 0 0 0 0 0 
your work for the past year. The decision about lay-offs has been made and will be 
• When I gel sick, I am to blame. announced in several days. Tick .!!!!_of the statements that might apply to you. 
• Luck plays a big part in determining how soon I 0 0 0 0 0 0 • I would talk to my fellow workers to see if they knew anything about what the supervisor 0 
recover from illness. evaluation of me said. 
• Health professionals control my health . 0 0 0 0 0 0 • I would review the list of duties for my present job and try to figure out if I had fulfilled them all. 0 
• 1 would go to the movies to lake my mind off things. 0 
• My good health is largely a matter of good fortune. 0 0 0 0 0 0 t 1 would try to remember any arguments or disagreements I might have had that would 0 
0 
have resulted in the supervisor having a lower opinion of me. 
• The main thing which affects my health is what I 0 0 0 0 0 t I would push all thoughts of being laid off out of my mind. 0 
myself do. 
t 1 would tell my spouse that I'd rather not discuss my chances of being laid off. 0 
• If I lake care of myself, I can avoid illness . 0 0 0 0 0 0 t I would try to think which employees in my department the supervisor might have 0 
• When I recover from an Illness, it's usually because 0 0 0 0 0 0 
thought had done the worst job. 
t I would continue doing my work as if nothing special was happening. 0 
other people (for example doctors, nurses, family, 
friends) have been laking good care of me. 
• No matter what I do, I'm likely to gel sick. 0 0 0 0 0 0 
• If it's meant to be, I will stay healthy . 0 0 0 0 0 0 
• If I lake the right actions, I can stay healthy . 0 0 0 0 0 0 
• Regarding my health, I can only do what my doctor 0 0 0 0 0 0 
tells me to do. 
Consumer Medlclnelnlormation (CMI} Ouestionnslro· Version 2 (19.12.02} Consumer Medicine lnfom~otion (CMI} Oueslionnsiro· Version 2 (19.12.02} 
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Co de. Oete: _ _ t _ _ l __ 
Section E 
In the section below, there are two passages with a few sentences that have some of the 
words missing. Where a word is missing, a blank line is drawn, and 4 possible words that 
could go in the blank appear just below it in the box. Please fill in the blanks by circling 
the letter in front of the word which makes the sentence make sense. You have 7 minutes 
to complete as much of this as you can. 
PASSAGE A 
Your doctor has sent you to have a X-ray. You must have an 
a. stomach 
b. diabetes 
c. stitches 
d. germs 
1 stomach when you come fo1 ___ . !The X-ray will 
a. asthma a. is 
b. empty b. am 
c. incest c. if 
d. anaemia d. it 
1 to 3 to do. 
a. beds 
b. brains 
c. hours 
d. diets 
THEDA Y BEFORE THE X-RAY. 
---
a. take 
b. view 
c: talk 
d. look 
from 
For supper have only a snack of fruit, and jelly, with coffee 
a. little 
b. broth 
c. attack 
d. nausea 
a. toes 
b. throat 
c. toast 
.d. thigh 
"-----=--
or tea. After I , I you must not or drink anything at, __ _ 
a. minute 
b. midnight 
a. easy 
b. ate 
c. during c. drank 
d. before d. eat 
Coosumer Medicine lnformBiion (CMI) Ouestl0flf18ire· Verslon 2 (19.12.02) 
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a. ill 
b. all 
c. each 
d~ any 
Code: Oete. _ /_1_ 
until after you have 1--- I the X-ray. 
a. are 
b. has 
c. had 
d. was 
THEDA Y OF THE X-RAY. 
Do not eat Do not 1 , I even 
a. appoin~ent 
b. walk-in 
c. breakfast 
d. clinic 
If you have any 
a. answers · 
.I:Lexercfses 
c. tracts 
d. questions 
a. drive a.-heart 
b. drink b. breath 
c. dr.ass c. water 
d. dose d. cancer 
call the X-ray 
a. 'Department 
b. Sprain 
c. Pharmacy 
d. Toothache 
on 9616 4500. 
Coosumer Medicine tnfOrmBtion (CMI) OUestlonneire· Versloo 2 (19. 12.02) 
Pegs IOof 14 
Code: Dele: _1_1_ 
PASSAGE B 
I agree to give correct information to 1--- l if I can receive health benefits. 
a. hair 
b. salt 
c . see 
d. ache 
----1 to provide the government information tor 1 any statements 
a. hide a. agree 
b. probe 
c. send 
b. risk. 
c. discharge 
d. gain d. prove 
given in this and hereby give permission to the I I to 
a. inflammation 
b. religion 
c. iron 
\.d. governmen! 
a. emphysema 
b. application 
c. gallbladder 
d. relationship 
get such proof. If 1 that for my health benefits, I must report any 
a. investigate 
b. entertain 
c. understand 
d. establish 
in my circumstances within [ 1 (10) days of becoming ll---
a. award 
b .. awar~ 
a. changes a. three 
b. hormones b. one 
c. antacids c. five 
d. charges d. ten 
of the change. I understand 1-- I if I DO NOT like the 
a. thus 
b. this 
c. that 
d. than 
Consumer Medicinelnlormation (CMI} Questionnaire- Version 2 (19.12.02) 
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c. away 
d. await 
made on 
Code: Dele: _ 1_ 1_ 
my case, I have the to a fair hearing. I can a hearing by 
a. bright 
b. left 
a. request 
b. refuse 
c. wrong 
d. right 
c. fail 
d. mend 
writing or the centre where I applied. 
a. counting 
b. reading 
c. calling 
d. smelling 
"~·wash 
b. want 
If you additional benefit for any family 
a. member 
b. history 
you will have to 
c. cover c. weight 
d. tape d. seatbelt 
a different application form . we will use the ___ 1on 
a. relax 
b. break 
c. inhale 
d. sign 
a. Since 
b. Whether 
c. Howevet 
d. Because 
_ _) 
a. lung 
b. date 
c. meal 
d. pelvic 
this form to determine your1 ~----.;...,-
a. hypoglycaemia 
.:b. eligibilitY 
c::.osteol)orosis 
d. schizophrenia 
Total: 0-16 
17-22 
23-36 
Consumer Medicine Information (CMI) Questionnaire· Varsion 2 (19.12.02) 
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0 1 
0 2 
0 3 
--
Code.· Dale: _!_!_ 
Section F 
The following questions col lect some demographic details about you. Please answer all 
questions. 
1. Sex: 
2. Age: 
Male 
Female 
__ years 
o, 
0 2 
3. Country of birth: Australia 
Overseas 
o, 
0 please slate--------
4. Main language spoken at home: English 
Other 
o , 
0 please slate------ --
5. Other languages spoken at home (can list more than one): 
English 0 1 
None 0 2 
Other 0 please state--------
6. Highest level of education: None o, 
0 2 
0 3 
7. Occupation: 
Primary school 
School Certificate (Year 10) 
Higher School Certificate (Year 12) 0• 
Trade or other certificate Os 
Tertiary (Diploma, Bachelor or higher) Os 
Managers and administrators 0 1 
Professionals and associate professionals 0 2 
Tradespersons and related workers 0 3 
Clerical workers 0• 
Production and transport workers Os 
t---_..go to 0 8 
Sales and service workers Os 
Labourers and related workers 0 7 
Homemaker 
Student 
Others (please specify) _____ _ 
O a 
0 9 
0 10 
Consumer Mediclnelnformslion (CMI} Ouestionnsire- Version 2 (19.12.02} 
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goto09 
goto09 
gotoOB 
Code: Dale:_!_!_ 
8. Employment status: Full time 
Part time 
Retired 
Unable to work due to health reasons 
Unemployed 
9. Current medical conditions: 
10. Current medications prescribed by doctor: 
o , 
0 2 
0 3 
o~ 
Os 
Thank you for participating in this study. Your lime is greatly appreciated and your input 
is highly valued. Are there any comments relevant to CMis or written drug information 
which you would like to make? 
Consumer Medicine Informs/ion (CMI) Oueslionnslre- Version 2 (19. 12.02) 
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COMMON MEDICATIONS FOR ARTHRITIS 
GENERIC NAME COMMON BRAND NAMES 
Auranofin Rid aura® 
Azathioprine lmuran® 
Thioprine® 
Celecoxib Celebrex® 
Chloroquine Chlorquin® 
Codeine Codeine Phosphate 
Codeine/ paracetamol Panadeine Forte® 
Cortisone Cortate® 
Cyclophosphamide Cycloblastin® 
Cyclosporin Neoral® 
Sandimmun® 
Dexamethasone Dexmethsone® 
Dextropropoxyphene/ Capadex® 
paracetamol Di-Gesic® 
Paradex® 
Diclofenac Fenac® 
Voltaren® 
Diflunisal Dolobid® 
Hydrocortisone Hysone® 
Hydroxychloroquine Plaquenil® 
Ibuprofen Brufen® 
Indomethacin Arthrexin® 
lndocid® 
Ketoprofen Orudis® 
Oruvail® 
Leflunomide Arava® 
Common Medications for Arthritis (Version 2)- Page 1 of 2 (03.03.03) 
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COMMON MEDICATIONS FOR ARTHRITIS 
GENERIC NAME COMMON BRAND NAMES 
Meloxicam Mobic® 
Methotrexate Ledertrexate® 
Methoblastin® 
Methotrexate tablets (Fauldings) 
Morphine Kapanol® 
MS Cantin® 
MS Mono® 
Naproxen lnza® 
Naprosyn® 
Proxen® 
Oxycodone End one® 
Oxycontin® 
Oxynorm® 
Paracetamol Panamax® 
Penicillamine D-Penamine® 
Piroxicam Feldene® 
Mobilis® 
Rosig® 
Prednisolone Panafcortelone® 
So lone® 
Prednisone Panafcort® 
Sone® 
Rofecoxib Vioxx® 
Sulfasalazine Pyralin® 
Salazopyrin® 
Sulindac Clinoril® 
Tramadol Tramal® 
Common Medications for Arthritis (Version 2)- Page 2 of 2 (03.03.03) 
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COMMON MEDICATIONS FOR HIGH BLOOD PRESSURE 
GENERIC NAME COMMON BRAND NAMES 
Amlodipine Norvasc® 
Atenolol No ten® 
Tenormin® 
Tensig® 
Bendrofluazide Aprinox® 
Candesartan Atacand® 
Candesartan/ HCT Atacand Plus® 
Captopril Ace norm® 
Capoten® 
Clonidine Catapres® 
Diltiazem Cardizem® 
Caras® 
Vasocardol® 
Enalapril Alphapril® 
Amp race® 
Auspril® 
Renitec® 
Enalapril/ HCT Renitec Plus® 
Eprosartan Teveten® 
Eprosartan/ HCT Teveten Plus® 
Felodipine Agon® 
Felodur® 
Plendil® 
Fosinopril Monopril® 
Fosinopril/ HCT Monoplus® 
Hydralazine Alpha press® 
Hydrochlorothiazide. (HCT) Dichlotride® 
' HCT/ amiloride Amizide® 
Moduretic® 
HCT/ triamterene Hydrene® 
lndapamide Natrilix® 
Natrilix SR® 
Dapa-tabs® 
lrbesartan Ava pro® 
Karvea® 
Common Medications lor High Blood Pressure (Version 2)- Page 1 ol 2 (12.11 .03) 
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COMMON MEDICATIONS FOR HIGH BLOOD PRESSURE 
GENERIC NAME COMMON BRAND NAMES 
lrbesartan/ HCT Avapro HCT® 
Karvezide® 
Lercanidipine Zanidip® 
Lisinopril Lisodur® 
Prinivil® 
Zestril® 
Methyldopa Aldomet® 
Metoprolol Betaloc® 
Lopresor® 
Minax® 
Nifedipine Ad ala!® 
Adalat Oros® 
Nifecard® 
Perindopril Covers vi® 
Perindopril/ indapamide Coversyl Plus® 
Prazosin Minipress® 
Pressin® 
Propranolol Deralin® 
lnderal® 
Quinapril Accupril® 
Asiq® 
Quinaoril/ HCT Accuretic® 
Ramipril Ram ace® 
Tritace® 
Telmisartan Micardis® 
Pritor® 
Telmisartan/ HCT Micardis Plus® 
Trandolapril Gopten® 
Odrik® 
Verapamil An pee® 
Cordi lox® 
lsoptin® 
Veracaps® __ 
Common Medications lor High Blood Pressure (Version 2)- Page 2 ol 2 (12.11 .03) 
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Section A (Question 1) 
(a) How interested would you say you are in reading written information about your 
prescription medicines? 
1 2 3 4 5 
Not interested at all Very interested 
(b) How likely are you to seek written information about your prescription medicines? 
1 2 3 4 5 
Not likely at all Very likely 
(c) Typically, how often would you seek written information about your prescription 
medicines? 
1 2 3 4 5 
Not often at all Very often 
(d) How likely are you to read written information about your prescription medicines? 
1 2 3 4 5 
Not likely at all Very likely 
Section A (Question 14) 
Consider all the different types of written medicine information that you have used in the past. 
Please rank your top 3 choices in terms of how often you use them and then in terms of 
usefulness (with '1' being the most frequently used or the most useful). 
How often :iOU used it? How useful you found it? 
CMI D D 
Internet D D 
Reference books D D 
Print-outs D D 
Journals or magazines 0 0 
Other 0 0 
Section B (1 of 4) 
1. Overall, how easy or hard would you say the information in the CMI is to ......... ? 
Very Quite In Quite Very 
easy easy between hard hard 
Read 0 0 0 0 0 
Understand 0 0 0 0 0 
Remember 0 0 0 0 0 
Locate important information 0 0 0 0 0 
Keep for future reference 0 0 0 0 0 
Section B (Cont'd- 2 of 4) 
2. If you were taking this medication for the first time and found this CMI in the medication box 
(for package inserts)/ received this CMI from the pharmacist (for computer print out), how 
likely is it that you would ... . ..... the CMI? 
Very Somewhat Unsure Somewhat Very 
likely likely unlikely unlikely 
Read 0 0 0 0 0 
Use 0 0 0 0 0 
Keep 0 0 0 0 0 
• 
Section 8 (Cont'd- 3 of 4} 
3. Below is a list of topics. Please indicate your opinion about how much information was 
provided on each topic and how useful you think this information would be if you were taking 
this medicine for the first time. 
How much information? How useful is the information? 
Too About Too None Very Fairly Not so 
much right little at all useful useful useful 
The benefits of taking the 0 0 0 0 0 0 0 
medication 
Who should not use the 0 0 0 0 I 0 0 0 
medication 
Specific directions about how 0 0 0 0 I 0 0 0 
to take the medication 
Precautions that need to be 0 0 0 0 I 0 0 0 
taken while using the medication 
Possible side effects 0 0 0 0 0 0 0 
What to do about side effects 0 0 0 0 0 0 0 
How to store the medication 0 0 0 0 0 0 0 
General information 0 0 0 0 0 0 0 
(e.g. description of medication) 
Section 8 (Cont'd- 4 of 4} 
4. Below is a list of words on a scale of 1 - 5 describing the design, layout and tone of the CMI. 
Which best describes your opinion? 
1 2 3 4 5 
poorly organized well organized 
1 2 3 4 5 
unattractive attractive 
1 2 3 4 5 
poor print size ideal print size 
1 2 3 4 5 
alarming in tone encouraging in tone 
1 2 3 4 5 
unhelpful helpful 
1 2 3 4 5 
biased unbiased 
1 2 3 4 5 
poor spacing between lines ideal spacing between lines 
Section C (1 of 3) 
Strongly Disagree Slightly Slightly Agree Strongly 
disagree disagree agree agree 
If I get sick, it is my own D D D D D 0 
behaviour which determines 
how soon I get well again. 
No matter what I do, if I am D D D D D D 
going to get sick, I will get sick. 
Having regular contact with D D D D D D 
my physician is the best way 
for me to avoid illness. 
Most things that affect my D 0 D D D D 
health happen to me by accident. 
Whenever I don't feel well, I D D D D D D 
should consult a medically 
trained professional. 
I am in control of my health. D 0 D D D 0 
Section C (Cont'd- 2 of 3) 
Strongly Disagree Slightly Slightly Agree Strongly 
disagree disagree agree agree 
My family has a lot to do with D D D D D D 
my becoming sick or staying 
healthy. 
When I get sick, I am to D D D 0 0 D 
blame. 
Luck plays a big part in 0 0 0 0 D D 
determining how soon I 
recover from illness. 
Health professionals control my D D D D D D 
health. 
My good health is largely a D D D 0 D 0 
matter of good fortune. 
The main thing which affects D D 0 0 0 D 
my health is what I myself do. 
Section C (Cont'd- 3 of 3) 
Strongly Disagree Slightly Slightly Agree Strongly 
disagree disagree agree agree 
If I take care of myself, I can 0 0 0 0 0 0 
, avoid illness. 
When I recover from an illness, 0 0 0 0 0 0 
it's usually because other people 
(for example doctors, nurses, 
fami ly, friends) have been taking 
good care of me. 
No matter what I do, I'm likely 0 0 0 0 0 0 
to get sick. 
If it's meant to be, I will stay 0 0 0 0 0 0 
healthy. 
If I take the right actions, I can 0 0 0 0 0 0 
stay_ healthy. 
Regarding my health, I can only 0 0 0 0 0 0 
do what my doctor tells me to do. 
Section D ( 1 of 2) 
1. Vividly imagine that you are afraid of the dentist and have to get some dental work done. 
Which of the following would you do? Tick all of the statements that might apply to you. 
I would ask the dentist exactly what work was going to be done. 0 
I would take a tranquil izer or have a drink before going. 0 
I would try to think about pleasant memories. 0 
I would want the dentist to tell me when I would feel pain. 0 
I would try to sleep. 0 
I would watch all the dentist's movements and listen for the sound of the drill. 0 
I would watch the flow of water from my mouth to see if it contained blood . 0 
I would do mental puzzles in my mind. 0 
Section D (Cont'd- 2 of 2) 
2. Vividly imagine that, due to a large drop in sales, it is rumoured that several people in your 
department at work will be laid off. Your supervisor has turned in an evaluation of your work 
for the past year. The decision about lay-offs has been made and will be announced in several 
days . Tick all of the statements that might apply to you. 
I would talk to my fellow workers to see if they knew anything about what the 0 
supervisor evaluation of me said . 
I would review the list of duties for my present job and try to figure out if I had fulfilled 0 
them all. 
I would go to the movies to take my mind off things. 0 
I would try to remember any arguments or disagreements I might have had that would 0 
have resulted in the supervisor having a lower opinion of me. 
I would push all thoughts of being laid off out of my mind. 0 
I would tell my spouse that I'd rather not discuss my chances of being laid off. 0 
I would try to think which employees in my department the supervisor might have 0 
e thought had done the worst job. 
I would continue doing my work as if nothing special was happening. 0 
Section E 
In the section below, there are two passages with a few sentences that have some of the 
words missing. Where a word is missing, a blank line is drawn, and 4 possible words that 
could go in the blank appear just below it in the box. Please fill in the blanks by circling the 
letter in front of the word which makes the sentence make sense. You have 7 minutes to 
complete as much of this as you can. 
Example: 
This medication will help you your infection. Swallow one 1 ____ _ 
a. eat a. tablet 
b. fire b. table 
c. fight c. stomach 
d. drink d. food 
with a glass of 
1 
____ _ twice a day at least half an hour before you eat. 
b . lunch 
c. water 
d. food 
e. wafer 
APPENDIX G 
• WMI Study Phase 1 patient information sheet (St George Hospital} 
• WMI Study Phase 1 patient information sheet (Concord Hospital) 
• WMI Study Phase 1 patient information sheet (St Vincent's Hospital} 
• WMI Study Phase 1 patient consent form (St George Hospital} 
• WMI Study Phase 1 patient consent form (Concord Hospital) 
• WMI Study Phase 1 patient consent form (St Vincent's Hospital) 
• WMI Study Phase 1 pharmacist-in-charge information sheet 
• WMI Study Phase 1 pharmacist on duty information sheet 
• WMI Study Phase 1 pharmacist consent form 
• WMI Study Phase 1 patient information sheet (community pharmacy) 
• WMI Study Phase 1 patient consent form (community pharmacy) 
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Miclrei/C' Koo, BPhamt (Hans) (Tel: 9351 3647) 
In<'.< Kms.<. 8Pharm, DipHospPiwrm. PhD (Tel: 9351 3507) 
Pan.a As/ani, BPharm (Hans). MSc. PhD (Tel: 9351 6711) 
Faculty of Pharmacy (Bldg A 15), 
The Umversity of Sydney, 
NSW 1006. AUSTRALIA. 
PARTICIPANT INFORMATION SHEET- PHASE 1 
The Use of Written Medicine Information by Consumers 
Dear Participant, 
The StGeorge Hospital & 
Community Health Sen·ice. 
Gray Street, Kogorah, 
NSW 2117. AUSTRALIA 
You are invited to take part in the above-mentioned study. The study aims to investigate how 
you use printed information about medications. We are also interested in the factors that 
influence your use of this information. 
This study is being conducted by Ms Michelle Koo as part of the degree of Doctor of Philosophy 
under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of Pharmacy, The 
University of Sydney. 
In order to take part in this study, you must be: 
1. Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking one of the medications specified by the researcher 
If you meet the above criteria and agree to participate in the study, you will be interviewed by 
the researcher using a questionnaire. The interview will last approximately 30 minutes. 
All aspects of the study, including results, will be strictly confidential and only the investigators 
named above will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report. 
Participation in this study is entirely voluntary: you are not obliged to participate and - if you do 
participate • you can withdraw at any time. Whatever your decision, please be assured that it will 
not affect your medical treatment or your relationship with medical staff. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on (02) 
9351 3647. This information sheet is for you to keep. 
Thank you for your time and participation. 
This study has been approved by the Human Research Ethics Committee of the South East Health 
Southern Section and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
the Coordinator of the Human Research Ethics Committee of the South East Health Southern 
Section, Ms Ooukessa Lerias [tel: (02) 9350 2481 , fax: (02) 9350 3968, email: 
leriasO@sesahs.nsw.GOV.AU] or the Manager of Ethics and Biosafety Administration, University 
of Sydney, on (02) 9351 4811 . 
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CONCORD 
REPATRIATION GENERAL 
HOSPITAL 
Michelle Koo, BPharm (Hons) (Tel: 9351 3647) 
lnes Krass, BPI10nn, DipHospPhann, PhD (Tel: 9351 3507) 
ParisaAslani, BPhann (Hons), MSc, PhD (Tel: 9351 6711) 
F ac11lty of Pharmacy (Bldg A 15), 
17te University of Sydney. 
NSW 1006. AUSTRALIA. 
PARTICIPANT INFORMATION SHEET- PHASE 1 
The Use of Written Medicine Information by Consumers 
Dear Participant, 
You are invited to take part in the above-mentioned study. The study aims to investigate how 
you use printed information about medications. We are also interested in the factors that 
influence your use of this information. These include your opinions about the current format 
of written medicine information, how you cope with stressful situations such as medical 
conditions and how easy it is for you to understand and use general written information that 
you come across in the health setting. 
This study is being conducted by Ms Michelle Koo as part of the degree of Doctor of 
Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of 
Pharmacy, The University of Sydney. This study is not being conducted by the 
Rheumatology Department of Concord Hospital and does not form part of your normal visit 
to the clinic, however, Dr Shenstone, one of the specialists has kindly given his support and 
granted permission for us to recruit and interview patients from this clinic. 
In order to take part in this study, you must be: 
1. Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking one of the medications specified by the researcher 
If you meet the above criteria and agree to participate in the study, you will be interviewed by 
the researcher using a questionnaire. The interview will last approximately 30 minutes. If you 
are called for your appointment in the middle of the interview, we will put the interview on 
hold to allow you to see your specialist. We request that you return after your consultation to 
complete the questionnaire. 
If we have your permission, we may also contact you for a separate follow-up telephone 
interview at a time which is convenient for you. The telephone interview will last 
approximately 30-45 minutes. 
(please turn over) 
All aspects of the study, including results, will be strictly conrodentoal and only the 
investigators named above will have access to information on participants. A report of the 
study may be submitted for publication, but individual participants will not be identi fiable in 
such a report. Participation in this study is entirely voluntary: you are not obliged to 
participate and - if you do participate - you can withdraw at any time. Whatever your 
decision, please be assured that it will not affect your medical treatment or your relationship 
with your doctors and other members of your health care team. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
(02) 9351 3647. This information sheet is for you to keep. 
Thank you for your time and participation. 
This study has been approved by the Human Research Ethics Committee - CRGH Zone of the 
Central Sydney Area Health Service and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact the Secretary of the Concord Hospital Human Research Ethics Committee, on (02) 
9767 6233 or the Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 
9351 4811 . 
Alternatively, if you wish to speak with an independent person within the Hospital about any 
problems or queries about the way In which the study was conducted, you may contact the 
Patient Representative on (02) 9767 7 488. 
+ \if 
ST VINCENT'S 
HOSPITAL 
Michelle Koo, BPhnrm (Hons) (Tel: 9351 3647) 
lne.< Krass, BPharm, DipHospPharm, PhD (Tcl:9351 3507) 
Pnrisa A.<lmri, BPhamr (Hans). MSc, PhD (Tel: 9351 6711) 
F nculty of Pharmacy (Bldg A 15), 
The University of Sydney, 
NSW 2006, AUSTRALIA. 
PARTICIPANT INFORMATION SHEET- PHASE 1 
The Use of Written Medicine Information by Consumers 
Dear Participant, 
You are invited to take part in the above-mentioned study. The study aims to investigate how 
you use printed information about medications. We are also interested in the factors that 
influence your use of this information. These include your opinions about the current format of 
written medicine information, how you cope with stressful situations such as medical conditions 
and how easy it is for you to understand and use general written information that you come 
across in the health setting. 
This study is being conducted by Ms Michelle Koo as part of the degree of Doctor of Philosophy 
under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of Pharmacy, The 
University of Sydney. This study is not being conducted by the Rheumatology Department of St 
Vincent's Hospital and does not form part of your normal visit to the clinic, however, NProf 
Cohen, one of the specialists has kindly given his support and granted permission for us to 
recruit and interview patients from this clinic. 
In order to take part in this study, you must be: 
1 Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking one of the medications specified by the researcher 
If you meet the above criteria and agree to participate in the study, you will be interviewed by 
the researcher using a questionnaire. The interview will last approximately 30 minutes. If you 
are called for your appointment in the middle of the interview, we will put the interview on hold to 
allow you to see your specialist. We request that you return after your consultation to complete 
the questionnaire. 
If we have your permission, we may also contact you for a separate follow-up telephone 
interview at a time which is convenient for you. The telephone interview will last approximately 
30-45 minutes. 
(please turn over) 
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All aspects of the study, including results, will be strictly confidential and only the investigators 
named above will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report. 
Participation in this study is entirely voluntary: you are not obliged to participate and - if you do 
participate - you can withdraw at any time. Whatever your 
decision, please be assured that it will not affect your medical treatment or your relationship with 
your doctors and other members of your health care team. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 02-
9351 3647. This information sheet is for you to keep. 
Thank you for your time and participation. 
This study has been approved by the St Vincent's Hospital Human Research Ethics Committee 
and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
The Executive Officer, St Vincent's Hospital Research Ethics Committee (phone 02-8382 2075, fax 
02-8382 3667, email recciestone@stvincents.com.au) or the Manager of Ethics and Biosafety 
Administration, University of Sydney (phone 02-9351 4811 ). 
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Michelle Koo. BPhorm (Hans) (Tel: 9351 3647) 
lne.< Krass. BP/uwm. DipHospPh01111, PhD (Tel: 9351 3507) 
Ponto As/ani, BPhorm (Hons), MSc, PhD (Tel: 9351 6711) 
Faculty o(Phormocy (Bldg A/5), 
The University of Sydney, 
NSW 1006. AUSTRALIA. 
PARTICIPANT CONSENT FORM- PHASE 1 
The Use of Written Medicine Information by Consumers 
The St George Hospital & 
Community Heal tit Service. 
Groy Street. Kogorah. 
NSW ZZ/ 7, AUSTRALIA 
I, .......... (please print your name) 
have read and understood the "Participant Information Sheet" on the above research study and 
have discussed it with one of the researchers, Ms Michelle Koo. I am aware of the procedures 
involved in the study and understand what is expected of me. 
I freely choose to participate in this study and understand that I can withdraw from the study at 
any time without penalty or prejudice. 1 also understand that the research study is strictly 
confidential and that only group data will be published and used in future research. No personal 
details will be revealed at any time during or after the study. 
Signature: 
Name (please print): 
Date: 
Sign ature of witness: .................................................................................................. .... ... . 
Name o f w itness (please print): 
Date : 
This study has been approved by the Human Research Ethics Committee of the South East Health 
Southern Section and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
the Coordinator of the Human Research Ethics Committee of the South East Health Southern 
Section, Ms Doukessa Lerias [tel : (02) 9350 2481 , fax: (02) 9350 3968, email: 
LeriasD@sesahs.nsw.GOV.AU) or the Manager of Ethics and Biosafety Administration, University 
of Sydney, on (02) 9351 4811. 
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CONCORD 
REPATRIATION GENERAL 
HOSPITAL 
Michelle Koo. BP/rarm (Hans) (Tel: 9351 3647} 
lnes Krass, BPham1, DipHospPhann. PhD (Tel: 9351 3507) 
ParisoAslani, BPharm (Hans). MSc, PhD (Tel: 93516711) 
FaCility of Pharmacy (Bldg A 15), 
The University of Sydney, 
NSW 1006, AUSTRALIA. 
PARTICIPANT CONSENT FORM- PHASE 1 
The Use o f Printed Medicine Information by Consumers 
I, [name] 
cl ~ddffiS~ 
have been invited to participate in the above named research study and have discussed the 
study with one of the researchers, Ms Michelle Koo. 
I acknowledge that I have received and read the Participant Information Sheet and the 
purpose and nature of this research has been explained to me. 
I understand that my participation in this study is entirely voluntary and I may withdraw at 
any stage. If I withdraw, this decision will not affect in any way my future treatment or my 
relationship with my doctors and other members of my health care team. 
I also understand that information relating to my participation in the study is strictly 
confidential. I agree that research data gathered from the results of the study may be 
published, provided I cannot be identified. 
I understand that the research project will be carried out according to the principles of the 
National Health & Medical Research Council Statement on Ethical Conduct in Research 
Involving Humans. 
(please turn over) 
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I understand that if I have any questions relating to my participation in this research study I 
may contact Ms Michelle Koo on (02) 9351 3647 who will discuss any concerns I may have. 
I understand that if I have any questions about my rights as a research subject, or on other 
administrative matters, I may contact the Secretary of the Concord Hospital Human 
Research Ethics Committee on (02) 9767 6233. 
I also understand that if I wish to speak with an independent person within the Hospital with 
any problems or queries about the way in which the study is being conducted, I may contact 
the Patient Representative on (02) 9767 7488. 
I hereby freely agree to participate in this research study. 
Name (Print):--------------------
Signature: Date:------
Name of Witness (Print):-----------------
Signature of Witness: Date:-------
This study has been approved by the Human Research Ethics Committee - CRGH Zone of the 
Central Sydney Area Health Service and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
the Secretary of the Concord Hospital Human Research Ethics Committee, on (02) 9767 6233 or 
the Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 9351 4811. 
Alternatively, If you wish to speak with an independent person within the Hospital about any 
problems or queries about the way in which the study was conducted, you may contact the 
Patient Representative on (02) 9767 7488. 
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ST VINCENT'S 
HOSPITAL 
Michelle Koo. BPharm (Hans) (Tel: 9351 3647) 
lnes Krass, BPharm, DipHospPhorm, PhD (Tel:9351 3507) 
Parisa A.<lani, BPhomr (Hans). MSc, PhD (Tel: 9351 6711) 
Faculry ofPharmac,v (Bldg Al5), 
Tire University of Sydney, 
NSW 2006, AUSTRALIA. 
PARTICIPANT CONSENT FORM- PHASE 1 
The Use of Printed Medicine Information by Consumers 
I, name] 
of Jaddress] 
agree to participate as a subject in the study described in the Participant Information Sheet 
provided to me. 
I acknowledge that I have read the Participant Information Sheet, which explains the aims 
of the study and the nature of the investigation, and the information has been explained to 
me to my satisfaction. 
2 I understand that I can withdraw from the study at any time without prejudice to my 
relationship to The University of Sydney or the doctors and staff of St Vincent's Hospital. 
I also understand that information relating to my participation in the study is strictly 
confidential. I agree that research data gathered from the results of the study may be 
published, provided that I cannot be identified. 
I understand that if I have any questions relating to my participation in this research, I may 
contact Ms Michelle Koo on 02-9351 3647, who will be happy to answer them. 
I understand that if I have any complaints or questions about my rights as a research 
subject, or on other administrative matters, I may contact the Executive Officer, St 
Vincent's Hospital Research Ethics Committee on 02-8382 2075. 
Name {Print):------------------- - -
Signature: Date:------
Name of Witness (Print):------------------
Signature of Witness: Date: - -----
This study has been approved by the St Vincent's Hospital Human Research Ethics Committee 
and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact The Executive Officer, St Vincent's Hospital Research Ethics Committee (phone 02-
8382 2075, fax 02-8382 3667, email recclestone@stvincents.com.au) or the Manager of Ethics 
and Biosafety Adm~nistration, U_niversity of Sydney (phone 02-9351 4811). 
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The University of Sydney 
Michelle Knn BPharm (Hans) 
lnes Krn.<s BPharm. DipHospPharm. PhD 
Pnri.<o As/ani BPharm (Hans). MSc, PhD 
PHARMACIST INFORMATION SHEET 
For the attention of the Pharmacist-in-Charge 
The Use of Written Medicine Information by Consumers 
Dear Colleague, 
Faculty of Pharmacy 
NSW 2006 Australia 
Tel: (612) 9351 4445 
Tel: (612) 9351 3507 
Tel: (612) 9351 6711 
The above study is being conducted by Ms Michelle Koo as part of the degree of Doctor of 
Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of 
Pharmacy, The University of Sydney. Your pharmacy appeared in a random selection of Sydney 
community pharmacies, and your participation in this study will be greatly appreciated. 
Our study focuses on written medicine information, in particular Consumer Medicine Information 
(CMI). The National Strategy for Quality Use of Medicines has identified CMI as a means of 
facilitating the uptake of objective information about all medicines by consumers. You may also 
be aware that as of this year, all prescriptions are required to have a CMI, and that pharmacies 
have been given financial assistance under the Third Community Pharmacy Agreement to 
ensure that they are well-equipped to provide CMI to consumers. 
Despite all the efforts and resources put into CMI, few research studies have been conducted to 
determine the readership of CMI and the factors which influence the use of CMI by consumers. 
Hence, our research aims to investigate the awareness and use of CMI in the community and to 
investigate the factors influencing the use of CMI by consumers. The results of this study will 
reveal to the profession the needs of consumers and aid pharmacists in tailoring information to 
meet these needs. 
If you agree to take part in the study, Ms Michelle Koo will be visiting your pharmacy to recruit 
consumers and administer the questionnaires on-site to eligible and consenting consumers. It is 
anticipated that the interviews will last approximately 30 minutes. We would like to engage 
your assistance in referring all consumers who meet the inclusion criteria lis ted below to 
Ms Koo. 
In order to participate, consumers must be: 
1. Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking at least one prescription medication for hypertension 
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We would also appreciate it if you could inform the pharmacist(s) on duty about the 
s tudy. Together with this letter, we have included several copies of Pharmacist Information 
Sheet for the pharmacist(s) on duty. 
This study has been approved by the Human Ethics Committee of The University of Sydney. All 
aspects of the study, including results, will be strictly confidential and only the investigators 
named below will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report and 
only group data will be reported. Participation in this study is entirely voluntary, and you and 
your consumers can withdraw at any time without penalty or prejudice. 
We look forward to a favourable reply from you. Ms Michelle Koo will be contacting you by 
telephone approximately one week after the initial mailing to confirm that you have received this 
information sheet and to ascertain your willingness to participate in the study. If you do agree to 
take part, we will obtain written consent from you when we commence recruiting consumers 
from your pharmacy. 
This information sheet is for you to keep. If you would like further information at any stage, 
please feel free to contact Ms Michelle Koo on (02) 9351 4445. 
Thank you very much for your time and assistance. 
Yours sincerely, 
MICHELLE KOO INES KRASS PARISA ASLANI 
Any person with concerns or complaints about the conduct of a research study can contact the 
Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 9351 4811. 
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The University of Sydney 
Michelfe Kon BPharm (Hans) 
lues Krass BPharm, DipHospPhann, PhD 
Pnri.m As/ani BPharm (Hons), MSc. PhD 
PHARMACIST INFORMATION SHEET 
For the attention of the Pharmacist on duty 
The Use of Written Medicine Information by Consumers 
Dear Colleague, 
Faculty of Pharmacy 
NSW 2006 Australia 
Tel: (612) 9351 4445 
Tel: (612) 9351 3507 
Tel: (612) 9351 6711 
The above study is being conducted by Ms Michelle Koo as part of the degree of Doctor of 
Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of 
Pharmacy, The University of Sydney. 
Our study focuses on written medicine information. in particular Consumer Medicine Information 
(CMI). The National Strategy for Quality Use of Medicines has identified CMI as a means of 
facilitating the uptake of objective information about all medicines by consumers. You may also 
be aware that as of this year, all prescriptions are required to have a CMI, and that pharmacies 
have been given financial assistance under the Third Community Pharmacy Agreement to 
ensure that they are well-equipped to provide CMI to consumers. 
Despite all the efforts and resources put into CMI, few research studies have been conducted to 
determine the readership of CMI and the factors which influence the use of CMI by consumers. 
Hence. our research aims to investigate the awareness and use of CMI in the community and to 
investigate the factors innuencing the use of CMI by consumers. The results of this study will 
reveal to the profession the needs of consumers and aid pharmacists in tailoring information to 
meet these needs. 
If your pharmacy agrees to take part in the study, Ms Michelle Koo will be visiting your 
pharmacy to recruit consumers and administer the questionnaires on-site to eligible and 
consenting consumers. It is anticipated that the interviews will last approximately 30 minutes. 
We would like to engage your assistance in referring all consumers who meet the 
inclusion criteria lis ted below to Ms Koo. 
In order to participate, consumers must be: 
1 . Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking at least one prescription medication for hypertension 
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This study has been approved by the Human Ethics Committee of The University of Sydney. All 
aspects of the study, including results, will be strictly confidential and only the investigators 
named below will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report and 
only group data will be reported. Participation in this study is entirely voluntary, and you and 
your consumers can withdraw at any time without penalty or prejudice. 
This information sheet is for you to keep. If you would like further information at any stage, 
please feel free to contact Ms Michelle Koo on (02) 9351 4445. 
Thank you very much for your time and assistance. 
Yours sincerely, 
MICHELLE KOO INES KRASS PARISA ASLANI 
Any person with concerns or complaints about the conduct of a research study can contact the 
Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 9351 4811 . 
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Michelle Koo BPharm (Hons) 
fur..< Krass BPharm, DipHospPharm. PhD 
Pari.m Asfani BPharm (Hons). MSc. PhD 
PHARMACIST CONSENT FORM 
The University of Sydney 
Faculty of Pharmacy 
NSW 2006 Australia 
Tel: (612) 9351 4445 
Tel: (612) 93513507 
Tel: (612) 9351 6711 
The Use of Written Medicine Information by Consumers 
I . .. .. .. ........................ (please print your name) 
of .............................................. (your address) 
have read and understood the "Pharmacist Information Sheet" on the above research study 
and have discussed it with one of the researchers, Ms Michelle Koo. I am aware of the 
procedures involved in the study and understand what is expected of me. 
I freely choose to participate in this study and understand that I can withdraw at any time 
without penalty or prejudice. I also understand that the research study is strictly confidential 
and that only group data will be published and used in future research. No personal details 
will be revealed at any time during or after the study. 
Signature: 
Name (please print) : 
Date: 
Sign<~ture of witness: ................ ...... .............. .... ................................................................. . 
Name of witness (please print) : 
Date: 
Any person with concerns or complaints about the conduct of a research study can contact 
the Manager of Ethics and Blosafety Administration, University of Sydney, on (02) 9351 4811 . 
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T he University of Sydney 
Michelle Koo BPirorm (Hons) 
l nes Krass BPitamr,DipHospPitarm. PhD 
Pnrisn As/ani BPitorm (Hons). MSc. PhD 
PARTICIPANT INFORMATION SHEET- PHASE 1 
The Use of Written Medicine Information by Consumers 
Dear Participant. 
Faculty of PharmAcy 
NSW 2006 Australia 
Tel: (612) 9351 3647 
Tel: (612) 9351 3507 
Tel: (612) 9351 6711 
You are invited to take part in the above study which aims to investigate how you use written 
information about your medicines. We are also interested in the factors that innuence your use 
of the information. These indude your opinions about the current format of written medicine 
information, how you cope with stressful situations such as medical conditions and how easy it 
is for you to understand and use general written information that you come across in the health 
setting. 
This study is being conducted by Ms Michelle Koo as part of the degree of Doctor of Philosophy 
under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty of Pharmacy, The 
University of Sydney. 
In order to take part in this study, you must be: 
1 . Over the age of 18 years 
2. Able to take part in this study without the help of a translator 
3. Currently taking one of the medications specified by the researcher 
If you meet the above criteria and agree to participate in the study, you will be interviewed by 
the researcher using a questionnaire. The interview will last approximately 30 minutes. 
If we have your permission. we may also contact you for a separate follow-up telephone 
interview at a time which is convenient for you. The telephone interview will last approximately 
30-45 minutes. 
All aspects of the study, including results, will be strictly confidential and only the investigators 
named above will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report and 
only group data will be reported. Participation in this study is entirely voluntary: you are not 
obliged to participate and - if you do participate - you can withdraw at any time without penalty 
or prejudice. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
(02) 9351 3647. This information sheet is for you to keep. 
Thank you for your time and participation. 
Any person with concerns or complaints about the conduct of a research study can contact the 
Manager of Ethics and Blosafety Administration, University of Sydney, on (02) 9351 4811 . 
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T he Univer sity of Sydney 
Michelle Koo BPhorm (HoJPS) 
Jnes Krass BPhorm, DipHospPirorm, PhD 
Porisa As/ani BPharm (Hons). MSc, PhD 
PARTICIPANT CONSENT FORM· PHASE 1 
The Use of Written Medicine Information by Consumers 
Faculty of Pharmacy 
NSW 2006 Australia 
Tel: (612) 9351 3647 
Tel: (612) 9351 3507 
Tel: (612) 93516711 
I, .................................... .. ........................ ......................... (please print your name) 
have read and understood the "Participant Information Sheet" on the above research study 
and have discussed it with one of the researchers, Ms Michelle Koo. I am aware of the 
procedures involved in the study and understand what is expected of me. 
I freely choose to participate in this study and understand that I can withdraw from the study 
at any time without penalty or prejudice. I also understand that the research study is strictly 
confidential and that only group data will be published and used in future research. No 
personal details will be revealed at any time during or after the study. 
Signature: 
Name (please print): 
Date: 
Signature of witness: ...................................................................................................... ... . 
Name of witness (please print) : 
Date: 
Any person with concerns or complaints about the conduct of a research study can contact 
the Manager of Ethics and Blosafety Administration, University of Sydney, on (02) 9351 4811 . 
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Phase 2: Telephone Interview Guide 
I Please note that the questions below are only a guide. I 
1. COPING 
(a) When you found out that you had (insert diagnosis), how did you react 
to that? 
How did you cope? 
How do you think receiving information (written vs verbal) about your 
condition and your medicines would have affected how you reacted? 
• Any preference as to when this information should be given? 
(b)* With (insert diagnosis), you have to put up with (insert symptom). If you 
knew that the (insert symptom) would be short term, would that have 
changed your reaction to the diagnosis? 
How do you think that would influence your interest in reading the 
information about your medicines? 
(c)' What about if it was a chronic condition without symptoms? 
•NB Sections 1 (b) and 1 (c) to be adapted based on presenting condition 
2. INTEREST IN INFORMATION 
(a) In general, how interested would you say you are in getting any kind of 
information (eg verbal , written) about your medicines? Why? 
(b) In what way would you prefer to get information about your prescription 
medicines? 
(Prompt: Verbal? Written? Both?) 
(c) If we look in more detail about written information, do you normally read 
written information about your prescription medicines? 
Can you recall the last time you did this? Can you recall what the 
medicine was? 
What was the source of this written information? 
Besides this source, what other sources of written information have you 
used in the past? 
How do they compare? 
3. ACCESS TO INFORMATION/ ROLE OF HEALTH PROFESSIONAL 
(a) How have you been receiving information about your medicines? 
(Prompt: From health professional? By reading CMI? By searching the net?) 
(b) Some people find it easy and others find it difficult to find written 
information about medicines. 
• How about yourself? 
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• 
(c) 
(d) 
4. 
(a) 
5. 
(a) 
6. 
(a) 
(b) 
7. 
(a) 
What do you think could be done to improve the situation? 
Following on from that, who do you think should provide the information 
on medicines? 
What do you think is the role of the health care professional when it comes 
to information about medicines? 
(Prompt: What about the Dr? The Pharmacist?) 
FORMAT AND PRESENTATION OF CMI 
There have also been a lot of comments about Consumer Medicine 
Information or CMI (define CMI if necessary), which is the commonly 
available form of written information about medicines. 
What are your impressions about the current layouVuser-friendliness of 
the two different kinds of CMis, ie the one that you find in the box and the 
one which is printed from a computer? 
How do you think this affects your use of CMI? 
LITERACY 
Besides the overall layout and design, some people have also commented 
that CMI is difficult to understand. 
What do you think? 
How do you think the situation could be improved? 
HEALTH LOCUS OF CONTROL 
Who would you say is involved in making decisions that affect your 
health? 
Of the people that you have mentioned, who would you say has the most 
influence on your health care? 
How do you think th is affects the way you use written information about 
your medicines? 
If I can once again touch on what we have mentioned earlier, how do you 
think the severity of your condition influences who makes decisions with 
regards to your health care? 
How would this affect your need of written information? 
MISCELLANEOUS 
Finally, are there any comments that you would like to make in relation to 
written information that we may or may not have covered today? 
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Interview procedure 
1. The interviewer greeted and thanked the participant for consenting to be interviewed 
2. The interviewer reminded the participant that the interview will be recorded and hence 
the requirement to use a speaker phone. However, the patient was assured that no one 
else was present in the room. The interviewer also informed the patient that their verbal 
consent to record the interview would once again be obtained when the recording 
commenced. 
3. The interviewer informed the participant that he/she will be introduced as a coded 
person to maintain anonymity. 
4. Both digital and tape recorders were started. 
5. The interviewer introduced the participant on 'tape' and started off the interview by 
obtaining consent to record the interview. 
6. The interviewer interviewed the participant using the interview guide. 
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APPENDIX I 
• WMI Study Phase 2 patient information sheet (StGeorge Hospital) 
• WMI Study Phase 2 patient information sheet (Concord Hospital ) 
• WMI Study Phase 2 patient information sheet (St Vincent's Hospita l) 
• WMI Study Phase 2 patient information sheet (community pharmacy) 
• WMI Study Phase 2 consent form (St George Hospital) 
• WMI Study Phase 2 consent form (Concord Hospital) 
• WMI Study Phase 2 consent form (St Vincent's Hospital) 
• WMI Study Phase 2 consent form (community pharmacy) 
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Michelle Koo. BPharm (Hans) (Tel: 9351 3647) 
Jne.< Kra.<.<. BPharm, DipHaspPharm. PhD (Tel: 9351 3507) 
Poriso As/ani. BPhonn (Hans). MSc. PhD (Tel: 935 1 67111 
Faculty of Pharmacy (Bldg A 15). 
The U11i1'ersity of Sydm!y. 
NSW 2006. AUSTRALIA. 
PARTICIPANT INFORMATION SHEET- PHASE 2 
The Use of Written Medicine Information by Consumers 
Dear Participant, 
The St George Ho.rpital & 
Commrmiry Health Scrvrce. 
Gray Street, Kogoroh, 
NSH' ll/7, AUSTRALIA. 
Thank you for taking part in our initial questionnaire and for giving us permission to contact you 
for this follow-up telephone interview. 
This interview forms part of the study conducted by Ms Michelle Koo as part of the degree of 
Doctor of Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty 
of Pharmacy, The University of Sydney. 
We would like to find out more about your opinions on written medicine information and how you 
use it. These include your opinions about the current format of written medicine information, 
how you cope with stressful situations such as medical conditions and how easy it is for you to 
understand and use general written information that you come across in the health setting. The 
telephone interview will last approximately 30-45 minutes. With your permission, we would like 
to audiotape the telephone interview to make sure we do not miss any important information 
that you provide. 
All data collected from this interview will be strictly confidential and only the investigators named 
above will have access to information on participants. A report of the study may be submitted for 
publication, but individual participants will not be identifiable in such a report. Participation in this 
study is entirely voluntary: you are not obliged to participate and - if you do participate - you can 
withdraw at any time without penalty or prejudice. Whatever your decision, please be assured 
that it will not affect your medical treatment or your relationship with medical staff. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
(02) 9351 3647. This information sheet is for you to keep. Ms Michelle Koo will contact you by 
telephone within the next week to arrange a suitable time for the telephone interview. 
Thank you for your time and participation. 
This study has been approved by the Human Research Ethics Committee of the South East Health 
Southern Section and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
the Coordinator of the Human Research Ethics Committee of the South East Health Southern 
Section, Ms Doukessa l erlas [tel: (02) 9350 2481 , fax: (02) 9350 3968, email: 
LeriasD@sesahs.nsw.GOV.AU] or the Manager of Ethics and Blosafety Administration, University 
of Sydney, on (02) 9351 481 1. 
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/nes Krass. BPhomr. DipHosp Phorm, PhD (Tel: 935 1 3507) 
ParisoAsloni, BPhorm (Hans). MSc. PhD (Tel: 9351 6711) 
FOClllty of Pharmacy (Bldg A 15), 
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NS H' 2006, AUSTRALIA. 
PARTICIPANT INFORMATION SHEET- PHASE 2 
The Use of Written Medicine Information by Consumers 
Dear Participant, 
Thank you for taking part in our initial questionnaire and for giving us permission to contact 
you for this follow-up telephone interview. 
This interview forms part of the study conducted by Ms Michelle Koo as part of the degree of 
Doctor of Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the 
Faculty of Pharmacy, The University of Sydney. 
We would like to find out more about your opinions on written medicine information and how 
you use it. These include your opinions about the current format of written medicine 
information. how you cope with stressful situations such as medical conditions and how easy 
it is for you to understand and use general written infonmation that you come across in the 
health setting. The telephone interview will last approximately 30-45 minutes. With your 
permission, we would like to audiotape the telephone interview to make sure we do not miss 
any important information that you provide. 
All data collected from this interview will be strictly confidential and only the investigators 
named above will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report. 
Participation in this study is entirely voluntary: you are not obliged to participate and - if you 
do participate - you can withdraw at any time without penalty or prejudice. Whatever your 
decision, please be assured that it will not affect your medical treatment or your relationship 
with your doctors and other members of your health care team. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
(02) 9351 3647. This information sheet is for you to keep. Ms Michelle Koo will contact you 
by telephone within the next week to arrange a suitable time for the telephone interview. 
Thank you for your time and participation. 
This study has been approved by the Human Research Ethics Committee - CRGH Zone of the 
Central Sydney Area Health Service and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact the Secretary of the Concord Hospital Human Research Ethics Committee, on (02) 
9767 6233 or the Manager of Ethics and Blosafety Administration, University of Sydney, on (02) 
9351 4811 . 
Alternatively, If you wish to speak with an Independent person within the Hospital about any 
problems or queries about the way in which the study was conducted, you may contact the 
Patient Representative on (02) 9767 7488. 
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HOSPITAL 
Michelle Koo. BPhorm (lions) (J'e/: 9351 3647) 
lues Krass. 8Pham1. DipliospPharm, PhD (J'e/:9351 3507) 
Pansa As /am, 8 Pham1 (lions). MSc, PhD (J'el: 9351 6711) 
Fac11/ty of Pham •acy (Bldg A 15), 
The University o/ S,vdney, 
NSW 1006, AUSTRALIA 
PARTICIPANT INFORMATION SHEET- PHASE 2 
The Use of Written Medicine Information by Consumers 
Dear Participant. 
Thank you for taking part in our initial questionnaire and for giving us permission to contact 
you for this follow-up telephone interview. 
This interview forms part of the study conducted by Ms Michelle Koo as part of the degree of 
Doctor of Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the 
Faculty of Pharmacy, The University of Sydney. 
We would like to find out more about your opinions on written medicine information and how 
you use it. These include your opinions about the current format of written medicine 
information, how you cope with stressful situations such as medical conditions and how easy 
it is for you to understand and use general written information that you come across in the 
health setting. The telephone interview will last approximately 30-45 minutes. With your 
permission. we would like to audiotape the telephone interview to make sure we do not miss 
any important information that you provide. 
All data collected from this interview will be strictly confidential and only the investigators 
named above will have access to information on participants. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a report. 
Participation in this study is entirely voluntary: you are not obliged to participate and - if you 
do participate - you can withdraw at any time without penalty or prejudice. Whatever your 
decision. please be assured that it will not affect your medical treatment or your relationship 
with your doctors and other members of your health care team. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
02-9351 3647. This information sheet is for you to keep. Ms Michelle Koo will contact you by 
telephone within the next week to arrange a suitable time for the telephone interview. 
Thank you for your time and participation. 
This study has been approved by the St Vincent's Hospital Human Research Ethics Committee 
and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact The Executive Officer, St Vincent's Hospital Research Ethics Committee (phone 02-
8382 2075, fax 02-8382 3667, email recclestone@stvincents.com.au) or the Manager of Ethics 
and Biosafety Administration, University of Sydney (phone 02-9351 4811). 
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The University of Sydney 
Michelle Koo BPharm (Hons) 
lnes Krass BPharm, DipHospPhonn, PhD 
Pariso As/ani BPharm (Hans) . MSc, PhD 
PARTICIPANT INFORMATION SHEET- PHASE 2 
The Use of Written Medicine Information by Consumers 
Dear Participant. 
Faculty of Phar macy 
NSW 2006 Australia 
Tel: (612) 93513647 
Tel: (612) 9351 3507 
Tel: {6 12) 9351 6 7 I I 
Thank you for taking part in our initial questionnaire and for giving us permission to contact you 
for this follow-up telephone interview. 
This interview forms part of the study conducted by Ms Michelle Koo as part of the degree of 
Doctor of Philosophy under the supervision of Dr Parisa Aslani and Dr lnes Krass at the Faculty 
of Pharmacy, The University of Sydney. 
We would like to find out more about your opinions on written medicine information and how you 
use it. These include your opinions about the current format of written medicine information. 
how you cope with stressful situations such as medical conditions and how easy it is for you to 
understand and use general written information that you come across in the health setting. The 
telephone interview will last approximately 30-45 minutes. With your permission, we would like 
to audiotape the telephone interview to make sure we do not miss any important info rmation 
that you provide. 
All data collected from this interview will be strictly confidential and only the investigators named 
above will have access to information on participants. A report of the study may be submitted for 
publication, but individual participants will not be identifiable in such a report. Participation in this 
study is entirely voluntary: you are not obliged to participate and - if you do participate - you can 
withdraw at any time without penalty or prej udice. 
If you would like to know more at any stage, please feel free to contact Ms Michelle Koo on 
(02) 9351 3647. This information sheet is for you to keep. Ms Michelle Koo will contact you by 
telephone within the next week to arrange a suitable time for the telephone interview. 
Thank you for your time and participation. 
Any person with concerns or complaints about the conduct of a research study can contact the 
Manager of Ethics and Blosafety Administration, University of Sydney, on (02) 9351 4811 . 
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Mirltel/e Koo. BPimrm (Hn11s) (Tel' 9351 3647) 
h1r.< Kmu, BPimrm. DipHospPharm, PhD (Tel: 9351 3507) 
Parisa A.<ln11i. BPharm (Ho11s). MSc, PhD (Tel: 9351 6711) 
Fnrulty of Pharmacy (Bldg A I 5). 
Tht Universifl' nf Sydm!)', 
NSW 2006. AUSTRALIA 
CONSENT FORM FOR FURTHER CONTACT 
The Use of Written Medicine Information by Consumers 
n,e St George Hnspllol & 
Community Health Serwce, 
Gray Street. Kogarah. 
NSW 2217. AUSTRALIA. 
We are interested in following up some of the respondents of the questionnaire you have just 
completed. This would involve a telephone interview which will take approximately 30-45 
minutes, at a time which is convenient for you. Would you be interested to participate and do we 
have your permission to contact you? 
I, .......... . .. ... ... (please print your name) 
of ........ .. ............... . . .. . .. ...... ... .... .. .. . .. ...... .... ... ... ..... (please print your address) 
agree to be contacted by one of the researchers, Ms Michelle Koo, to participate in a follow-up 
telephone interview. I am aware of the procedures involved in the telephone interview and 
understand what is expected of me. 
I freely choose to participate in this study and understand that I can withdraw from the study at 
any time without penalty or prejudice. I also understand that the study is strictly confidential and 
that only group data will be published and used in future research. No personal details will be 
revealed at ;my time during or after the study. 
Telephone: 
Best time of day for contact: .. ........... . 
(please turn over) 
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Signature: Date: 
Name (please print): 
Signature of witness: .... ....... ... .. .... ... ... .. Date: 
Name (please print): 
l 6~~:ffice use only I 
This study has been approved by the Human Research Ethics Committee of the South East Health 
Southern Section and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may contact 
the Coordinator of the Human Research Ethics Committee of the South East Health Southern 
Section, Ms Doukessa Lerlas (tel: (02) 9350 2481 , fax : (02) 9350 3968, email: 
LeriasD@sesahs.nsw.GOV.AU] or the Manager of Ethics and Biosafety Administration, University 
of Sydney, on (02) 9351 4811 . 
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HOSPITAL 
Michelle Koo, BPhann (Hom) (Tel. 9351 3647) 
lnes Krass. BPhamr, DipHospPiramr, PhD (Tel· 9351 3507) 
Pama As/ani. BPiramr (Hans). MSc. PhD (Tel: 9351 6711) 
Faculty of Pharmacy (Bldg A/5), 
17re Universi~y of Sydnl!)', 
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CONSENT FORM FOR FURTHER CONTACT 
The Use of Written Medicine Information by Consumers 
We are interested in following up some of the respondents of lhe questionnaire you have 
just completed. This would involve a telephone interview which will take approximately 
30-45 minutes, at a time which is convenient for you. Would you be interested to 
participate and do we have your permission to contact you? 
I, [name] 
of address] 
agree to be contacted by one of the researchers. Ms Michelle Koo. to participate in a 
follow-up telephone interview. 
I understand that my participation in this telephone interview is entirely voluntary and 
I may withdraw at any stage. If I withdraw. this decision will not affect in any way my 
future treatment or my relationship with my doctors and other members of my health 
care team. 
I also understand that information relating to my participation in the interview is 
strictly confidential. I agree that research data gathered from the results of the 
interview may be published, provided I cannot be identified. 
I understand that the research project of which this interview is part of, will be carried 
out according to the principles of the National Health & Medical Research Council 
Statement on Ethical Conduct in Research Involving Humans. 
(please turn over) 
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I understand that if I have any questions relating to my participation in this research 
study I may contact Ms Michelle Koo on (02) 9351 3647 who will discuss any 
concerns I may have. 
I understand that if I have any questions about my rights as a research subject, or on 
other administrative matters, I may contact the Secretary of the Concord Hospital 
Human Research Ethics Committee on (02) 9767 6233. 
I also understand that if I wish to speak with an independent person within the 
Hospital with any problems or queries about the way in which the study is being 
conducted, I may contact the Patient Representative on (02) 9767 7488. 
Telephone: __________________________________________________ _ 
Best time of day for contact: --------------------------------------
Name (print):--- ---------------------
Signature: Date: --------------
Name of Witness (print): ------------------------------------------
Signature: Date:--------------
I For office use only I 
Code: 
This study has been approved by the Human Research Ethics Committee • CRGH Zone of 
the Central Sydney Area Health Service and The University of Sydney Human Ethics 
Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact the Secretary of the Concord Hospital Human Research Ethics Committee, on (02) 
9767 6233 or the Manager of Ethics and Biosafety Administration, University of Sydney, on 
(02) 9351 4811 . 
Alternatively, If you wish to speak with an independent person within the Hospital about 
any problems or queries about the way in which the study was conducted, you may 
contact the Patient Representative on (02) 9767 7488. 
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ST VINCENT'S 
HOSPITAL 
Michelle Koo. BPhorm (Hans) (fel· 9351 3M7) 
lne.< Krass. BPharm, DipHospPhorm, PhD (Tei:93SI 3507) 
Poriso A.<loni. BPharm (Halls). MSc, PhD (Tel: 9151 6711) 
Faculty of Pharmacy (Bldg A IS). 
The Uniwrsity of Sydney, 
NSW 2006. AUSTRALIA. 
CONSENT FORM FOR FURTHER CONTACT 
The Use of Written Medicine Information by Consumers 
We are interested in following up some of the respondents of the questionnaire you have just 
completed. This would involve a telephone interview which will take approximately 30-45 
minutes, at a time which is convenient for you. Would you be interested to participate and do 
we have your permission to contact you? 
I, [name) 
of address] 
agree to be contacted by one of the researchers. Ms Michelle Koo, to participate in a follow-
up telephone interview. 
understand that I can withdraw from the study at any lime without prejudice to my 
relationship to The University of Sydney or the doctors and staff of St Vincent's Hospital. 
I also understand that information relating to my participation in the study is strictly 
confidential. I agree that research data gathered from the results of the study may be 
published, provided that I cannot be identified. 
I understand that if I have any questions relating to my participation in this research, I may 
contact Ms Michelle Koo on 02-9351 3647, who will be happy to answer them. 
I understand that if I have any complaints or questions about my rights as a research 
subject, or on other administrative matters, I may contact the Executive Officer. St 
Vincent's Hospital Research Ethics Committee on 02-6362 2075. 
(please turn over) 
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Best time of day for contact:--------------------
Name (print):------------------------
Signature: Date:--------
Name of Witness (print):---------------------
Signature: Date:--------
I For office use only I 
Code: 
- - ---
This study has been approved by the St VIncent's Hospital Human Research Ethics Committee 
and The University of Sydney Human Ethics Committee. 
If you have any concerns or complaints about the conduct of the research study, you may 
contact The Executive Officer, St VIncent's Hospital Research Ethics Committee (phone 02-
8382 2075, fax 02-8382 3667, email recclestone@stvincents.com.au) or the Manager of Ethics 
and Biosafety Administration, University of Sydney (phone 02-9351 4811 ). 
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The University of Sydney 
Michelle Knn BPharm (HallS} 
lues Krass BPharm. DipHospPharm, PhD 
Pnrisn A.~lnni BPharnr (Ho11s). MSc. PhD 
CONSENTFORMFORFURTHERCONTACT 
The Use of Written Medicine Information by Consumers 
Faculty of Pharmacy 
NSW 2006 Auslralia 
Tel: (612) 9351 3647 
Tel: (612) 9351 3507 
Tel: (61 2) 9351 6711 
We are interested in following up some of the respondents of the questionnaire you have 
just completed. This would involve a telephone interview which will take approximately 
30-45 minutes, at a time which is convenient for you. Would you be interested to 
participate and do we have your permission to contact you? 
1. name] 
of address] 
agree to be contacted by one of the researchers, Ms Michelle Koo, to participate in a 
follow-up telephone interview. I am aware of the procedures involved in the study and 
understand what is expected of me. 
I freely choose to participate in this study and understand that I can withdraw from the 
study at any time without penalty or prejudice. I also understand that the research study 
is strictly confidential and that only group data will be published and used in future 
research. No personal details will be revealed at any time during or after the study. 
Telephone: ____________________________________________________ __ 
Best time of day for contact: ----------------------------------------
Name (print): --------------------------------
Signature: Date: -------------
Name of Witness (print):-------------- ---------
Signature: Date:--------------
I For office use only ] 
Code: 
Any person with concerns or complaints about the conduct of a research study can 
contact the Manager of Ethics and Biosafety Administration, University of Sydney, on (02) 
9351 4811 . 
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Suggestions for CMI 
1. Participants did not mind the use of medical terms in CMI but requested that these 
were explained in simple language that a lay person could understand. 
" ... a better understanding of what a beta blocker is would be more appropriate 
that just saying it's a beta blocker.· (C15007) 
2. In addition to wanting explanations of medical terms, there was also a request for 
explanation on why things are to be done a certain way rather than just being given 
instructions. 
"I probably wonder why I'm taking it at that particular time and if I forget it, I can 
go to the leaflet and see why I'm taking it at that time and see if it's safe to take 
it at another time. • (C19003) 
3. Participants requested for a summary of all the important points at the start of CMI. 
This was considered useful for people who did not have time to read the whole 
CMI. 
"{Reading through all sections} takes time and people don't always have time 
between when they pick it up and when they got to take the first dose." 
(C33005) 
4. A similar request to the one above was made by another participant who requested 
for the more important information to be placed at the start of CMI. 
"I think it just needs a bit more prioritisation? Important things up front, little bit 
more with the information towards the back ... " (H02046) 
5. Participants requested for the information to be presented in point form to make 
CMI more succinct. 
"Probably less words ... I don 't know if it's possible to explain things in point 
form. When I say point form, you might start off with a major heading ... and it 
might say something like, "these are the possible side effects" and then you can 
Jist them." (H01 002) 
6. There was a request for CMI to be improved to make it more appealing to the 
reader. 
"They should make it more interesting to read somehow, I don't know how but 
yeah ... " (H01 009) 
7. One participant requested for the inclusion of a statement to inform the patient 
where to go for further information. 
':4t the bottom of the CMI they could write "for more information, see this 
website" and ... then you could go on the internet and have a look." (H03028) 
8. A participant requested for the benefits in CMI to be expressed more explicitly as it 
was felt that CMI currently emphasised the potential negative effects more than its 
potential benefits. 
• ... it needs to express the benefits as well as the, the potential side effects ... 
you sort of fee/like you're taking a poison as opposed to a something that can 
have an efficacious effect ... when you read these things, you can be depressed 
by the extent of .. . (laughs) of down side and you know you're being generally 
being given it for positive reasons ... but there is nothing positive about ... written 
about the drug that ... in the information. • (H03043) 
Other factors influencing interest in WMI 
1. Some interviewees viewed personality as a factor that influenced their own interest 
inWMI. 
"I'm that sort of person, I'm interested about things, so I'm interested in things 
that things that you know, happen to me or my family or friends. So I think it's 
me. I'm interested that way. " (C34004) 
2. In addition to personality, some participants attributed their interest in WMI to their 
occupational background or career. 
"I'm the sort of person who likes to get to the bottom of everything and I've got a 
research mind ... I've been an academic in the past and ... I'm obviously got that 
desire to know as much as possible." (H03043) 
"I guess I'm that sort of person. I worked in the medical field, I was a dental 
assistant ... " (C34004) 
3 . Past experience seemed to play an important role in influencing participants' 
interest in medicine information. On the one hand, positive experience in using the 
information was thought to motivate future use of it. On the other hand, negative 
experience with medication or treatment was also considered an impetus to seek 
and use medicine information. 
" .. .But I think it really depends on whether you've had positive experiences one 
way or the other, you know, with trying to find info or being given information. n 
(H01020) 
"So I wasn't reading about sickness or medication at all. Because I had the bad 
reaction, like I came out it like oedemas and lumps all over my body from 
medication ... I had to be [interested]." (C20003) 
" Fairly interested [in information about medicines] ... Yeah you see, I've had a 
bit of trouble ... Because sometimes the medicines have worked for a while and 
then sort of ... not worked for a bit." (H01 031) 
"I've had yeah {bad experience in the past] ... I mean, I know {doctors] know ... 
but they don't know me. I know me better than they do ... So, now I ... read as 
much as I can." (H03028) 
4. The timing of information was thought to be important in influencing interest in 
WMI. 
"Depending on the time of point. I mean, for my injury, like I mean usually I like 
to know what I am taking ... but for the injury, I was more concerned about the 
rehabilitation that I didn't care what they gave me, that if it did the job, it's all that 
mattered to me." (H03007) 
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